title,publication_date,product_name,company_in_the_list,company_name_variants,multiple_nationality,main_country,no_total_authors,no_author_with_any_coi,coi_employment,coi_advisory_consulting,coi_speakers_bureau,coi_honoraria,first_author_coi_all,last_author_coi_all,coi_employment_first_author,coi_employment_last_author,coi_advisory_first_author,coi_advisory_last_author,coi_speakers_first_author,coi_speakers_last_author,coi_honoraria_first_author,coi_honoraria_last_author
Adjuvant Nivolumab in High-Risk Muscle-Invasive Urothelial Carcinoma: Expanded Efficacy From CheckMate 274,2025-01-01,nivolumab,True,"['Bristol Myers Squibb', 'Bristol Myers Squibb/Pfizer', 'Bristol Myers Squibb Foundation', 'Bristol Myers Squibb Japan', 'Bristol Myers Squibb/Roche', 'Bristol Myers Squibb/Medarex', 'Bristol Myers Squibb/Celgene']",1,USA,22,16,6,7,1,6,1,1,0,0,0,1,0,0,0,0
Impact of an Epstein-Barr Virus Serology-Based Screening Program on Nasopharyngeal Carcinoma Mortality: A Cluster-Randomized Controlled Trial,2025-01-01,,False,[],1,China,23,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Single or Double Induction With 7 + 3 Containing Standard or High-Dose Daunorubicin for Newly Diagnosed AML: The Randomized DaunoDouble Trial by the Study Alliance Leukemia,2025-01-01,daunorubicin,False,[],0,Germany,44,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Menin Inhibition With Revumenib for KMT2A-Rearranged Relapsed or Refractory Acute Leukemia (AUGMENT-101),2025-01-01,revumenib,True,"['Syndax', 'syndax']",1,USA,27,18,6,6,0,1,1,1,0,0,1,1,0,0,0,0
Inotuzumab Ozogamicin and Low-Intensity Chemotherapy in Older Patients With Newly Diagnosed CD22+ Philadelphia Chromosomeâ€“Negative B-Cell Precursor Acute Lymphoblastic Leukemia,2024-12-20,inotuzumab ozogamicin,True,"['Pfizer', 'Bristol Myers Squibb/Pfizer', 'Servier/Pfizer']",1,France,40,8,0,5,0,1,1,0,0,0,0,0,0,0,0,0
"Cediranib and Olaparib Combination Compared With Cediranib or Olaparib Alone, or Chemotherapy in Platinum-Resistant or Primary Platinum-Refractory Ovarian Cancer: NRG-GY005",2024-12-20,cediranib,True,"['AstraZeneca', 'AstraZeneca/Merck', 'AstraZeneca/MedImmune', 'AstraZeneca - Merck Alliance']",1,USA,24,9,0,5,0,2,0,1,0,0,0,0,0,0,0,0
PEARL: A Phase Ib/II Biomarker Study of Adding Radiation Therapy to Pembrolizumab Before Neoadjuvant Chemotherapy in Human Epidermal Growth Factor Receptor 2â€“Negative Breast Cancer,2024-12-20,pembrolizumab,True,['Merck'],0,USA,17,6,0,2,0,1,1,1,0,0,0,1,0,0,1,0
Atezolizumab Combined With Platinum and Maintenance Niraparib for Recurrent Ovarian Cancer With a Platinum-Free Interval >6 Months: ENGOT-OV41/GEICO 69-O/ANITA Phase III Trial,2024-12-20,atezolizumab,True,"['Roche/Genentech', 'Roche']",1,Spain,36,15,0,10,4,4,1,0,0,0,1,0,1,0,0,0
NeuroCARE: A Randomized Controlled Trial of a Psychological Intervention for Caregivers of Patients With Primary Malignant Brain Tumors,2024-12-20,,False,[],0,USA,13,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Darolutamide in Combination With Androgen-Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer From the Phase III ARANOTE Trial,2024-12-20,darolutamide,True,"['Bayer', 'Bayer Germany']",1,Canada,18,9,3,6,1,3,1,1,0,1,1,0,0,0,1,0
STRIvE-02: A First-in-Human Phase I Study of Systemically Administered B7-H3 Chimeric Antigen Receptor T Cells for Patients With Relapsed/Refractory Solid Tumors,2024-12-10,B7-H3 CAR T cells,False,[],0,USA,20,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Naldemedine for Opioid-Induced Constipation in Patients With Cancer: A Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial",2024-12-10,naldemedine,True,['Shionogi'],0,Japan,26,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0
"Imlunestrant, an Oral Selective Estrogen Receptor Degrader, as Monotherapy and in Combination With Targeted Therapy in Estrogen Receptorâ€“Positive, Human Epidermal Growth Factor Receptor 2â€“Negative Advanced Breast Cancer: Phase Ia/Ib EMBER Study",2024-12-10,imlunestrant,True,"['Eli Lilly/Loxo Oncology', 'Loxo@Lilly | Eli Lilly and Company', 'Lilly', 'Loxo/Lilly', 'Eli Lilly Kinsale Limited', 'Lilly Japan']",1,USA,38,31,7,12,4,3,1,1,0,0,1,0,0,0,0,0
"First Results of NURE-Combo: A Phase II Study of Neoadjuvant Nivolumab and Nab-Paclitaxel, Followed by Postsurgical Adjuvant Nivolumab, for Muscle-Invasive Bladder Cancer",2024-12-10,nivolumab,True,['Bristol Myers Squibb'],0,Italy,23,1,0,1,0,1,0,1,0,0,0,1,0,0,0,1
Radiotherapy Versus Transoral Robotic Surgery for Oropharyngeal Squamous Cell Carcinoma: Final Results of the ORATOR Randomized Trial,2024-12-01,,False,[],0,Canada,32,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Effect of Adding Electroacupuncture to Standard Triple Antiemetic Therapy on Chemotherapy-Induced Nausea and Vomiting: A Randomized Controlled Clinical Trial,2024-12-01,,False,[],0,China,25,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Bladder-Preserving Trimodality Treatment for High-Grade T1 Bladder Cancer: Results From Phase II Protocol NRG Oncology/RTOG 0926,2024-12-01,,False,[],0,USA,17,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Phase III KEYNOTE-789 Study of Pemetrexed and Platinum With or Without Pembrolizumab for Tyrosine Kinase Inhibitorâ€’Resistant, EGFRâ€“Mutant, Metastatic Nonsquamous Nonâ€“Small Cell Lung Cancer",2024-12-01,pembrolizumab,True,"['MSD', 'MSD Oncology', 'Merck Sharp & Dohme']",1,Taiwan,22,12,1,6,3,3,1,0,0,0,1,0,0,0,1,0
"US Food and Drug Administration Approval Summary: Capivasertib With Fulvestrant for Hormone Receptorâ€“Positive, Human Epidermal Growth Factor Receptor 2â€“Negative Locally Advanced or Metastatic Breast Cancer With PIK3CA/AKT1/PTEN Alterations",2024-12-01,capivasertib,False,[],0,USA,19,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Omission of Radiotherapy in Primary Mediastinal B-Cell Lymphoma: IELSG37 Trial Results,2024-12-01,,False,[],1,Italy,49,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Oral Cannabis Extract for Secondary Prevention of Chemotherapy-Induced Nausea and Vomiting: Final Results of a Randomized, Placebo-Controlled, Phase II/III Trial",2024-12-01,THC:CBD,False,[],0,Australia,24,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Primary Results of NRG-RTOG1106/ECOG-ACRIN 6697: A Randomized Phase II Trial of Individualized Adaptive (chemo)Radiotherapy Using Midtreatment 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Stage III Nonâ€“Small Cell Lung Cancer,2024-11-20,18F-fluorodeoxyglucose (FDG),False,[],1,China,27,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Final Overall Survival Analysis of S1500: A Randomized, Phase II Study Comparing Sunitinib With Cabozantinib, Crizotinib, and Savolitinib in Advanced Papillary Renal Cell Carcinoma",2024-11-20,cabozantinib,True,['Exelixis'],0,USA,23,10,0,8,2,1,1,1,0,0,1,0,0,0,0,0
"Phase I/Ib Trial of Inavolisib Plus Palbociclib and Endocrine Therapy for PIK3CA-Mutated, Hormone Receptorâ€“Positive, Human Epidermal Growth Factor Receptor 2â€“Negative Advanced or Metastatic Breast Cancer",2024-11-20,inavolisib,True,"['Roche/Genentech', 'Genentech/Roche', 'Genentech']",1,USA,23,20,8,6,0,1,1,1,0,0,1,1,0,0,0,0
Extent of Lymphadenectomy for Surgical Management of Right-Sided Colon Cancer: The Randomized Phase III RELARC Trial,2024-11-20,,False,[],0,China,31,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Oxaliplatin Added to Fluoropyrimidine/Bevacizumab as Initial Therapy for Unresectable Metastatic Colorectal Cancer in Older Patients: A Multicenter, Randomized, Open-Label Phase III Trial (JCOG1018)",2024-11-20,bevacizumab,True,"['Chugai/Roche', 'Chugai Pharma']",0,Japan,21,11,0,0,1,8,1,0,0,0,0,0,0,0,1,0
A Multicenter Phase II Trial of Ruxolitinib for Treatment of Corticosteroid Refractory Sclerotic Chronic Graft-Versus-Host Disease,2024-11-20,ruxolitinib,True,['Incyte'],0,USA,11,4,0,4,0,0,1,1,0,0,1,1,0,0,0,0
Long-Term Follow-Up of the Prospective Randomized AATT Study (Autologous or Allogeneic Transplantation in Patients With Peripheral T-Cell Lymphoma),2024-11-10,,False,[],1,France,43,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Addition of Metastasis-Directed Therapy to Systemic Therapy for Oligometastatic Pancreatic Ductal Adenocarcinoma (EXTEND): A Multicenter, Randomized Phase II Trial",2024-11-10,,False,[],0,USA,30,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Trastuzumab Deruxtecan in Advanced Solid Tumors With Human Epidermal Growth Factor Receptor 2 Amplification Identified by Plasma Cell-Free DNA Testing: A Multicenter, Single-Arm, Phase II Basket Trial",2024-11-10,trastuzumab deruxtecan,True,"['Daiichi Sankyo Company', 'Daiichi Sankyo', 'Daiichi Sankyo/UCB Japan', 'Daiichi Sankyo Co']",0,Japan,21,12,0,2,2,6,1,1,0,0,0,1,0,1,1,0
Adjuvant Pertuzumab and Trastuzumab in Early Human Epidermal Growth Factor Receptor 2â€“Positive Breast Cancer in the APHINITY Trial: Third Interim Overall Survival Analysis With Efficacy Update,2024-11-01,pertuzumab,True,"['Roche/Genentech', 'Genentech', 'Roche', 'F. Hoffmann-La Roche Ltd (support for third-party writing assistance)']",1,Germany,25,21,3,8,4,5,1,1,0,0,1,1,1,0,0,0
Outcomes With Postrecurrence Systemic Therapy Following Adjuvant Checkpoint Inhibitor Treatment for Resected Melanoma in CheckMate 238,2024-11-01,nivolumab,True,"['Bristol Myers Squibb/Pfizer', 'Bristol Myers Squibb', 'Bristol Myers Squibb/Roche', 'Bristol Myers Squibb/Medarex', 'Bristol Myers Squibb/Sanofi', 'Bristol Myers Squibb/Celgene']",1,USA,26,24,2,16,2,8,1,1,0,0,1,1,0,0,1,1
"Devimistat (CPI-613) With Modified Fluorouarcil, Oxaliplatin, Irinotecan, and Leucovorin (FFX) Versus FFX for Patients With Metastatic Adenocarcinoma of the Pancreas: The Phase III AVENGER 500 Study",2024-11-01,devimistat,True,['Rafael Pharmaceuticals'],1,USA,21,10,1,3,0,1,1,0,0,0,0,0,0,0,1,0
"Vebreltinib for Advanced Nonâ€“Small Cell Lung Cancer Harboring c-Met Exon 14 Skipping Mutation: A Multicenter, Single-Arm, Phase II KUNPENG Study",2024-11-01,vebreltinib,True,['Beijing Pearl Biotechnology Co'],0,China,23,4,4,0,0,0,0,0,0,0,0,0,0,0,0,0
"Open-Label, Multicenter, Phase I/II, First-in-Human Trial of TK216: A First-Generation EWS::FLI1 Fusion Protein Antagonist in Ewing Sarcoma",2024-11-01,TK216,True,['Oncternal Therapeutics'],0,USA,14,5,2,0,0,0,0,0,0,0,0,0,0,0,0,0
Adjuvant Trastuzumab Emtansine Versus Paclitaxel Plus Trastuzumab for Stage I Human Epidermal Growth Factor Receptor 2â€“Positive Breast Cancer: 5-Year Results and Correlative Analyses From ATEMPT,2024-11-01,trastuzumab emtansine (T-DM1),True,"['Hoffmann-La Roche AG/Genentech', 'Genentech', 'Roche/Genentech', 'ROCHE/Genentech', 'Genentech/Roche', 'Roche']",1,USA,51,21,0,9,2,2,1,1,0,0,1,1,0,0,0,0
Menopausal Hormone Therapy and Ovarian and Endometrial Cancers: Long-Term Follow-Up of the Women's Health Initiative Randomized Trials,2024-10-20,conjugated equine estrogen,False,"['release and nanoscale heat treatment of cancerous cellsâ€""]), (']",0,USA,12,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Randomized Controlled Trial of a Nurse-Led Brief Behavioral Intervention for Dyspnea in Patients With Advanced Lung Cancer,2024-10-20,,False,[],0,USA,15,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Utility of the 70-Gene MammaPrint Assay for Prediction of Benefit From Extended Letrozole Therapy in the NRG Oncology/NSABP B-42 Trial,2024-10-20,MammaPrint,True,['Agendia'],1,USA,18,5,4,1,0,0,0,1,0,1,0,0,0,0,0,0
Estrogen Plus Progestin and Colorectal Cancer: Long-Term Findings From the Women's Health Initiative Randomized Clinical Trial,2024-10-20,conjugated equine estrogen (CEE) plus medroxyprogesterone acetate (MPA),True,['Pfizer'],0,USA,12,1,0,1,0,0,1,0,0,0,1,0,0,0,0,0
"Subcutaneous Versus Intravenous Amivantamab, Both in Combination With Lazertinib, in Refractory Epidermal Growth Factor Receptorâ€“Mutated Nonâ€“Small Cell Lung Cancer: Primary Results From the Phase III PALOMA-3 Study",2024-10-20,amivantamab,True,"['Johnson and Johnson', 'Johnson & Johnson', 'Jonhson and Johnson', 'Johnson & Johnson/Janssen']",1,Canada,49,14,9,3,1,1,0,1,0,0,0,1,0,1,0,0
Results From First-in-Human Phase I Dose-Escalation Study of a Novel Bicycle Toxin Conjugate Targeting EphA2 (BT5528) in Patients With Advanced Solid Tumors,2024-10-10,BT5528,True,['Bicycle Therapeutics'],1,USA,19,13,7,1,0,0,1,1,0,0,0,0,0,0,0,0
Sustained Clinical Benefit and Intracranial Activity of Tarlatamab in Previously Treated Small Cell Lung Cancer: DeLLphi-300 Trial Update,2024-10-10,tarlatamab,False,[],1,USA,20,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
TROPHY-U-01 Cohort 2: A Phase II Study of Sacituzumab Govitecan in Cisplatin-Ineligible Patients With Metastatic Urothelial Cancer Progressing After Previous Checkpoint Inhibitor Therapy,2024-10-10,Sacituzumab govitecan,True,"['Gilead Sciences', 'Patent Royalty from Immunomedics/Gilead']",0,USA,19,15,3,7,2,1,1,1,0,0,1,1,0,0,0,0
Efficacy and Safety of Sacituzumab Govitecan in Patients With Advanced Solid Tumors (TROPiCS-03): Analysis in Patients With Advanced Endometrial Cancer,2024-10-10,sacituzumab govitecan,True,"['Immunomedics', 'Immunomedics/Gilead', 'Gilead Sciences']",0,USA,12,8,3,0,0,0,1,1,0,0,0,0,0,0,0,0
Evaluation of CD3 and CD8 T-Cell Immunohistochemistry for Prognostication and Prediction of Benefit From Adjuvant Chemotherapy in Early-Stage Colorectal Cancer Within the QUASAR Trial,2024-10-10,fluorouracil,False,[],0,United Kingdom,25,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Safety, Efficacy, and Pharmacokinetics of SHR-A1811, a Human Epidermal Growth Factor Receptor 2â€“Directed Antibody-Drug Conjugate, in Human Epidermal Growth Factor Receptor 2â€“Expressing or Mutated Advanced Solid Tumors: A Global Phase I Trial",2024-10-10,SHR-A1811,True,"['Hengrui Pharmaceutical', 'Jiangsu Hengrui Pharmaceuticals']",1,China,33,5,4,0,0,0,0,1,0,1,0,0,0,0,0,0
Lorlatinib Versus Crizotinib in Patients With Advanced ALK-Positive Nonâ€“Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study,2024-10-10,Lorlatinib,True,['Pfizer'],1,Australia,18,17,7,8,2,5,1,1,0,0,1,1,0,0,1,0
Personalized Chemotherapy on the Basis of Tumor Marker Decline in Poor-Prognosis Germ-Cell Tumors: Updated Analysis of the GETUG-13 Phase III Trial,2024-10-01,"bleomycin, etoposide, cisplatin (BEP)",False,[],1,France,20,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Longitudinal Health-Related Quality of Life Among Patients With High-Risk Pediatric Hodgkin Lymphoma Treated on the Children's Oncology Group AHOD 1331 Study,2024-10-01,brentuximab vedotin,True,['Seagen'],0,USA,9,4,0,2,0,0,1,1,0,0,0,1,0,0,0,0
Randomized Phase II Trial of Immunotherapy-Based Total Neoadjuvant Therapy for Proficient Mismatch Repair or Microsatellite Stable Locally Advanced Rectal Cancer (TORCH),2024-10-01,toripalimab,False,[],0,China,36,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Trastuzumab Deruxtecan in Human Epidermal Growth Factor Receptor 2â€“Expressing Biliary Tract Cancer (HERB; NCCH1805): A Multicenter, Single-Arm, Phase II Trial",2024-09-20,trastuzumab deruxtecan,True,"['Daiichi Sankyo RD Novare', 'Daiichi Sankyo Company', 'Daiichi Sankyo', 'Daiichi Sankyo/UCB Japan', 'Daiichi Sankyo Co']",0,Japan,20,11,0,2,1,6,0,1,0,0,0,0,0,0,0,1
"Bevacizumab Erlotinib Switch Maintenance in Chemo-Responsive Advanced Gallbladder and Cholangiocarcinoma (BEER BTC): A Multicenter, Open-Label, Randomized, Phase II Trial",2024-09-20,bevacizumab,False,[],0,India,19,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Durability of Response With Selpercatinib in Patients With RET-Activated Thyroid Cancer: Long-Term Safety and Efficacy From LIBRETTO-001,2024-09-20,selpercatinib,True,"['Loxo', 'Lilly', 'LOXO', 'Loxo/Lilly', 'Loxo/Bayer/Lilly']",1,USA,17,15,4,11,1,3,1,1,0,0,1,0,0,0,0,0
Pertuzumab Plus Trastuzumab in Patients With Biliary Tract Cancer With ERBB2/3 Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study,2024-09-20,pertuzumab-trastuzumab,True,['Genentech/Roche'],0,USA,24,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0
Neoadjuvant Osimertinib for the Treatment of Stage I-IIIA Epidermal Growth Factor Receptorâ€“Mutated Nonâ€“Small Cell Lung Cancer: A Phase II Multicenter Study,2024-09-10,osimertinib,True,"['AstraZeneca/MedImmune', 'AstraZeneca', 'Daiichi Sankyo/Astra Zeneca']",0,USA,24,8,0,4,0,4,1,0,0,0,0,0,0,0,0,0
Tailored Dose-Dense Versus Standard Adjuvant Chemotherapy for High-Risk Early Breast Cancer: End-of-Study Results of the Randomized PANTHER Trial,2024-09-10,docetaxel,True,"['Sanofi', 'Sanofi Aventis GmbH']",1,Sweden,17,4,0,1,0,1,0,1,0,0,0,0,0,0,0,0
Dendritic Cellâ€“Based Immunotherapy in Patients With Resected Pancreatic Cancer,2024-09-10,autologous dendritic cell-based immunotherapy,True,['Amphera'],0,the Netherlands,15,2,1,1,0,0,1,0,1,0,0,0,0,0,0,0
Scalp Cooling in Preventing Persistent Chemotherapy-Induced Alopecia: A Randomized Controlled Trial,2024-09-10,scalp cooling,True,['Nokwon Medical'],0,Republic of Korea,12,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1
Nanoliposomal Irinotecan With Fluorouracil and Leucovorin or Gemcitabine Plus Cisplatin in Advanced Cholangiocarcinoma: A Phase II Study of the AIO Hepatobiliary-YMO Cancer Groups (NIFE-AIO-YMO HEP-0315),2024-09-10,nal-IRI/FU/LV,True,['Servier'],0,Germany,25,6,0,5,1,2,1,1,0,0,1,1,0,0,0,0
Pembrolizumab Plus Carboplatin and Paclitaxel as First-Line Therapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-B10): A Single-Arm Phase IV Trial,2024-09-01,pembrolizumab,True,"['Merck', 'MSD', 'Merck Serono', 'Merck Sharp & Dohme']",1,Australia,22,11,4,7,3,3,1,1,0,0,1,1,0,1,1,1
"Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer: Updated Overall Survival Outcomes From Phase III PRODIGY",2024-09-01,S-1,True,['Taiho Pharmaceutical'],0,Republic of Korea,35,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0
Final Results From a Phase I Trial and Expansion Cohorts of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced/Metastatic Genitourinary Tumors,2024-09-01,cabozantinib,True,['Exelixis'],0,USA,40,2,0,2,0,0,0,0,0,0,0,0,0,0,0,0
Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Proteinâ€“Overexpressing Advanced Nonsquamous EGFR-Wildtype Nonâ€“Small Cell Lung Cancer in the Phase II LUMINOSITY Trial,2024-09-01,Telisotuzumab vedotin,True,['Seagen'],1,USA,33,3,0,2,0,1,1,0,0,0,0,0,0,0,1,0
"Phase III Randomized, Placebo-Controlled Trial of Endocrine Therapy Â± 1 Year of Everolimus in Patients With High-Risk, Hormone Receptorâ€“Positive, Early-Stage Breast Cancer",2024-09-01,everolimus,True,['Novartis'],0,USA,22,8,0,4,1,1,1,1,0,0,0,1,0,0,0,0
"Neoadjuvant Chemotherapy With Oxaliplatin and Fluoropyrimidine Versus Upfront Surgery for Locally Advanced Colon Cancer: The Randomized, Phase III OPTICAL Trial",2024-09-01,oxaliplatin,False,[],0,China,51,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Phase I Study of Fianlimab, a Human Lymphocyte Activation Gene-3 (LAG-3) Monoclonal Antibody, in Combination With Cemiplimab in Advanced Melanoma",2024-08-20,fianlimab,True,"['Regeneron', 'Sanofi/Regeneron']",1,USA,32,27,15,7,2,2,1,1,0,1,1,0,1,0,1,0
Improved Survival With Adjuvant Cyclooxygenase 2 Inhibition in PIK3CA-Activated Stage III Colon Cancer: CALGB/SWOG 80702 (Alliance),2024-08-20,celecoxib,True,['Pfizer'],1,USA,22,2,0,1,0,0,0,0,0,0,0,0,0,0,0,0
"Sacituzumab Govitecan Versus Docetaxel for Previously Treated Advanced or Metastatic Nonâ€“Small Cell Lung Cancer: The Randomized, Open-Label Phase III EVOKE-01 Study",2024-08-20,sacituzumab govitecan,True,['Gilead Sciences'],1,Spain,18,7,3,3,0,0,0,1,0,0,0,1,0,0,0,0
"Lenvatinib Plus Pembrolizumab Versus Standard of Care for Previously Treated Metastatic Colorectal Cancer: Final Analysis of the Randomized, Open-Label, Phase III LEAP-017 Study",2024-08-20,lenvatinib,True,['Eisai'],1,Japan,22,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Adjunctive Statistical Standardization of Adjuvant Estrogen Receptor and Progesterone Receptor in Canadian Cancer Trials Group MA.27 Postmenopausal Breast Cancer Trial of Exemestane Versus Anastrozole,2024-08-20,exemestane,False,['NanoString Technologies'],1,Canada,26,2,0,0,0,1,0,0,0,0,0,0,0,0,0,0
Bempegaldesleukin Plus Nivolumab Versus Sunitinib or Cabozantinib in Previously Untreated Advanced Clear Cell Renal Cell Carcinoma: A Phase III Randomized Study (PIVOT-09),2024-08-10,bempegaldesleukin,True,['Nektar'],1,USA,15,10,4,2,0,3,1,0,0,0,1,0,0,0,1,0
"Olanzapine Plus Triple Antiemetic Therapy for the Prevention of Carboplatin-Induced Nausea and Vomiting: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial",2024-08-10,olanzapine,True,['Lilly'],0,Japan,29,4,0,0,1,2,1,0,0,0,0,0,1,0,0,0
Phase II Efficacy and Safety of 80 mg Osimertinib in Patients With Leptomeningeal Metastases Associated With Epidermal Growth Factor Receptor Mutationâ€“Positive Nonâ€“Small Cell Lung Cancer (BLOSSOM),2024-08-10,osimertinib,True,"['AstraZeneca/MedImmune', 'Daiichi Sankyo/Astra Zeneca', 'Daiichi Sankyo/AstraZeneca', 'AstraZeneca']",0,Republic of Korea,18,6,1,5,0,4,1,1,1,0,0,1,0,0,0,1
LACC Trial: Final Analysis on Overall Survival Comparing Open Versus Minimally Invasive Radical Hysterectomy for Early-Stage Cervical Cancer,2024-08-10,,False,[],1,USA,15,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Patient-Reported Outcomes From the Phase III HIMALAYA Study of Tremelimumab Plus Durvalumab in Unresectable Hepatocellular Carcinoma,2024-08-10,durvalumab,True,"['AstraZeneca/MedImmune', 'AstraZeneca']",1,Spain,16,14,4,7,2,4,1,1,0,0,1,1,1,0,0,0
Final Results of RIGHT Choice: Ribociclib Plus Endocrine Therapy Versus Combination Chemotherapy in Premenopausal Women With Clinically Aggressive Hormone Receptorâ€“Positive/Human Epidermal Growth Factor Receptor 2â€“Negative Advanced Breast Cancer,2024-08-10,ribociclib,True,"['Novartis', 'Sandoz-Novartis']",1,Taiwan,22,15,5,10,4,9,1,1,0,0,1,0,0,0,1,1
Phase I Trial of GD2.CART Cells Augmented With Constitutive Interleukin-7 Receptor for Treatment of High-Grade Pediatric CNS Tumors,2024-08-10,GD2.CARTs,False,[],0,USA,33,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Minimal Residual Disease Status in Multiple Myeloma 1 Year After Autologous Hematopoietic Cell Transplantation and Lenalidomide Maintenance Are Associated With Long-Term Overall Survival,2024-08-10,lenalidomide,True,"['Bristol Myers Squibb', 'Bristol Myers Squibb/Celgene', 'BMS']",0,USA,23,7,0,3,1,1,1,0,0,0,1,0,0,0,0,0
"Randomized Phase III Study of Amcenestrant Plus Palbociclib Versus Letrozole Plus Palbociclib in Estrogen Receptorâ€“Positive, Human Epidermal Growth Factor Receptor 2â€“Negative Advanced Breast Cancer: Primary Results From AMEERA-5",2024-08-01,amcenestrant,True,"['Sanofi', 'sanofi', 'Patent for new drug developed by Sanofi']",1,Spain,16,11,6,3,0,1,0,1,0,0,0,1,0,0,0,0
Linvoseltamab for Treatment of Relapsed/Refractory Multiple Myeloma,2024-08-01,linvoseltamab,True,"['Regeneron', 'Sanofi/Regeneron', 'Multiple patents assigned to regeneron (no personal compensation related to patents above employment)']",1,USA,32,21,10,6,0,0,0,0,0,0,0,0,0,0,0,0
"Upfront Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Bevacizumab With or Without Atezolizumab for Patients With Metastatic Colorectal Cancer: Updated and Overall Survival Results of the ATEZOTRIBE Study",2024-08-01,atezolizumab,True,['Roche'],0,Italy,27,6,0,3,1,2,0,1,0,0,0,1,0,0,0,1
Efficacy and Safety of Taletrectinib in Chinese Patients With ROS1+ Nonâ€“Small Cell Lung Cancer: The Phase II TRUST-I Study,2024-08-01,Taletrectinib,True,"['AnHeart Therapeutics Ltd', 'AnHeart Therapeutics']",0,China,20,4,2,0,0,2,1,1,1,0,0,0,0,0,0,1
Impact of Propofol Exposure on Neurocognitive Outcomes in Children With High-Risk B ALL: A Children's Oncology Group Study,2024-08-01,propofol,False,[],0,Canada,17,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CNS Protective Effect of Selpercatinib in First-Line RET Fusion-Positive Advanced Nonâ€“Small Cell Lung Cancer,2024-07-20,selpercatinib,True,['Loxo'],1,France,14,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Safety and Efficacy of CT041 in Patients With Refractory Metastatic Pancreatic Cancer: A Pooled Analysis of Two Early-Phase Trials,2024-07-20,CT041,True,"['CARsgen Therapeutics', 'CARsgen Therapeutics Co']",0,China,19,5,5,0,0,0,0,0,0,0,0,0,0,0,0,0
Phase I/II Study of a Vascular Endothelial Growth Factor Receptor Vaccine in Patients With NF2-Related Schwannomatosis,2024-07-20,VEGFR1 and VEGFR2 peptide vaccine,True,['OncoTherapy Science'],0,Japan,19,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0
Phase I and Randomized Phase II Study of Ruxolitinib With Frontline Neoadjuvant Therapy in Advanced Ovarian Cancer: An NRG Oncology Group Study,2024-07-20,ruxolitinib,False,[],0,USA,18,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Phase III Randomized, Placebo-Controlled Clinical Trial of Donepezil for Treatment of Cognitive Impairment in Breast Cancer Survivors After Adjuvant Chemotherapy (WF-97116)",2024-07-20,donepezil,False,[],0,USA,11,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Elective Pelvic Lymph Node Radiation Therapy and the Risk of Death in Patients With Unfavorable-Risk Prostate Cancer: A Postrandomization Analysis,2024-07-20,docetaxel,False,['Nanocan Therapeutics'],0,USA,8,1,0,1,0,0,0,1,0,0,0,1,0,0,0,0
Long-Term Analysis of NRG Oncology RTOG 0415: A Randomized Phase III Noninferiority Study Comparing Two Fractionation Schedules in Patients With Low-Risk Prostate Cancer,2024-07-10,,False,['Nanocan Therapeutics'],0,USA,18,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
"Methylphenidate Versus Placebo for Treating Fatigue in Patients With Advanced Cancer: Randomized, Double-Blind, Multicenter, Placebo-Controlled Trial",2024-07-10,methylphenidate,False,[],0,United Kingdom,7,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Capecitabine or Capecitabine Plus Oxaliplatin Versus Fluorouracil Plus Cisplatin in Definitive Concurrent Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma (CRTCOESC): A Multicenter, Randomized, Open-Label, Phase 3 Trial",2024-07-10,capecitabine,False,[],0,China,38,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Phase Ib Study of Unesbulin (PTC596) Plus Dacarbazine for the Treatment of Locally Recurrent, Unresectable or Metastatic, Relapsed or Refractory Leiomyosarcoma",2024-07-10,unesbulin,True,['Bionaut Labs'],0,USA,13,1,0,1,0,0,0,1,0,0,0,1,0,0,0,0
Radiation Therapy With or Without Cisplatin for Local Recurrences of Endometrial Cancer: Results From an NRG Oncology/GOG Prospective Randomized Multicenter Clinical Trial,2024-07-10,cisplatin,False,[],0,USA,20,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CONTACT-01: A Randomized Phase III Trial of Atezolizumab + Cabozantinib Versus Docetaxel for Metastatic Nonâ€“Small Cell Lung Cancer After a Checkpoint Inhibitor and Chemotherapy,2024-07-10,cabozantinib,True,['Exelixis'],1,USA,22,3,2,1,0,0,1,0,0,0,1,0,0,0,0,0
Datopotamab Deruxtecan in Advanced or Metastatic HR+/HER2â€“ and Triple-Negative Breast Cancer: Results From the Phase I TROPION-PanTumor01 Study,2024-07-01,datopotamab deruxtecan,True,"['AstraZeneca/Daiichi Sankyo', 'Daiichi Sankyo Europe GmbH', 'Daiichi Sankyo', 'Daiichi Dankyo', 'Daiichi Sankyo Nordics', 'Daiichi Sankyo Co.', 'Daiichi Sankyo/Astra Zeneca']",1,USA,20,15,5,9,0,2,1,1,0,0,1,1,0,0,0,0
"RESILIENT Part 2: A Randomized, Open-Label Phase III Study of Liposomal Irinotecan Versus Topotecan in Adults With Relapsed Small Cell Lung Cancer",2024-07-01,liposomal irinotecan,True,['Ipsen'],1,USA,18,8,4,2,0,0,1,1,0,0,1,1,0,0,0,0
"Phase II, Single-Arm Trial of Induction and Concurrent Vismodegib With Curative-Intent Radiation Therapy for Locally Advanced, Unresectable Basal Cell Carcinoma",2024-07-01,vismodegib,True,"['Genentech/Roche', 'Genentech', 'Husband has patents related to his employment at Genentech/Roche']",0,USA,11,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Durable Responses With Mosunetuzumab in Relapsed/Refractory Indolent and Aggressive B-Cell Non-Hodgkin Lymphomas: Extended Follow-Up of a Phase I/II Study,2024-07-01,mosunetuzumab,True,"['Roche/Genentech', 'Genentech/Roche', 'Roche', 'Genentech']",1,USA,20,19,4,10,1,7,1,1,0,0,1,1,0,0,0,0
Mitoxantrone Versus Liposomal Daunorubicin in Induction of Pediatric AML With Risk Stratification Based on Flow Cytometry Measurement of Residual Disease,2024-06-20,liposomal daunorubicin,True,['Jazz Pharmaceuticals'],1,Canada,18,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Electronic Patient-Reported Outcomeâ€“Based Symptom Management Versus Usual Care After Lung Cancer Surgery: Long-Term Results of a Multicenter, Randomized, Controlled Trial",2024-06-20,,False,[],1,China,33,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Giredestrant for Estrogen Receptorâ€“Positive, HER2-Negative, Previously Treated Advanced Breast Cancer: Results From the Randomized, Phase II acelERA Breast Cancer Study",2024-06-20,giredestrant,True,"['Roche/Genentech', 'Genentech/Roche', 'F. Hoffmann-La Roche Ltd/Genentech', 'Genentech', 'Roche', 'F. Hoffmann-La Roche Ltd']",1,Spain,22,19,7,4,3,3,1,1,0,0,1,0,1,0,1,0
Targeting Molecular Measurable Residual Disease and Low-Blast Relapse in AML With Venetoclax and Low-Dose Cytarabine: A Prospective Phase II Study (VALDAC),2024-06-20,venetoclax,True,"['AbbVie', 'AbbVie/Genentech']",0,Australia,20,11,0,7,3,5,1,1,0,0,1,1,0,1,0,1
First-Line Nivolumab and Relatlimab Plus Chemotherapy for Gastric or Gastroesophageal Junction Adenocarcinoma: The Phase II RELATIVITY-060 Study,2024-06-10,nivolumab,True,"['Bristol Myers Squibb Argentina', 'Bristol Myers Squibb', 'Inventor of pending BMS patents', 'Bristol Myers Squibb/Medarex', 'Bristol Myers Squibb/Celgene', 'Bristol Myers Squibb GmbH & Co KG']",1,Germany,19,15,6,9,5,3,1,1,0,0,1,1,1,0,0,1
Randomized Controlled Trial of Virtually Delivered Cognitive Behavioral Therapy for Insomnia to Address Perceived Cancer-Related Cognitive Impairment in Cancer Survivors,2024-06-10,,False,[],0,USA,9,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Randomized, Double-Blind Phase III Study of Pazopanib Versus Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease After Metastasectomy: ECOG-ACRIN E2810",2024-06-10,pazopanib,True,"['GlaxoSmithKline', 'GlaxoSmithKline/Novartis']",0,USA,18,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"PACE: A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab After Progression on Cyclin-Dependent Kinase 4/6 Inhibitor and Aromatase Inhibitor for Hormone Receptorâ€“Positive/Human Epidermal Growth Factor Receptorâ€“Negative Metastatic Breast Cancer",2024-06-10,palbociclib,True,['Pfizer'],0,USA,29,12,2,7,0,1,0,1,0,0,0,1,0,0,0,0
"Reduced-Volume Irradiation of Uninvolved Neck in Patients With Nasopharyngeal Cancer: Updated Results From an Open-Label, Noninferiority, Multicenter, Randomized Phase III Trial",2024-06-10,,False,[],0,China,19,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Nurse-Led Individualized Follow-Up Versus Regular Physician-Led Visits After Early Breast Cancer (MyHealth): A Phase III Randomized, Controlled Trial",2024-06-10,,False,[],0,Denmark,15,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"First-Line Nivolumab Plus Chemotherapy for Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: 3-Year Follow-Up of the Phase III CheckMate 649 Trial",2024-06-10,nivolumab,True,"['Bristol Myers Squibb GmbH & Co', 'BMS Bristol Myers Squibb Argentina', 'Bristol Myers Squibb Argentina', 'Bristol Myers Squibb', 'Bristol Myers Squibb Japan', 'Inventor of pending BMS patents', 'BMS Bristol Myers Squibb', 'Bristol Myers Squibb/Medarex', 'Bristol Myers Squibb/Celgene']",1,USA,26,21,3,11,6,7,1,1,0,0,1,1,0,0,1,1
"Phase II Trial of Cisplatin, Gemcitabine, and Intensity-Modulated Radiation Therapy for Locally Advanced Vulvar Squamous Cell Carcinoma: NRG Oncology/GOG Study 279",2024-06-01,cisplatin,False,[],0,USA,17,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
HER2 Gene Expression Levels Are Predictive and Prognostic in Patients With Metastatic Colorectal Cancer Enrolled in CALGB/SWOG 80405,2024-06-01,bevacizumab,False,[],0,USA,14,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Laparoscopic Versus Open Hemihepatectomy: The ORANGE II PLUS Multicenter Randomized Controlled Trial,2024-05-20,,False,[],1,the Netherlands,36,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Gilteritinib as Post-Transplant Maintenance for AML With Internal Tandem Duplication Mutation of FLT3,2024-05-20,gilteritinib,True,['Astellas Pharma'],1,USA,40,17,6,7,2,4,1,1,0,0,1,1,0,0,0,0
US Food and Drug Administration Approval Summary: Talazoparib in Combination With Enzalutamide for Treatment of Patients With Homologous Recombination Repair Gene-Mutated Metastatic Castration-Resistant Prostate Cancer,2024-05-20,talazoparib,True,['Astellas Pharma'],1,USA,22,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0
Final Results From the Randomized Phase III ASCENT Clinical Trial in Metastatic Triple-Negative Breast Cancer and Association of Outcomes by Human Epidermal Growth Factor Receptor 2 and Trophoblast Cell Surface Antigen 2 Expression,2024-05-20,sacituzumab govitecan,True,"['Gilead Sciences', 'Immunomedics/Gilead']",1,USA,20,18,4,10,0,7,1,1,0,0,1,0,0,0,0,0
Topical Diclofenac for Prevention of Capecitabine-Associated Hand-Foot Syndrome: A Double-Blind Randomized Controlled Trial,2024-05-20,capecitabine,False,[],0,India,18,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Effectiveness of Endoscopic Screening on Esophageal Cancer Incidence and Mortality: A 9-Year Report of the Endoscopic Screening for Esophageal Cancer in China (ESECC) Randomized Trial,2024-05-10,Lugol's solution,False,[],0,China,20,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Pembrolizumab Versus Placebo as Adjuvant Therapy in Resected Stage IIB or IIC Melanoma: Final Analysis of Distant Metastasis-Free Survival in the Phase III KEYNOTE-716 Study,2024-05-10,pembrolizumab,True,"['a subsidiary of Merck & Co', 'Merck & Co', 'MSD', 'Merck Sharp & Dohme LLC', 'MSD Oncology']",1,USA,20,18,6,16,2,7,1,1,0,0,1,1,0,0,0,0
"Romidepsin Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Versus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Final Analysis of the Ro-CHOP Trial",2024-05-10,romidepsin,True,"['Bristol Myers Squibb/Celgene', 'Celgene', 'Celgene/Bristol Myers Squibb']",1,France,33,8,1,3,0,5,1,0,0,0,0,0,0,0,1,0
Continuous PEGasparaginase Dosing Reduces Hypersensitivity Reactions in Pediatric ALL: A Dutch Childhood Oncology Group ALL11 Randomized Trial,2024-05-10,PEGasparaginase,True,['Jazz Pharmaceuticals'],0,the Netherlands,11,2,0,1,0,1,1,1,0,0,1,1,0,0,0,1
Phase II Trial of nab-Sirolimus in Patients With Advanced Malignant Perivascular Epithelioid Cell Tumors (AMPECT): Long-Term Efficacy and Safety Update,2024-05-01,nab-sirolimus,True,"['AADI', 'Aadi', 'AADi']",0,USA,15,12,3,6,0,0,1,1,0,0,1,0,0,0,0,0
Primary Tumor Resection Before Systemic Therapy in Patients With Colon Cancer and Unresectable Metastases: Combined Results of the SYNCHRONOUS and CCRe-IV Trials,2024-05-01,,False,[],0,Germany,19,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Improved Disease-Free Survival With Adjuvant Chemotherapy After Nephroureterectomy for Upper Tract Urothelial Cancer: Final Results of the POUT Trial,2024-05-01,cisplatin,False,[],0,United Kingdom,17,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Single-Agent Trabectedin Versus Physician's Choice Chemotherapy in Patients With Recurrent Ovarian Cancer With BRCA-Mutated and/or BRCAness Phenotype: A Randomized Phase III Trial,2024-05-01,trabectedin,True,['PharmaMar'],0,Italy,23,5,0,3,1,2,1,1,0,0,1,1,1,0,0,0
"Azacitidine, Venetoclax, and Gilteritinib in Newly Diagnosed and Relapsed or Refractory FLT3-Mutated AML",2024-05-01,gilteritinib,True,"['Astellas Pharma', 'Astellas Pharma Inc']",0,USA,24,8,0,4,0,4,1,1,0,0,0,1,0,0,1,1
Sacituzumab Govitecan in Combination With Pembrolizumab for Patients With Metastatic Urothelial Cancer That Progressed After Platinum-Based Chemotherapy: TROPHY-U-01 Cohort 3,2024-04-20,sacituzumab govitecan,True,"['Patent Royalty from Immunomedics/Gilead', 'Gilead Sciences']",0,USA,20,14,3,6,1,3,1,1,0,0,1,0,0,0,0,0
Patient-Reported Outcomes in Patients With Advanced Urothelial Cancer Who Are Ineligible for Cisplatin and Treated With First-Line Enfortumab Vedotin Alone or With Pembrolizumab,2024-04-20,enfortumab vedotin,True,"['Seagen', 'Seattle Genetics/Astellas', 'Astellas Pharma', 'Astellas Scientific and Medical Affairs Inc', 'Astellas Medivation']",1,USA,23,18,5,11,4,6,1,1,0,0,0,1,0,0,0,0
Streptococcus salivarius K12 Alleviates Oral Mucositis in Patients Undergoing Radiotherapy for Malignant Head and Neck Tumors: A Randomized Controlled Trial,2024-04-20,Streptococcus salivarius K12 (SsK12),False,[],0,China,8,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Efficacy and Safety of Disitamab Vedotin in Patients With Human Epidermal Growth Factor Receptor 2â€“Positive Locally Advanced or Metastatic Urothelial Carcinoma: A Combined Analysis of Two Phase II Clinical Trials,2024-04-20,disitamab vedotin,True,"['RemeGen Biosciences Inc', 'RemeGen Co. Ltd', 'RemeGen']",0,China,22,2,1,0,1,0,1,0,0,0,0,0,1,0,0,0
"Patient-Reported Outcomes in OlympiA: A Phase III, Randomized, Placebo-Controlled Trial of Adjuvant Olaparib in gBRCA1/2 Mutations and High-Risk Human Epidermal Growth Factor Receptor 2â€“Negative Early Breast Cancer",2024-04-10,olaparib,False,[],1,USA,46,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Nivolumab Plus Chemotherapy in Epidermal Growth Factor Receptorâ€“Mutated Metastatic Nonâ€“Small-Cell Lung Cancer After Disease Progression on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Final Results of CheckMate 722,2024-04-10,nivolumab,True,"['Bristol Myers Squibb/China', 'Bristol Myers Squibb', 'Bristol Myers Squibb Japan', 'Bristol Myers Squibb Company', 'Bristol Myers Squibb/Celgene', 'BMS', 'Bristol Myers Squibb K.K']",1,China,23,15,2,7,2,6,1,1,0,0,1,1,0,0,1,1
"Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study",2024-04-10,lenvatinib,True,"['Eisai', 'Ezai Co', 'EISAI']",1,USA,37,26,2,19,5,9,1,1,0,0,1,1,0,0,0,1
"Fluorouracil, Leucovorin, and Irinotecan Plus Cetuximab Versus Cetuximab as Maintenance Therapy in First-Line Therapy for RAS and BRAF Wild-Type Metastatic Colorectal Cancer: Phase III ERMES Study",2024-04-10,cetuximab,True,"['Merck Serono', 'Merck', 'Merck KGaA']",0,Italy,20,7,0,4,0,1,1,1,0,0,0,0,0,0,0,0
"Phase III, Randomized Study of Atezolizumab Plus Bevacizumab and Chemotherapy in Patients With EGFR- or ALK-Rearranged or Translocated Nonâ€“Small-Cell Lung Cancer (ATTLAS, KCSG-LU19-04)",2024-04-10,atezolizumab,True,"['Roche/Genentech', 'Roche']",0,Korea,24,4,0,2,0,2,1,0,0,0,0,0,0,0,0,0
"US Food and Drug Administration Approval Summary: Elacestrant for Estrogen Receptorâ€“Positive, Human Epidermal Growth Factor Receptor 2â€“Negative, ESR1-Mutated Advanced or Metastatic Breast Cancer",2024-04-01,elacestrant,False,[],0,USA,28,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"PRESTO: A Phase III, Open-Label Study of Intensification of Androgen Blockade in Patients With High-Risk Biochemically Relapsed Castration-Sensitive Prostate Cancer (AFT-19)",2024-04-01,apalutamide,True,"['Janssen', 'Janssen-Ortho', 'Janssen Oncology']",0,USA,24,10,0,6,0,4,1,1,0,0,1,0,0,0,0,0
"Fludarabine, Cytarabine, Granulocyte Colony-Stimulating Factor, and Idarubicin With Gemtuzumab Ozogamicin Improves Event-Free Survival in Younger Patients With Newly Diagnosed AML and Overall Survival in Patients With NPM1 and FLT3 Mutations",2024-04-01,gemtuzumab ozogamicin,True,['Pfizer'],1,United Kingdom,19,5,0,2,0,3,1,0,0,0,0,0,0,0,1,0
Secondary Analysis of the Rate of Second Primary Lung Cancer From Cancer and Leukemia Group B 140503 (Alliance) Trial of Lobar Versus Sublobar Resection for T1aN0 Nonâ€“Small-Cell Lung Cancer,2024-04-01,,False,[],0,USA,16,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Bevacizumab, Irinotecan, or Topotecan Added to Temozolomide for Children With Relapsed and Refractory Neuroblastoma: Results of the ITCC-SIOPEN BEACON-Neuroblastoma Trial",2024-04-01,bevacizumab,False,[],1,Spain,48,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Lisocabtagene Maraleucel in Relapsed/Refractory Mantle Cell Lymphoma: Primary Analysis of the Mantle Cell Lymphoma Cohort From TRANSCEND NHL 001, a Phase I Multicenter Seamless Design Study",2024-04-01,lisocabtagene maraleucel,True,"['Bristol Myers Squibb/Celgene/Juno', 'Bristol Myers Squibb Foundation', 'Bristol Myers Squibb', 'Bristol Myers Squibb/Celgene', 'Bristol Myers Squibb/Sanofi', 'Juno intellectual property rights', 'Juno Therapeutics', 'Celgene']",0,USA,20,18,7,9,1,4,1,1,0,0,0,1,0,0,1,0
Cemiplimab for Kidney Transplant Recipients With Advanced Cutaneous Squamous Cell Carcinoma,2024-03-20,cemiplimab,True,['Regeneron'],0,USA,16,2,0,0,0,0,1,0,0,0,0,0,0,0,0,0
Overall Survival With Palbociclib Plus Letrozole in Advanced Breast Cancer,2024-03-20,palbociclib,True,['Pfizer'],1,USA,15,13,4,8,0,4,1,1,0,0,1,1,0,0,0,0
"Gemcitabine and Paclitaxel Versus Gemcitabine Alone After 5-Fluorouracil, Oxaliplatin, and Irinotecan in Metastatic Pancreatic Adenocarcinoma: A Randomized Phase III PRODIGE 65-UCGI 36-GEMPAX UNICANCER Study",2024-03-20,gemcitabine,False,[],0,France,26,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Hypoxia-Directed Treatment of Human Papillomavirusâ€“Related Oropharyngeal Carcinoma,2024-03-10,18F-fluoromisonidazole,False,['Nanobiotix'],0,USA,42,1,0,1,0,0,1,0,0,0,1,0,0,0,0,0
"Neoadjuvant Chemotherapy in High-Grade Myxoid Liposarcoma: Results of the Expanded Cohort of a Randomized Trial From Italian (ISG), Spanish (GEIS), French (FSG), and Polish Sarcoma Groups (PSG)",2024-03-10,trabectedin,True,['PharmaMar'],1,Italy,28,10,0,5,2,3,1,1,0,0,1,0,0,0,1,0
Long-Term Follow-Up of the RESORT Study (E4402): A Randomized Phase III Comparison of Two Different Rituximab Dosing Strategies for Lowâ€“Tumor Burden Follicular Lymphoma,2024-03-01,rituximab,False,[],0,USA,10,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CNS Efficacy of Osimertinib With or Without Chemotherapy in Epidermal Growth Factor Receptorâ€“Mutated Advanced Nonâ€“Small-Cell Lung Cancer,2024-03-01,osimertinib,True,"['AstraZeneca Japan', 'AstraZeneca/MedImmune', 'Daiichi Sankyo/AstraZeneca', 'AstraZeneca South Africa', 'Astra Zeneca']",1,USA,25,7,0,2,0,2,0,1,0,0,0,1,0,0,0,1
Bosutinib in Resistant and Intolerant Pediatric Patients With Chronic Phase Chronic Myeloid Leukemia: Results From the Phase I Part of Study ITCC054/COG AAML1921,2024-03-01,bosutinib,True,['Pfizer'],1,the Netherlands,36,9,2,1,0,0,1,1,0,0,0,1,0,0,0,0
"Trastuzumab Plus Gemcitabine-Cisplatin for Treatment-NaÃ¯ve Human Epidermal Growth Factor Receptor 2â€“Positive Biliary Tract Adenocarcinoma: A Multicenter, Open-Label, Phase II Study (TAB)",2024-03-01,trastuzumab,False,[],0,India,20,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Prostate-Specific Membrane Antigenâ€“Targeting Alpha Emitter via Antibody Delivery for Metastatic Castration-Resistant Prostate Cancer: A Phase I Dose-Escalation Study of 225Ac-J591,2024-03-01,actinium-225-labeled J591 (225Ac-J591),False,['Convergent Therapeutics'],0,USA,15,3,1,3,0,0,1,1,0,0,1,1,0,0,0,0
FDA Approval Summary: Olaparib in Combination With Abiraterone for Treatment of Patients With BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer,2024-02-10,olaparib,True,['AstraZeneca'],0,USA,23,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Minimal Residual Disease Status Predicts Outcome in Patients With Previously Untreated Follicular Lymphoma: A Prospective Analysis of the Phase III GALLIUM Study,2024-02-10,obinutuzumab,True,"['Roche Pharma AG', 'Roche/Genentech', 'Roche']",1,Germany,22,15,7,1,2,2,1,1,0,0,0,0,1,0,1,0
Olaparib for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer and Alterations in BRCA1 and/or BRCA2 in the PROfound Trial,2024-02-10,olaparib,True,"['AstraZeneca/Merck', 'AstraZeneca Spain', 'AstraZeneca', 'AstraZeneca/MedImmune', 'Phastar/AstraZeneca']",1,Spain,23,20,5,10,4,6,1,1,0,0,1,1,1,0,0,1
Long-Term Results of Organ Preservation in Patients With Rectal Adenocarcinoma Treated With Total Neoadjuvant Therapy: The Randomized Phase II OPRA Trial,2024-02-10,,False,[],0,USA,43,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Personalized Biomarker-Based Umbrella Trial for Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: KCSG HN 15-16 TRIUMPH Trial,2024-02-10,durvalumab,True,"['AstraZeneca/MedImmune', 'Daiichi Sankyo/Astra Zeneca', 'AstraZeneca']",0,Republic of Korea,22,4,0,3,0,1,1,0,0,0,0,0,0,0,0,0
Effect of a Community Health Workerâ€“Led Intervention Among Low-Income and Minoritized Patients With Cancer: A Randomized Clinical Trial,2024-02-10,,False,[],0,USA,7,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
DNA Mutational Profiling in Patients With Colorectal Cancer Treated With Standard of Care Reveals Differences in Outcome and Racial Distribution of Mutations,2024-02-01,bevacizumab,True,"['Genentech', 'Genentech/Roche']",0,USA,9,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0
Everolimus for Children With Recurrent or Progressive Low-Grade Glioma: Results From the Phase II PNOC001 Trial,2024-02-01,everolimus,True,['Novartis'],1,USA,20,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Perioperative Atezolizumab Plus Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel for Resectable Esophagogastric Cancer: Interim Results From the Randomized, Multicenter, Phase II/III DANTE/IKF-s633 Trial",2024-02-01,atezolizumab,True,"['Roche Pharma AG', 'Roche']",0,Germany,27,7,0,6,1,3,1,1,0,0,1,0,0,0,0,0
Overall Survival With Circulating Tumor Cell Countâ€“Driven Choice of Therapy in Advanced Breast Cancer: A Randomized Trial,2024-02-01,CellSearch,True,"['Menarini', 'Menarini Group', 'Menarini Silicon Biosystems']",0,France,20,6,0,4,1,1,1,1,0,0,1,1,1,0,0,0
SKYSCRAPER-02: Tiragolumab in Combination With Atezolizumab Plus Chemotherapy in Untreated Extensive-Stage Small-Cell Lung Cancer,2024-01-20,tiragolumab,True,"['Roche/Genentech', 'Genentech/Roche', 'Genentech']",1,USA,22,13,6,6,2,2,1,1,0,0,1,1,0,1,0,0
"Standard Versus Modified Ipilimumab, in Combination With Nivolumab, in Advanced Renal Cell Carcinoma: A Randomized Phase II Trial (PRISM)",2024-01-20,Ipilimumab,True,"['Bristol Myers Squibb/Celgene', 'BMS', 'Britol Myers Squibb', 'BMS GmbH & Co KG', 'Bristol Myers Squibb']",0,United Kingdom,27,18,0,10,4,7,1,1,0,0,0,1,1,0,0,1
Inotuzumab Ozogamicin as Induction Therapy for Patients Older Than 55 Years With Philadelphia Chromosomeâ€“Negative B-Precursor ALL,2024-01-20,inotuzumab ozogamicin,True,['Pfizer'],0,Germany,23,11,0,4,1,6,1,1,0,0,1,0,1,0,0,1
"Open-Label, Multicenter, Randomized, Biomarker-Integrated Umbrella Trial for Second-Line Treatment of Advanced Gastric Cancer: K-Umbrella Gastric Cancer Study",2024-01-20,nivolumab,True,['Bristol Myers Squibb'],0,South Korea,15,2,0,1,0,0,0,1,0,0,0,0,0,0,0,0
Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E Trial,2024-01-20,durvalumab,True,"['AstraZeneca/Columbia', 'AstraZeneca', 'AstraZeneca/Daiichi Sankyo']",1,USA,30,19,3,8,4,6,1,1,0,0,1,1,0,0,0,0
Canakinumab Versus Placebo in Combination With First-Line Pembrolizumab Plus Chemotherapy for Advanced Nonâ€“Small-Cell Lung Cancer: Results From the CANOPY-1 Trial,2024-01-10,canakinumab,True,['Novartis'],1,Singapore,23,19,6,9,2,5,1,1,0,0,1,1,0,0,1,0
Adjuvant Hyperthermic Intraperitoneal Chemotherapy in Patients With Locally Advanced Colon Cancer (COLOPEC): 5-Year Results of a Randomized Multicenter Trial,2024-01-10,oxaliplatin,False,[],0,the Netherlands,29,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Ofranergene Obadenovec (Ofra-Vec, VB-111) With Weekly Paclitaxel for Platinum-Resistant Ovarian Cancer: Randomized Controlled Phase III Trial (OVAL Study/GOG 3018)",2024-01-10,ofranergene obadenovec (ofra-vec),True,"['VBL Therapeutics', 'Vascular Biogenics']",1,USA,23,12,3,6,0,2,1,1,0,0,1,1,0,0,0,1
Effect of Hyperthermic Intraperitoneal Chemotherapy on Cytoreductive Surgery in Gastric Cancer With Synchronous Peritoneal Metastases: The Phase III GASTRIPEC-I Trial,2024-01-10,mitomycin C,False,[],0,Germany,28,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Canakinumab as Adjuvant Therapy in Patients With Completely Resected Nonâ€“Small-Cell Lung Cancer: Results From the CANOPY-A Double-Blind, Randomized Clinical Trial",2024-01-10,canakinumab,True,"['Novartis', 'Novartis Pharma S.A.S', 'Novartis Pharma SAS France', 'Novartis Parma AG Switzerland']",1,USA,19,17,6,7,1,6,1,1,0,0,1,1,0,0,0,0
Long-Term Follow-Up of the Response-Adapted Intergroup EORTC/LYSA/FIL H10 Trial for Localized Hodgkin Lymphoma,2024-01-01,doxorubicin,False,[],1,Italy,23,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Long-Term Follow-Up of the Response-Adjusted Therapy for Advanced Hodgkin Lymphoma Trial,2024-01-01,"ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine)",False,[],1,Italy,12,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Eflornithine as Postimmunotherapy Maintenance in High-Risk Neuroblastoma: Externally Controlled, Propensity Scoreâ€“Matched Survival Outcome Comparisons",2024-01-01,eflornithine,False,[],0,USA,17,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial,2024-01-01,trastuzumab deruxtecan,True,"['Daiichi Sankyo', 'Daiichi Sankyo (less than $10', 'Daiichi Sankyo/AstraZeneca (less than $10']",1,USA,18,3,0,2,0,0,1,0,0,0,0,0,0,0,0,0
"Prophylactic Radiation Therapy Versus Standard of Care for Patients With High-Risk Asymptomatic Bone Metastases: A Multicenter, Randomized Phase II Clinical Trial",2024-01-01,,False,[],0,USA,20,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Improvements in Survival and Clinical Benefit With Gemcitabine as First-Line Therapy for Patients With Advanced Pancreas Cancer: A Randomized Trial,2023-12-20,gemcitabine,False,[],0,USA,14,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Patritumab Deruxtecan (HER3-DXd), a Human Epidermal Growth Factor Receptor 3â€“Directed Antibody-Drug Conjugate, in Patients With Previously Treated Human Epidermal Growth Factor Receptor 3â€“Expressing Metastatic Breast Cancer: A Multicenter, Phase I/II Trial",2023-12-20,patritumab deruxtecan,True,"['Daiichi Sankyo RD Novare', 'Daiichi Sankyo/Japan', 'Daiichi Sankyo', 'Daiichi Sankyo/AstraZeneca', 'Daiichi Sankyo/UCB Japan', 'Daiichi Sankyo Co', 'Daiichi Sankyo/Lilly']",0,USA,25,24,9,6,1,10,1,1,0,0,1,0,0,0,0,1
Tucatinib and Trastuzumab for Previously Treated Human Epidermal Growth Factor Receptor 2â€“Positive Metastatic Biliary Tract Cancer (SGNTUC-019): A Phase II Basket Study,2023-12-20,tucatinib,True,"['Seagen', 'Genmab/Seattle Genetics']",1,Japan,28,17,2,6,1,4,1,1,0,0,0,1,0,0,0,0
Stereotactic Body Radiation Therapy and Abiraterone Acetate for Patients Affected by Oligometastatic Castrate-Resistant Prostate Cancer: A Randomized Phase II Trial (ARTO),2023-12-20,abiraterone acetate,True,"['Janssen Oncology', 'Janssen']",0,Italy,20,3,0,2,0,0,1,0,0,0,0,0,0,0,0,0
Inaugural Results of the Individualized Screening Trial of Innovative Glioblastoma Therapy: A Phase II Platform Trial for Newly Diagnosed Glioblastoma Using Bayesian Adaptive Randomization,2023-12-20,abemaciclib,True,['Lilly'],1,USA,50,5,0,0,0,0,1,1,0,0,0,0,0,0,0,0
"Tisotumab Vedotin in Combination With Carboplatin, Pembrolizumab, or Bevacizumab in Recurrent or Metastatic Cervical Cancer: Results From the innovaTV 205/GOG-3024/ENGOT-cx8 Study",2023-12-20,tisotumab vedotin,True,"['Seagen', 'Genmab/Seagen', 'Genmab/Seattle Genetics', 'SeaGen', 'Seagan']",1,Belgium,31,13,1,9,2,3,1,1,0,0,1,1,0,0,0,1
Health-Related Quality of Life With Nivolumab Plus Chemotherapy Versus Chemotherapy in Patients With Advanced Gastric/Gastroesophageal Junction Cancer or Esophageal Adenocarcinoma From CheckMate 649,2023-12-10,nivolumab,True,"['Bristol Myers Squibb', 'BMS Argentina', 'BMS GmbH & Co KG', 'Bristol Myers Squibb Japan', 'Bristol Myers Squib', 'Bristol Myers Squibb/Medarex', 'Bristol Myers Squibb/Celgene', 'BMS']",1,Germany,24,20,4,11,6,4,1,1,0,0,1,0,0,1,1,1
Effect of Metformin Versus Placebo on New Primary Cancers in Canadian Cancer Trials Group MA.32: A Secondary Analysis of a Phase III Randomized Double-Blind Trial in Early Breast Cancer,2023-12-10,metformin,False,[],1,Canada,19,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptorâ€“Mutated Nonâ€“Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy",2023-12-10,patritumab deruxtecan (HER3-DXd),True,"['Daiichi Sankyo Europe GmbH', 'Daiichi Sankyo', 'Daiichi-Sankyo Inc', 'Daiichi Sankyo/UCB Japan', 'Daiichi Sankyo Co', 'Daiichi Sankyo/Arqule', 'Daiichi Sankyo/Lilly']",1,USA,29,24,6,10,1,5,1,1,0,0,1,1,0,0,0,0
Oral Selinexor as Maintenance Therapy After First-Line Chemotherapy for Advanced or Recurrent Endometrial Cancer,2023-12-10,selinexor,True,"['Karyopharm Therapeutics', 'Karyopharm Therapeutics Inc']",1,Belgium,32,11,3,6,0,1,1,1,0,0,1,1,0,0,0,0
"Randomized Trial of Exercise and Nutrition on Chemotherapy Completion and Pathologic Complete Response in Women With Breast Cancer: The Lifestyle, Exercise, and Nutrition Early After Diagnosis Study",2023-12-01,,False,[],0,USA,20,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Five-Year Overall Survival Analysis of the JIPANG Study: Pemetrexed or Vinorelbine Plus Cisplatin for Resected Stage II-IIIA Nonsquamous Nonâ€“Small-Cell Lung Cancer,2023-12-01,pemetrexed,True,"['Lilly', 'Lilly Japan']",0,Japan,20,13,0,3,0,12,1,1,0,0,0,0,0,0,1,1
"Initial Panitumumab Plus Fluorouracil, Leucovorin, and Oxaliplatin or Plus Fluorouracil and Leucovorin in Elderly Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer: The PANDA Trial by the GONO Foundation",2023-12-01,panitumumab,True,['Amgen'],0,Italy,28,9,0,5,3,4,1,1,0,0,1,1,1,0,0,1
Randomized Double-Blind Phase II Trial of Fecal Microbiota Transplantation Versus Placebo in Allogeneic Hematopoietic Cell Transplantation and AML,2023-12-01,fecal microbiota transplantation,False,[],0,USA,16,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer,2023-11-20,oxaliplatin,False,[],0,Spain,18,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Nimotuzumab Plus Gemcitabine for K-Ras Wild-Type Locally Advanced or Metastatic Pancreatic Cancer,2023-11-20,nimotuzumab,False,[],0,China,25,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Phase II Trial of Dabrafenib Plus Trametinib in Relapsed/Refractory BRAF V600â€“Mutant Pediatric High-Grade Glioma,2023-11-20,dabrafenib,True,['Novartis'],1,United Kingdom,14,10,2,5,1,1,1,1,0,0,1,1,0,0,0,0
Perioperative Chemoimmunotherapy With Durvalumab for Muscle-Invasive Urothelial Carcinoma: Primary Analysis of the Single-Arm Phase II Trial SAKK 06/17,2023-11-20,durvalumab,True,['AstraZeneca'],0,Switzerland,20,5,0,0,0,0,1,1,0,0,1,1,0,0,0,0
Impact of BMI in Patients With Early Hormone Receptorâ€“Positive Breast Cancer Receiving Endocrine Therapy With or Without Palbociclib in the PALLAS Trial,2023-11-20,palbociclib,True,['Pfizer'],1,Austria,52,33,2,15,4,10,1,0,0,0,1,0,1,0,1,0
ROSEWOOD: A Phase II Randomized Study of Zanubrutinib Plus Obinutuzumab Versus Obinutuzumab Monotherapy in Patients With Relapsed or Refractory Follicular Lymphoma,2023-11-20,zanubrutinib,True,"['BeiGene Shanghai', 'BeiGene', 'Beigene']",1,Italy,26,11,4,4,1,3,1,1,0,0,1,0,0,0,0,0
Zanubrutinib Versus Ibrutinib in Symptomatic WaldenstrÃ¶m Macroglobulinemia: Final Analysis From the Randomized Phase III ASPEN Study,2023-11-20,zanubrutinib,True,"['BeiGene', 'BeiGene USA']",1,Greece,34,29,5,18,4,10,1,1,0,0,1,1,0,0,1,1
Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma,2023-11-10,bevacizumab,False,[],0,USA,14,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Nine-Week Versus One-Year Trastuzumab for Early Human Epidermal Growth Factor Receptor 2â€“Positive Breast Cancer: 10-Year Update of the ShortHER Phase III Randomized Trial,2023-11-10,trastuzumab,True,['Roche/Genentech'],0,Italy,21,1,0,0,1,0,1,0,0,0,0,0,1,0,0,0
Randomized Phase III Study Comparing Neoadjuvant Chemotherapy Followed by Surgery Versus Chemoradiation in Stage IB2-IIB Cervical Cancer: EORTC-55994,2023-11-10,,False,[],1,the Netherlands,16,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Randomized Phase II Multicenter Trial of Abiraterone Acetate With or Without Cabazitaxel in the Treatment of Metastatic Castration-Resistant Prostate Cancer,2023-11-10,cabazitaxel,True,['Sanofi'],0,USA,14,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
MANIFEST: Pelabresib in Combination With Ruxolitinib for Janus Kinase Inhibitor Treatment-NaÃ¯ve Myelofibrosis,2023-11-10,pelabresib,True,['MorphoSys'],1,USA,24,3,0,1,0,0,0,0,0,0,0,0,0,0,0,0
Kinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal Tumor,2023-11-01,imatinib,False,[],0,Switzerland,18,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Tolerability and Efficacy of the Anticluster of Differentiation 47 Antibody Magrolimab Combined With Azacitidine in Patients With Previously Untreated AML: Phase Ib Results,2023-11-01,magrolimab,True,"['Forty Seven', 'Gilead/Forty Seven']",0,USA,21,6,0,2,0,0,0,0,0,0,0,0,0,0,0,0
"Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic Nonâ€“Small-Cell Lung Cancer: Primary Results From the Randomized, Phase II DESTINY-Lung02 Trial",2023-11-01,trastuzumab deruxtecan,True,"['Daiichi Sankyo/AstraZeneca', 'Daiichi Sankyo/Astra Zeneca']",1,Japan,24,3,0,1,0,2,0,0,0,0,0,0,0,0,0,0
Adding Ovarian Suppression to Tamoxifen for Premenopausal Women With Hormone Receptorâ€“Positive Breast Cancer After Chemotherapy: An 8-Year Follow-Up of the ASTRRA Trial,2023-11-01,tamoxifen,False,[],0,South Korea,20,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Homoharringtonine-Based Induction Regimen Improved the Remission Rate and Survival Rate in Chinese Childhood AML: A Report From the CCLG-AML 2015 Protocol Study,2023-11-01,homoharringtonine,False,[],0,China,50,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Outcomes After Preoperative Chemoradiation With or Without Pazopanib in Non-Rhabdomyosarcoma Soft Tissue Sarcoma: A Report From Children's Oncology Group and NRG Oncology,2023-11-01,pazopanib,True,['Novartis'],0,USA,27,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Atezolizumab With or Without Radiotherapy for Advanced Squamous Cell Carcinoma of the Penis (The PERICLES Study): A Phase II Trial,2023-11-01,atezolizumab,True,"['Roche/Genentech', 'Roche']",0,the Netherlands,18,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0
Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group,2023-10-20,erlotinib,False,[],0,Singapore,17,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Bempegaldesleukin Plus Nivolumab in Untreated Advanced Melanoma: The Open-Label, Phase III PIVOT IO 001 Trial Results",2023-10-20,bempegaldesleukin,True,['Nektar'],1,USA,26,5,1,3,0,0,1,1,0,0,1,1,0,0,0,0
Long-Term Outcomes in Patients With Localized Ewing Sarcoma Treated With Interval-Compressed Chemotherapy on Children's Oncology Group Study AEWS0031,2023-10-20,vincristine,False,[],0,USA,15,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Atezolizumab Combined With Bevacizumab and Platinum-Based Therapy for Platinum-Sensitive Ovarian Cancer: Placebo-Controlled Randomized Phase III ATALANTE/ENGOT-ov29 Trial,2023-10-20,atezolizumab,True,"['Roche/Genentech', 'Roche', 'Roche Pharma AG']",1,France,31,15,0,9,1,4,1,1,0,0,0,1,0,0,0,1
"Relacorilant + Nab-Paclitaxel in Patients With Recurrent, Platinum-Resistant Ovarian Cancer: A Three-Arm, Randomized, Controlled, Open-Label Phase II Study",2023-10-20,relacorilant,True,['Corcept Therapeutics'],1,Italy,13,9,5,3,0,0,0,1,0,0,0,1,0,0,0,0
Concurrent Chemotherapy and Pelvic Radiation Therapy Compared With Pelvic Radiation Therapy Alone as Adjuvant Therapy After Radical Surgery in High-Risk Early-Stage Cancer of the Cervix,2023-10-10,cisplatin,False,[],0,USA,10,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Financial Toxicity Monitoring in a Randomized Controlled Trial of Patient-Reported Outcomes During Cancer Treatment (Alliance AFT-39),2023-10-10,,False,[],0,USA,17,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Contribution of MEK Inhibition to BRAF/MEK Inhibitor Combination Treatment of BRAF-Mutant Melanoma: Part 2 of the Randomized, Open-Label, Phase III COLUMBUS Trial",2023-10-10,encorafenib,False,[],1,Italy,17,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Busulfan Plus Fludarabine Compared With Busulfan Plus Cyclophosphamide for AML Undergoing HLA-Haploidentical Hematopoietic Cell Transplantation: A Multicenter Randomized Phase III Trial,2023-10-10,busulfan,False,[],0,China,23,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"First-in-Human, Phase I Dose-Escalation and Dose-Expansion Study of Trophoblast Cell-Surface Antigen 2â€“Directed Antibody-Drug Conjugate Datopotamab Deruxtecan in Nonâ€“Small-Cell Lung Cancer: TROPION-PanTumor01",2023-10-10,datopotamab deruxtecan,True,"['Daiichi Sankyo', 'Daiichi Sankyo Europe GmbH', 'Daiichi Sankyo/AstraZeneca', 'Daiichi Sankyo/UCB Japan', 'Daiichi Sankyo Co']",1,Japan,17,16,6,5,0,3,1,1,0,0,1,1,0,0,1,0
"Phase II Trial of Atezolizumab Combined With Carboplatin and Pemetrexed for Patients With Advanced Nonsquamous Nonâ€“Small-Cell Lung Cancer With Untreated Brain Metastases (Atezo-Brain, GECP17/05)",2023-10-01,atezolizumab,True,"['Roche/Genentech', 'Genentech', 'Roche']",0,Spain,18,11,0,8,7,2,1,0,0,0,1,0,0,0,0,0
Cluster Randomized Pragmatic Clinical Trial Testing Behavioral Economic Implementation Strategies to Improve Tobacco Treatment for Patients With Cancer Who Smoke,2023-10-01,,False,[],0,USA,30,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Eltrombopag for Low-Risk Myelodysplastic Syndromes With Thrombocytopenia: Interim Results of a Phase II, Randomized, Placebo-Controlled Clinical Trial (EQOL-MDS)",2023-10-01,eltrombopag,True,"['Novartis Italy', 'Novartis']",1,Italy,42,12,0,5,6,4,1,1,0,0,1,0,1,0,1,0
"Prognostic Factors in High-Grade Osteosarcoma of theExtremities or Trunk: An Analysis of 1,702 Patients Treatedon Neoadjuvant Cooperative Osteosarcoma Study GroupProtocols",2023-09-20,,False,[],0,Switzerland,13,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Lazertinib Versus Gefitinib as First-Line Treatment in Patients With EGFR-Mutated Advanced Nonâ€“Small-Cell Lung Cancer: Results From LASER301,2023-09-10,lazertinib,True,['Yuhan'],1,Republic of Korea,24,14,5,8,0,2,1,1,0,0,1,1,0,0,0,0
Gilteritinib in Combination With Induction and Consolidation Chemotherapy and as Maintenance Therapy: A Phase IB Study in Patients With Newly Diagnosed AML,2023-09-10,gilteritinib,True,['Astellas Pharma'],0,USA,18,14,5,5,1,1,0,1,0,0,0,0,0,0,0,0
Phase III Trial of Carboplatin and Paclitaxel Compared With Cisplatin and Paclitaxel in Patients With Optimally Resected Stage III Ovarian Cancer: A Gynecologic Oncology Group Study,2023-09-01,carboplatin,False,[],0,TX),10,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Enfortumab Vedotin With or Without Pembrolizumab in Cisplatin-Ineligible Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer,2023-09-01,enfortumab vedotin,True,"['Seagen', 'Seattle Genetics/Astellas', 'Astellas Pharma', 'Astellas Scientific and Medical Affairs Inc', 'Astellas Medivation']",1,USA,25,22,3,18,4,7,1,1,0,0,0,1,0,0,1,0
FOLFOXIRI Plus Cetuximab or Bevacizumab as First-Line Treatment of BRAFV600E-Mutant Metastatic Colorectal Cancer: The Randomized Phase II FIRE-4.5 (AIO KRK0116) Study,2023-09-01,cetuximab,True,['Lilly'],1,Germany,20,9,0,5,0,3,1,0,0,0,0,0,0,0,0,0
"Children's Oncology Group AALL1331: Phase III Trial of Blinatumomab in Children, Adolescents, and Young Adults With Low-Risk B-Cell ALL in First Relapse",2023-09-01,blinatumomab,True,['Amgen'],1,USA,18,3,1,1,0,0,0,1,0,0,0,0,0,0,0,0
Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099.,2023-08-20,cisplatin,False,[],0,,11,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"AMEERA-3: Randomized Phase II Study of Amcenestrant (Oral Selective Estrogen Receptor Degrader) Versus Standard Endocrine Monotherapy in Estrogen Receptorâ€“Positive, Human Epidermal Growth Factor Receptor 2â€“Negative Advanced Breast Cancer",2023-08-20,amcenestrant,True,"['Sanofi R&D', 'Sanofi']",1,USA,16,13,7,3,0,0,1,0,0,0,1,0,0,0,0,0
Ensuring Ethical Postprogression Therapy for Patients in Randomized Trial Control Arms,2023-08-20,,False,[],0,USA,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Effect of Brachytherapy With External Beam Radiation Therapy Versus Brachytherapy Alone for Intermediate-Risk Prostate Cancer: NRG Oncology RTOG 0232 Randomized Clinical Trial,2023-08-20,125-Iodine,False,[],0,USA,20,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Randomized Phase II Trial of Endocrine Therapy With or Without Ribociclib After Progression on Cyclin-Dependent Kinase 4/6 Inhibition in Hormone Receptorâ€“Positive, Human Epidermal Growth Factor Receptor 2â€“Negative Metastatic Breast Cancer: MAINTAIN Trial",2023-08-20,ribociclib,False,[],0,USA,23,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study",2023-08-10,gemcitabine,False,[],0,USA,18,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"First-Line, Fixed-Duration Nivolumab Plus Ipilimumab Followed by Nivolumab in Clinically Diverse Patient Populations With Unresectable Stage III or IV Melanoma: CheckMate 401",2023-08-10,nivolumab,True,"['Bristol Myers Squibb', 'Bristol Myers Squibb/Celgene']",1,Switzerland,26,21,2,17,4,8,1,1,0,0,1,1,0,0,1,1
Impact of 18F-Labeled Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography Versus Conventional Staging in Patients With Locally Advanced Breast Cancer,2023-08-10,fluorodeoxyglucose (FDG),False,[],0,Canada,11,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Pembrolizumab Plus Olaparib for Patients With Previously Treated and Biomarker-Unselected Metastatic Castration-Resistant Prostate Cancer: The Randomized, Open-Label, Phase III KEYLYNK-010 Trial",2023-08-01,pembrolizumab,True,"['Merck Serono', 'AstraZeneca/Merck', 'a subsidiary of Merck & Co', 'Merck/Pfizer', 'MSD', 'MSD K.K', 'MSD Life Science Foundation', 'a subsidiary of Merck & Co Inc', 'Merck Sharp & Dohme', 'Merck Sharp & Dohme LLC', 'Merck', 'Merck & Co Inc', 'MSD Oncology']",1,USA,31,25,8,16,4,12,1,1,0,0,1,1,0,0,1,0
Endosonography With or Without Confirmatory Mediastinoscopy for Resectable Lung Cancer: A Randomized Clinical Trial,2023-08-01,,False,[],0,the Netherlands,7,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Randomized Phase II Trial of Ficlatuzumab With or Without Cetuximab in Pan-Refractory, Recurrent/Metastatic Head and Neck Cancer",2023-08-01,ficlatuzumab,False,[],0,USA,20,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
De-Escalated Neoadjuvant Trastuzumab-Emtansine With or Without Endocrine Therapy Versus Trastuzumab With Endocrine Therapy in HR+/HER2+ Early Breast Cancer: 5-Year Survival in the WSG-ADAPT-TP Trial,2023-08-01,trastuzumab-emtansine,True,"['Roche Pharma AG', 'F. Hoffmann LaRoche', 'Roche/Genentech', 'Roche']",0,Germany,28,15,2,9,1,11,1,1,0,0,0,1,0,0,1,1
Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study,2023-07-20,bevacizumab,False,[],0,United Kingdom,13,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200",2023-07-20,bevacizumab,False,[],0,USA,8,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Phase II, Open-Label Study of Encorafenib Plus Binimetinib in Patients With BRAFV600-Mutant Metastatic Nonâ€“Small-Cell Lung Cancer",2023-07-20,encorafenib plus binimetinib,True,['Array BioPharma'],1,USA,25,5,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Patient-Reported Outcomes During and After Treatment for Locally Advanced Rectal Cancer in the PROSPECT Trial (Alliance N1048),2023-07-20,fluorouracil,False,[],0,USA,23,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Darolutamide Plus Androgen-Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase III ARASENS Trial,2023-07-10,darolutamide,False,[],1,USA,19,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Darolutamide Maintenance in Patients With Metastatic Castration-Resistant Prostate Cancer With Nonprogressive Disease After Taxane Treatment (SAKK 08/16),2023-07-10,darolutamide,True,['Bayer'],1,Switzerland,20,9,0,4,1,1,1,1,0,0,1,1,0,0,0,0
FOLFIRI Followed by FOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer: A Randomized GERCOR Study,2023-07-01,irinotecan,False,[],0,Belgium,14,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"A Randomized Controlled Trial of Fluorouracil Plus Leucovorin, Irinotecan, and Oxaliplatin Combinations in Patients With Previously Untreated Metastatic Colorectal Cancer  ",2023-07-01,oxaliplatin,False,[],0,Canada,9,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Long-Term Outcomes of TROG 13.01 SAFRON II Randomized Trial of Single- Versus Multifraction Stereotactic Ablative Body Radiotherapy for Pulmonary Oligometastases,2023-07-01,stereotactic ablative body radiotherapy (SABR),False,[],1,Australia,22,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Childhood Acute Lymphoblastic Leukemia: Results of the Randomized Acute Lymphoblastic Leukemia Intercontinental-Berlin-Frankfurt-MÃ¼nster 2009 Trial,2023-07-01,methotrexate,False,[],1,Chile,27,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Ruxolitinib Versus Best Available Therapy for Polycythemia Vera Intolerant or Resistant to Hydroxycarbamide in a Randomized Trial,2023-07-01,ruxolitinib,True,"['Incyte', 'ARIAD/Incyte']",0,United Kingdom,33,4,0,0,1,2,0,0,0,0,0,0,0,0,0,0
Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Results From the JAVELIN Bladder 100 Trial After â‰¥2 Years of Follow-Up,2023-07-01,avelumab,True,['the healthcare business of Merck KGaA (Darmstadt'],1,United Kingdom,16,10,0,8,1,4,1,1,0,0,1,1,0,0,1,0
Randomized Phase III Trial Evaluating Subcutaneous Rituximab for the First-Line Treatment of Lowâ€“Tumor Burden Follicular Lymphoma: Results of a LYSA Study,2023-07-01,rituximab,True,"['Roche', 'Chugai/Roche', 'Roche/Genentech']",0,France,31,12,0,8,0,10,1,1,0,0,1,0,0,0,1,0
Phase II Randomized Trial of Lenalidomide in Children With Pilocytic Astrocytomas and Optic Pathway Gliomas: A Report From the Children's Oncology Group,2023-06-20,lenalidomide,True,"['Bristol Myers Squibb/Celgene', 'Celgene']",0,USA,12,2,0,0,0,0,1,0,0,0,0,0,0,0,0,0
"Postoperative Adjuvant Anastrozole for 10 or 5 Years in Patients With Hormone Receptorâ€“Positive Breast Cancer: AERAS, a Randomized Multicenter Open-Label Phase III Trial",2023-06-20,anastrozole,True,['AstraZeneca'],0,Japan,18,2,0,0,0,2,1,0,0,0,0,0,0,0,1,0
Effect of Peritumoral Infiltration of Local Anesthetic Before Surgery on Survival in Early Breast Cancer,2023-06-20,lidocaine,False,[],0,India,20,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Randomized Phase III Study of Enzalutamide Compared With Enzalutamide Plus Abiraterone for Metastatic Castration-Resistant Prostate Cancer (Alliance A031201 Trial),2023-06-20,enzalutamide,True,"['Astellas Pharma', 'Astellas Scientific and Medical Affairs']",0,USA,23,4,0,2,0,2,0,0,0,0,0,0,0,0,0,0
Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer,2023-06-20,niraparib,False,['GlaxoSmithKline'],1,Canada,21,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0
"GET FIT: A Randomized Clinical Trial of Tai Ji Quan Versus Strength Training for Fall Prevention After Chemotherapy in Older, Postmenopausal Women Cancer Survivors",2023-06-20,,False,[],0,USA,8,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Dose-Escalated Radiation Alone or in Combination With Short-Term Total Androgen Suppression for Intermediate-Risk Prostate Cancer: Patient-Reported Outcomes From NRG/Radiation Therapy Oncology Group 0815 Randomized Trial,2023-06-10,luteinizing hormone-releasing hormone agonists/antagonists,False,[],0,USA,22,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Randomized Placebo Controlled Trial of Low-Dose Tamoxifen to Prevent Recurrence in Breast Noninvasive Neoplasia: A 10-Year Follow-Up of TAM-01 Study,2023-06-10,tamoxifen,True,['AstraZeneca'],0,Italy,23,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0
"Anti-GD2 Antibody Dinutuximab Beta and Low-Dose Interleukin 2 After Haploidentical Stem-Cell Transplantation in Patients With Relapsed Neuroblastoma: A Multicenter, Phase I/II Trial",2023-06-10,dinutuximab beta,True,"['EUSA Pharma', 'EUSA Pharma/Recordati']",1,Germany,27,6,0,2,0,2,1,1,0,0,0,0,0,0,1,0
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations,2023-06-01,afatinib,False,[],0,Germany,20,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Lenvatinib Plus Pembrolizumab in Previously Treated Advanced Endometrial Cancer: Updated Efficacy and Safety From the Randomized Phase III Study 309/KEYNOTE-775,2023-06-01,lenvatinib plus pembrolizumab,True,['Eisai'],1,USA,21,12,2,11,1,3,1,0,0,0,0,0,0,0,0,0
"Consensus Molecular Subtypes as Biomarkers of Fluorouracil and Folinic Acid Maintenance Therapy With or Without Panitumumab in RAS Wild-Type Metastatic Colorectal Cancer (PanaMa, AIO KRK 0212)",2023-06-01,panitumumab,True,['Amgen'],0,Germany,22,9,0,7,0,8,1,1,0,0,0,1,0,0,0,1
"Sugemalimab Monotherapy for Patients With Relapsed or Refractory Extranodal Natural Killer/T-Cell Lymphoma (GEMSTONE-201): Results From a Single-Arm, Multicenter, Phase II Study",2023-06-01,sugemalimab,True,"['CStone Pharmaceuticals', 'Cstone Pharmaceuticals']",0,China,25,8,8,0,0,0,0,1,0,1,0,0,0,0,0,0
"Isolated Hepatic Perfusion With Melphalan for Patients With Isolated Uveal Melanoma Liver Metastases: A Multicenter, Randomized, Open-Label, Phase III Trial (the SCANDIUM Trial)",2023-06-01,melphalan,False,[],0,Sweden,17,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Surgery in Early Metastatic Seminoma: A Phase II Trial of Retroperitoneal Lymph Node Dissection for Testicular Seminoma With Limited Retroperitoneal Lymphadenopathy,2023-06-01,,False,[],0,USA,22,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I Study",2023-06-01,tarlatamab,False,[],1,Spain,25,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Prospective Randomized Trial of Docetaxel Versus Best Supportive Care in Patients With Nonâ€“Small-Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy,2023-05-20,docetaxel,False,[],0,France,13,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non-Small-Cell Lung Cancer Previously Treated With Chemotherapy,2023-05-20,pemetrexed,False,[],0,Pakistan,20,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Differential Efficacy From the Addition of Bortezomib to R-CHOP in Diffuse Large B-Cell Lymphoma According to the Molecular Subgroup in the REMoDL-B Study With a 5-Year Follow-Up,2023-05-20,bortezomib,True,"['Takeda Science Foundation', 'Takeda']",0,United Kingdom,23,5,0,2,1,3,1,0,0,0,0,0,0,0,0,0
Efficacy of a Smoking Cessation Intervention for Survivors of Cervical Intraepithelial Neoplasia or Cervical Cancer: A Randomized Controlled Trial,2023-05-20,nicotine replacement therapy,False,[],0,USA,14,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Phase II Clinical Trial of Axitinib and Avelumab in Patients With Recurrent/Metastatic Adenoid Cystic Carcinoma,2023-05-20,axitinib,True,"['Pfizer', 'Pfizer/EMD Serono']",0,USA,20,2,0,0,0,0,1,0,0,0,0,0,0,0,0,0
Magrolimab in Combination With Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes: Final Results of a Phase Ib Study,2023-05-20,Magrolimab,True,"['Gilead Sciences', 'Kite/Gilead', 'Gilead/Forty Seven', 'a Gilead company']",0,USA,25,19,7,11,1,1,1,1,0,0,1,1,0,0,0,0
Improving Uptake of Cancer Genetic Risk Assessment in a Remote Tailored Risk Communication and Navigation Intervention: Large Effect Size but Room to Grow,2023-05-20,,False,"['Pfizer', 'Pfizer Global']",0,USA,15,2,1,0,0,0,1,0,0,0,0,0,0,0,0,0
Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Nonâ€“Small-Cell Lung Cancer,2023-05-10,pemetrexed,False,[],0,USA,20,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Randomized Double-Blind Placebo-Controlled Study of Olanzapine for Chemotherapy-Related Anorexia in Patients With Locally Advanced or Metastatic Gastric, Hepatopancreaticobiliary, and Lung Cancer",2023-05-10,olanzapine,False,[],0,India,9,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Initial Evidence for the Efficacy of Naporafenib in Combination With Trametinib in NRAS-Mutant Melanoma: Results From the Expansion Arm of a Phase Ib, Open-Label Study",2023-05-10,naporafenib,True,"['Novartis', 'Novartis Italy', 'Novartis Institutes for Biomedical Research', 'Novartis Institutes for BioMedical Research']",1,Italy,29,23,10,10,5,7,1,1,0,0,1,0,0,0,0,0
"Antiâ€“G Proteinâ€“Coupled Receptor, Class C Group 5 Member D Chimeric Antigen Receptor T Cells in Patients With Relapsed or Refractory Multiple Myeloma: A Single-Arm, Phase â…¡ Trial",2023-05-10,Anti-GPRC5D CAR T-Cell Therapy,True,['Shanghai YaKe Biotechnology Ltd'],0,China,27,4,4,0,0,0,1,1,1,1,0,0,0,0,0,0
Phase II Study Investigating the Safety and Efficacy of Savolitinib and Durvalumab in Metastatic Papillary Renal Cancer (CALYPSO),2023-05-10,savolitinib,True,['AstraZeneca'],1,Spain,16,9,2,3,0,2,1,1,0,0,0,1,0,0,0,1
"Bortezomib-Dexamethasone, Rituximab, and Cyclophosphamide as First-Line Treatment for WaldenstrÃ¶m's Macroglobulinemia: A Prospectively Randomized Trial of the European Consortium for WaldenstrÃ¶m's Macroglobulinemia",2023-05-10,bortezomib,True,['Takeda'],1,Germany,25,6,0,5,1,4,0,0,0,0,0,0,0,0,0,0
"ANCHOR CRC: Results From a Single-Arm, Phase II Study of Encorafenib Plus Binimetinib and Cetuximab in Previously Untreated BRAFV600E-Mutant Metastatic Colorectal Cancer",2023-05-10,encorafenib,True,['Array BioPharma'],1,Belgium,19,5,0,3,0,1,1,1,0,0,1,1,0,0,0,0
"Camrelizumab Plus Apatinib in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma: An Open-Label, Single-Arm, Phase II Study",2023-05-10,Camrelizumab,False,[],0,China,20,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Randomized Phase II Trial Comparing Bevacizumab Plus Carboplatin and Paclitaxel With Carboplatin and Paclitaxel Alone in Previously Untreated Locally Advanced or Metastatic Non-Small-Cell Lung Cancer  ,2023-05-01,bevacizumab,False,[],0,USA,12,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Nonmetastatic Rhabdomyosarcoma in Children and Adolescents: Overall Results of the European Pediatric Soft Tissue Sarcoma Study Group RMS2005 Study,2023-05-01,vincristine,False,[],1,Italy,20,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer With High Folate Receptor Alpha Expression: Results From the SORAYA Study,2023-05-01,mirvetuximab soravtansine,True,['ImmunoGen'],1,USA,17,12,4,6,0,1,1,1,0,0,1,1,0,0,0,0
"Results of Phase III Randomized Trial for Use of Docetaxel as a Radiosensitizer in Patients With Head and Neck Cancer, Unsuitable for Cisplatin-Based Chemoradiation",2023-05-01,Docetaxel,False,['Alkem Laboratories'],0,India,37,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0
High-Dose Once-Daily Thoracic Radiotherapy in Limited-Stage Small-Cell Lung Cancer: CALGB 30610 (Alliance)/RTOG 0538,2023-05-01,,False,[],0,USA,14,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma,2023-04-20,pemetrexed,False,[],0,Turkey,12,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Advancing Survivors Knowledge (ASK Study) of Skin Cancer Surveillance After Childhood Cancer: A Randomized Controlled Trial in the Childhood Cancer Survivor Study,2023-04-20,,False,[],0,USA,14,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Cosmetic Results and Side Effects of Accelerated Partial-Breast Irradiation Versus Whole-Breast Irradiation for Low-Risk Invasive Carcinoma of the Breast: The Randomized Phase III IRMA Trial,2023-04-20,,False,[],1,Italy,26,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Neoadjuvant Pembrolizumab in Localized Microsatellite Instability High/Deficient Mismatch Repair Solid Tumors,2023-04-20,pembrolizumab,True,['Merck'],0,USA,25,6,0,2,0,0,1,1,0,0,0,1,0,0,0,0
"Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cellâ€“Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial",2023-04-20,Epcoritamab,False,['AbbVie'],1,France,23,11,1,3,1,3,1,1,0,0,0,1,0,0,1,0
Nivolumab Plus Ipilimumab Versus EXTREME Regimen as First-Line Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: The Final Results of CheckMate 651,2023-04-20,nivolumab,True,"['Bristol Myers Squibb', 'Bristol Myers Squibb Japan', 'Bristol Myers Squibb/Celgene', 'BMS', 'BMS Brazil', 'BMS GmbH & Co. KG', 'BMS GmbH & Co KG']",1,USA,25,22,6,11,4,5,1,1,0,0,1,1,0,1,0,0
Radiotherapy or Surgery of the Axilla After a Positive Sentinel Node in Breast Cancer: 10-Year Results of the Randomized Controlled EORTC 10981-22023 AMAROS Trial,2023-04-20,,False,[],1,Belgium,26,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial,2023-04-10,pazopanib,False,[],0,USA,16,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma,2023-04-10,sunitinib,False,[],0,Spain,19,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Nonâ€“Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study,2023-04-10,pembrolizumab,True,"['Merck & Co', 'Merck Serono', 'Merck Sharp & Dohme', 'Merck Sharp & Dohme LLC', 'Merck', 'MSD', 'MSD Oncology']",1,USA,21,16,3,13,8,7,1,1,0,0,1,1,1,1,1,0
US Food and Drug Administration Approval Summary: Fam-Trastuzumab Deruxtecan-nxki for Human Epidermal Growth Factor Receptor 2-Low Unresectable or Metastatic Breast Cancer,2023-04-10,trastuzumab deruxtecan,False,[],0,USA,15,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Pembrolizumab Plus Chemotherapy in Squamous Nonâ€“Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study,2023-04-10,pembrolizumab,True,"['Merck Sharp & Dohme LLC', 'MSD', 'MSD K.K', 'MSD Oncology', 'Merck']",1,Italy,18,14,3,7,3,4,1,1,0,0,0,0,1,1,0,1
Randomized Phase III Trial of Ganitumab With Interval-Compressed Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma: A Report From the Children's Oncology Group,2023-04-10,ganitumab,True,['Amgen'],0,USA,25,2,0,1,0,0,1,0,0,0,1,0,0,0,0,0
"Interactive Effects of Molecular, Therapeutic, and Patient Factors on Outcome of Diffuse Low-Grade Glioma",2023-04-10,,False,[],1,USA,36,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Adjuvant nab-Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial",2023-04-10,nab-paclitaxel,True,"['BMSi', 'Bristol Myers Squibb/Celgene/Juno (I)', 'Bristol Myers Squibb', 'BMS GmbH & Co KG', 'Bristol Myers Squibb/Ono Pharmaceutical', 'Bristol Myers Squibb/Medarex', 'Bristol Myers Squibb/Celgene', 'BMS']",1,USA,31,14,4,4,3,1,1,0,0,0,1,0,0,0,0,0
Five-Year Outcomes With Pembrolizumab Versus Chemotherapy as First-Line Therapy in Patients With Nonâ€“Small-Cell Lung Cancer and Programmed Death Ligand-1 Tumor Proportion Score â‰¥ 1% in the KEYNOTE-042 Study,2023-04-10,pembrolizumab,True,"['EMD Serono', 'Merck Serono', 'MSD', 'Merck Sharp & Dohme', 'Merck']",1,Brazil,18,10,2,8,3,4,1,1,0,0,1,1,1,0,1,0
Effect of preoperative chemotherapy on the outcome of women with operable breast cancer,2023-04-01,doxorubicin,False,[],0,USA. bfisher@aherf.edu,16,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Nonâ€“Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial,2023-04-01,osimertinib,True,"['AstraZeneca Japan', 'AstraZeneca/MedImmune', 'AstraZeneca Canada', 'AstraZeneca']",1,USA,25,18,3,15,3,7,1,1,0,0,1,1,0,0,0,1
Evaluation of the Sensitivity to Endocrine Therapy Index and 21-Gene Breast Recurrence Score in the SWOG S8814 Trial,2023-04-01,tamoxifen,False,[],0,USA,16,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Ibrutinib for First-Line Treatment of Chronic Graft-Versus-Host Disease: Results From the Randomized Phase III iNTEGRATE Study,2023-04-01,ibrutinib,True,"['Pharmacyclics LLC', 'an AbbVie Company', 'an AbbVie Company/Janssen', 'AbbVie/Pharmacyclics LLC', 'AbbVie', 'Patent held with Pharmacyclics LLC']",1,USA,21,9,5,7,3,3,1,0,0,0,1,0,0,0,0,0
"Postoperative Adjuvant Hepatic Arterial Infusion Chemotherapy With FOLFOX in Hepatocellular Carcinoma With Microvascular Invasion: A Multicenter, Phase III, Randomized Study",2023-04-01,oxaliplatin,False,[],0,China,27,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Axatilimab for Chronic Graft-Versus-Host Disease After Failure of at Least Two Prior Systemic Therapies: Results of a Phase I/II Study,2023-04-01,axatilimab,True,"['Syndax Pharmaceuticals', 'Syndax Pharmaceuticals Inc', 'Syndax']",0,USA,21,11,6,4,0,1,0,1,0,0,0,0,0,0,0,0
Decitabine Versus Hydroxyurea for Advanced Proliferative Chronic Myelomonocytic Leukemia: Results of a Randomized Phase III Trial Within the EMSCO Network,2023-04-01,decitabine,True,"['BMSi', 'BMS GmbH & Co. KG', 'Bristol Myers Squibb/Celgene', 'BMS', 'Celgene/Bristol Myers Squibb']",1,France,33,7,0,6,0,6,1,0,0,0,1,0,0,0,1,0
Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer,2023-03-20,trastuzumab,False,[],0,USA,13,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"A First-in-Human Phase I Study of Milademetan, an MDM2 Inhibitor, in Patients With Advanced Liposarcoma, Solid Tumors, or Lymphomas",2023-03-20,milademetan,True,"['Rain Oncology', 'Licensing fees for patent from Rain Oncology']",0,USA,15,5,3,3,0,0,1,1,0,0,1,1,0,0,0,0
Nivolumab Plus Cabozantinib With or Without Ipilimumab for Advanced Hepatocellular Carcinoma: Results From Cohort 6 of the CheckMate 040 Trial,2023-03-20,nivolumab,True,"['Bristol Myers Squibb/Medarex', 'Bristol Myers Squibb/Celgene', 'Bristol Myers Squibb']",1,China,19,12,2,7,4,3,1,0,0,0,1,0,0,0,1,0
Multicenter Phase II Trial of the WEE1 Inhibitor Adavosertib in Refractory Solid Tumors Harboring CCNE1 Amplification,2023-03-20,adavosertib,True,"['AstraZeneca', 'AstraZeneca/MedImmune']",0,USA,20,5,0,2,1,0,0,1,0,0,0,1,0,0,0,0
Three-Year Update of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia in the ELIANA Trial,2023-03-20,tisagenlecleucel,True,"['Novartis', 'Novartis Canada Pharmaceuticals Inc', 'Novartis Oncology Canada', 'Novartis Ireland Ltd']",1,USA,26,25,2,17,6,11,1,1,0,0,1,1,0,0,0,0
"Coadministration of CD19- and CD22-Directed Chimeric Antigen Receptor T-Cell Therapy in Childhood B-Cell Acute Lymphoblastic Leukemia: A Single-Arm, Multicenter, Phase II Trial",2023-03-20,CD19-/CD22-CAR T-cell therapy,True,['Miltenyi Biotec'],0,China,42,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0
Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic Disease ,2023-03-10,trastuzumab,False,[],0,France,11,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Preoperative Chemotherapy for Operable Colon Cancer: Mature Results of an International Randomized Controlled Trial,2023-03-10,oxaliplatin-fluoropyrimidine,False,[],1,United Kingdom,14,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Multicenter Phase II Clinical Trial of Gemcitabine and Cisplatin as Neoadjuvant Chemotherapy for Patients With High-Grade Upper Tract Urothelial Carcinoma,2023-03-10,gemcitabine,False,[],0,USA,33,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Overall Survival With Daratumumab, Bortezomib, and Dexamethasone in Previously Treated Multiple Myeloma (CASTOR): A Randomized, Open-Label, Phase III Trial",2023-03-10,daratumumab,True,"['Janssen Research & Development', 'Janssen Oncology', 'Janssen', 'Janssen-Cilag']",1,the Netherlands,19,16,4,9,3,7,1,1,0,0,1,1,0,1,0,1
Phase IIa Study of SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma,2023-03-01,SurVaxM,True,['MimiVax'],0,USA,20,5,2,0,0,0,1,1,0,0,0,0,0,0,0,0
Adjuvant Exemestane With Ovarian Suppression in Premenopausal Breast Cancer: Long-Term Follow-Up of the Combined TEXT and SOFT Trials,2023-03-01,exemestane,False,[],1,Switzerland,27,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Adjuvant Endocrine Therapy in Premenopausal Breast Cancer: 12-Year Results From SOFT,2023-03-01,exemestane,False,[],1,Australia,28,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Pembrolizumab Versus Placebo as Second-Line Therapy in Patients From Asia With Advanced Hepatocellular Carcinoma: A Randomized, Double-Blind, Phase III Trial",2023-03-01,pembrolizumab,True,"['Merck Sharp & Dohme', 'MSD', 'Merck']",1,China,20,6,4,2,0,1,1,1,0,1,1,0,0,0,0,0
"Phase IIb Randomized, Placebo-Controlled, Dose-Escalating, Double-Blind Study of Cannabidiol Oil for the Relief of Symptoms in Advanced Cancer (MedCan1-CBD)",2023-03-01,cannabidiol,False,[],0,Australia,6,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Randomized Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors (ECOG-ACRIN E2211),2023-03-01,temozolomide,False,[],0,USA,19,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Nonâ€“Small-Cell Lung Cancer,2023-02-20,gefitinib,False,[],0,Spain,20,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Nivolumab and Doxorubicin, Vinblastine, and Dacarbazine in Early-Stage Unfavorable Hodgkin Lymphoma: Final Analysis of the Randomized German Hodgkin Study Group Phase II NIVAHL Trial",2023-02-20,nivolumab,True,"['Bristol Myers Squibb', 'BMS', 'BMS Germany', 'BMVS/Celgene', 'BMS GmbH & Co KG']",0,Germany,18,6,0,3,0,4,1,1,0,0,0,1,0,0,1,1
Mepitel Film for the Prevention of Acute Radiation Dermatitis in Breast Cancer: A Randomized Multicenter Open-Label Phase III Trial,2023-02-20,mepitel film,True,['MÃ¶lnlycke'],0,Canada,30,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Phase II Randomized Study of Salvage Radiation Therapy Plus Enzalutamide or Placebo for High-Risk Prostate-Specific Antigen Recurrent Prostate Cancer After Radical Prostatectomy: The SALV-ENZA Trial,2023-02-20,enzalutamide,True,['Astellas Pharma'],0,USA,31,6,0,5,0,2,1,1,0,0,1,1,0,0,0,1
Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Nonâ€“Small-Cell Lung Cancer: The Phase III POSEIDON Study,2023-02-20,tremelimumab,True,['AstraZeneca'],1,USA,20,12,2,7,3,2,1,1,0,0,1,1,0,0,0,1
"Phase II, Open-Label Study of Ciltacabtagene Autoleucel, an Antiâ€“B-Cell Maturation Antigen Chimeric Antigen Receptorâ€“T-Cell Therapy, in Chinese Patients With Relapsed/Refractory Multiple Myeloma (CARTIFAN-1)",2023-02-20,ciltacabtagene autoleucel,True,"['Janssen Oncology', 'Janssen', 'Johnson & Johnson/Janssen', 'Janssen Research & Development']",0,China,19,7,7,0,0,0,0,0,0,0,0,0,0,0,0,0
NRG Oncology/RTOG1205: A Randomized Phase II Trial of Concurrent Bevacizumab and Reirradiation Versus Bevacizumab Alone as Treatment for Recurrent Glioblastoma,2023-02-20,bevacizumab,False,[],0,USA,17,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Nonâ€“Small-Cell Lung Cancer in CheckMate 227,2023-02-20,nivolumab,True,"['Bristol Myers Squibb/Pfizer', 'Bristol Myers Squibb', 'Bristol Myers Squibb Japan', 'Bristol Myers Squibb/Celgene', 'BMS']",1,USA,24,16,5,9,3,6,1,1,0,0,1,1,0,0,0,0
"Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab",2023-02-10,nivolumab,False,[],0,USA,21,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
A Phase Ib/II Study of Lenvatinib and Pembrolizumab in Advanced Endometrial Carcinoma (Study 111/KEYNOTE-146): Long-Term Efficacy and Safety Update,2023-02-10,lenvatinib,True,['Eisai'],0,USA,13,8,3,4,1,2,1,1,0,0,1,1,0,1,0,1
Zanubrutinib Versus Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: Interim Analysis of a Randomized Phase III Trial,2023-02-10,zanubrutinib,True,"['BeiGene', 'BeiGene Beijing']",1,United Kingdom,28,17,6,7,1,4,1,1,1,1,0,0,0,0,0,0
Potential Mediators of Oxaliplatin-Induced Peripheral Neuropathy From Adjuvant Therapy in Stage III Colon Cancer: Findings From CALGB (Alliance)/SWOG 80702,2023-02-10,oxaliplatin,False,[],0,USA,15,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Smartphone Psychotherapy Reduces Fear of Cancer Recurrence Among Breast Cancer Survivors: A Fully Decentralized Randomized Controlled Clinical Trial (J-SUPPORT 1703 Study),2023-02-10,,False,[],0,Japan,19,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Phase Ib Study of Telisotuzumab Vedotin in Combination With Erlotinib in Patients With c-Met Proteinâ€“Expressing Nonâ€“Small-Cell Lung Cancer,2023-02-10,telisotuzumab vedotin,True,"['AbbVie', 'A patent on the DR4/5 and KRAS relationship. Patent filed by AbbVie and I am listed as a coinventor. No royalties are received']",1,USA,18,16,6,4,0,1,1,1,0,1,0,0,0,0,1,0
"Phase I Study of Single-Agent Antiâ€“Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates",2023-02-01,nivolumab,False,[],0,USA,20,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Trastuzumab Deruxtecan in Antiâ€“Human Epidermal Growth Factor Receptor 2 Treatmentâ€“Naive Patients With Human Epidermal Growth Factor Receptor 2â€“Low Gastric or Gastroesophageal Junction Adenocarcinoma: Exploratory Cohort Results in a Phase II Trial,2023-02-01,trastuzumab deruxtecan,True,"['Daiichi Sankyo', 'Daiichi Sankyo/AstraZeneca', 'Daiichi Sankyo Co. Ltd', 'Daiichi-Sankyo Co', 'Daiichi Sankyo/UCB Japan', 'Daiichi Sankyo Co']",1,Japan,18,13,5,5,2,3,1,1,0,0,1,1,1,0,0,0
Effects of a Geriatric Assessment Intervention on Patient-Reported Symptomatic Toxicity in Older Adults With Advanced Cancer,2023-02-01,,False,[],0,USA,17,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Optimal Treatment Duration of Bevacizumab as Front-Line Therapy for Advanced Ovarian Cancer: AGO-OVAR 17 BOOST/GINECO OV118/ENGOT Ov-15 Open-Label Randomized Phase III Trial,2023-02-01,bevacizumab,True,"['Roche/Genentech', 'Roche Pharma', 'Roche Pharma AG', 'Roche']",1,Germany,30,21,0,15,2,13,1,1,0,0,1,1,0,0,1,1
Randomized Trial of Olaparib With or Without Cediranib for Metastatic Castration-Resistant Prostate Cancer: The Results From National Cancer Institute 9984,2023-02-01,Cediranib,True,"['AstraZeneca', 'AstraZeneca/MedImmune']",0,USA,24,8,0,6,1,2,0,1,0,0,0,1,0,0,0,0
Pembrolizumab With or Without Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase III KEYNOTE-048 Study,2023-02-01,pembrolizumab,True,"['Merck Serono', 'Merck Sharp & Dohme', 'Merck', 'Merck sharp & Dohme', 'Merck KGaA']",1,United Kingdom,21,19,3,10,5,9,1,1,0,0,1,0,1,0,1,0
Interferon Alfa-2b Adjuvant Therapy of High-Risk Resected Cutaneous Melanoma: The Eastern Cooperative Oncology Group Trial EST 1684,2023-01-20,interferon alfa-2b,False,[],0,USA,6,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
High-Dose Cytarabine and Autologous Stem-Cell Transplantation in Mantle Cell Lymphoma: Long-Term Follow-Up of the Randomized Mantle Cell Lymphoma Younger Trial of the European Mantle Cell Lymphoma Network,2023-01-20,rituximab,True,"['Roche/Genentech', 'Roche']",1,France,27,14,0,11,2,8,0,1,0,0,0,1,0,0,0,1
Efficacy and Safety of Trametinib Monotherapy or in Combination With Dabrafenib in Pediatric BRAF V600â€“Mutant Low-Grade Glioma,2023-01-20,trametinib,True,['Novartis'],1,Canada,11,8,4,3,0,0,1,1,0,1,1,0,0,0,0,0
Alliance A071401: Phase II Trial of Focal Adhesion Kinase Inhibition in Meningiomas With Somatic NF2 Mutations,2023-01-20,GSK2256098,True,['GlaxoSmithKline'],0,USA,45,4,0,2,0,0,0,0,0,0,0,0,0,0,0,0
FORT-1: Phase II/III Study of Rogaratinib Versus Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Carcinoma Selected Based on FGFR1/3 mRNA Expression,2023-01-20,rogaratinib,True,"['Bayer', 'Bayer HealthCare Pharmacuticals', 'Bayer Schering Pharma', 'Bayer Yakuhin']",1,USA,23,16,7,7,0,1,1,1,0,1,0,0,0,0,0,0
A Pragmatic Cluster-Randomized Trial of a Standing Order Entry Intervention for Colony-Stimulating Factor Use Among Patients at Intermediate Risk for Febrile Neutropenia,2023-01-20,colony-stimulating factors,False,[],0,USA,14,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Toripalimab Plus Chemotherapy for Patients With Treatment-Naive Advanced Nonâ€“Small-Cell Lung Cancer: A Multicenter Randomized Phase III Trial (CHOICE-01),2023-01-20,Toripalimab,True,"['Shanghai Junshi BioSciences Inc patent', 'Shanghai Junshi BioSciences']",0,China,67,2,2,0,0,0,0,0,0,0,0,0,0,0,0,0
"A Phase II, Two-Stage Study of Letrozole and Abemaciclib in Estrogen Receptorâ€“Positive Recurrent Endometrial Cancer",2023-01-20,abemaciclib,True,['Lilly'],0,USA,21,2,0,0,0,0,1,0,0,0,0,0,0,0,0,0
Adjuvant Therapy of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Patients With Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915),2023-01-20,nivolumab,True,"['Bristol-Myers Squibb', 'Bristol Myers Squibb Foundation', 'Bristol Myers Squibb (I)', 'Bristol Myers Squibb/Roche', 'Bristol- Myers Squibb', 'Bristol Myers Squibb/Celgene', 'BMS']",1,USA,36,11,1,3,1,4,0,1,0,0,0,0,0,0,0,1
Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial,2023-01-20,olaparib,True,"['AstraZeneca/Merck', 'AstraZeneca', 'AstraZeneca (I)']",1,USA,23,19,3,13,2,4,1,1,0,0,1,1,0,0,0,0
Acquired Genomic Alterations on First-Line Chemotherapy With Cetuximab in Advanced Colorectal Cancer: Circulating Tumor DNA Analysis of the CALGB/SWOG-80405 Trial (Alliance),2023-01-20,cetuximab,True,"['Lilly', 'Daiichi Sankyo/Lilly']",0,USA,7,2,0,1,0,0,0,0,0,0,0,0,0,0,0,0
"Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced Melanoma",2023-01-20,talimogene laherparepvec (T-VEC),True,['Amgen'],1,USA,29,19,4,9,1,4,1,1,0,0,0,1,0,0,0,0
EphrinB2 Inhibition and Pembrolizumab in Metastatic Urothelial Carcinoma,2023-01-20,sEphB4-HSA,False,[],0,USA,18,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Elotuzumab Plus Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Final Overall Survival Analysis From the Randomized Phase II ELOQUENT-3 Trial,2023-01-20,elotuzumab,True,"['Bristol Myers Squibb/Celgene', 'Celgene/Bristol Myers Squibb', 'Briston Myers Squibb', 'BMS Canada', 'Bristol Myers Squibb']",1,Greece,16,11,4,5,0,4,1,1,1,0,0,1,0,0,0,0
Rituximab Chimeric Anti-CD20 Monoclonal Antibody Therapy for Relapsed Indolent Lymphoma: Half of Patients Respond to a Four-Dose Treatment Program,2023-01-10,rituximab,False,[],0,USA. pmclaugh@notes.mdacc.tmc.edu,16,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Margetuximab Versus Trastuzumab in Patients With Previously Treated HER2-Positive Advanced Breast Cancer (SOPHIA): Final Overall Survival Results From a Randomized Phase 3 Trial,2023-01-10,margetuximab,True,['MacroGenics'],1,USA,35,13,4,4,0,1,1,1,0,1,1,0,0,0,0,0
Low-Dose Immunotherapy in Head and Neck Cancer: A Randomized Study,2023-01-10,nivolumab,False,[],0,India,27,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"DaBlaCa-13 Study: Oncological Outcome of Short-Term, Intensive Chemoresection With Mitomycin in Nonmuscle Invasive Bladder Cancer: Primary Outcome of a Randomized Controlled Trial",2023-01-10,mitomycin,True,['Medac'],0,Denmark,6,2,0,0,0,1,1,1,0,0,0,0,0,0,1,0
Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF-Mutant Melanoma: The DREAMseq Trialâ€”ECOG-ACRIN EA6134,2023-01-10,,False,[],0,USA,36,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Selpercatinib in Patients With RET Fusionâ€“Positive Nonâ€“Small-Cell Lung Cancer: Updated Safety and Efficacy From the Registrational LIBRETTO-001 Phase I/II Trial,2023-01-10,Selpercatinib,False,"['Lilly', 'Lilly (I)', 'Loxo/Lilly', 'Lilly Japan', 'Loxo/Bayer/Lilly']",1,USA,18,13,5,7,0,3,1,1,0,0,1,0,0,0,0,0
"Busulfan Plus Cyclophosphamide Versus Total Body Irradiation Plus Cyclophosphamide for Adults Acute B Lymphoblastic Leukemia: An Open-Label, Multicenter, Phase III Trial",2023-01-10,busulfan,False,[],0,China,25,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
A Phase III Study of Pafolacianine Injection (OTL38) for Intraoperative Imaging of Folate Receptorâ€“Positive Ovarian Cancer (Study 006),2023-01-10,pafolacianine,False,[],0,USA,14,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Safety, Immunogenicity, and 1-Year Efficacy of Universal Cancer Peptideâ€“Based Vaccine in Patients With Refractory Advanced Nonâ€“Small-Cell Lung Cancer: A Phase Ib/Phase IIa De-Escalation Study",2023-01-10,UCPVax,True,['OSE Immunotherapeutics'],0,France,30,3,0,2,0,0,0,0,0,0,0,0,0,0,0,0
"Sequencing of Ipilimumab Plus Nivolumab and Encorafenib Plus Binimetinib for Untreated BRAF-Mutated Metastatic Melanoma (SECOMBIT): A Randomized, Three-Arm, Open-Label Phase II Trial",2023-01-10,encorafenib,True,['Pfizer'],1,Italy,30,6,0,3,1,3,1,0,0,0,1,0,0,0,0,0
"Neoadjuvant Chemotherapy, Excision, and Observation for Early Rectal Cancer: The Phase II NEO Trial (CCTG CO.28) Primary End Point Results",2023-01-10,modified folinic acid-fluorouracil-oxaliplatin 6 (FOLFOX),False,[],0,USA,20,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Neoadjuvant Nivolumab Plus Ipilimumab and Adjuvant Nivolumab in Localized Deficient Mismatch Repair/Microsatellite Instabilityâ€“High Gastric or Esophagogastric Junction Adenocarcinoma: The GERCOR NEONIPIGA Phase II Study,2023-01-10,nivolumab,True,"['BMS', 'Bristol Myers Squibb (Mexico)', 'Bristol Myers Squibb']",0,France,19,9,0,6,1,6,1,1,0,0,1,1,0,0,1,1
Physical Activity in Stage III Colon Cancer: CALGB/SWOG 80702 (Alliance),2023-01-10,fluorouracil,False,[],0,USA,16,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Brentuximab Vedotin Plus AVD for First-Line Treatment of Early-Stage Unfavorable Hodgkin Lymphoma (BREACH): A Multicenter, Open-Label, Randomized, Phase II Trial",2023-01-10,brentuximab vedotin,True,"['Takeda', 'Takeda Science Foundation']",1,France,26,1,0,1,0,1,1,1,0,0,1,1,0,0,1,1
"A Randomized, Double-Blind, Biomarker-Selected, Phase II Clinical Trial of Maintenance Poly ADP-Ribose Polymerase Inhibition With Rucaparib Following Chemotherapy for Metastatic Urothelial Carcinoma",2023-01-01,rucaparib,True,['Clovis Oncology'],0,United Kingdom,21,3,0,0,0,1,1,1,0,0,0,0,0,0,0,0
"Lenvatinib Combined With Transarterial Chemoembolization as First-Line Treatment for Advanced Hepatocellular Carcinoma: A Phase III, Randomized Clinical Trial (LAUNCH)",2023-01-01,lenvatinib,False,[],0,China,19,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Phase II LEAP-004 Study of Lenvatinib Plus Pembrolizumab for Melanoma With Confirmed Progression on a Programmed Cell Death Protein-1 or Programmed Death Ligand 1 Inhibitor Given as Monotherapy or in Combination,2023-01-01,lenvatinib,True,['Eisai'],1,Spain,22,2,2,0,0,0,0,0,0,0,0,0,0,0,0,0
"Open-Label, Randomized, Multicenter, Phase III Study Comparing Oral Paclitaxel Plus Encequidar Versus Intravenous Paclitaxel in Patients With Metastatic Breast Cancer",2023-01-01,encequidar,True,"['Athenex', 'Multiple patents held as an employee of Athenex Inc']",1,USA,14,5,4,0,0,0,0,1,0,1,0,0,0,0,0,0
"Durvalumab Plus Olaparib in Previously Untreated, Platinum-Ineligible Patients With Metastatic Urothelial Carcinoma: A Multicenter, Randomized, Phase II Trial (BAYOU)",2023-01-01,,False,[],1,USA,12,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Partial Breast Irradiation Versus Whole Breast Irradiation for Early Breast Cancer Patients in a Randomized Phase III Trial: The Danish Breast Cancer Group Partial Breast Irradiation Trial,2022-12-20,,False,[],0,Denmark,16,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Phase II Study of Enzalutamide for Patients With Androgen Receptorâ€“Positive Salivary Gland Cancers (Alliance A091404),2022-12-20,enzalutamide,True,['Astellas Pharma'],0,USA,17,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0
"COLUMBUS 5-Year Update: A Randomized, Open-Label, Phase III Trial of Encorafenib Plus Binimetinib Versus Vemurafenib or Encorafenib in Patients With BRAF V600â€“Mutant Melanoma",2022-12-20,encorafenib,True,"['Array BioPharma', 'Array BioPharma/Pfizer']",1,Switzerland,18,2,0,1,0,1,0,1,0,0,0,1,0,0,0,0
Time to Cure for Childhood and Young Adult Acute Lymphoblastic Leukemia Is Independent of Early Risk Factors: Long-Term Follow-Up of the UKALL2003 Trial,2022-12-20,,False,[],0,United Kingdom,13,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Twenty-Year Benefit From Adjuvant Goserelin and Tamoxifen in Premenopausal Patients With Breast Cancer in a Controlled Randomized Clinical Trial,2022-12-10,goserelin,False,[],0,Sweden,16,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Venetoclax Plus Gilteritinib for FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia,2022-12-10,gilteritinib,True,['Astellas Pharma'],0,USA,19,9,1,6,1,1,1,1,0,0,1,1,0,0,0,0
Phase III Randomized Trial of Maintenance Taxanes Versus Surveillance in Women With Advanced Ovarian/Tubal/Peritoneal Cancer: A Gynecologic Oncology Group 0212:NRG Oncology Study,2022-12-10,paclitaxel,False,[],0,USA,21,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Identification of Patients With Ovarian Cancer Experiencing the Highest Benefit From Bevacizumab in the First-Line Setting on the Basis of Their Tumor-Intrinsic Chemosensitivity (KELIM): The GOG-0218 Validation Study,2022-12-01,bevacizumab,True,"['Roche/Genentech', 'Genentech/Roche', '`Roche/Genentech', 'Roche', 'Genentech']",0,France,20,10,1,6,2,1,1,1,0,1,1,0,0,0,0,0
"Updated Overall Survival and Exploratory Analysis From Randomized, Phase II EVAN Study of Erlotinib Versus Vinorelbine Plus Cisplatin Adjuvant Therapy in Stage IIIA Epidermal Growth Factor Receptor+ Nonâ€“Small-Cell Lung Cancer",2022-12-01,erlotinib,True,['Roche China'],0,China,19,1,0,1,0,0,1,1,0,0,1,1,0,0,0,0
"Ripretinib Versus Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumor After Treatment With Imatinib (INTRIGUE): A Randomized, Open-Label, Phase III Trial",2022-12-01,ripretinib,True,"['Deciphera', 'DEciphera']",1,Germany,19,18,5,9,0,4,1,1,0,1,1,0,0,0,1,0
Overall Survival Results From the POLO Trial: A Phase III Study of Active Maintenance Olaparib Versus Placebo for Germline BRCA-Mutated Metastatic Pancreatic Cancer,2022-12-01,olaparib,True,"['AstraZeneca/MedImmune', 'MSD/AstraZeneca', 'AstraZeneca (I)', 'AstraZeneca']",1,USA,19,16,3,12,2,3,1,1,0,0,1,1,0,1,0,1
"A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENAâ€“MONO/GOG-3020/ENGOT-ov45)",2022-12-01,rucaparib,True,"['Clovis Oncology Inc', 'Clovis Oncology']",1,USA,39,19,4,9,3,4,1,1,0,0,1,1,1,0,1,1
Long-Term Efficacy and Safety of Luspatercept for Anemia Treatment in Patients With Lower-Risk Myelodysplastic Syndromes: The Phase II PACE-MDS Study,2022-11-20,luspatercept,True,"['Bristol Myers Squibb/Celgene', 'BMS', 'Celgene/BMS', 'Celgene/Bristol Myers Squibb', 'BMS GmbH & Co KG', 'Celgene/BMSD']",1,Germany,19,10,1,4,0,5,1,1,0,0,1,1,0,0,0,1
"Effectiveness of Intensive Versus Minimalist Follow-Up Regimen on Survival in Patients With Endometrial Cancer (TOTEM Study): A Randomized, Pragmatic, Parallel Group, Multicenter Trial",2022-11-20,,False,"['MSD/AstraZeneca', 'AstraZeneca']",0,Italy,14,2,0,2,0,0,1,1,0,0,1,1,0,0,0,0
Intensive Multimodality Therapy for Extraocular Retinoblastoma: A Children's Oncology Group Trial (ARET0321),2022-11-20,carboplatin,False,[],1,USA,15,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Early Local Therapy for the Primary Site in De Novo Stage IV Breast Cancer: Results of a Randomized Clinical Trial (EA2108),2022-11-20,,False,[],0,Turkey,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Randomized Phase II Trial of Proton Craniospinal Irradiation Versus Photon Involved-Field Radiotherapy for Patients With Solid Tumor Leptomeningeal Metastasis,2022-11-20,proton craniospinal irradiation (pCSI),False,"['Nanobiotix', 'Nanocan Therapeutics']",0,USA,22,2,0,2,0,0,1,0,0,0,1,0,0,0,0,0
Oxaliplatin (3 months v 6 months) With 6 Months of Fluoropyrimidine as Adjuvant Therapy in Patients With Stage II/III Colon Cancer: KCSG CO09-07,2022-11-20,oxaliplatin,True,['Sanofi'],0,South Korea,23,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Phase II Study of Venetoclax Added to Cladribine Plus Low-Dose Cytarabine Alternating With 5-Azacitidine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia,2022-11-20,venetoclax,True,"['Genentech/AbbVie', 'AbbVie', 'AbbVie/Genentech', 'Genentech']",0,USA,27,12,0,11,0,10,1,1,0,0,1,1,0,0,0,1
Radiotherapy or Autologous Stem-Cell Transplantation for Primary CNS Lymphoma in Patients Age 60 Years and Younger: Long-Term Results of the Randomized Phase II PRECIS Study,2022-11-10,methotrexate,False,[],0,France,33,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
FLOT Versus FLOT/Trastuzumab/Pertuzumab Perioperative Therapy of Human Epidermal Growth Factor Receptor 2â€“Positive Resectable Esophagogastric Adenocarcinoma: A Randomized Phase II Trial of the AIO EGA Study Group,2022-11-10,trastuzumab,True,['Roche/Genentech'],0,Germany,25,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Metastatic Rhabdomyosarcoma: Results of the European Paediatric Soft Tissue Sarcoma Study Group MTS 2008 Study and Pooled Analysis With the Concurrent BERNIE Study,2022-11-10,bevacizumab,True,"['Roche/Genentech', 'Roche']",1,the Netherlands,22,6,1,3,0,0,0,0,0,0,0,0,0,0,0,0
"Everolimus Added to Adjuvant Endocrine Therapy in Patients With High-Risk Hormone Receptorâ€“Positive, Human Epidermal Growth Factor Receptor 2â€“Negative Primary Breast Cancer",2022-11-10,everolimus,True,"['GlaxoSmithKline/Novartis', 'Novartis', 'NovartisÂ¸ Seattle Genetics', 'Sandoz-Novartis']",1,France,27,10,0,3,1,2,1,1,0,0,1,0,0,0,0,0
"A Phase I First-in-Human Study of ABBV-383, a B-Cell Maturation Antigen Ã— CD3 Bispecific T-Cell Redirecting Antibody, in Patients With Relapsed/Refractory Multiple Myeloma",2022-11-01,ABBV-383,True,"['AbbVie', 'AbbVie/Pharmacyclics', 'Genentech/Abbvie', 'Abbvie/Pharmacyclics']",0,USA,17,15,9,1,0,1,1,1,0,0,0,1,0,0,0,0
Updated Analysis of NEJ009: Gefitinib-Alone Versus Gefitinib Plus Chemotherapy for Nonâ€“Small-Cell Lung Cancer With Mutated EGFR,2022-11-01,gefitinib,True,"['AstraZeneca', 'AstraZeneca Japan']",0,Japan,16,10,0,1,2,8,1,1,0,0,0,1,0,0,1,1
Food to Overcome Outcomes Disparities: A Randomized Controlled Trial of Food Insecurity Interventions to Improve Cancer Outcomes,2022-11-01,,False,[],0,USA,11,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Post Hoc Analysis of Lorlatinib Intracranial Efficacy and Safety in Patients With ALK-Positive Advanced Nonâ€“Small-Cell Lung Cancer From the Phase III CROWN Study,2022-11-01,lorlatinib,True,['Pfizer'],1,Australia,15,14,4,6,2,7,1,1,0,0,1,1,0,0,1,1
Sacituzumab Govitecan in Hormone Receptorâ€“Positive/Human Epidermal Growth Factor Receptor 2â€“Negative Metastatic Breast Cancer,2022-10-10,sacituzumab govitecan,True,"['Immunomedics', 'Gilead Sciences', 'Immunomedics/Gilead', 'Immunomedics (I)']",1,USA,16,12,4,7,0,2,1,1,0,0,0,1,0,0,0,0
Final Analysis of 3 Versus 6 Months of Adjuvant Oxaliplatin and Fluoropyrimidine-Based Therapy in Patients With Stage III Colon Cancer: The Randomized Phase III ACHIEVE Trial,2022-10-10,oxaliplatin,False,[],0,Japan,23,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"COAST: An Open-Label, Phase II, Multidrug Platform Study of Durvalumab Alone or in Combination With Oleclumab or Monalizumab in Patients With Unresectable, Stage III Nonâ€“Small-Cell Lung Cancer",2022-10-10,durvalumab,True,"['AstraZeneca', 'AstraZeneca Spain', 'AstraZeneca/MedImmune', 'Daiichi Sankyo/AstraZeneca']",1,USA,16,14,5,9,4,4,1,1,0,0,1,1,0,1,0,0
TP53 Sequencing and p53 Immunohistochemistry Predict Outcomes When Bevacizumab Is Added to Frontline Chemotherapy in Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group Study,2022-10-01,bevacizumab,True,"['Genentech', 'Genentech/Roche', 'Roche/Genentech']",0,USA,16,5,0,3,2,0,0,1,0,0,0,1,0,0,0,0
"Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptorâ€“Positive, Human Epidermal Growth Factor Receptor 2â€“Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial",2022-10-01,elacestrant,True,['Radius Health'],1,France,29,7,1,3,0,0,1,1,0,0,1,1,0,0,0,0
"Orteronel for Metastatic Hormone-Sensitive Prostate Cancer: A Multicenter, Randomized, Open-Label Phase III Trial (SWOG-1216)",2022-10-01,orteroneal,True,['Takeda'],0,USA,20,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0
Intensity-Modulated Radiation Therapy Reduces Patient-Reported Chronic Toxicity Compared With Conventional Pelvic Radiation Therapy: Updated Results of a Phase III Trial,2022-09-20,intensity-modulated radiation therapy,True,['Varian Medical Systems'],1,USA,22,2,0,0,0,1,0,0,0,0,0,0,0,0,0,0
AENEAS: A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or MetastaticNonâ€“Small-Cell Lung Cancer With EGFR Exon 19 Deletion or L858R Mutations,2022-09-20,aumolertinib,True,"['Hansoh', 'Jiangsu Hansoh Pharmaceutical Group Co', 'Hansoh Pharma', 'Hansoh Pharmaceutical Group Co']",0,China,59,20,4,12,1,0,1,1,0,1,0,0,1,0,0,0
Randomized Phase II Study of Nivolumab With or Without Ipilimumab Combined With Stereotactic Body Radiotherapy for Refractory Metastatic Pancreatic Cancer (CheckPAC),2022-09-20,nivolumab,True,"['Bristol Myers Squibb', 'BMS']",0,Denmark,18,3,0,0,0,1,1,1,0,0,0,0,0,0,0,1
"Circulating Tumor DNA as a Biomarker in Patients With Stage III and IV Wilms Tumor: Analysis From a Children's Oncology Group Trial, AREN0533",2022-09-10,circulating tumor DNA (ctDNA),True,['Acceleron Pharma'],0,USA,12,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0
Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III Study,2022-09-10,tislelizumab,True,"['BeiGene', 'Beigene']",1,China,31,10,3,4,0,2,0,0,0,0,0,0,0,0,0,0
Atezolizumab With Neoadjuvant Antiâ€“Human Epidermal Growth Factor Receptor 2 Therapy and Chemotherapy in Human Epidermal Growth Factor Receptor 2â€“Positive Early Breast Cancer: Primary Results of the Randomized Phase III IMpassion050 Trial,2022-09-01,atezolizumab,True,"['Roche/Genentech', 'Roche', 'Roche Products Limited']",1,Switzerland,16,15,6,6,1,3,1,1,0,0,1,1,0,0,1,0
"Upfront Modified Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Panitumumab Versus Fluorouracil, Leucovorin, and Oxaliplatin Plus Panitumumab for Patients With RAS/BRAF Wild-Type Metastatic Colorectal Cancer: The Phase III TRIPLETE Study by GONO",2022-09-01,panitumumab,True,['Amgen'],0,Italy,28,7,0,6,2,4,0,1,0,0,0,1,0,0,0,1
Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Nonâ€“Small-Cell Lung Cancer (NADIM phase II trial),2022-09-01,nivolumab,True,"['Bristol Myers Squibb/Medarex', 'Bristol Myers Squibb/Celgene', 'BMS', 'Bristol Myers Squibb', 'Bristol Myers Squibb Foundation']",0,Spain,29,15,0,11,7,0,1,1,0,0,1,0,1,0,0,0
Daily Oral Ibandronate With Adjuvant Endocrine Therapy in Postmenopausal Women With Estrogen Receptorâ€“Positive Breast Cancer (BOOG 2006-04): Randomized Phase III TEAM-IIB Trial,2022-09-01,ibandronate,True,"['Genentech/Roche', 'Roche']",0,the Netherlands,18,3,0,0,0,1,0,1,0,0,0,0,0,0,0,0
Phase II Study of Nivolumab and Salvage Nivolumab/Ipilimumab in Treatment-Naive Patients With Advanced Clear Cell Renal Cell Carcinoma (HCRN GU16-260-Cohort A),2022-09-01,nivolumab,True,"['Bristol Myers Squibb', 'Bristol Myers Squibb Foundation', 'Bristol Myers Squibb/Medarex', 'Bristol Myers Squibb/Celgene']",0,USA,20,12,0,11,1,2,1,1,0,0,1,1,0,0,0,1
"Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone With Minimal Residual Disease Response-Adapted Therapy in Newly Diagnosed Multiple Myeloma",2022-09-01,daratumumab,True,"['Janssen Oncology', 'TakedaÃ‚Â¸ Janssen Oncology', 'Janssen', 'Janssen OncologyÃ‚Â¸ Akcea Therapeutics']",0,USA,17,9,0,6,0,3,1,1,0,0,0,1,0,0,1,1
Organ Preservation in Patients With Rectal Adenocarcinoma Treated With Total Neoadjuvant Therapy,2022-08-10,capecitabine,False,[],0,USA,42,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Phase Ib Study of Navicixizumab Plus Paclitaxel in Patients With Platinum-Resistant Ovarian, Primary Peritoneal, or Fallopian Tube Cancer",2022-08-10,navicixizumab,True,['Mereo BioPharma'],0,USA,12,2,0,2,0,0,0,1,0,0,0,1,0,0,0,0
First-in-Human Phase I/IB Dose-Finding Study of Adagrasib (MRTX849) in Patients With Advanced KRASG12C Solid Tumors (KRYSTAL-1),2022-08-10,adagrasib,True,"['Mirati Therapeutics', 'Multiple patents in the last 2 years while employed at Mirati Therapeutics covering discovery of KRAS']",0,USA,14,10,5,2,0,0,1,1,0,0,0,0,0,0,0,0
"Final Overall Survival Analysis of Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma: A Multicenter, Randomized Phase III Trial",2022-08-01,gemcitabine,False,[],0,China,46,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Narsoplimab, a Mannan-Binding Lectin-Associated Serine Protease-2 Inhibitor, for the Treatment of Adult Hematopoietic Stem-Cell Transplantationâ€“Associated Thrombotic Microangiopathy",2022-08-01,narsoplimab,True,"['Omeros', 'OmerosCorporation']",1,USA,13,7,2,4,0,0,1,1,0,0,1,1,0,0,0,0
"Fuzuloparib Maintenance Therapy in Patients With Platinum-Sensitive, Recurrent Ovarian Carcinoma (FZOCUS-2): A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Trial",2022-08-01,fuzuloparib,True,['Jiangsu Hengrui Pharmaceuticals Co'],0,China,38,3,3,0,0,0,1,1,1,1,0,0,0,0,0,0
"Selinexor in Advanced, Metastatic Dedifferentiated Liposarcoma: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial",2022-08-01,selinexor,True,"['Karyopharm Inc', 'Karyopharm', 'Karyopharm Therapeutics']",1,USA,71,31,11,2,1,1,1,1,0,0,1,0,0,0,0,0
"Imaging Modality and Frequency in Surveillance of Stage I Seminoma Testicular Cancer: Results From a Randomized, Phase III, Noninferiority Trial (TRISST)",2022-08-01,,False,[],0,United Kingdom,41,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Phase II Randomized Study of Ramucirumab and Pembrolizumab Versus Standard of Care in Advanced Nonâ€“Small-Cell Lung Cancer Previously Treated With Immunotherapyâ€”Lung-MAP S1800A,2022-07-20,ramucirumab,True,"['Eli Lilly', 'Eli Lilly and Company', 'Lilly', 'Daiichi Sankyo/Lilly']",0,USA,18,12,0,9,0,0,1,1,0,0,1,1,0,0,0,0
High-Dose Treosulfan and Melphalan as Consolidation Therapy Versus Standard Therapy for High-Risk (Metastatic) Ewing Sarcoma,2022-07-20,treosulfan,False,[],1,Germany,42,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Pembrolizumab Alone or With Chemotherapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma in KEYNOTE-048: Subgroup Analysis by Programmed Death Ligand-1 Combined Positive Score,2022-07-20,pembrolizumab,True,"['a subsidiary of Merck & Co', 'Merck Sharp & Dohme Corp', 'Merck & Co', 'MSD', 'Merck', 'Merck Sharp & Dohme']",1,USA,21,20,6,12,5,7,1,1,0,0,1,1,0,1,0,1
Laparoscopic Sentinel Node Navigation Surgery for Stomach Preservation in Patients With Early Gastric Cancer: A Randomized Clinical Trial,2022-07-20,,False,[],0,Korea,17,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Phase II Trial of Cabozantinib Plus Nivolumab in Patients With Nonâ€“Clear-Cell Renal Cell Carcinoma and Genomic Correlates,2022-07-20,cabozantinib,True,['Exelixis'],0,USA,18,3,0,3,0,0,1,1,0,0,1,1,0,0,0,0
Phase II Study of Selumetinib in Children and Young Adults With Tumors Harboring Activating Mitogen-Activated Protein Kinase Pathway Genetic Alterations: Arm E of the NCI-COG Pediatric MATCH Trial,2022-07-10,selumetinib,True,['AstraZeneca'],0,USA,22,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Actionable Tumor Alterations and Treatment Protocol Enrollment of Pediatric and Young Adult Patients With Refractory Cancers in the National Cancer Instituteâ€“Children's Oncology Group Pediatric MATCH Trial,2022-07-10,,False,[],0,USA,22,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Long-Term Follow-Up of Combination of B-Cell Maturation Antigen and CD19 Chimeric Antigen Receptor T Cells in Multiple Myeloma,2022-07-10,Anti-BCMA and anti-CD19 CAR T cells,False,[],0,China,28,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Olaparib With or Without Cediranib Versus Platinum-Based Chemotherapy in Recurrent Platinum-Sensitive Ovarian Cancer (NRG-GY004): A Randomized, Open-Label, Phase III Trial",2022-07-01,olaparib,True,"['AstraZeneca', 'AstraZeneca/Merck']",0,USA,21,7,0,4,0,0,1,1,0,0,1,1,0,0,0,0
Tailored Immunotherapy Approach With Nivolumab in Advanced Transitional Cell Carcinoma,2022-07-01,nivolumab,True,"['Bristol Myers Squibb/Pfizer', 'Bristol Myers Squibb', 'Bristol Myers Squibb Foundation', 'BMS']",0,Germany,13,7,0,5,0,2,1,0,0,0,1,0,0,0,1,0
Children's Oncology Group Trial AALL1231: A Phase III Clinical Trial Testing Bortezomib in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia and Lymphoma,2022-07-01,bortezomib,True,['Takeda'],0,USA,36,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Long-Term Outcomes and Exploratory Analyses of the Randomized Phase III BILCAP Study,2022-06-20,capecitabine,True,"['Roche/Genentech', 'Roche', 'Roche Pharma AG']",0,United Kingdom,27,10,0,6,1,2,1,1,0,0,1,0,0,0,0,0
"Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients With Nonmetastatic Muscle-Invasive Bladder Cancer: Results of the GETUG-AFU V05 VESPER Trial",2022-06-20,"methotrexate, vinblastine, doxorubicin, and cisplatin (dd-MVAC) chemotherapy regimen",False,[],0,France,13,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Weekly Cisplatin Plus Radiation for Postoperative Head and Neck Cancer (JCOG1008): A Multicenter, Noninferiority, Phase II/III Randomized Controlled Trial",2022-06-20,cisplatin,False,[],0,Japan,34,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Prophylactic Use of Compression Sleeves Reduces the Incidence of Arm Swelling in Women at High Risk of Breast Cancerâ€“Related Lymphedema: A Randomized Controlled Trial,2022-06-20,compression sleeves,True,['SIGVARIS AG GrÃ¶belistrasse 8 CH-9000 St Gallen'],1,Australia,8,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0
Trends in Grade 5 Toxicity and Response in Phase I Trials in Hematologic Malignancy: 20-Year Experience From the Cancer Therapy Evaluation Program at the National Cancer Institute,2022-06-10,,False,[],0,USA,12,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Phase I Study of Safety, Tolerability, and Efficacy of Tebentafusp Using a Step-Up Dosing Regimen and Expansion in Patients With Metastatic Uveal Melanoma",2022-06-10,tebentafusp,True,['Immunocore'],1,USA,14,13,5,7,0,1,1,1,0,0,1,1,0,0,0,0
Intelligent Vacuum-Assisted Biopsy to Identify Breast Cancer Patients With Pathologic Complete Response (ypT0 and ypN0) After Neoadjuvant Systemic Treatment for Omission of Breast and Axillary Surgery,2022-06-10,vacuum-assisted biopsy (VAB) intelligent algorithm,False,[],0,Germany,27,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Selumetinib Plus Adjuvant Radioactive Iodine in Patients With High-Risk Differentiated Thyroid Cancer: A Phase III, Randomized, Placebo-Controlled Trial (ASTRA)",2022-06-10,selumetinib,True,"['AstraZeneca', 'AstraZeneca (I)', 'AstraAzeneca/Merck', 'AstraZeneca/MedImmune']",1,USA,19,6,2,2,0,1,1,0,0,0,1,0,0,0,0,0
"External Validation of the 2003 Leibovich Prognostic Score in Patients Randomly Assigned to SORCE, an International Phase III Trial of Adjuvant Sorafenib in Renal Cell Cancer",2022-06-01,sorafenib,True,[],1,United Kingdom,20,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Effect of an Antiracism Intervention on Racial Disparities in Time to Lung Cancer Surgery,2022-06-01,,False,[],0,USA,13,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Breast Cancers Are Immunogenic: Immunologic Analyses and a Phase II Pilot Clinical Trial Using Mutation-Reactive Autologous Lymphocytes,2022-06-01,tumor-infiltrating lymphocytes (TILs),False,[],0,USA,26,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Efficacy and Safety of Sintilimab Plus Anlotinib for PD-L1Ã¢â‚¬â€œPositive Recurrent or Metastatic Cervical Cancer: A Multicenter, Single-Arm, Prospective Phase II Trial",2022-06-01,sintilimab,False,[],0,China,17,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Improved Survival With Enzalutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer,2022-05-20,enzalutamide,True,"['Astellas', 'Astellas Pharma', 'Astellas Scientific and Medical Affairs Inc', 'Astellas Medivation', 'Medivation/Astellas']",1,USA,16,14,2,11,5,4,1,1,0,0,1,1,0,0,0,0
"Multicenter, Randomized, Phase III Trial of Short-Term Radiotherapy Plus Chemotherapy Versus Long-Term Chemoradiotherapy in Locally Advanced Rectal Cancer (STELLAR)",2022-05-20,capecitabine,False,[],0,China,35,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Addition of Navitoclax to Ongoing Ruxolitinib Therapy for Patients With Myelofibrosis With Progression or Suboptimal Response: Phase II Safety and Efficacy,2022-05-20,navitoclax,True,['AbbVie'],0,United Kingdom,19,13,6,3,0,2,0,1,0,0,0,0,0,0,0,1
Frontline Dual Checkpoint Inhibition in Metastatic Melanoma Over Antiâ€“PD-1 Monotherapy: The Case for a Comparative Randomized Controlled Trial,2022-05-10,,False,[],0,USA,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Temozolomide Followed by Combination With Low-Dose Ipilimumab and Nivolumab in Patients With Microsatellite-Stable, O6-Methylguanineâ€“DNA Methyltransferaseâ€“Silenced Metastatic Colorectal Cancer: The MAYA Trial",2022-05-10,temozolomide,False,[],0,Italy,33,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Minority Enrollment in Phase II and III Clinical Trials in Urologic Oncology,2022-05-10,,False,[],0,USA,5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
SWOG 1318: A Phase II Trial of Blinatumomab Followed by POMP Maintenance in Older Patients With Newly Diagnosed Philadelphia Chromosomeâ€“Negative B-Cell Acute Lymphoblastic Leukemia,2022-05-10,blinatumomab,True,['Amgen'],0,USA,19,8,0,6,0,4,1,1,0,0,1,1,0,0,0,0
Phase II Study of Copanlisib in Patients With Tumors With PIK3CA Mutations: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1F,2022-05-10,copanlisib,True,['Bayer'],0,USA,19,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
Effects of the WRITE Symptoms Interventions on Symptoms and Quality of Life Among Patients With Recurrent Ovarian Cancers: An NRG Oncology/GOG Study (GOG-0259),2022-05-01,,False,[],0,USA,18,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for BRAF V600â€“Mutant Unresectable or Metastatic Melanoma,2022-05-01,spartalizumab,True,['Novartis'],1,Switzerland,25,24,5,17,6,7,1,1,0,0,1,1,0,1,1,1
Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Nonâ€“Small-Cell Lung Cancer,2022-04-20,durvalumab,True,"['AstraZeneca/MedImmune', 'AstraZeneca', 'Daiichi Sankyo/Astra Zeneca']",1,USA,25,23,3,17,4,9,1,0,0,0,1,0,0,0,0,0
"Neoadjuvant Atezolizumab With Gemcitabine and Cisplatin in Patients With Muscle-Invasive Bladder Cancer: A Multicenter, Single-Arm, Phase II Trial",2022-04-20,atezolizumab,True,"['Roche/Genentech', 'Roche', 'Genentech/Roche']",0,USA,39,4,0,2,0,1,1,1,0,0,0,1,0,0,0,0
CALGB 40603 (Alliance): Long-Term Outcomes and Genomic Correlates of Response and Survival After Neoadjuvant Chemotherapy With or Without Carboplatin and Bevacizumab in Triple-Negative Breast Cancer,2022-04-20,bevacizumab,True,"['Roche/Genentech', 'Genentech/Roche', 'Genentech']",0,USA,31,4,0,3,1,2,0,0,0,0,0,0,0,0,0,0
Phase II Randomized Study of CMB305 and Atezolizumab Compared With Atezolizumab Alone in Soft-Tissue Sarcomas Expressing NY-ESO-1,2022-04-20,CMB305,True,['Immune Design'],0,USA,21,8,2,2,1,1,1,0,0,0,1,0,1,0,1,0
Neoadjuvant Chemoradiotherapy Versus Upfront Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Long-Term Results of the Dutch Randomized PREOPANC Trial,2022-04-10,gemcitabine,False,[],0,the Netherlands,33,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Ibrutinib in Combination With Rituximab for Indolent Clinical Forms of Mantle Cell Lymphoma (IMCL-2015): A Multicenter, Open-Label, Single-Arm, Phase II Trial",2022-04-10,ibrutinib,True,"['Janssen', 'Janssen Oncology', 'Janssen-Cilag']",0,Spain,23,10,0,6,1,6,1,1,0,0,0,1,0,0,1,0
Naive T-Cell Depletion to Prevent Chronic Graft-Versus-Host Disease,2022-04-10,,False,[],0,USA,18,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Deintensified Chemoradiotherapy for Pretreatment Epstein-Barr Virus DNA-Selected Low-Risk Locoregionally Advanced Nasopharyngeal Carcinoma: A Phase II Randomized Noninferiority Trial,2022-04-10,cisplatin,False,[],0,China,27,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Adjuvant Capecitabine for Early Breast Cancer: 15-Year Overall Survival Results From a Randomized Trial,2022-04-01,capecitabine,True,['Roche'],0,Finland,16,3,0,2,1,1,0,1,0,0,0,0,0,0,0,0
Positron Emission Tomographyâ€“Driven Strategy in Advanced Hodgkin Lymphoma: Prolonged Follow-Up of the AHL2011 Phase III Lymphoma Study Association Study,2022-04-01,,False,[],0,France,24,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Phase II Trial of Imatinib Plus Binimetinib in Patients With Treatment-Naive Advanced Gastrointestinal Stromal Tumor,2022-03-20,imatinib,True,['Novartis'],0,USA,28,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0
Randomized Phase III Trial of Paclitaxel and Carboplatin Versus Paclitaxel and Ifosfamide in Patients With Carcinosarcoma of the Uterus or Ovary: An NRG Oncology Trial,2022-03-20,paclitaxel,False,[],0,USA,15,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Early Local Therapy for the Primary Site in De Novo Stage IV Breast Cancer: Results of a Randomized Clinical Trial (E2108),2022-03-20,,False,[],0,USA,19,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Patient-Reported Outcome-Based Symptom Management Versus Usual Care After Lung Cancer Surgery: A Multicenter Randomized Controlled Trial,2022-03-20,,False,[],1,China,30,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Randomized Trial of Radiotherapy Versus Transoral Robotic Surgery for Oropharyngeal Squamous Cell Carcinoma: Long-Term Results of the ORATOR Trial,2022-03-10,,False,[],0,Canada,32,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Health-Related Quality of Life in Metastatic, Hormone-Sensitive Prostate Cancer: ENZAMET (ANZUP 1304), an International, Randomized Phase III Trial Led by ANZUP",2022-03-10,enzalutamide,True,"['Astellas Pharma', 'Astellas']",1,Australia,34,12,0,4,3,3,1,1,0,0,0,1,1,0,0,0
Measurable Residual Disease Response and Prognosis in Treatment-NaÃ¯ve Acute Myeloid Leukemia With Venetoclax and Azacitidine,2022-03-10,venetoclax,True,"['AbbVie', 'AbbVie/Genentech']",1,USA,20,16,2,12,2,3,1,1,0,0,1,1,0,0,0,0
Quality of Life in Men With Prostate Cancer Randomly Allocated to Receive Docetaxel or Abiraterone in the STAMPEDE Trial,2022-03-10,abiraterone acetate,True,"['Janssen', 'Janssen (I)', 'Janssen-Cilag', 'Janssen Oncology']",1,United Kingdom,37,15,0,7,6,10,1,0,0,0,1,0,0,0,1,0
"Combination of Trastuzumab, Pertuzumab, and Docetaxel in Patients With Advanced Nonâ€“Small-Cell Lung Cancer Harboring HER2 Mutations: Results From the IFCT-1703 R2D2 Trial",2022-03-01,trastuzumab,True,"['Roche', 'Roche/Genentech']",0,France,19,13,0,8,1,6,1,1,0,0,1,0,0,0,0,0
Pembrolizumab in Patients With Microsatellite Instabilityâ€“High Advanced Endometrial Cancer: Results From the KEYNOTE-158 Study,2022-03-01,pembrolizumab,True,"['Merck Sharp & Dohme', 'Merck', 'MSD', 'MSD Oncology']",1,USA,14,12,3,6,0,3,1,1,0,0,0,1,0,0,0,1
Dual PD-1 and CTLA-4 Checkpoint Blockade Using Balstilimab and Zalifrelimab Combination as Second-Line Treatment for Advanced Cervical Cancer: An Open-Label Phase II Study,2022-03-01,balstilimab,True,"['Agenus', 'Agen7s']",1,USA,15,6,2,3,0,2,1,1,0,0,1,0,0,0,0,1
Poziotinib in Nonâ€“Small-Cell Lung Cancer Harboring HER2 Exon 20 Insertion Mutations After Prior Therapies: ZENITH20-2 Trial,2022-03-01,poziotinib,True,['Spectrum Pharmaceuticals'],1,USA,11,11,3,3,0,2,1,1,0,0,1,0,0,0,0,0
Response-Adapted Postinduction Strategy in Patients With Advanced-Stage Follicular Lymphoma: The FOLL12 Study,2022-03-01,rituximab,True,"['Roche/Genentech', 'Roche']",0,Italy,34,8,0,6,1,2,1,0,0,0,1,0,0,0,0,0
Poziotinib for Patients With HER2 Exon 20 Mutant Nonâ€“Small-Cell Lung Cancer: Results From a Phase II Trial,2022-03-01,poziotinib,True,['Spectrum Pharmaceuticals'],0,USA,16,4,0,2,0,0,1,1,0,0,0,1,0,0,0,0
Treatment Exposure and Discontinuation in the PALbociclib CoLlaborative Adjuvant Study of Palbociclib With Adjuvant Endocrine Therapy for Hormone Receptorâ€“Positive/Human Epidermal Growth Factor Receptor 2â€“Negative Early Breast Cancer (PALLAS/AFT-05/ABCSG-42/BIG-14-03),2022-02-10,palbociclib,True,"['Pfizer (I)', 'Pfizer']",1,USA,33,21,2,6,1,4,1,1,0,0,0,0,0,0,0,0
"Arterial Chemotherapy of Oxaliplatin Plus Fluorouracil Versus Sorafenib in Advanced Hepatocellular Carcinoma: A Biomolecular Exploratory, Randomized, Phase III Trial (FOHAIC-1)",2022-02-10,sorafenib,False,[],0,China,10,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Trastuzumab Emtansine Plus Pertuzumab Versus Taxane Plus Trastuzumab Plus Pertuzumab After Anthracycline for High-Risk Human Epidermal Growth Factor Receptor 2â€“Positive Early Breast Cancer: The Phase III KAITLIN Study,2022-02-10,trastuzumab emtansine (T-DM1),True,"['Roche/Genentech', 'Genentech/Roche', 'Genentech', 'Roche']",1,USA,23,18,6,12,1,6,1,1,0,0,1,1,0,0,1,1
Single-Agent Mosunetuzumab Shows Durable Complete Responses in Patients With Relapsed or Refractory B-Cell Lymphomas: Phase I Dose-Escalation Study,2022-02-10,mosunetuzumab,True,"['Roche/Genentech', 'Genentech/Roche', 'Roche', 'Genentech']",1,USA,21,20,6,11,1,4,1,1,0,0,1,1,0,0,0,0
"BRE12-158: A Postneoadjuvant, Randomized Phase II Trial of Personalized Therapy Versus Treatment of Physician's Choice for Patients With Residual Triple-Negative Breast Cancer",2022-02-01,capecitabine,False,[],0,USA,33,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Randomized Controlled Phase II Evaluation of Two Dose Levels of Bupropion Versus Placebo for Sexual Desire in Female Cancer Survivors: NRG-CC004,2022-02-01,bupropion,False,[],1,USA,17,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Randomized Phase III BMT CTN Trial of Calcineurin Inhibitorâ€“Free Chronic Graft-Versus-Host Disease Interventions in Myeloablative Hematopoietic Cell Transplantation for Hematologic Malignancies,2022-02-01,Tacrolimus,False,[],0,USA,24,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Impact of Pembrolizumab Versus Chemotherapy as Second-Line Therapy for Advanced Esophageal Cancer on Health-Related Quality of Life in KEYNOTE-181,2022-02-01,pembrolizumab,True,"['Merck Sharp & Dohme Corp', 'MSD', 'Merck Serono', 'Merck', 'a subsidiary of Merck & Co']",1,France,13,10,5,4,1,4,1,1,0,0,1,0,0,0,1,1
Improved Outcome in Children With Newly Diagnosed High-Risk Neuroblastoma Treated With Chemoimmunotherapy: Updated Results of a Phase II Study Using hu14.18K322A,2022-02-01,hu14.18K322A,True,['United Therapeutics'],1,USA,23,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03),2022-01-20,palbociclib,True,"['Pfizer', 'PfizerÂ¸ Lilly', 'PfizerÂ¸ AmgenÂ¸ Lilly']",1,Austria,41,21,2,6,2,5,0,1,0,0,0,0,0,0,0,0
Prospective Phase II Open-Label Randomized Controlled Trial to Compare Mandibular Preservation in Upfront Surgery With Neoadjuvant Chemotherapy Followed by Surgery in Operable Oral Cavity Cancer,2022-01-20,docetaxel,True,['Sanofi/Aventis'],0,India,18,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Romidepsin Plus CHOP Versus CHOP in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Results of the Ro-CHOP Phase III Study (Conducted by LYSA),2022-01-20,romidepsin,True,"['Bristol Myers Squibb/Celgene', 'Celgene', 'Celgene/Bristol Myers Squibb', 'CelgeneÂ¸ Servier']",1,France,26,11,2,4,0,5,0,1,0,1,0,0,0,0,0,0
Randomized Phase III Study of Gefitinib Versus Cisplatin Plus Vinorelbine for Patients With Resected Stage II-IIIA Nonâ€“Small-Cell Lung Cancer With EGFR Mutation (IMPACT),2022-01-20,gefitinib,True,"['AstraZeneca KK', 'AstraZeneca Japan', 'AstraZeneca', 'Astra Zeneca']",0,Japan,20,14,0,4,3,11,0,1,0,0,0,0,0,0,0,1
Modified FOLFIRINOX Versus CISGEM Chemotherapy for Patients With Advanced Biliary Tract Cancer (PRODIGE 38 AMEBICA): A Randomized Phase II Study,2022-01-20,gemcitabine,False,['Lilly'],0,France,21,1,0,0,0,1,1,0,0,0,0,0,0,0,1,0
Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma,2022-01-10,nivolumab,True,"['Bristol Myers Squibb', 'Bristol-Myers Squibb', 'BMS']",1,USA,29,26,1,19,5,11,1,1,0,0,1,1,0,0,0,0
Ibrutinib With Rituximab in First-Line Treatment of Older Patients With Mantle Cell Lymphoma,2022-01-10,ibrutinib,True,"['Pharmacyclics/Janssen', 'Pharmacyclics', 'Janssen Research & Development', 'Janssen Oncology']",0,USA,27,2,0,3,0,1,0,1,0,0,0,1,0,0,0,1
"Randomized, Double-Blind, Phase III Study of Fosnetupitant Versus Fosaprepitant for Prevention of Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: CONSOLE",2022-01-10,fosnetupitant,True,['Eisai'],0,Japan,13,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Phase II Randomized Trial of Transoral Surgery and Low-Dose Intensity Modulated Radiation Therapy in Resectable p16+ Locally Advanced Oropharynx Cancer: An ECOG-ACRIN Cancer Research Group Trial (E3311),2022-01-10,cisplatin,False,['Nanobiotix'],0,USA,20,1,0,1,0,0,0,1,0,0,0,1,0,0,0,0
"Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin Versus Transarterial Chemoembolization for Large Hepatocellular Carcinoma: A Randomized Phase III Trial",2022-01-10,"FOLFOX (combination therapy of oxaliplatin, leucovorin, and fluorouracil)",False,[],0,China,12,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study,2022-01-10,nivolumab,True,['Bristol Myers Squibb'],1,USA,17,11,3,6,1,1,1,1,0,0,1,1,0,1,0,0
Venetoclax in Previously Treated WaldenstrÃ¶m Macroglobulinemia,2022-01-01,venetoclax,True,['AbbVie/Genentech'],0,USA,23,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
Ibrutinib Plus Rituximab Versus Placebo Plus Rituximab for WaldenstrÃ¶m's Macroglobulinemia: Final Analysis From the Randomized Phase III iNNOVATE Study,2022-01-01,ibrutinib,True,"['Janssen Oncology', 'Janssen']",1,Germany,20,13,1,8,2,5,1,1,0,0,1,1,1,0,1,1
Panitumumab Plus Fluorouracil and Folinic Acid Versus Fluorouracil and Folinic Acid Alone as Maintenance Therapy in RAS Wild-Type Metastatic Colorectal Cancer: The Randomized PANAMA Trial (AIO KRK 0212),2022-01-01,panitumumab,True,['Amgen'],0,Germany,21,10,0,8,0,7,1,1,0,0,1,0,0,0,1,0
Combining Ixazomib With Subcutaneous Rituximab and Dexamethasone in Relapsed or Refractory WaldenstrÃ¶m's Macroglobulinemia: Final Analysis of the Phase I/II HOVON124/ECWM-R2 Study,2022-01-01,ixazomib,True,['Takeda'],1,the Netherlands,18,5,0,4,0,3,1,1,0,0,1,1,0,0,0,1
Minimal Residual Disease Dynamics after Venetoclax-Obinutuzumab Treatment: Extended Off-Treatment Follow-up From the Randomized CLL14 Study,2021-12-20,venetoclax,True,['AbbVie/Genentech'],1,Germany,22,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0
Phase III Trial Adding Vincristine-Topotecan-Cyclophosphamide to the Initial Treatment of Patients With Nonmetastatic Ewing Sarcoma: A Children's Oncology Group Report,2021-12-20,vincristine,False,[],0,USA,24,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Abiraterone Acetate in Patients With Castration-Resistant, Androgen ReceptorÃ¢â‚¬â€œExpressing Salivary Gland Cancer: A Phase II Trial",2021-12-20,abiraterone acetate,False,[],0,Italy,13,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Radioembolization With Chemotherapy for Colorectal Liver Metastases: A Randomized, Open-Label, International, Multicenter, Phase III Trial",2021-12-10,Yttrium-90 radioembolization,True,"['Sirtex Medical', 'SIR-Tex']",1,USA,25,4,0,4,1,2,0,1,0,0,0,1,0,0,0,0
Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study,2021-12-01,ibrutinib,True,"['Pharmacyclics/Janssen', 'Verastem/Pharmacyclics', 'Janssen', 'Janssen/Pharmacyclics', 'Pharmacyclics', 'AbbVie/Pharmacyclics']",1,USA,21,16,1,9,5,6,1,1,0,0,0,1,0,0,0,1
Hepatectomy Followed by mFOLFOX6 Versus Hepatectomy Alone for Liver-Only Metastatic Colorectal Cancer (JCOG0603): A Phase II or III Randomized Controlled Trial,2021-12-01,mFOLFOX6,False,[],0,Japan,21,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Clinical Responses of Oncolytic Coxsackievirus A21 (V937) in Patients With Unresectable Melanoma,2021-12-01,Coxsackievirus A21 (V937),True,"['Merck', 'Merck Sharp & Dohme', 'Merck (at the time the work was conducted)']",0,USA,13,6,3,2,1,0,1,0,1,0,0,0,0,0,0,0
nab-Sirolimus for Patients With Malignant Perivascular Epithelioid Cell Tumors,2021-11-20,nab-sirolimus,True,"['Aadi Bioscience', 'I hold patents as an employee of Aadi Bioscience']",0,Boston MA,17,13,4,3,0,0,1,1,0,0,0,0,0,0,0,0
"Dose-Adjusted Etoposide, Doxorubicin, and Cyclophosphamide With Vincristine and Prednisone Plus Rituximab Therapy in Children and Adolescents With Primary Mediastinal B-Cell Lymphoma: A Multicenter Phase II Trial",2021-11-20,rituximab,True,"['Genentech (I)', 'F. Hoffmann-La Roche-Genentech', 'Roche/Genentech', 'Roche']",1,United Kingdom,21,5,1,3,0,0,1,1,0,0,1,1,0,0,0,0
Inhibition of WEE1 Is Effective in TP53- and RAS-Mutant Metastatic Colorectal Cancer: A Randomized Trial (FOCUS4-C) Comparing Adavosertib (AZD1775) With Active Monitoring,2021-11-20,adavosertib,True,['AstraZeneca'],0,United Kingdom,23,8,0,1,2,1,0,1,0,0,0,1,0,0,0,0
Late Toxicity After Adjuvant Conventional Radiation Versus Image-Guided Intensity-Modulated Radiotherapy for Cervical Cancer (PARCER): A Randomized Controlled Trial,2021-11-20,image-guided intensity-modulated radiotherapy (IG-IMRT),True,['Varian Medical Systems'],0,India,18,2,0,0,1,1,1,0,0,0,0,0,1,0,1,0
Cabozantinib in Combination With Atezolizumab for Advanced Renal Cell Carcinoma: Results From the COSMIC-021 Study,2021-11-20,cabozantinib,True,['Exelixis'],1,USA,21,19,4,8,2,2,1,1,0,0,0,1,0,0,0,0
Capecitabine Versus Active Monitoring in Stable or Responding Metastatic Colorectal Cancer After 16 Weeks of First-Line Therapy: Results of the Randomized FOCUS4-N Trial,2021-11-20,capecitabine,True,"['Roche Molecular Diagnostics', 'Roche have filed a patent jointly with my University', 'Roche Pharma AG', 'Roche/Genentech', 'Roche']",0,United Kingdom,22,6,0,4,2,2,0,0,0,0,0,0,0,0,0,0
"Nivolumab Versus Gemcitabine or Pegylated Liposomal Doxorubicin for Patients With Platinum-Resistant Ovarian Cancer: Open-Label, Randomized Trial in Japan (NINJA)",2021-11-20,nivolumab,True,['Bristol-Myers Squibb K.K.'],0,Japan,42,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
Consolidation and Maintenance in Newly Diagnosed Multiple Myeloma,2021-11-10,lenalidomide,True,"['Bristol Myers Squibb/Celgene', 'Celgene', 'Celgene/Bristol Myers Squibb', 'Bristol Myers Squibb', 'BMS']",1,the Netherlands,40,20,0,15,8,18,1,1,0,0,1,1,0,1,0,1
"Veliparib in Combination With Platinum-Based Chemotherapy for First-Line Treatment of Advanced Squamous Cell Lung Cancer: A Randomized, Multicenter Phase III Study",2021-11-10,veliparib,True,"['AbbVie', 'Two patent applications pending review assigned to AbbVie Inc', 'Genentech/AbbVie']",1,USA,21,12,6,4,1,3,1,0,0,0,0,0,0,0,0,0
Radiotherapy Versus Inguinofemoral Lymphadenectomy as Treatment for Vulvar Cancer Patients With Micrometastases in the Sentinel Node: Results of GROINSS-V II,2021-11-10,,False,[],1,the Netherlands,59,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Randomized Phase III Trial Evaluating Radiation Following Surgical Excision for Good-Risk Ductal Carcinoma In Situ: Long-Term Report From NRG Oncology/RTOG 9804,2021-11-10,tamoxifen,False,[],0,USA,19,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Phase I Study of Venetoclax Plus Daratumumab and Dexamethasone, With or Without Bortezomib, in Patients With Relapsed or Refractory Multiple Myeloma With and Without t(11;14)",2021-11-10,venetoclax,True,['AbbVie/Genentech'],1,Canada,15,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0
Predicted Risks of Cardiovascular Disease Following Chemotherapy and Radiotherapy in the UK NCRI RAPID Trial of Positron Emission Tomographyâ€“Directed Therapy for Early-Stage Hodgkin Lymphoma,2021-11-10,"doxorubicin, bleomycin, vinblastine, dacarbazine",True,['Nordic Nanovector'],0,United Kingdom,11,1,0,1,0,0,0,1,0,0,0,1,0,0,0,0
Phase I or II Study of Ribociclib in Combination With Topotecan-Temozolomide or Everolimus in Children With Advanced Malignancies: Arms A and B of the AcSÃ©-ESMART Trial,2021-11-10,ribociclib,True,['Novartis'],1,Spain,17,3,0,2,0,0,0,1,0,0,0,1,0,0,0,0
Targeting Depressive Symptoms in Younger Breast Cancer Survivors: The Pathways to Wellness Randomized Controlled Trial of Mindfulness Meditation and Survivorship Education,2021-11-01,,False,[],0,USA,9,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial,2021-11-01,acalabrutinib,True,"['Acerta Pharma', 'Patents pending for Acerta Pharma', 'Acerta Pharma/AstraZeneca']",1,USA,24,12,2,6,0,2,1,1,0,0,1,0,0,0,0,0
Efficacy and Toxicity of Pegaspargase and Calaspargase Pegol in Childhood Acute Lymphoblastic Leukemia: Results of DFCI 11-001,2021-11-01,calaspargase pegol,True,['Jazz Pharmaceuticals'],1,USA,22,1,0,1,0,0,0,1,0,0,0,1,0,0,0,0
"Randomized Phase II Trial of MIBG Versus MIBG, Vincristine, and Irinotecan Versus MIBG and Vorinostat for Patients With Relapsed or Refractory Neuroblastoma: A Report From NANT Consortium",2021-11-01,131I-metaiodobenzylguanidine (MIBG),False,[],0,USA,26,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Durable Responses and Low Toxicity After Fast Off-Rate CD19 Chimeric Antigen Receptor-T Therapy in Adults With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia,2021-10-20,AUTO1 (CAT19-41BB-Z CAR T cells),True,"['Autolus Therapeutics', 'Autolus', 'Autolus Ltd', 'Autolous Therapeutics', 'Autous Ltd', 'Autolus Lts', 'some of which have been licensed to Autolus Therapeutics']",0,United Kingdom,27,5,2,4,0,0,0,1,0,0,0,1,0,0,0,0
Amivantamab in EGFR Exon 20 Insertionâ€“Mutated Nonâ€“Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study,2021-10-20,amivantamab,True,"['Janssen', 'Jenssen', 'Johnson & Johnson/Janssen', 'Janssen Pharmaceuticals of Johnson & Johnson', 'Janssen Research & Development', 'Janssen Oncology', 'Janssen Biotech', 'Janssen Pharmaceutical Company of Johnson & Johnson']",1,South Korea,34,21,5,14,3,2,0,1,0,0,0,1,0,0,0,0
"Donor-Derived CD7 Chimeric Antigen Receptor T Cells for T-Cell Acute Lymphoblastic Leukemia: First-in-Human, Phase I Trial",2021-10-20,anti-CD7 chimeric antigen receptor (CAR) T cells,True,['Shanghai YaKe Biotechnology Ltd'],1,China,22,3,3,0,0,0,1,0,1,0,0,0,0,0,0,0
Biologic Assignment Trial of Reduced-Intensity Hematopoietic Cell Transplantation Based on Donor Availability in Patients 50-75 Years of Age With Advanced Myelodysplastic Syndrome,2021-10-20,,False,[],0,USA,22,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Comparison Between 5-Azacytidine Treatment and Allogeneic Stem-Cell Transplantation in Elderly Patients With Advanced MDS According to Donor Availability (VidazaAllo Study),2021-10-20,azacitidine,True,"['Bristol Myers Squibb/Celgene', 'Celgene', 'Celgene/Bristol Myers Squibb', 'Celgene/Jazz']",0,Germany,22,9,0,7,0,8,1,1,0,0,1,1,0,0,1,1
Gemcitabine Plus Cisplatin Versus Fluorouracil Plus Cisplatin as First-Line Therapy for Recurrent or Metastatic Nasopharyngeal Carcinoma: Final Overall Survival Analysis of GEM20110714 Phase III Study,2021-10-10,gemcitabine,False,[],0,China,30,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Randomized Phase II Trial Evaluating Two Sequential Treatments in First Line of Metastatic Pancreatic Cancer: Results of the PANOPTIMOX-PRODIGE 35 Trial,2021-10-10,oxaliplatin,True,"['Sanofi', 'Sanofi/Aventis']",0,France,19,7,0,2,1,4,0,0,0,0,0,0,0,0,0,0
"Open-Label Phase II Prospective, Randomized, Controlled Study of Romyelocel-L Myeloid Progenitor Cells to Reduce Infection During Induction Chemotherapy for Acute Myeloid Leukemia",2021-10-10,romyelocel-L,True,"['Cellerant Therapeutics', 'Cellerant', 'Hold a patent (Cellerant Therapeutics)']",0,USA,32,5,2,2,0,0,0,1,0,0,0,0,0,0,0,0
Gonadal Function Recovery in Patients With Advanced Hodgkin Lymphoma Treated With a PET-Adapted Regimen: Prospective Analysis of a Randomized Phase III Trial (AHL2011),2021-10-10,doxorubicin,False,[],0,Belgium,21,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Phase II Study of Gemcitabine and Split-Dose Cisplatin Plus Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Bladder Cancer,2021-10-01,pembrolizumab,True,"['Merck Sharp & Dohme', 'Merck']",0,USA,20,7,0,3,0,0,1,1,0,0,0,0,0,0,0,0
Randomized Phase III Trial of Prophylactic Cranial Irradiation With or Without Hippocampal Avoidance for Small-Cell Lung Cancer (PREMER): A GICOR-GOECP-SEOR Study,2021-10-01,,False,"['AstraZeneca', 'AstraZeneca Spain']",0,Spain,27,2,0,1,1,1,1,0,0,0,1,0,1,0,0,0
E2112: Randomized Phase III Trial of Endocrine Therapy Plus Entinostat or Placebo in Hormone Receptorâ€“Positive Advanced Breast Cancer. A Trial of the ECOG-ACRIN Cancer Research Group,2021-10-01,entinostat,True,['Syndax'],0,USA,19,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Avapritinib Versus Regorafenib in Locally Advanced Unresectable or Metastatic GI Stromal Tumor: A Randomized, Open-Label Phase III Study",2021-10-01,avapritinib,True,['Blueprint Medicines'],1,South Korea,22,17,4,10,0,1,1,1,0,0,1,1,0,0,0,0
"Phase II Trial of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin as Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma",2021-10-01,pembrolizumab,True,"['Merck Sharp & Dohme', 'AstraZeneca/Merck', 'Merck']",0,USA,42,6,0,6,0,1,1,1,0,0,1,1,0,0,0,0
Arsenic Combined With All-Trans Retinoic Acid for Pediatric Acute Promyelocytic Leukemia: Report From the CCLG-APL2016 Protocol Study,2021-10-01,arsenic trioxide,False,[],0,China,48,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Gemtuzumab Ozogamicin Improves Event-Free Survival and Reduces Relapse in Pediatric KMT2A-Rearranged AML: Results From the Phase III Children's Oncology Group Trial AAML0531,2021-10-01,gemtuzumab ozogamicin,False,[],0,USA,12,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Randomized Phase II Trial of Vincristine-Irinotecan With or Without Temozolomide, in Children and Adults With Relapsed or Refractory Rhabdomyosarcoma: A European Paediatric Soft Tissue Sarcoma Study Group and Innovative Therapies for Children With Cancer Trial",2021-09-20,temozolomide,True,"['BMS', 'Bristol Myers Squibb/Pfizer']",1,France,16,2,0,1,0,0,1,0,0,0,1,0,0,0,0,0
"Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study",2021-09-20,tremelimumab,True,"['Patent with AstraZeneca', 'AstraZeneca/MedImmune', 'AstraZeneca']",1,USA,24,16,4,9,1,5,1,1,0,0,1,1,0,0,0,0
"Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial",2021-09-20,donafenib,True,['Suzhou Zelgen Biopharmaceuticals Co'],0,China,30,1,1,0,0,0,1,1,1,1,0,0,0,0,0,0
Bempegaldesleukin Plus Nivolumab in First-Line Metastatic Melanoma,2021-09-10,bempegaldesleukin,True,"['Nektar Therapeutics', 'Nektar']",1,USA,21,17,7,4,0,2,1,1,0,0,1,1,0,0,0,0
SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Nonâ€“Small-Cell Lung Cancerâ€”A Multicenter Single-Arm Phase II Trial,2021-09-10,durvalumab,True,"['AstraZeneca AG', 'AstraZeneca']",0,Switzerland,28,13,0,12,1,1,1,1,0,0,1,1,0,0,0,0
Radiation and Androgen Deprivation Therapy With or Without Docetaxel in the Management of Nonmetastatic Unfavorable-Risk Prostate Cancer: A Prospective Randomized Trial,2021-09-10,docetaxel,False,[],0,USA,17,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Randomized, Single-Blind, Multicenter Phase II Study of Two Doses of Imetelstat in Relapsed or Refractory Myelofibrosis",2021-09-10,imetelstat,True,"['Geron', 'Geron Corp']",1,USA,22,10,5,3,0,0,1,0,0,0,1,0,0,0,0,0
"PRODIGY: A Phase III Study of Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 Versus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer",2021-09-10,S-1,True,['Taiho Pharmaceutical'],0,Republic of Korea,37,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0
Randomized Study on Dose Escalation in Definitive Chemoradiation for Patients With Locally Advanced Esophageal Cancer (ARTDECO Study),2021-09-01,paclitaxel,False,[],0,the Netherlands,15,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Randomized Phase II Study of PET Responseâ€“Adapted Combined Modality Therapy for Esophageal Cancer: Mature Results of the CALGB 80803 (Alliance) Trial,2021-09-01,oxaliplatin,False,[],0,USA,18,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia,2021-09-01,venetoclax,True,"['AbbVie/Genentech', 'Genentech/AbbVie', 'AbbVie', 'Genentech']",0,USA,27,12,0,9,0,9,1,1,0,0,1,0,0,0,1,1
"Ixazomib, Daratumumab, and Low-Dose Dexamethasone in Frail Patients With Newly Diagnosed Multiple Myeloma: The Hovon 143 Study",2021-09-01,ixazomib,True,['Takeda'],0,the Netherlands,25,4,0,3,0,1,0,1,0,0,0,1,0,0,0,0
Children's Oncology Group Phase III Trial of Reduced-Dose and Reduced-Volume Radiotherapy With Chemotherapy for Newly Diagnosed Average-Risk Medulloblastoma,2021-08-20,,False,[],0,USA,28,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Pertuzumab Plus High-Dose Trastuzumab in Patients With Progressive Brain Metastases and HER2-Positive Metastatic Breast Cancer: Primary Analysis of a Phase II Study,2021-08-20,Trastuzumab,True,"['Genentech/Roche', 'Genentech', 'Roche']",0,USA,9,6,4,1,0,0,1,0,0,0,0,0,0,0,0,0
Pembrolizumab Plus Ipilimumab Following Anti-PD-1/L1 Failure in Melanoma,2021-08-20,ipilimumab,True,"['Bristol Myers Squibb', 'Licensing to BMS']",0,USA,20,8,0,5,2,1,0,1,0,0,0,1,0,0,0,0
Third-Party BK Virus-Specific Cytotoxic T Lymphocyte Therapy for Hemorrhagic Cystitis Following Allotransplantation,2021-08-20,BKV-specific cytotoxic T lymphocytes (CTLs),False,[],0,USA,43,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Randomized Trial of Two Induction Therapy Regimens for High-Risk Neuroblastoma: HR-NBL1.5 International Society of Pediatric Oncology European Neuroblastoma Group Study,2021-08-10,dinutuximab beta,True,['Apeiron Biologics'],1,Italy,22,1,0,1,0,1,0,1,0,0,0,1,0,0,0,1
Randomized Phase III Postoperative Trial of Platinum-Based Chemotherapy Versus Capecitabine in Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy: ECOG-ACRIN EA1131,2021-08-10,Capecitabine,False,[],0,USA,25,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Secondary Cytoreduction and Carboplatin Hyperthermic Intraperitoneal Chemotherapy for Platinum-Sensitive Recurrent Ovarian Cancer: An MSK Team Ovary Phase II Study,2021-08-10,carboplatin,False,[],0,USA,31,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Final Overall Survival Analysis of the TOURMALINE-MM1 Phase III Trial of Ixazomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma",2021-08-01,ixazomib,True,['Takeda'],1,USA,22,13,3,11,0,4,1,0,0,0,1,0,0,0,0,0
Randomized Phase III Trial of Gemcitabine and Cisplatin With Bevacizumab or Placebo in Patients With Advanced Urothelial Carcinoma: Results of CALGB 90601 (Alliance),2021-08-01,bevacizumab,True,"['Genentech/Roche', 'Roche/Genentech', 'Roche', 'Genentech']",0,USA,21,10,0,5,1,0,1,1,0,0,1,0,0,0,0,0
"Phase II Study of Maintenance Rucaparib in Patients With Platinum-Sensitive Advanced Pancreatic Cancer and a Pathogenic Germline or Somatic Variant in BRCA1, BRCA2, or PALB2",2021-08-01,rucaparib,True,['Clovis Oncology'],0,USA,17,2,0,0,0,1,1,1,0,0,0,0,0,0,0,1
TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors,2021-08-01,sacituzumab govitecan,True,"['Immunomedics', 'Immunomedics/Gilead']",0,USA,19,11,3,7,0,0,1,1,0,0,1,1,0,0,0,0
Pembrolizumab in Patients With Metastatic Breast Cancer With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study,2021-08-01,pembrolizumab,True,"['Merck', 'Merck Sharp & Dohme']",0,USA,20,2,0,1,0,0,1,1,0,0,1,0,0,0,0,0
"Treatment of Pediatric Adrenocortical Carcinoma With Surgery, Retroperitoneal Lymph Node Dissection, and Chemotherapy: The Children's Oncology Group ARAR0332 Protocol",2021-08-01,mitotane,False,[],1,USA,18,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial,2021-07-20,trastuzumab emtansine (T-DM1),True,"['Roche/Genentech', 'Genentech/Roche']",0,USA,47,14,0,7,3,3,1,1,0,0,0,1,0,0,0,1
"Open-Label, Single-Arm, Multicenter, Phase II Trial of Lenvatinib for the Treatment of Patients With Anaplastic Thyroid Cancer",2021-07-20,lenvatinib,True,"['Eisai Europe', 'Eisai']",1,USA,18,13,2,7,2,2,1,1,0,0,1,0,0,0,0,0
Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Nonâ€“Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score â‰¥ 50%,2021-07-20,pembrolizumab,True,"['Merck Sharp & Dohme', 'MSD', 'Merck']",1,Germany,19,16,3,7,1,5,1,1,0,0,1,1,1,0,0,0
Comparison of Radiation With or Without Concurrent Trastuzumab for HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy: A Phase III Clinical Trial,2021-07-20,trastuzumab,True,"['Genentech/Roche', 'Genentech', 'Roche/Genentech']",0,USA,20,2,0,2,1,1,1,1,0,0,1,1,0,1,0,1
"Pembrolizumab Plus Ipilimumab or Placebo for Metastatic Nonâ€“Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score â‰¥ 50%: Randomized, Double-Blind Phase III KEYNOTE-598 Study",2021-07-20,pembrolizumab,True,"['Merck Sharp & Dohme Corp', 'Merck & Co', 'Merck Sharp & Dohme', 'Merck', 'a subsidiary of Merck & Co']",1,Australia,21,20,5,8,3,3,1,1,0,0,1,1,0,1,0,0
Updated Results of TBCRC026: Phase II Trial Correlating Standardized Uptake Value With Pathological Complete Response to Pertuzumab and Trastuzumab in Breast Cancer,2021-07-10,Pertuzumab and Trastuzumab,True,"['Roche/Genentech', 'Roche', 'Genentech/Roche', 'Genentech']",0,USA,23,11,0,4,0,4,1,0,0,0,0,0,0,0,0,0
Lenvatinib in Patients With Advanced Grade 1/2 Pancreatic and Gastrointestinal Neuroendocrine Tumors: Results of the Phase II TALENT Trial (GETNE1509),2021-07-10,lenvatinib,True,"['Eisai', 'EISAI']",1,Spain,29,8,0,6,3,3,1,1,0,0,1,1,1,0,0,0
"Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer: Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN Study",2021-07-10,apalutamide,True,"['Janssen', 'Janssen Research & Development', 'Janssen Oncology', 'Janssen-Cilag']",1,Canada,20,18,8,9,4,4,1,1,0,0,1,1,0,0,1,0
Excellent Outcome for Pediatric Patients With High-Risk Hodgkin Lymphoma Treated With Brentuximab Vedotin and Risk-Adapted Residual Node Radiation,2021-07-10,brentuximab vedotin,True,['Seattle Genetics'],0,USA,21,3,0,0,0,0,1,0,0,0,0,0,0,0,0,0
"National Marrow Donor Programâ€“Sponsored Multicenter, Phase II Trial of HLA-Mismatched Unrelated Donor Bone Marrow Transplantation Using Post-Transplant Cyclophosphamide",2021-06-20,cyclophosphamide,False,[],0,USA,29,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Ten-Year Outcome of Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal Cancer: The Randomized Controlled CROSS Trial,2021-06-20,carboplatin,False,[],0,the Netherlands,31,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Neck Dissections Based on Sentinel Lymph Node Navigation Versus Elective Neck Dissections in Early Oral Cancers: A Randomized, Multicenter, and Noninferiority Trial",2021-06-20,,False,[],0,Japan,21,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
The Randomized AMBORA Trial: Impact of Pharmacological/Pharmaceutical Care on Medication Safety and Patient-Reported Outcomes During Treatment With New Oral Anticancer Agents,2021-06-20,oral anticancer drugs,False,[],0,Germany,23,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Glofitamab, a Novel, Bivalent CD20-Targeting T-Cellâ€“Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial",2021-06-20,glofitamab,True,"['Roche Canada', 'Roche TCRC', 'Co-inventor in Roche-owned patents on glofitamab and obinutuzumab', 'Coinventor in Roche patents', 'F. Hoffmann LaRoche', 'Roche/Genentech', 'Roche']",1,Denmark,23,22,13,5,2,4,1,1,0,0,1,1,0,0,0,1
"Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050/GOG 3015/ENGOT-OV39)",2021-06-10,atezolizumab,True,"['Genentech/Roche', 'Roche/Genentech', 'Roche', 'Roche Diagnostics', 'Roche Pharma AG', 'Genentech']",1,USA,28,17,5,10,0,5,1,1,0,0,1,1,0,0,0,1
ROCK2 Inhibition With Belumosudil (KD025) for the Treatment of Chronic Graft-Versus-Host Disease,2021-06-10,belumosudil,True,"['Kadmon', 'Kadmon Corporation LLC', 'Kadmon Holdings']",0,USA,17,13,8,6,0,1,1,1,0,0,1,1,0,0,0,0
Tipifarnib in Head and Neck Squamous Cell Carcinoma With HRAS Mutations,2021-06-10,tipifarnib,True,['Kura Oncology'],1,USA,26,9,3,2,0,1,1,1,0,1,1,0,0,0,0,0
Low-Dose Tamoxifen for Mammographic Density Reduction: A Randomized Controlled Trial,2021-06-10,tamoxifen,False,[],0,Sweden,17,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Phase II Trial of Costimulation Blockade With Abatacept for Prevention of Acute GVHD,2021-06-10,abatacept,True,"['Bristol-Myers Squibb', 'Bristol Myers Squibb']",0,USA,46,4,0,1,0,0,1,1,0,0,1,0,0,0,0,0
Impact of a Genomic Test on Treatment Decision in a Predominantly African American Population With Favorable-Risk Prostate Cancer: A Randomized Trial,2021-05-20,Genomic Prostate Score (GPS),False,[],0,USA,16,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Long-Term Follow-Up of CD19-CAR T-Cell Therapy in Children and Young Adults With B-ALL,2021-05-20,CD19.28Î¶-CAR T cells,True,['Lentigen'],0,USA,14,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0
"Umbralisib, a Dual PI3KÎ´/CK1Îµ Inhibitor in Patients With Relapsed or Refractory Indolent Lymphoma",2021-05-20,umbralisib,True,"['TG Therapeutics', 'TG-Therapeutics']",1,USA,28,17,4,8,0,1,1,1,0,0,1,1,0,0,0,0
Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancerâ€”The Penelope-B Trial,2021-05-10,palbociclib,True,"['Pfizer', 'pfizer']",1,Germany,27,17,2,8,2,7,1,0,0,0,1,0,0,0,0,0
Phase II Study of the WEE1 Inhibitor Adavosertib in Recurrent Uterine Serous Carcinoma,2021-05-10,adavosertib,True,['AstraZeneca'],0,USA,14,4,0,3,0,1,1,1,0,0,1,1,0,0,0,0
Eprenetapopt Plus Azacitidine in TP53-Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Phase II Study by the Groupe Francophone des MyÃ©lodysplasies (GFM),2021-05-10,eprenetapopt,True,['Aprea AB'],0,France,26,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
Eprenetapopt (APR-246) and Azacitidine in TP53-Mutant Myelodysplastic Syndromes,2021-05-10,eprenetapopt,True,"['Aprea AB', 'Aprea Therapeutics']",0,USA,24,4,2,1,0,0,1,0,0,0,1,0,0,0,0,0
Correlative Biomarker Analysis of Intrinsic Subtypes and Efficacy Across the MONALEESA Phase III Studies,2021-05-01,ribociclib,True,['Novartis'],1,Spain,12,8,6,0,0,1,1,1,0,1,0,0,0,0,1,0
"Phase III, Randomized, Placebo-Controlled Trial of CC-486 (Oral Azacitidine) in Patients With Lower-Risk Myelodysplastic Syndromes",2021-05-01,azacitidine,True,"['Celgene/Bristol-Myers Squibb', 'Celgene', 'Celgene/Jazz']",1,USA,28,18,3,10,3,11,1,1,0,0,1,1,0,0,1,1
Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years' Follow-Up,2021-05-01,pertuzumab,True,"['Roche/Genentech', 'Hoffmann LaRoche Ltd', 'Roche', 'Genentech/Roche', 'Genentech', 'F. Hoffmann-La Roche Ltd (support for third-party writing assistance)']",1,Belgium,29,20,3,7,3,8,1,1,0,0,1,1,0,0,0,1
T-Cell Therapy for Lymphoma Using Nonengineered Multiantigen-Targeted T Cells Is Safe and Produces Durable Clinical Effects,2021-05-01,autologous multi-TAA-specific T cells,True,"['Marker Therapeutics', 'Marker Therapeutics (I)', 'Marker Therapeutics Inc']",0,USA,22,4,1,3,0,0,0,1,0,0,0,1,0,0,0,0
Excellent Outcomes With Reduced Frequency of Vincristine and Dexamethasone Pulses in Standard-Risk B-Lymphoblastic Leukemia: Results From Children's Oncology Group AALL0932,2021-05-01,methotrexate,False,[],0,USA,21,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ROBUST: A Phase III Study of Lenalidomide Plus R-CHOP Versus Placebo Plus R-CHOP in Previously Untreated Patients With ABC-Type Diffuse Large B-Cell Lymphoma,2021-04-20,lenalidomide,True,"['Celgene/Bristol-Myers Squibb', 'Celgene']",1,USA,31,15,4,8,1,5,1,1,0,0,1,1,0,1,0,0
TRANSFORMER: A Randomized Phase II Study Comparing Bipolar Androgen Therapy Versus Enzalutamide in Asymptomatic Men With Castration-Resistant Metastatic Prostate Cancer,2021-04-20,enzalutamide,True,"['Astellas Pharma', 'Astellas Medivation', 'Medivation/Astellas']",0,USA,28,11,0,5,1,3,0,1,0,0,0,0,0,0,0,1
Addition of Lenalidomide to R-CHOP Improves Outcomes in Newly Diagnosed Diffuse Large B-Cell Lymphoma in a Randomized Phase II US Intergroup Study ECOG-ACRIN E1412,2021-04-20,lenalidomide,True,"['Bristol-Myers Squibb', 'Celgene/BMS', 'Research Funding: Celgene/BMS']",1,USA,21,11,0,8,0,0,1,1,0,0,1,1,0,0,0,0
"Phase I Study of Elacestrant (RAD1901), a Novel Selective Estrogen Receptor Degrader, in ER-Positive, HER2-Negative Advanced Breast Cancer",2021-04-20,elacestrant,True,"['Radius Health', 'RDUS']",0,USA,14,5,3,1,0,0,1,1,0,0,1,0,0,0,0,0
Nivolumab and Ipilimumab as Maintenance Therapy in Extensive-Disease Small-Cell Lung Cancer: CheckMate 451,2021-04-20,nivolumab,True,"['Bristol-Myers Squibb', 'BMS Brazil', 'Bristol-Myers Squibb (Mexico)']",1,USA,25,17,5,10,3,2,1,0,0,0,1,0,0,0,0,0
Prostate-Only Versus Whole-Pelvic Radiation Therapy in High-Risk and Very High-Risk Prostate Cancer (POP-RT): Outcomes From Phase III Randomized Controlled Trial,2021-04-10,,False,[],0,India,20,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Primary Tumor Resection Plus Chemotherapy Versus Chemotherapy Alone for Colorectal Cancer Patients With Asymptomatic, Synchronous Unresectable Metastases (JCOG1007; iPACS): A Randomized Clinical Trial",2021-04-01,bevacizumab,True,['Chugai Pharma'],0,Japan,21,7,0,0,0,6,1,1,0,0,0,0,0,0,1,1
CanDirect: Effectiveness of a Telephone-Supported Depression Self-Care Intervention for Cancer Survivors,2021-04-01,,False,[],0,Canada,9,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Cost-Effectiveness of First-Line Versus Second-Line Use of Daratumumab in Older, Transplant-Ineligible Patients With Multiple Myeloma",2021-04-01,daratumumab,True,"['Janssen', 'Janssen Scientific Affairs']",0,USA,6,2,0,1,0,0,0,1,0,0,0,1,0,0,0,0
Randomized Phase III Study of FOLFOX Alone or With Pegilodecakin as Second-Line Therapy in Patients With Metastatic Pancreatic Cancer That Progressed After Gemcitabine (SEQUOIA),2021-04-01,pegilodecakin,True,['ARMO BioSciences'],1,USA,16,2,0,1,0,0,1,0,0,0,0,0,0,0,0,0
Phase III Study to Evaluate Efficacy and Safety of Andecaliximab With mFOLFOX6 as First-Line Treatment in Patients With Advanced Gastric or GEJ Adenocarcinoma (GAMMA-1),2021-03-20,andecaliximab,True,['Gilead Sciences'],1,USA,11,5,2,2,0,0,0,1,0,0,0,0,0,0,0,0
"Open-Label, Single-Arm, Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Nonâ€“Clear Cell Renal Cell Carcinoma",2021-03-20,pembrolizumab,True,"['MSD', 'Merck Sharp & Dohme', 'Merck', 'MSD Oncology']",1,USA,19,16,3,11,5,6,1,1,0,0,1,1,0,0,0,0
"Open-Label, Single-Arm Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Clear Cell Renal Cell Carcinoma",2021-03-20,pembrolizumab,True,"['Merck Sharp & Dohme', 'MSD', 'Merck']",1,USA,20,14,2,9,1,4,1,1,0,0,1,1,0,0,0,0
Reduced-Dose Radiation Therapy for HPV-Associated Oropharyngeal Carcinoma (NRG Oncology HN002),2021-03-20,cisplatin,False,[],1,USA,22,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Phase III Trial of Avelumab Maintenance After First-Line Induction Chemotherapy Versus Continuation of Chemotherapy in Patients With Gastric Cancers: Results From JAVELIN Gastric 100,2021-03-20,avelumab,True,"['Merck KGaA', 'EMD Serono Research & Development Institute', 'EMD Serono', 'Inc (an affiliate of Merck KGaA', 'Merck Serono']",1,Germany,21,10,6,5,2,1,1,1,0,0,1,1,0,0,1,0
Laparoscopic Versus Open Gastrectomy for Gastric Cancer (LOGICA): A Multicenter Randomized Clinical Trial,2021-03-20,Laparoscopic gastrectomy,True,['Intuitive Surgical'],0,the Netherlands,21,2,0,2,0,0,0,1,0,0,0,1,0,0,0,0
Lenalidomide-Epoetin Alfa Versus Lenalidomide Monotherapy in Myelodysplastic Syndromes Refractory to Recombinant Erythropoietin,2021-03-20,lenalidomide,True,['Celgene'],0,USA,17,7,0,3,0,2,1,0,0,0,1,0,0,0,1,0
Randomized Phase II Study of Bevacizumab in Combination With Carboplatin Plus Paclitaxel in Patients With Previously Untreated Advanced Mucosal Melanoma,2021-03-10,bevacizumab,True,['Roche'],0,China,16,1,0,1,0,0,0,1,0,0,0,1,0,0,0,0
Defining the Optimal Total Number of Chemotherapy Courses in Younger Patients With Acute Myeloid Leukemia: A Comparison of Three Versus Four Courses,2021-03-10,gemtuzumab ozogamicin,False,[],1,United Kingdom,13,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas,2021-03-01,mirdametinib,True,['SpringWorks Therapeutics'],0,USA,21,2,0,1,0,0,0,1,0,0,0,0,0,0,0,0
"Efficacy, Safety, and Correlative Biomarkers of Toripalimab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma: A Phase II Clinical Trial (POLARIS-02)",2021-03-01,toripalimab,True,"['Shanghai Junshi BioSciences', 'Shanghai Junshi Biosciences Inc Patent', 'I am on a few patents issued to JunShi Biosciences']",0,China,24,3,2,0,0,0,0,1,0,1,0,0,0,0,0,0
Focal Boost to the Intraprostatic Tumor in External Beam Radiotherapy for Patients With Localized Prostate Cancer: Results From the FLAME Randomized Phase III Trial,2021-03-01,External beam radiotherapy,False,[],0,the Netherlands,14,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Phase III Randomized Controlled Trial of eRAPID: eHealth Intervention During Chemotherapy,2021-03-01,eRAPID,False,[],0,United Kingdom,20,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Early Interdisciplinary Supportive Care in Patients With Previously Untreated Metastatic Esophagogastric Cancer: A Phase III Randomized Controlled Trial,2021-03-01,,False,[],0,China,18,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Outcomes by Clinical and Molecular Features in Children With Medulloblastoma Treated With Risk-Adapted Therapy: Results of an International Phase III Trial (SJMB03),2021-03-01,,False,[],1,USA,38,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Augmented Reduced-Intensity Regimen Does Not Improve Postallogeneic Transplant Outcomes in Acute Myeloid Leukemia,2021-03-01,fludarabine,False,[],0,United Kingdom,27,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Gefitinib Versus Vinorelbine Plus Cisplatin as Adjuvant Treatment for Stage II-IIIA (N1-N2) EGFR-Mutant NSCLC: Final Overall Survival Analysis of CTONG1104 Phase III Trial,2021-03-01,gefitinib,True,['AstraZeneca'],0,China,29,4,0,2,0,3,1,1,0,0,0,1,0,0,1,1
Melflufen and Dexamethasone in Heavily Pretreated Relapsed and Refractory Multiple Myeloma,2021-03-01,melphalan flufenamide,False,[],1,USA,26,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133)",2021-02-20,atezolizumab,True,"['Roche/Genentech', 'Roche Pharma AG', 'Roche SA', 'Roche', 'Genentech/Roche', 'Genentech']",1,USA,20,13,1,13,6,5,1,1,0,0,1,1,0,0,0,0
"Nivolumab Plus Ipilimumab for Treatment-NaÃ¯ve Metastatic Uveal Melanoma: An Open-Label, Multicenter, Phase II Trial by the Spanish Multidisciplinary Melanoma Group (GEM-1402)",2021-02-20,nivolumab,True,['Bristol-Myers Squibb'],0,Spain,14,6,0,4,2,2,1,1,0,0,1,1,0,0,0,1
Nivolumab and Ipilimumab in Metastatic Uveal Melanoma: Results From a Single-Arm Phase II Study,2021-02-20,nivolumab and ipilimumab,True,['Bristol Myers Squibb'],0,USA,12,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0
Prediction of Outcome in Patients With Chronic Lymphocytic Leukemia Treated With Ibrutinib: Development and Validation of a Four-Factor Prognostic Model,2021-02-20,ibrutinib,True,"['AbbVie/Pharmacyclics', 'AbbVie', 'AbbVie stock through Pharmacyclics', 'Pharmacyclics']",0,USA,13,6,5,0,0,0,1,1,1,0,0,0,0,0,0,0
Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600EÃ¢â‚¬â€œMutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study,2021-02-01,encorafenib,False,[],1,Spain,19,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Randomized Trial of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF-Mutant Metastatic Colorectal Cancer (SWOG S1406),2021-02-01,vemurafenib,False,[],0,USA,20,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Total Body Irradiation or Chemotherapy Conditioning in Childhood ALL: A Multinational, Randomized, Noninferiority Phase III Study",2021-02-01,Total Body Irradiation,False,[],1,Austria,36,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Radical Cystectomy Against Intravesical BCG for High-Risk High-Grade Nonmuscle Invasive Bladder Cancer: Results From the Randomized Controlled BRAVO-Feasibility Study,2021-01-20,Bacillus Calmette-Guerin,True,['MSD Oncology'],0,United Kingdom,18,1,0,0,1,0,1,0,0,0,0,0,1,0,0,0
Health-Related Quality of Life in Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: Findings From the Phase III MAIA Trial,2021-01-20,daratumumab,True,"['Janssen Biotech', 'Janssen', 'Janssen Oncology']",1,France,26,25,7,14,3,9,1,1,0,0,0,1,0,0,1,1
"Pan-AKT Inhibitor Capivasertib With Docetaxel and Prednisolone in Metastatic Castration-Resistant Prostate Cancer: A Randomized, Placebo-Controlled Phase II Trial (ProCAID)",2021-01-20,capivasertib,True,['AstraZeneca'],0,United Kingdom,24,8,3,2,0,2,1,1,0,0,1,0,0,0,0,1
Survival Impact of Anti-GD2 Antibody Response in a Phase II Ganglioside Vaccine Trial Among Patients With High-Risk Neuroblastoma With Prior Disease Progression,2021-01-20,GD2/GD3 vaccine,False,[],0,USA,9,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"First-in-Human Phase I Study of MP0250, a First-in-Class DARPin Drug Candidate Targeting VEGF and HGF, in Patients With Advanced Solid Tumors",2021-01-10,MP0250,False,[],1,United Kingdom,15,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Mutant Isocitrate Dehydrogenase 1 Inhibitor Ivosidenib in Combination With Azacitidine for Newly Diagnosed Acute Myeloid Leukemia,2021-01-01,ivosidenib,True,"['Agios', 'Patents derived from my work at Agios']",1,USA,28,19,8,9,1,3,1,0,0,0,1,0,0,0,1,0
Imetelstat Achieves Meaningful and Durable Transfusion Independence in High Transfusionâ€“Burden Patients With Lower-Risk Myelodysplastic Syndromes in a Phase II Study,2021-01-01,imetelstat,True,"['Geron', 'Geron Corporation']",1,USA,23,10,5,3,0,0,1,0,0,0,1,0,0,0,0,0
"Pre- and Postoperative Capecitabine Without or With Oxaliplatin in Locally Advanced Rectal Cancer: PETACC 6 Trial by EORTC GITCG and ROG, AIO, AGITG, BGDO, and FFCD",2021-01-01,capecitabine,True,['Roche'],1,Germany,20,9,0,5,2,4,1,0,0,0,1,0,0,0,0,0
Randomized Phase II Trial of Nivolumab With Stereotactic Body Radiotherapy Versus Nivolumab Alone in Metastatic Head and Neck Squamous Cell Carcinoma,2021-01-01,nivolumab,True,['Bristol Myers Squibb'],0,USA,19,2,0,1,0,0,0,0,0,0,0,0,0,0,0,0
ARTSCAN III: A Randomized Phase III Study Comparing Chemoradiotherapy With Cisplatin Versus Cetuximab in Patients With Locoregionally Advanced Head and Neck Squamous Cell Cancer,2021-01-01,cisplatin,False,[],0,Sweden,15,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Phase III, Randomized Study of Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade With Lapatinib Plus Trastuzumab in Combination With an Aromatase Inhibitor in Postmenopausal Women With HER2-Positive, Hormone ReceptorÃ¢â‚¬â€œPositive Metastatic Breast Cancer: Updated Results of ALTERNATIVE",2021-01-01,lapatinib,False,[],1,United Kingdom,15,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Randomized Phase III Study of Irinotecan Plus Cisplatin Versus Etoposide Plus Cisplatin for Completely Resected High-Grade Neuroendocrine Carcinoma of the Lung: JCOG1205/1206,2020-12-20,irinotecan,False,[],0,Japan,20,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
B7H3-Directed Intraperitoneal Radioimmunotherapy With Radioiodinated Omburtamab for Desmoplastic Small Round Cell Tumor and Other Peritoneal Tumors: Results of a Phase I Study,2020-12-20,omburtamab,True,"['Y-mAbs Therapeutics', 'Y-mAbs Therapeutics (I)', 'Y-mAbs']",0,USA,12,6,0,3,0,0,1,0,0,0,1,0,0,0,0,0
"Multicenter, Randomized, Phase III Trial of Neoadjuvant Chemoradiation With Capecitabine and Irinotecan Guided by UGT1A1 Status in Patients With Locally Advanced Rectal Cancer",2020-12-20,irinotecan,False,[],0,China,23,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes,2020-12-20,olaparib,True,"['AstraZeneca', 'AstraZeneca/Daiichi Sanyo']",0,USA,25,9,0,2,0,2,1,0,0,0,0,0,0,0,0,0
"Effect of rhG-CSF Combined With Decitabine Prophylaxis on Relapse of Patients With High-Risk MRD-Negative AML After HSCT: An Open-Label, Multicenter, Randomized Controlled Trial",2020-12-20,recombinant human granulocyte colony-stimulating factor (rhG-CSF),False,[],0,China,33,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Optimized Management of Nivolumab and Ipilimumab in Advanced Renal Cell Carcinoma: A Response-Based Phase II Study (OMNIVORE),2020-12-20,nivolumab,True,['Bristol Myers Squibb'],0,USA,13,10,0,6,0,1,1,1,0,0,1,1,0,0,0,1
"First-in-Human Phase I Study of Iadademstat (ORY-1001): A First-in-Class Lysine-Specific Histone Demethylase 1A Inhibitor, in Relapsed or Refractory Acute Myeloid Leukemia",2020-12-20,iadademstat,True,"['Oryzon Genomics', 'Oryzon Genomics (I)']",1,Spain,16,6,7,0,0,1,0,0,0,0,0,0,0,0,0,0
Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline,2020-12-20,Atezolizumab + Bevacizumab,True,"['Genentech/Roche', 'Roche/Genentech', 'Genentech']",0,USA,27,9,0,6,0,1,1,0,0,0,1,0,0,0,0,0
"Survival, Pathologic Response, and Genomics in CALGB 40601 (Alliance), a Neoadjuvant Phase III Trial of Paclitaxel-Trastuzumab With or Without Lapatinib in HER2-Positive Breast Cancer",2020-12-10,trastuzumab,True,['Genentech'],0,USA,19,5,0,4,0,3,1,1,0,0,1,0,0,0,1,0
Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer,2020-12-10,pembrolizumab,True,"['Merck & Co', 'MSD', 'Merck Sharp & Dohme Corp', 'Merck Sharp & Dohme Corp.', 'Merck', 'a subsidiary of Merck & Co']",1,Japan,28,23,8,10,1,7,1,1,0,0,1,0,0,0,0,0
Accelerated Partial-Breast Irradiation Compared With Whole-Breast Irradiation for Early Breast Cancer: Long-Term Results of the Randomized Phase III APBI-IMRT-Florence Trial,2020-12-10,,False,[],0,Italy,20,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Adjuvant Sorafenib for Renal Cell Carcinoma at Intermediate or High Risk of Relapse: Results From the SORCE Randomized Phase III Intergroup Trial,2020-12-01,sorafenib,True,['Bayer'],1,United Kingdom,25,5,0,2,0,0,1,0,0,0,0,0,0,0,0,0
Equivalence Randomized Trial to Compare Treatment on the Basis of Sentinel Node Biopsy Versus Neck Node Dissection in Operable T1-T2N0 Oral and Oropharyngeal Cancer,2020-12-01,,False,[],0,France,19,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Randomized Trial of Afatinib Plus Cetuximab Versus Afatinib Alone for First-Line Treatment of EGFR-Mutant Nonâ€“Small-Cell Lung Cancer: Final Results From SWOG S1403,2020-12-01,afatinib,True,['Boehringer Ingelheim'],0,USA,16,3,0,2,0,0,1,1,0,0,1,1,0,0,0,0
Ixazomib as Postinduction Maintenance for Patients With Newly Diagnosed Multiple Myeloma Not Undergoing Autologous Stem Cell Transplantation: The Phase III TOURMALINE-MM4 Trial,2020-12-01,ixazomib,True,"['a wholly owned subsidiary of Takeda Pharmaceutical Company Limited', 'Takeda Pharmaceuticals', 'Takeda']",1,Greece,20,17,6,9,2,10,1,1,0,0,1,1,0,0,1,0
Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations From the MURANO Phase III Study,2020-12-01,venetoclax,True,"['Roche and AbbVie', 'AbbVie/Pharmacyclics', 'AbbVie', 'AbbVie/Genentech', 'Pharmacyclics/AbbVie']",1,the Netherlands,28,14,2,10,5,8,1,1,0,0,1,1,0,1,1,1
"Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2âˆ’, Node-Positive, High-Risk, Early Breast Cancer (monarchE)",2020-12-01,abemaciclib,True,"['Lilly', 'Eli Lilly/ImClone', 'Eli Lilly Japan', 'Eli Lilly', 'Eli Lilly and Company']",1,United Kingdom,30,25,7,10,6,9,1,1,0,0,1,0,0,0,1,0
"Camrelizumab Plus Apatinib in Patients With Advanced Cervical Cancer (CLAP): A Multicenter, Open-Label, Single-Arm, Phase II Trial",2020-12-01,camrelizumab,False,[],0,China,18,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Stem Cell Transplantation and Vinblastine Monotherapy for Relapsed Pediatric Anaplastic Large Cell Lymphoma: Results of the International, Prospective ALCL-Relapse Trial",2020-12-01,vinblastine,False,[],1,Germany,15,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Carboplatin and Paclitaxel for Advanced Endometrial Cancer: Final Overall Survival and Adverse Event Analysis of a Phase III Trial (NRG Oncology/GOG0209),2020-11-20,paclitaxel,False,[],0,USA,18,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Molecular Landscape and Actionable Alterations in a Genomically Guided Cancer Clinical Trial: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH),2020-11-20,,False,[],0,USA,26,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Five-Year Outcomes With Nivolumab in Patients With Wild-Type BRAF Advanced Melanoma,2020-11-20,nivolumab,True,"['Bristol Myers Squibb France', 'Bristol-Myers Squibb', 'Bristol Myers Squibb']",1,France,27,23,1,18,6,12,1,1,0,0,1,1,0,1,0,1
Consolidation Radiotherapy Could Be Safely Omitted in Advanced Hodgkin Lymphoma With Large Nodal Mass in Complete Metabolic Response After ABVD: Final Analysis of the Randomized GITIL/FIL HD0607 Trial,2020-11-20,ABVD,False,[],0,France,25,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial,2020-11-20,pembrolizumab,True,"['Merck & Co', 'MSD', 'Merck Sharp & Dohme', 'Merck', 'MSD Oncology']",1,the Netherlands,31,28,2,21,6,13,1,1,0,0,1,1,1,0,1,0
Continuous Versus 1-Year Fixed-Duration Nivolumab in Previously Treated Advanced Nonâ€“Small-Cell Lung Cancer: CheckMate 153,2020-11-20,nivolumab,True,"['Bristol Myers Squibb', 'Bristol Myers Squibb Company', 'E.R. Squibb Sons']",0,USA,23,15,1,6,4,2,1,1,0,0,1,1,1,0,0,0
Long-Term Follow-Up of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy,2020-11-10,axicabtagene ciloleucel,True,"['Kite', 'Kite Pharma', 'I have received royalties from Kite']",0,USA,8,3,0,0,0,0,1,1,0,0,0,0,0,0,0,0
"Olanzapine for Prevention of Vomiting in Children and Adolescents Receiving Highly Emetogenic Chemotherapy: Investigator-Initiated, Randomized, Open-Label Trial",2020-11-10,olanzapine,False,[],0,India,6,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma,2020-11-10,CD30 CAR-T cells,True,"['Tessa Therapeutics', 'TESSA', 'Tessa Therapeutics (I)']",0,USA,24,9,1,6,0,0,1,1,0,0,0,1,0,0,0,0
Randomized Controlled Trial of Trastuzumab With or Without Chemotherapy for HER2-Positive Early Breast Cancer in Older Patients,2020-11-10,trastuzumab,False,[],0,Japan,22,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"MILO/ENGOT-ov11: Binimetinib Versus PhysicianÃ¢â‚¬â„¢s Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum",2020-11-10,binimetinib,True,"['Array BioPharma', 'Array Biopharma']",1,USA,30,5,2,0,0,0,1,0,0,0,0,0,1,0,0,0
Phase I Study of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced or Metastatic Urothelial Carcinoma and Other Genitourinary Tumors,2020-11-01,Cabozantinib,True,['Exelixis'],0,USA,35,2,0,2,0,0,0,0,0,0,0,0,0,0,0,0
Hypofractionated Versus Standard Fractionated Radiotherapy in Patients With Early Breast Cancer or Ductal Carcinoma In Situ in a Randomized Phase III Trial: The DBCG HYPO Trial,2020-11-01,,False,[],1,Denmark,12,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Exploring Spatial-Temporal Changes in 18F-Sodium Fluoride PET/CT and Circulating Tumor Cells in Metastatic Castration-Resistant Prostate Cancer Treated With Enzalutamide,2020-11-01,Enzalutamide,True,['Pfizer/Astellas'],0,USA,14,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
System for High-Intensity Evaluation During Radiation Therapy (SHIELD-RT): A Prospective Randomized Study of Machine Learningâ€“Directed Clinical Evaluations During Radiation and Chemoradiation,2020-11-01,,False,[],0,USA,12,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Phase II Study of Combination Obinutuzumab, Ibrutinib, and Venetoclax in Treatment-NaÃ¯ve and Relapsed or Refractory Chronic Lymphocytic Leukemia",2020-11-01,ibrutinib,True,"['Pharmacyclics/Janssen', 'Pharmacyclics', 'Janssen Oncology', 'Janssen']",0,USA,19,7,0,8,0,2,1,1,0,0,1,1,0,0,0,1
"Hypofractionated Versus Conventional Fractionated Radiotherapy After Breast-Conserving Surgery in the Modern Treatment Era: A Multicenter, Randomized Controlled Trial From China",2020-11-01,,False,[],0,China,24,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Brigatinib Versus Crizotinib in Advanced ALK Inhibitorâ€“Naive ALK-Positive Nonâ€“Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial,2020-11-01,brigatinib,True,"['Ariad/Takeda', 'Takeda Oncology', 'Takeda Pharmaceutical', 'Takeda']",1,USA,22,17,5,7,3,7,1,1,0,0,0,1,0,0,1,1
Randomized Comparison of Pazopanib and Doxorubicin as First-Line Treatment in Patients With Metastatic Soft Tissue Sarcoma Age 60 Years or Older: Results of a German Intergroup Study,2020-10-20,pazopanib,True,['GlaxoSmithKline'],0,Germany,18,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
Chemotherapy and Venetoclax in Elderly Acute Myeloid Leukemia Trial (CAVEAT): A Phase Ib Dose-Escalation Study of Venetoclax Combined With Modified Intensive Chemotherapy,2020-10-20,venetoclax,True,"['AbbVie', 'Abbvie']",0,Australia,15,6,0,3,1,1,1,1,0,0,0,1,0,1,0,1
Rituximab-CHOP With Early Rituximab Intensification for Diffuse Large B-Cell Lymphoma: A Randomized Phase III Trial of the HOVON and the Nordic Lymphoma Group (HOVON-84),2020-10-10,rituximab,True,"['Roche/Genentech', 'Roche']",1,the Netherlands,34,5,0,3,0,1,1,0,0,0,1,0,0,0,0,0
Ivosidenib in Isocitrate Dehydrogenase 1â€“Mutated Advanced Glioma,2020-10-10,ivosidenib,True,"['Agios', 'Agios (Ins)', 'Agios Pharmaceuticals', 'Agios Therapeutics']",0,USA,21,20,8,11,0,0,1,1,0,0,1,1,0,0,0,0
"Antithymocyte Globulin for Matched Sibling Donor Transplantation in Patients With Hematologic Malignancies: A Multicenter, Open-Label, Randomized Controlled Study",2020-10-10,antithymocyte globulin,False,[],0,China,25,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Long-Term Outcomes of Laparoscopic Distal Gastrectomy for Locally Advanced Gastric Cancer: The KLASS-02-RCT Randomized Clinical Trial,2020-10-01,,False,[],0,Republic of Korea,21,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Childrenâ€™s Oncology Group AALL0434: A Phase III Randomized Clinical Trial Testing Nelarabine in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia,2020-10-01,nelarabine,True,['Jazz Pharmaceuticals'],1,USA,21,2,0,1,0,1,0,0,0,0,0,0,0,0,0,0
Switch Control Inhibition of KIT and PDGFRA in Patients With Advanced Gastrointestinal Stromal Tumor: A Phase I Study of Ripretinib,2020-10-01,Ripretinib,True,"['Deciphera Pharmaceuticals', 'Deciphera']",1,USA,16,15,3,9,0,0,1,1,0,0,1,1,0,0,0,0
"Bortezomib, Melphalan, and Dexamethasone for Light-Chain Amyloidosis",2020-10-01,bortezomib,True,['Takeda'],1,Greece,28,11,1,7,1,9,1,0,0,0,1,0,0,0,1,0
Ten-Year Results of FAST: A Randomized Controlled Trial of 5-Fraction Whole-Breast Radiotherapy for Early Breast Cancer,2020-10-01,,False,[],1,United Kingdom,26,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Bevacizumab Plus mFOLFOX6 Versus mFOLFOX6 Alone as First-Line Treatment for RAS Mutant Unresectable Colorectal Liver-Limited Metastases: The BECOME Randomized Controlled Trial,2020-09-20,bevacizumab,False,[],0,China,12,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Randomized Phase III Trial of Pegvorhyaluronidase Alfa With Nab-Paclitaxel Plus Gemcitabine for Patients With Hyaluronan-High Metastatic Pancreatic Adenocarcinoma,2020-09-20,pegvorhyaluronidase alfa,True,"['Halozyme Therapeutics', 'Halozyme']",1,Belgium,28,14,2,7,0,0,1,0,0,0,1,0,0,0,0,0
Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With â‰¥ 2 HER2-Directed Regimens: Phase III NALA Trial,2020-09-20,neratinib,True,"['Puma Biotechnology', 'Puma']",1,Spain,36,15,4,5,0,1,1,1,0,0,1,1,0,0,0,0
Phase I Trial of First-in-Class ATR Inhibitor M6620 (VX-970) as Monotherapy or in Combination With Carboplatin in Patients With Advanced Solid Tumors,2020-09-20,M6620,True,"['Vertex', 'Vertex Pharmaceuticals (Europe)', 'and Vertex Pharmaceuticals', 'Vertex Pharmaceuticals']",0,United Kingdom,23,6,4,0,0,1,1,0,0,0,0,0,0,0,0,0
Avelumab in Patients With Gestational Trophoblastic Tumors With Resistance to Single-Agent Chemotherapy: Cohort A of the TROPHIMMUN Phase II Trial,2020-09-20,avelumab,True,['Pfizer'],0,France,19,2,0,1,0,1,0,1,0,0,0,0,0,0,0,1
"Phase II Study of Pembrolizumab As First-Line, Single-Drug Therapy for Patients With Unresectable Cutaneous Squamous Cell Carcinomas",2020-09-10,pembrolizumab,True,"['Merck', 'MSD', 'MSD Oncology']",0,France,35,14,0,12,1,2,1,0,0,0,1,0,0,0,0,0
Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma,2020-09-10,lenvatinib,True,"['Eisai', 'Eisai Japan']",1,USA,20,17,4,9,1,6,1,1,0,0,1,0,0,0,0,0
"Cancer and Leukemia Group B 90203 (Alliance): Radical Prostatectomy With or Without Neoadjuvant Chemohormonal Therapy in Localized, High-Risk Prostate Cancer",2020-09-10,Docetaxel,True,"['Sanofi', 'Sanofi-Aventis', 'Sanofi/Genzyme']",0,USA,20,5,0,3,0,2,0,1,0,0,0,0,0,0,0,0
Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia With FLT3â€“Internal Tandem Duplication Mutation (SORMAIN),2020-09-10,sorafenib,True,"['Bayer', 'Bayer Health', 'Bayer Healthcare', 'Bayer Schering Pharma']",0,Germany,41,4,0,0,0,0,0,1,0,0,0,0,0,0,0,0
"Teriparatide Promotes Bone Healing in Medication-Related Osteonecrosis of the Jaw: A Placebo-Controlled, Randomized Trial",2020-09-10,teriparatide,True,['Eli Lilly'],0,Australia,10,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0
Successful Outcomes of Newly Diagnosed T Lymphoblastic Lymphoma: Results From Childrenâ€™s Oncology Group AALL0434,2020-09-10,nelarabine,True,['Jazz Pharmaceuticals'],0,USA,18,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0
Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer,2020-09-10,lenvatinib,True,"['Eisai', 'EISAI']",0,USA,19,12,6,5,1,1,1,1,0,0,1,1,0,0,1,0
Positron Emission TomographyÃ¢â‚¬â€œDirected Therapy for Patients With Limited-Stage Diffuse Large B-Cell Lymphoma: Results of Intergroup National Clinical Trials Network Study S1001,2020-09-10,rituximab,True,"['Hoffmann-LaRoche', 'Genentech/Roche', 'AbbVie/Genentech', 'Genentech', 'Roche']",0,USA,19,8,0,5,0,1,0,1,0,0,0,0,0,0,0,0
Pembrolizumab Monotherapy for Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma: A Single-Arm Phase II Trial (KEYNOTE-629),2020-09-01,pembrolizumab,True,"['Merck Sharp & Dohme', 'Merck']",1,France,14,7,3,2,0,0,1,0,0,0,1,0,0,0,0,0
Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial,2020-09-01,stereotactic ablative radiotherapy,True,['Varian Medical Systems'],1,Canada,24,5,0,1,1,1,1,1,0,0,0,1,0,0,0,0
"ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia",2020-09-01,acalabrutinib,True,"['Acerta Pharma/AstraZeneca', 'Acerta Pharma', 'AstraZeneca']",1,Italy,20,11,3,6,0,3,1,1,0,0,1,1,0,0,1,0
Long-Term Outcomes From a Randomized Dose Optimization Study of Chimeric Antigen Receptor Modified T Cells in Relapsed Chronic Lymphocytic Leukemia,2020-09-01,CART-19,True,"['Novartis', 'Patent Combination Therapies of CAR and PD-1 Inhibitors (via University of Pennsylvania with royalties to Novartis)', 'Patents and intellectual property related to CAR-T technology licensed to Novartis', 'Intellectual property rights licensed to Novartis (royalties paid to University of Pennsylvania)']",0,USA,20,9,0,4,1,4,1,1,0,0,1,1,0,0,0,1
"Pyrotinib in HER2-Mutant Advanced Lung Adenocarcinoma After Platinum-Based Chemotherapy: A Multicenter, Open-Label, Single-Arm, Phase II Study",2020-08-20,pyrotinib,True,"['Hengrui Therapeutics', 'Hengrui Medicine', 'Jiangsu Hengrui Medicine Co']",0,China,17,5,3,1,0,1,1,1,0,1,1,0,0,0,1,0
Randomized Trial Comparing Double Versus Triple Bortezomib-Based Regimen in Patients With Multiple Myeloma and Acute Kidney Injury Due to Cast Nephropathy,2020-08-10,bortezomib,True,['Takeda'],0,France,28,6,0,3,0,4,0,1,0,0,0,0,0,0,0,1
Long-Term Outcomes in KEYNOTE-052: Phase II Study Investigating First-Line Pembrolizumab in Cisplatin-Ineligible Patients With Locally Advanced or Metastatic Urothelial Cancer,2020-08-10,pembrolizumab,True,"['Merck', 'Merck Sharp & Dohme', 'MSD', 'MSD Oncology']",1,USA,16,16,4,10,0,5,1,1,0,0,0,1,0,0,0,0
Impact of Intrathecal Triple Therapy Versus Intrathecal Methotrexate on Disease-Free Survival for High-Risk B-Lymphoblastic Leukemia: Childrenâ€™s Oncology Group Study AALL1131,2020-08-10,methotrexate,False,[],0,USA,20,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial,2020-08-10,tucatinib,True,['Puma Biotechnology'],1,USA,29,10,0,5,0,3,1,0,0,0,1,0,0,0,0,0
PD-1 Blockade in Anaplastic Thyroid Carcinoma,2020-08-10,spartalizumab,True,"['Novartis', 'Patents related to drugs being developed by Novartis', 'Novartis Pharmaceuticals (I)', 'Novartis Pharmaceuticals']",1,Spain,24,18,6,9,2,2,1,1,0,0,1,1,1,0,0,0
International Rare Cancers Initiative Multicenter Randomized Phase II Trial of Cisplatin and Fluorouracil Versus Carboplatin and Paclitaxel in Advanced Anal Cancer: InterAAct,2020-08-01,cisplatin,False,[],1,United Kingdom,21,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Safety and Patient-Reported Outcomes of Atezolizumab Plus Chemotherapy With or Without Bevacizumab Versus Bevacizumab Plus Chemotherapy in Nonâ€“Small-Cell Lung Cancer,2020-08-01,atezolizumab,True,['Genentech'],1,Germany,19,13,7,5,2,4,1,1,0,0,1,1,1,1,0,1
Neoadjuvant Nivolumab for Patients With Resectable Merkel Cell Carcinoma in the CheckMate 358 Trial,2020-08-01,nivolumab,True,"['Bristol Myers Squibb (I)', 'Bristol Myers Squibb', 'BMS']",1,USA,24,20,5,10,2,4,1,1,0,0,0,0,0,0,0,0
Safety and Efficacy of Pembrolizumab With Chemoradiotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma: A Phase IB Study,2020-07-20,pembrolizumab,True,"['Merck Sharp & Dohme', 'Merck']",0,USA,18,3,0,3,0,0,1,1,0,0,0,1,0,0,0,0
"Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study",2020-07-20,pembrolizumab,True,"['Merck Serono', 'Merck Sharp & Dohme Corp', 'Merck & Co', 'MSD', 'Merck']",1,USA,21,19,3,10,1,4,1,1,0,0,0,0,0,0,0,0
Phase II Study of AZD4547 in Patients With Tumors Harboring Aberrations in the FGFR Pathway: Results From the NCI-MATCH Trial (EAY131) Subprotocol W,2020-07-20,AZD4547,True,"['AstraZeneca', 'Astra Zeneca']",0,USA,22,3,0,1,1,0,1,0,0,0,1,0,1,0,0,0
Phase I Escalation and Expansion Study of Bemarituzumab (FPA144) in Patients With Advanced Solid Tumors and FGFR2b-Selected Gastroesophageal Adenocarcinoma,2020-07-20,Bemarituzumab,True,['Five Prime Therapeutics'],0,USA,13,10,3,1,0,1,1,1,0,0,0,1,0,0,1,0
"Neoadjuvant Chemotherapy in High-Risk Soft Tissue Sarcomas: Final Results of a Randomized Trial From Italian (ISG), Spanish (GEIS), French (FSG), and Polish (PSG) Sarcoma Groups",2020-07-01,trabectedin,True,"['Pharmamar', 'PharmaMar']",1,Italy,28,9,0,5,2,5,1,1,0,0,1,0,0,0,1,0
Randomized Phase III Study of Pemetrexed Plus Cisplatin Versus Vinorelbine Plus Cisplatin for Completely Resected Stage II to IIIA Nonsquamous Nonâ€“Small-Cell Lung Cancer,2020-07-01,pemetrexed,True,"['Eli Lilly', 'Lilly', 'Eli Lilly Japan']",0,Japan,20,12,0,3,2,9,1,0,0,0,0,0,0,0,1,0
"Phase I/II Study of CPX-351 Followed by Fludarabine, Cytarabine, and Granulocyte-Colony Stimulating Factor for Children With Relapsed Acute Myeloid Leukemia: A Report From the Childrenâ€™s Oncology Group",2020-07-01,CPX-351,True,['Jazz Pharmaceuticals'],0,USA,10,2,0,1,0,0,0,0,0,0,0,0,0,0,0,0
Randomized Trial of Text Messaging to Reduce Early Discontinuation of Adjuvant Aromatase Inhibitor Therapy in Women With Early-Stage Breast Cancer: SWOG S1105,2020-07-01,Letrozole,True,['Novartis'],0,USA,16,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
"Irinotecan, Temozolomide, and Dinutuximab With GM-CSF in Children With Refractory or Relapsed Neuroblastoma: A Report From the Childrenâ€™s Oncology Group",2020-07-01,dinutuximab,True,['EUSA Pharma'],0,USA,19,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0
"Phase I, Open-Label, Dose-Escalation/Dose-Expansion Study of Lifirafenib (BGB-283), an RAF Family Kinase Inhibitor, in Patients With Solid Tumors",2020-07-01,lifirafenib,True,"['BeiGene (Beijing) Co', 'BeiGene', 'multiple patents awarded as BeiGene employee (I)', 'BeiGene (I)']",1,Australia,27,12,8,1,0,0,1,0,0,0,1,0,0,0,0,0
Implementation of Minimally Invasive Esophagectomy From a Randomized Controlled Trial Setting to National Practice,2020-07-01,minimally invasive esophagectomy,False,[],0,United Kingdom,10,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Regorafenib Plus Nivolumab in Patients With Advanced Gastric or Colorectal Cancer: An Open-Label, Dose-Escalation, and Dose-Expansion Phase Ib Trial (REGONIVO, EPOC1603)",2020-06-20,regorafenib,True,['Bayer AG'],0,Japan,18,3,0,0,0,1,1,0,0,0,0,0,0,0,0,0
Nonmetastatic Medulloblastoma of Early Childhood: Results From the Prospective Clinical Trial HIT-2000 and An Extended Validation Cohort,2020-06-20,methotrexate,False,[],1,Germany,49,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CD4/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: Updated Results From a Phase I Anti-CD22 CAR T-Cell Trial,2020-06-10,CD22 CAR T-cells,False,['An inventor on numerous patents related to CAR therapeutics and royalties from NIH for the CD22 CAR patent licensed to Juno Therapeutics.'],0,USA,25,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Randomized, Phase II Study of Trastuzumab Beyond Progression in Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction Cancer: WJOG7112G (T-ACT Study)",2020-06-10,trastuzumab,True,['Chugai/Roche'],0,Japan,22,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Lowâ€“Expressing Advanced Breast Cancer: Results From a Phase Ib Study,2020-06-10,trastuzumab deruxtecan,True,"['Daiichi Sankyo (I)', 'Daiichi Sankyo']",0,USA,17,14,6,6,0,4,1,1,0,0,1,0,0,0,0,1
Randomized Phase II Trial of Nivolumab Versus Nivolumab and Ipilimumab for Recurrent or Persistent Ovarian Cancer: An NRG Oncology Study,2020-06-01,nivolumab,True,['Bristol Myers Squibb'],0,USA,14,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Adjuvant Capecitabine With Docetaxel and Cyclophosphamide Plus Epirubicin for Triple-Negative Breast Cancer (CBCSG010): An Open-Label, Randomized, Multicenter, Phase III Trial",2020-06-01,capecitabine,True,['Roche'],0,China,40,1,0,0,1,0,1,1,0,0,0,0,1,1,0,0
Randomized Double-Blind Phase II Study of Maintenance Pembrolizumab Versus Placebo After First-Line Chemotherapy in Patients With Metastatic Urothelial Cancer,2020-06-01,pembrolizumab,True,"['Merck Sharp & Dohme', 'Merck']",0,USA,22,10,0,3,0,2,1,0,0,0,1,0,0,0,0,0
"First-in-Human, Multicenter, Phase I Dose-Escalation and Expansion Study of Anti-Mesothelin AntibodyÃ¢â‚¬â€œDrug Conjugate Anetumab Ravtansine in Advanced or Metastatic Solid Tumors",2020-06-01,Anetumab Ravtansine,True,"['Bayer', 'Bayer HealthCare', 'Bayer AG']",0,USA,16,10,4,1,0,0,1,1,0,0,0,1,0,0,0,0
Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III PREOPANC Trial,2020-06-01,gemcitabine,False,[],0,the Netherlands,31,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Phase I Study of the Mutant IDH1 Inhibitor Ivosidenib: Safety and Clinical Activity in Patients With Advanced Chondrosarcoma,2020-05-20,ivosidenib,True,"['Agios Pharmaceuticals (I)', 'Agios Pharmaceuticals', 'Patents derived from my work at Agios Pharmaceuticals']",0,USA,17,12,7,4,0,0,1,0,0,0,1,0,0,0,0,0
Improvement in Patient-Reported Outcomes With Intensity-Modulated Radiotherapy (RT) Compared With Standard RT: A Report From the NRG Oncology RTOG 1203 Study,2020-05-20,intensity-modulated radiotherapy,True,['Varian Medical Systems'],1,USA,21,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
Prognostic Value of Tumor Deposits for Disease-Free Survival in Patients With Stage III Colon Cancer: A Post Hoc Analysis of the IDEA France Phase III Trial (PRODIGE-GERCOR),2020-05-20,capecitabine and oxaliplatin,False,[],0,France,16,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Randomized Phase IIB Trial of Proton Beam Therapy Versus Intensity-Modulated Radiation Therapy for Locally Advanced Esophageal Cancer,2020-05-10,Proton Beam Therapy (PBT),True,"['Varian Medical Systems', 'Varian Medical Systems (I)']",0,USA,27,4,0,0,2,2,1,0,0,0,0,0,1,0,0,0
Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Nonâ€“Small-Cell Lung Cancer,2020-05-10,pembrolizumab,True,"['Merck', 'Merck Sharp & Dohme', 'MSD', 'MSD Oncology']",1,USA,26,21,3,10,6,8,1,1,0,0,0,1,0,1,1,1
Randomized Phase II Study of First-Line Cladribine With Concurrent or Delayed Rituximab in Patients With Hairy Cell Leukemia,2020-05-10,rituximab,True,['Genentech'],0,USA,17,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0
TBCRC 031: Randomized Phase II Study of Neoadjuvant Cisplatin Versus Doxorubicin-Cyclophosphamide in Germline BRCA Carriers With HER2-Negative Breast Cancer (the INFORM trial),2020-05-10,cisplatin,False,[],0,USA,19,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Long-Term Outcomes and Retreatment Among Patients With Previously Treated, Programmed Death-Ligand 1â€’Positive, Advanced Nonâ€’Small-Cell Lung Cancer in the KEYNOTE-010 Study",2020-05-10,pembrolizumab,True,"['Merck Serono', 'Merck', 'Merck Sharp & Dohme', 'MSD', 'MSD Oncology']",1,USA,19,17,3,6,2,3,1,1,0,0,1,1,0,0,0,0
"Liberal Versus Restrictive Red Blood Cell Transfusion Thresholds in Hematopoietic Cell Transplantation: A Randomized, Open Label, Phase III, Noninferiority Trial",2020-05-01,,False,[],0,Canada,12,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Dietary Modification and Breast Cancer Mortality: Long-Term Follow-Up of the Womenâ€™s Health Initiative Randomized Trial,2020-05-01,,False,[],0,USA,17,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Randomized, Multicenter, Phase II Trial of Gemcitabine and Cisplatin With or Without Veliparib in Patients With Pancreas Adenocarcinoma and a Germline BRCA/PALB2 Mutation",2020-05-01,veliparib,True,['AbbVie'],1,USA,20,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
Bendamustine With Dexamethasone in Relapsed/Refractory Systemic Light-Chain Amyloidosis: Results of a Phase II Study,2020-05-01,Bendamustine,False,[],0,USA,10,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Phase II Single-Arm Study of Preoperative Letrozole for Estrogen Receptorâ€“Positive Postmenopausal Ductal Carcinoma In Situ: CALGB 40903 (Alliance),2020-04-20,letrozole,True,['Novartis'],0,USA,21,2,0,0,1,1,0,0,0,0,0,0,0,0,0,0
Phase Ib/II Clinical Trial of Pembrolizumab With Bevacizumab for Metastatic Renal Cell Carcinoma: BTCRC-GU14-003,2020-04-10,bevacizumab,True,['Genentech'],0,USA,11,4,0,2,1,1,0,1,0,0,0,0,0,0,0,0
Standard Anthracycline Based Versus Docetaxel-Capecitabine in Early High Clinical and/or Genomic Risk Breast Cancer in the EORTC 10041/BIG 3-04 MINDACT Phase III Trial,2020-04-10,docetaxel,True,['Sanofi'],1,France,30,2,0,1,0,0,1,1,0,0,0,1,0,0,0,0
Olaparib Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer and a Germline BRCA1/2 Mutation (SOLO3): A Randomized Phase III Trial,2020-04-10,olaparib,True,['AstraZeneca'],1,USA,16,9,3,5,2,2,1,1,0,1,1,0,0,0,1,0
"Phase IB/II Trial of Lenvatinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma, Endometrial Cancer, and Other Selected Advanced Solid Tumors",2020-04-10,lenvatinib,True,['Eisai'],0,USA,9,9,4,4,1,1,1,1,0,0,1,1,1,0,0,0
Randomized Trial of Lenalidomide Versus Observation in Smoldering Multiple Myeloma,2020-04-10,lenalidomide,True,['Celgene'],0,USA,17,9,0,7,1,2,1,0,0,0,1,0,0,0,0,0
"EV-101: A Phase I Study of Single-Agent Enfortumab Vedotin in Patients With Nectin-4â€“Positive Solid Tumors, Including Metastatic Urothelial Carcinoma",2020-04-01,enfortumab vedotin,True,['Seattle Genetics'],0,USA,20,12,1,5,0,3,1,1,0,0,1,1,0,0,0,0
MK-2206 and Standard Neoadjuvant Chemotherapy Improves Response in Patients With Human Epidermal Growth Factor Receptor 2â€“Positive and/or Hormone Receptorâ€“Negative Breast Cancers in the I-SPY 2 Trial,2020-04-01,MK-2206,True,"['Merck (I)', 'Merck', 'Merck Sharp & Dohme']",0,USA,50,9,0,3,0,0,1,1,0,0,0,0,0,0,0,0
Efficacy of Ruxolitinib in Patients With Chronic Neutrophilic Leukemia and Atypical Chronic Myeloid Leukemia,2020-04-01,ruxolitinib,True,['Incyte'],0,USA,26,6,0,5,0,2,1,1,0,0,1,0,0,0,1,0
Hippocampal Avoidance During Whole-Brain Radiotherapy Plus Memantine for Patients With Brain Metastases: Phase III Trial NRG Oncology CC001,2020-04-01,memantine,False,[],0,USA,31,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
D-Indexâ€“Guided Early Antifungal Therapy Versus Empiric Antifungal Therapy for Persistent Febrile Neutropenia: A Randomized Controlled Noninferiority Trial,2020-03-10,micafungin,True,['Astellas Pharma'],0,Japan,20,6,0,0,1,4,1,0,0,0,0,0,0,0,1,0
Antiâ€“B-Cell Maturation Antigen BiTE Molecule AMG 420 Induces Responses in Multiple Myeloma,2020-03-10,AMG 420,True,['Amgen'],1,Germany,17,12,6,5,0,3,1,1,0,0,1,1,0,0,0,1
Randomized Phase III Study of Continuation Maintenance Bevacizumab With or Without Pemetrexed in Advanced Nonsquamous Nonâ€“Small-Cell Lung Cancer: COMPASS (WJOG5610L),2020-03-10,bevacizumab,True,['Roche'],0,Japan,20,3,0,0,0,1,0,0,0,0,0,0,0,0,0,0
Dietary Supplement Use During Chemotherapy and Survival Outcomes of Patients With Breast Cancer Enrolled in a Cooperative Group Clinical Trial (SWOG S0221),2020-03-10,,False,[],0,USA,20,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Long-Term Results of NRG Oncology RTOG 0617: Standard- Versus High-Dose Chemoradiotherapy With or Without Cetuximab for Unresectable Stage III NonÃ¢â‚¬â€œSmall-Cell Lung Cancer,2020-03-01,cetuximab,False,[],0,USA,20,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Phase III Study of Adjuvant Ipilimumab (3 or 10 mg/kg) Versus High-Dose Interferon Alfa-2b for Resected High-Risk Melanoma: North American Intergroup E1609,2020-02-20,ipilimumab,True,"['Bristol-Myers Squibb', 'Bristol-Myers Squibb (I)']",0,USA,21,13,1,7,1,3,1,1,0,0,1,1,0,0,0,0
Gemtuzumab Ozogamicin in NPM1-Mutated Acute Myeloid Leukemia: Early Results From the Prospective Randomized AMLSG 09-09 Phase III Study,2020-02-20,gemtuzumab ozogamicin,True,"['Pfizer', 'Pfizer (I)']",0,Germany,33,11,0,8,2,3,1,1,0,0,1,0,1,0,0,0
Sequencing of Androgen-Deprivation Therapy With External-Beam Radiotherapy in Localized Prostate Cancer: A Phase III Randomized Controlled Trial,2020-02-20,LHRH agonist,False,[],0,Canada,12,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"CYP2D6 Genotypeâ€“Guided Tamoxifen Dosing in Hormone Receptorâ€“Positive Metastatic Breast Cancer (TARGET-1): A Randomized, Open-Label, Phase II Study",2020-02-20,tamoxifen,False,[],0,Japan,16,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Osimertinib in Patients With Epidermal Growth Factor Receptor Mutationâ€“Positive Nonâ€“Small-Cell Lung Cancer and Leptomeningeal Metastases: The BLOOM Study,2020-02-20,osimertinib,True,"['AstraZeneca (I)', 'AstraZeneca']",1,China,16,14,6,5,0,5,1,1,0,0,1,1,0,0,1,1
"Randomized Phase III Study of Ganetespib, a Heat Shock Protein 90 Inhibitor, With Docetaxel Versus Docetaxel in Advanced NonÃ¢â‚¬â€œSmall-Cell Lung Cancer (GALAXY-2)",2020-02-20,ganetespib,False,[],1,USA,11,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Outcome in Children With Standard-Risk B-Cell Acute Lymphoblastic Leukemia: Results of ChildrenÃ¢â‚¬â„¢s Oncology Group Trial AALL0331,2020-02-20,pegaspargase,True,"['Amgen', 'Amgen (I)']",0,USA,20,4,0,0,0,2,0,1,0,0,0,0,0,0,0,0
Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial,2020-02-10,capivasertib,True,['AstraZeneca'],1,United Kingdom,29,14,4,5,1,3,1,1,0,0,1,1,0,0,1,0
"Osimertinib for Patients With Nonâ€“Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase II Trial (KCSG-LU15-09)",2020-02-10,osimertinib,True,['AstraZeneca'],0,Republic of Korea,14,5,0,3,0,3,1,1,0,0,0,1,0,0,0,1
NSABP B-47/NRG Oncology Phase III Randomized Trial Comparing Adjuvant Chemotherapy With or Without Trastuzumab in High-Risk Invasive Breast Cancer Negative for HER2 by FISH and With IHC 1+ or 2+,2020-02-10,trastuzumab,True,['Genentech'],1,USA,20,3,0,0,0,0,0,1,0,0,0,0,0,0,0,0
"Randomized, Phase II Study Prospectively Evaluating Treatment of Metastatic Esophageal, Gastric, or Gastroesophageal Cancer by Gene Expression of ERCC1: SWOG S1201",2020-02-10,,False,[],0,USA,12,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Optimizing Chimeric Antigen Receptor T-Cell Therapy for Adults With Acute Lymphoblastic Leukemia,2020-02-10,tisagenlecleucel,True,"['Novartis', 'Patents and intellectual property related to chimeric antigen receptor T-cell technology licensed to Novartis', 'Intellectual property licensed to Novartis', 'Patent owned by the University of Pennsylvania currently licensed to Novartis for an algorithm that predicts severe cytokine release syndrome for chimeric antigen receptor T-cell 19 therapy; receive 10% of the licensing fees']",0,USA,18,11,0,4,0,3,1,1,0,0,1,1,0,0,0,0
Phase II Feasibility and Biomarker Study of Neoadjuvant Trastuzumab and Pertuzumab With Chemoradiotherapy for Resectable Human Epidermal Growth Factor Receptor 2â€“Positive Esophageal Adenocarcinoma: TRAP Study,2020-02-10,trastuzumab,True,['Roche'],0,the Netherlands,25,4,0,0,0,0,1,1,0,0,0,0,0,0,0,0
"Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study",2020-02-10,pembrolizumab,True,"['MSD (I)', 'MSD', 'Merck Sharp & Dohme', 'MSD Oncology']",1,USA,24,23,4,10,1,4,1,1,0,0,1,1,0,0,1,0
Adding Ovarian Suppression to Tamoxifen for Premenopausal Breast Cancer: A Randomized Phase III Trial,2020-02-10,goserelin,True,['AstraZeneca'],0,Republic of Korea,30,3,0,2,1,0,1,0,0,0,1,0,0,0,0,0
Neoadjuvant Talazoparib for Patients With Operable Breast Cancer With a Germline BRCA Pathogenic Variant,2020-02-10,talazoparib,True,"['Pfizer', 'Pfizer (I)', 'Medivation/Pfizer']",0,USA,19,6,0,3,0,2,1,0,0,0,1,0,0,0,0,0
Treatment of Older Patients With Mantle Cell Lymphoma (MCL): Long-Term Follow-Up of the Randomized European MCL Elderly Trial,2020-01-20,rituximab,True,"['F. Hoffmann-La Roche', 'Roche Pharma AG', 'Roche']",1,the Netherlands,22,11,0,7,2,4,1,1,0,0,0,1,0,1,0,0
"Valproate and Retinoic Acid in Combination With Decitabine in Elderly Nonfit Patients With Acute Myeloid Leukemia: Results of a Multicenter, Randomized, 2 Ã— 2, Phase II Trial",2020-01-20,decitabine,True,"['Astex Pharmaceuticals', 'Astex']",0,Germany,33,2,0,1,0,0,1,1,0,0,0,1,0,0,0,0
"Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial",2020-01-20,pembrolizumab,True,"['Merck Sharp & Dohme', 'Merck', 'Merck Sharp & Dohme Oncology']",1,USA,21,15,3,10,0,5,1,1,0,0,1,1,0,0,0,0
Phase II Study of Nonmetastatic Desmoplastic Medulloblastoma in Children Younger Than 4 Years of Age: A Report of the Childrenâ€™s Oncology Group (ACNS1221),2020-01-20,,False,[],0,Canada,16,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Nivolumab Is Effective in Mismatch Repairâ€“Deficient Noncolorectal Cancers: Results From Arm Z1Dâ€”A Subprotocol of the NCI-MATCH (EAY131) Study,2020-01-20,nivolumab,True,"['Bristol-Myers Squibb', 'Bristol-Myers Squib']",0,USA,25,9,0,5,0,0,1,1,0,0,0,1,0,0,0,0
Health-Related Quality of Life With Carboplatin-Paclitaxel or nab-Paclitaxel With or Without Pembrolizumab in Patients With Metastatic Squamous Nonâ€“Small-Cell Lung Cancer,2020-01-20,pembrolizumab,True,"['a subsidiary of Merck & Co.', 'Merck (I)', 'Merck Sharp & Dohme', 'Merck Sharp & Dohme Corp.', 'Merck Sharp & Dohme Corp. a subsidiary of Merck & Co.', 'Merck', 'MSD', 'MSD Oncology']",1,France,20,15,4,7,2,3,1,1,0,0,1,0,0,0,0,1
Phase III Trial of Adjuvant Capecitabine After Standard Neo-/Adjuvant Chemotherapy in Patients With Early Triple-Negative Breast Cancer (GEICAM/2003-11_CIBOMA/2004-01),2020-01-20,capecitabine,True,"['Roche (I)', 'Roche']",1,Spain,41,20,0,11,8,4,1,1,0,0,0,0,0,0,0,0
Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma,2020-01-10,polatuzumab vedotin,True,['Genentech'],1,Canada,16,11,4,4,1,4,1,1,0,0,1,1,0,0,1,1
Gefitinib Alone Versus Gefitinib Plus Chemotherapy for Nonâ€“Small-Cell Lung Cancer With Mutated Epidermal Growth Factor Receptor: NEJ009 Study,2020-01-10,gefitinib,True,['AstraZeneca'],0,Japan,16,10,1,3,4,5,1,1,0,0,0,1,1,0,0,1
Gefitinib Versus Gefitinib Plus Pemetrexed and Carboplatin Chemotherapy in EGFR-Mutated Lung Cancer,2020-01-10,gefitinib,True,['Roche Holding AG'],0,India,21,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0
"Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instabilityâ€“High/Mismatch Repairâ€“Deficient Metastatic Colorectal Cancer: KEYNOTE-164",2020-01-01,pembrolizumab,True,"['Merck', 'Merck Serono', 'Merck Sharp & Dohme', 'MSD', 'Merck KGaA', 'MSD China', 'MSD Oncology']",1,USA,22,17,2,12,0,7,1,1,0,0,1,1,0,0,1,0
Results of a Multicenter Phase II Study of Atezolizumab and Bevacizumab for Patients With Metastatic Renal Cell Carcinoma With Variant Histology and/or Sarcomatoid Features,2020-01-01,atezolizumab,True,"['Genentech', 'Genentech (I)']",0,USA,20,7,0,4,0,1,1,1,0,0,1,1,0,0,0,1
Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repairâ€“Deficient Cancer: Results From the Phase II KEYNOTE-158 Study,2020-01-01,pembrolizumab,True,"['Merck', 'Merck Serono', 'Merck Sharp & Dohme', 'MSD', 'MSD Oncology']",1,France,22,20,3,19,2,4,1,1,0,0,1,1,1,0,0,0
PD-1 Blockade in Advanced Adrenocortical Carcinoma,2020-01-01,pembrolizumab,True,['Merck'],0,USA,17,3,0,3,0,0,0,0,0,0,0,0,0,0,0,0
Pembrolizumab in Relapsed and Refractory Mycosis Fungoides and SÃ©zary Syndrome: A Multicenter Phase II Study,2020-01-01,pembrolizumab,True,"['Merck Sharp & Dohme', 'Two patents pending resulting from work conducted as full-time Merck employee', 'Merck']",0,USA,33,5,1,0,0,0,0,1,0,0,0,0,0,0,0,0
"Phase I Study of DSTP3086S, an Antibody-Drug Conjugate Targeting Six-Transmembrane Epithelial Antigen of Prostate 1, in Metastatic Castration-Resistant Prostate Cancer",2019-12-20,DSTP3086S,True,['Genentech'],0,USA,15,11,9,0,1,0,1,0,0,0,0,0,0,0,0,0
"Phase II Trial of a DNA Vaccine Encoding Prostatic Acid Phosphatase (pTVG-HP [MVI-816]) in Patients With Progressive, Nonmetastatic, Castration-Sensitive Prostate Cancer",2019-12-20,pTVG-HP,True,['Madison Vaccines'],0,USA,10,2,0,1,0,0,1,1,0,0,1,0,0,0,0,0
Improving Stratification for Children With Late Bone Marrow B-Cell Acute Lymphoblastic Leukemia Relapses With Refined Response Classification and Integration of Genetics,2019-12-20,,False,[],1,Germany,19,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Improved CNS Control of Childhood Acute Lymphoblastic Leukemia Without Cranial Irradiation: St Jude Total Therapy Study 16,2019-12-10,PEG-asparaginase,False,[],0,USA,19,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Multicenter, Prospective, Phase II and Biomarker Study of High-Dose Bevacizumab as Induction Therapy in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannoma",2019-12-10,bevacizumab,True,['Genentech'],0,USA,16,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
Incidence of Late Relapses in Patients With HER2-Positive Breast Cancer Receiving Adjuvant Trastuzumab: Combined Analysis of NCCTG N9831 (Alliance) and NRG Oncology/NSABP B-31,2019-12-10,trastuzumab,True,['Genentech'],0,USA,12,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0
"FOLFOXIRI Plus Panitumumab As First-Line Treatment of RAS Wild-Type Metastatic Colorectal Cancer: The Randomized, Open-Label, Phase II VOLFI Study (AIO KRK0109)",2019-12-10,panitumumab,True,['Amgen'],0,Germany,19,7,0,4,0,5,1,1,0,0,1,1,0,0,1,0
Treatment-Free Survival: A Novel Outcome Measure of the Effects of Immune Checkpoint Inhibitionâ€”A Pooled Analysis of Patients With Advanced Melanoma,2019-12-10,nivolumab,True,['Bristol-Myers Squibb'],0,USA,15,14,3,11,0,3,1,1,0,0,1,1,0,0,0,0
Phase III Randomized Trial of Chemotherapy With or Without Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer,2019-12-01,bevacizumab,True,['Genentech'],0,USA,14,5,0,2,0,1,1,1,0,0,0,1,0,0,0,0
"Phase IIb, Randomized, Double-Blind Trial of GC4419 Versus Placebo to Reduce Severe Oral Mucositis Due to Concurrent Radiotherapy and Cisplatin For Head and Neck Cancer",2019-12-01,GC4419,True,"['Galera Therapeutics', 'Galera']",0,USA,27,6,2,1,0,0,1,1,0,0,0,1,0,0,0,0
Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma,2019-12-01,pembrolizumab,True,"['Merck Sharp & Dohme', 'Merck']",1,USA,29,12,2,4,1,3,1,1,0,0,1,1,0,1,1,0
Phase II Trial of Response-Based Radiation Therapy for Patients With Localized CNS Nongerminomatous Germ Cell Tumors: A Children's Oncology Group Study,2019-12-01,carboplatin,False,[],0,USA,15,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Maintaining Outstanding Outcomes Using Response- and Biology-Based Therapy for Intermediate-Risk Neuroblastoma: A Report From the Childrenâ€™s Oncology Group Study ANBL0531,2019-12-01,,False,[],0,USA,21,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Randomized Phase II Trial of Chemoradiotherapy Plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: CAO/ARO/AIO-12,2019-12-01,fluorouracil (5-FU),False,[],0,Germany,26,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Neoadjuvant Modified FOLFOX6 With or Without Radiation Versus Fluorouracil Plus Radiation for Locally Advanced Rectal Cancer: Final Results of the Chinese FOWARC Trial,2019-12-01,flourouracil,False,[],0,China,28,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"High-Dose Chemotherapy Compared With Standard Chemotherapy and Lung Radiation in Ewing Sarcoma With Pulmonary Metastases: Results of the European Ewing Tumour Working Initiative of National Groups, 99 Trial and EWING 2008",2019-12-01,busulfan,False,[],1,Germany,43,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Oxaliplatin-Based Adjuvant Chemotherapy for Rectal Cancer After Preoperative Chemoradiotherapy (ADORE): Long-Term Results of a Randomized Controlled Trial,2019-11-20,oxaliplatin,True,['Sanofi'],0,Republic of Korea,21,2,0,1,0,0,0,1,0,0,0,0,0,0,0,0
"Adjuvant Whole-Brain Radiation Therapy Compared With Observation After Local Treatment of Melanoma Brain Metastases: A Multicenter, Randomized Phase III Trial",2019-11-20,,False,[],1,Australia,24,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Negative Hyperselection of Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer Who Received Panitumumab-Based Maintenance Therapy,2019-11-20,panitumumab,True,['Amgen'],0,Italy,25,10,0,8,3,2,0,1,0,0,0,1,0,0,0,0
Neoadjuvant Chemotherapy With Cisplatin and Gemcitabine Followed by Chemoradiation Versus Chemoradiation for Locally Advanced Cervical Cancer: A Randomized Phase II Trial,2019-11-20,cisplatin,False,"['MSD Oncology', 'Merck Sharp & Dohme']",0,Brazil,13,2,0,0,0,1,0,1,0,0,0,0,0,0,0,0
Nivolumab Combined With Brentuximab Vedotin for Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma: Efficacy and Safety From the Phase II CheckMate 436 Study,2019-11-20,Nivolumab,True,"['Bristol-Myers Squibb', 'BMS']",1,Italy,14,9,1,5,1,1,1,1,0,0,1,1,1,0,0,0
Final Analysis of DeCOG-SLT Trial: No Survival Benefit for Complete Lymph Node Dissection in Patients With Melanoma With Positive Sentinel Node,2019-11-10,,False,[],0,Germany,20,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Phase I/II Study of Palliative Triple Metronomic Chemotherapy in Platinum-Refractory/Early-Failure Oral Cancer,2019-11-10,erlotinib,True,['Roche'],0,India,25,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0
"Axitinib in Combination With Toripalimab, a Humanized Immunoglobulin G4 Monoclonal Antibody Against Programmed Cell Death-1, in Patients With Metastatic Mucosal Melanoma: An Open-Label Phase IB Trial",2019-11-10,toripalimab,True,"['Shanghai Junshi Biosciences', 'Shanghai Junshi Biosciences patent', 'I am on a few patents issued to Junshi Biosciences']",0,China,22,6,5,1,0,0,0,1,0,0,0,1,0,0,0,0
"ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer",2019-11-10,enzalutamide,True,"['Medivation/Astellas', 'Astellas Medivation', 'Medivation', 'Astellas Scientific and Medical Affairs', 'Astellas Pharma (during conduct of the study)', 'Astellas Pharma', 'Astellas']",1,USA,15,14,3,10,3,2,1,1,0,0,1,0,0,0,0,0
Niraparib Maintenance Therapy in Patients With Recurrent Ovarian Cancer After a Partial Response to the Last Platinum-Based Chemotherapy in the ENGOT-OV16/NOVA Trial,2019-11-10,niraparib,True,"['TESARO: A GSK Company', 'TESARO']",1,Spain,21,12,2,5,3,3,0,1,0,0,0,1,0,0,0,1
Romiplostim Treatment of Chemotherapy-Induced Thrombocytopenia,2019-11-01,romiplostim,True,['Amgen'],0,USA,13,4,0,2,0,0,1,0,0,0,1,0,0,0,0,0
Randomized Phase II Trial of Bevacizumab or Temsirolimus in Combination With Chemotherapy for First Relapse Rhabdomyosarcoma: A Report From the Childrenâ€™s Oncology Group,2019-11-01,temsirolimus,True,['Bristol-Myers Squibb'],0,USA,12,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0
"Positron Emission Tomographyâ€“Guided Treatment in Early-Stage Favorable Hodgkin Lymphoma: Final Results of the International, Randomized Phase III HD16 Trial by the German Hodgkin Study Group",2019-11-01,"doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD regimen)",False,[],1,Germany,29,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Safety and Efficacy of Nivolumab Monotherapy in Recurrent or Metastatic Cervical, Vaginal, or Vulvar Carcinoma: Results From the Phase I/II CheckMate 358 Trial",2019-11-01,Nivolumab,True,"['Bristol-Myers Squibb', 'Bristol Myers Squibb', 'Bristol-Myers Squibb (I)']",1,USA,19,15,4,3,1,2,1,1,0,0,0,0,0,0,0,0
Sustained Progression-Free Survival Benefit of Rituximab Maintenance in Patients With Follicular Lymphoma: Long-Term Results of the PRIMA Study,2019-11-01,rituximab,True,"['Genentech (DMC)', 'AbbVie/Genentech', 'Genentech']",1,France,31,6,0,4,0,4,0,1,0,0,0,1,0,0,0,1
Phase II Study of Avelumab in Patients With Mismatch Repair Deficient and Mismatch Repair Proficient Recurrent/Persistent Endometrial Cancer,2019-10-20,avelumab,True,['Pfizer/EMD Serono'],0,USA,24,1,0,1,0,0,1,0,0,0,1,0,0,0,0,0
Phase II Study of Proton Beam Radiation Therapy for Patients With Breast Cancer Requiring Regional Nodal Irradiation,2019-10-20,proton beam radiation therapy,True,['Mevion Medical Systems (I)'],0,USA,18,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0
Ibrutinib Plus Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: The CLARITY Study,2019-10-20,ibrutinib,True,['Pharmacyclics'],0,United Kingdom,19,3,0,1,0,1,1,0,0,0,0,0,0,0,0,0
"T-Cell Receptor Gene Therapy for Human PapillomavirusÃ¢â‚¬â€œAssociated Epithelial Cancers: A First-in-Human, Phase I/II Study",2019-10-20,E6 T-cell receptor T cells,False,[],0,USA,12,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Safety and Efficacy of T-DM1 Plus Neratinib in Patients With Metastatic HER2-Positive Breast Cancer: NSABP Foundation Trial FB-10,2019-10-10,ado-trastuzumab emtansine,True,"['Roche (I)', 'Roche']",0,USA,18,2,1,0,0,1,1,0,0,0,0,0,0,0,1,0
"Pyrotinib or Lapatinib Combined With Capecitabine in HER2â€“Positive Metastatic Breast Cancer With Prior Taxanes, Anthracyclines, and/or Trastuzumab: A Randomized, Phase II Study",2019-10-10,pyrotinib,True,['Jiangsu Hengrui Medicine'],0,China,14,3,2,0,0,0,1,1,1,0,0,0,0,0,0,0
Dose Escalation Trial of the Wee1 Inhibitor Adavosertib (AZD1775) in Combination With Gemcitabine and Radiation for Patients With Locally Advanced Pancreatic Cancer,2019-10-10,adavosertib (AZD1775),True,['AstraZeneca'],0,USA,13,2,0,0,1,1,0,1,0,0,0,0,0,0,0,0
Phase II California Cancer Consortium Trial of Gemcitabine-Eribulin Combination in Cisplatin-Ineligible Patients With Metastatic Urothelial Carcinoma: Final Report (NCI-9653),2019-10-10,eribulin,True,['Eisai'],0,USA,12,2,0,2,0,0,0,0,0,0,0,0,0,0,0,0
Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy,2019-10-10,enfortumab vedotin,True,"['Astellas', 'Astellas Pharma', 'Astellas Medivation']",0,USA,13,11,2,6,0,1,1,1,0,0,1,1,0,0,0,0
Phase II Trial of De-Intensified Chemoradiotherapy for Human PapillomavirusÃ¢â‚¬â€œAssociated Oropharyngeal Squamous Cell Carcinoma,2019-10-10,cisplatin,False,"['Nanobiotix', 'NanoCarrier']",0,USA,22,3,0,1,1,0,0,0,0,0,0,0,0,0,0,0
Phase II Trial of Cediranib in Combination With Cisplatin and Pemetrexed in Chemotherapy-NaÃ¯ve Patients With Unresectable Malignant Pleural Mesothelioma (SWOG S0905),2019-10-01,cediranib,True,['AstraZeneca'],0,USA,14,7,0,8,1,1,1,1,0,0,1,1,0,0,0,0
Eliminating Postoperative Radiation to the Pathologically Node-Negative Neck: Long-Term Results of a Prospective Phase II Study,2019-10-01,,False,[],0,USA,18,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Five-Year Overall Survival for Patients With Advanced Nonâ€’Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study,2019-10-01,pembrolizumab,True,"['Merck', 'FundaciÃ³n Merck Salud', 'MSD', 'Merck (I)', 'Merck Sharp & Dohme']",1,USA,19,17,3,10,4,2,1,1,0,0,0,1,0,0,0,1
"Pemetrexed, Bevacizumab, or the Combination As Maintenance Therapy for Advanced Nonsquamous Nonâ€“Small-Cell Lung Cancer: ECOG-ACRIN 5508",2019-09-10,pemetrexed,True,"['Eli Lilly/ImClone', 'Eli Lilly']",0,USA,15,5,0,5,1,1,1,0,0,0,1,0,0,0,0,0
Immunotherapy of Relapsed and Refractory Solid Tumors With Ex Vivo Expanded Multi-Tumor Associated Antigen Specific Cytotoxic T Lymphocytes: A Phase I Study,2019-09-10,TAA-T (Tumor-Associated Antigen-Specific T Cells),True,"['Mana Therapeutics', 'Mana Therapeutics has licensed technology of which I am listed as an inventor from Childrenâ€™s National Health System']",0,USA,20,3,0,1,0,0,1,0,0,0,0,0,0,0,0,0
Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian Cancer,2019-09-10,bevacizumab,True,"['Roche/Genentech', 'Roche', 'Roche- and Genentech-related patents', 'Genentech']",0,USA,27,15,5,14,6,7,1,1,0,0,1,1,1,1,0,1
Randomized Trial of Standard Adjuvant Chemotherapy Regimens Versus Capecitabine in Older Women With Early Breast Cancer: 10-Year Update of the CALGB 49907 Trial,2019-09-10,capecitabine,False,[],0,USA,28,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Outcome of Infants Younger Than 1 Year With Acute Lymphoblastic Leukemia Treated With the Interfant-06 Protocol: Results From an International Phase III Randomized Study,2019-09-01,mitoxantrone,False,[],1,the Netherlands,23,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Erlotinib Versus Gemcitabine Plus Cisplatin as Neoadjuvant Treatment of Stage IIIA-N2 EGFR-Mutant Nonâ€“Small-Cell Lung Cancer (EMERGING-CTONG 1103): A Randomized Phase II Study,2019-09-01,erlotinib,True,['Roche'],0,China,21,3,0,1,0,3,1,1,0,0,0,1,0,0,1,1
Neoadjuvant Trastuzumab Emtansine and Pertuzumab in Human Epidermal Growth Factor Receptor 2â€“Positive Breast Cancer: Three-Year Outcomes From the Phase III KRISTINE Study,2019-09-01,trastuzumab emtansine,True,"['F Hoffmann-La Roche', 'Roche']",1,USA,21,9,1,2,2,5,0,0,0,0,0,0,0,0,0,0
NAB-Paclitaxel Improves Disease-Free Survival in Early Breast Cancer: GBG 69â€“GeparSepto,2019-09-01,NAB-paclitaxel,True,['Celgene'],0,Germany,23,10,0,4,2,4,1,1,0,0,0,1,0,0,1,0
"Neoadjuvant Three-Dimensional Conformal Radiotherapy for Resectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombus: A Randomized, Open-Label, Multicenter Controlled Study",2019-08-20,,False,[],0,China,21,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Promoting Breast Cancer Surveillance: The EMPOWER Study, a Randomized Clinical Trial in the Childhood Cancer Survivor Study",2019-08-20,,False,[],0,USA,20,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Pembrolizumab for Patients With Refractory or Relapsed Thymic Epithelial Tumor: An Open-Label Phase II Trial,2019-08-20,pembrolizumab,True,"['Merck Sharpe & Dohme', 'Merck Sharp & Dohme', 'MSD']",0,South Korea,11,4,1,2,0,2,1,1,1,0,0,1,0,0,0,1
Cost Effectiveness of Interval Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy in Stage III Ovarian Cancer on the Basis of a Randomized Phase III Trial,2019-08-10,,False,[],1,the Netherlands,21,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Safety and Efficacy of Nivolumab in Brain Metastases From Renal Cell Carcinoma: Results of the GETUG-AFU 26 NIVOREN Multicenter Phase II Study,2019-08-10,nivolumab,True,['Bristol-Myers Squibb'],0,France,26,14,0,11,0,5,0,1,0,0,0,1,0,0,0,0
Nivolumab for Newly Diagnosed Advanced-Stage Classic Hodgkin Lymphoma: Safety and Efficacy in the Phase II CheckMate 205 Study,2019-08-10,nivolumab,True,['Bristol-Myers Squibb'],1,USA,20,14,1,9,0,6,1,1,0,0,1,0,0,0,0,1
"Clofarabine Can Replace Anthracyclines and Etoposide in Remission Induction Therapy for Childhood Acute Myeloid Leukemia: The AML08 Multicenter, Randomized Phase III Trial",2019-08-10,clofarabine,False,"[, 'Nan ltd.', , 'nanpharma']",0,USA,18,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Prospective Multicenter Study on the Prognostic and Predictive Impact of Tumor Budding in Stage II Colon Cancer: Results From the SACURA Trial,2019-08-01,tegafur-uracil,True,['Taiho Pharmaceutical'],0,Japan,20,3,0,1,0,2,1,1,0,0,1,0,0,0,1,0
Impact of Consensus Molecular Subtype on Survival in Patients With Metastatic Colorectal Cancer: Results From CALGB/SWOG 80405 (Alliance),2019-08-01,bevacizumab,True,['Genentech'],1,USA,15,7,2,2,0,1,0,1,0,1,0,0,0,0,0,0
"Seven-Year Follow-Up Analysis of Adjuvant Paclitaxel and Trastuzumab Trial for Node-Negative, Human Epidermal Growth Factor Receptor 2â€“Positive Breast Cancer",2019-08-01,trastuzumab,True,['Roche'],0,USA,26,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0
Phase II Evaluation of Aggressive Dose De-Escalation for Adjuvant Chemoradiotherapy in Human PapillomavirusÃ¢â‚¬â€œAssociated Oropharynx Squamous Cell Carcinoma,2019-08-01,docetaxel,False,[],0,USA,21,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Phase III Trial: Adjuvant Pelvic Radiation Therapy Versus Vaginal Brachytherapy Plus Paclitaxel/Carboplatin in High-Intermediate and High-Risk Early-Stage Endometrial Cancer,2019-07-20,paclitaxel,False,[],0,USA,19,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303,2019-07-20,rituximab,True,"['Roche', 'Genentech/Roche', 'Genentech']",0,USA,26,10,0,8,0,0,1,1,0,0,0,1,0,0,0,0
Positron Emission Tomography Score Has Greater Prognostic Significance Than Pretreatment Risk Stratification in Early-Stage Hodgkin Lymphoma in the UK RAPID Study,2019-07-10,"doxorubicin, bleomycin, vinblastine, dacarbazine",False,[],0,United Kingdom,15,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Comparing Paclitaxel Plus Fluorouracil Versus Cisplatin Plus Fluorouracil in Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Cancer: A Randomized, Multicenter, Phase III Clinical Trial",2019-07-10,paclitaxel,False,[],0,China,17,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Multicenter Trial of [18F]fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Staging of Head and Neck Cancer and Negative Predictive Value and Surgical Impact in the N0 Neck: Results From ACRIN 6685,2019-07-10,fluorodeoxyglucose (FDG),False,[],0,USA,12,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Nivolumab Alone and With Ipilimumab in Previously Treated Metastatic Urothelial Carcinoma: CheckMate 032 Nivolumab 1 mg/kg Plus Ipilimumab 3 mg/kg Expansion Cohort Results,2019-07-01,nivolumab,True,"['Bristol-Myers Squibb', 'Bristol-Myers Squibb (I)', 'patents licensed to Bristol-Myers Squibb']",1,USA,17,15,5,8,1,2,1,1,0,0,1,1,0,0,0,1
Development and Validation of a Cytogenetic Prognostic Index Predicting Survival in Multiple Myeloma,2019-07-01,,False,[],0,France,29,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Intermittent Versus Continuous PEG-Asparaginase to Reduce Asparaginase-Associated Toxicities: A NOPHO ALL2008 Randomized Study,2019-07-01,pegaspargase,True,['Shire'],1,Denmark,10,2,0,0,0,1,1,1,0,0,0,0,0,0,1,0
Randomized Placebo Controlled Trial of Low-Dose Tamoxifen to Prevent Local and Contralateral Recurrence in Breast Intraepithelial Neoplasia,2019-07-01,tamoxifen,False,[],0,Italy,22,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Patient-Reported Outcome Results From the Open-Label, Randomized Phase III Myeloma X Trial Evaluating Salvage Autologous Stem-Cell Transplantation in Relapsed Multiple Myeloma",2019-07-01,,False,[],0,United Kingdom,22,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Nonâ€“Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study",2019-06-20,,False,[],0,USA,21,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Phase II Study of Lenvatinib in Patients With Progressive, Recurrent or Metastatic Adenoid Cystic Carcinoma",2019-06-20,lenvatinib,True,['Eisai'],0,USA,11,4,0,2,0,0,0,1,0,0,0,1,0,0,0,0
Addition of Low-Dose Decitabine to Antiâ€“PD-1 Antibody Camrelizumab in Relapsed/Refractory Classical Hodgkin Lymphoma,2019-06-10,camrelizumab,False,[],0,China,16,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 Study,2019-06-10,pembrolizumab,True,"['Merck Sharp and Dohme', 'Merck & Co', 'MSD', 'Merck Sharp & Dohme']",1,South Korea,12,10,3,1,0,1,1,1,0,0,1,0,0,0,1,0
"Prospective, Multicenter, Randomized Phase III Trial Evaluating the Impact of Lymphoscintigraphy as Part of Sentinel Node Biopsy in Early Breast Cancer: SenSzi (GBG80) Trial",2019-06-10,radioactive-labeled colloid,False,[],0,Germany,22,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Binimetinib, Encorafenib, and Cetuximab Triplet Therapy for Patients With BRAF V600EÃ¢â‚¬â€œMutant Metastatic Colorectal Cancer: Safety Lead-In Results From the Phase III BEACON Colorectal Cancer Study",2019-06-10,encorafenib,True,"['Array BioPharma', 'Array Biopharma']",1,Belgium,20,10,4,2,0,1,0,1,0,0,0,1,0,0,0,0
Randomized Double-Blind Phase II Study of Regorafenib in Patients With Metastatic Osteosarcoma,2019-06-01,regorafenib,True,['Bayer HealthCare Pharmaceuticals'],0,USA,17,7,0,5,2,2,0,1,0,0,0,1,0,0,0,0
Randomized Trial of Intravenous Versus Intraperitoneal Chemotherapy Plus Bevacizumab in Advanced Ovarian Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study,2019-06-01,bevacizumab,True,['Roche'],0,USA,21,4,0,3,2,1,0,0,0,0,0,0,0,0,0,0
"Final Results of a Randomized, Phase III Study of Rituximab With or Without Idelalisib Followed by Open-Label Idelalisib in Patients With Relapsed Chronic Lymphocytic Leukemia",2019-06-01,idelalisib,True,"['Gilead Sciences', 'Gilead']",1,USA,24,22,2,15,4,8,1,1,0,0,0,1,0,1,0,1
ALK Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Nonâ€“Small-Cell Lung Cancer,2019-06-01,lorlatinib,True,['Pfizer'],1,USA,19,16,5,6,1,5,1,1,0,1,1,0,0,0,1,0
Safety and Efficacy of a Five-Fraction Stereotactic Body Radiotherapy Schedule for Centrally Located Nonâ€“Small-Cell Lung Cancer: NRG Oncology/RTOG 0813 Trial,2019-05-20,stereotactic body radiotherapy (SBRT),True,['Varian Medical Systems'],0,Canada,21,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Self-Management in Long-Term Prostate Cancer Survivors: A Randomized, Controlled Trial",2019-05-20,,False,[],0,USA,10,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Addition of Docetaxel to Oral Fluoropyrimidine Improves Efficacy in Patients With Stage III Gastric Cancer: Interim Analysis of JACCRO GC-07, a Randomized Controlled Trial",2019-05-20,S-1,True,['Taiho Pharmaceutical'],0,Japan,20,9,0,0,1,7,1,1,0,0,0,0,0,0,1,0
"Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Nonâ€“Germinal Center B-Cell Diffuse Large B-Cell Lymphoma",2019-05-20,ibrutinib,True,['Pharmacyclics'],1,USA,31,2,1,0,0,0,1,0,0,0,0,0,0,0,0,0
Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study,2019-05-20,venetoclax,True,"['AbbVie', 'AbbVie/Genentech']",1,Australia,20,13,8,3,1,2,1,1,0,0,1,1,1,0,1,0
"Prophylactic Irradiation of Tracts in Patients With Malignant Pleural Mesothelioma: An Open-Label, Multicenter, Phase III Randomized Trial",2019-05-10,,False,[],0,United Kingdom,19,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma,2019-05-10,lenalidomide,True,['Celgene'],1,USA,23,13,4,6,0,2,1,1,0,0,1,1,0,0,0,1
Effect of Chemotherapy With Docetaxel With Androgen Suppression and Radiotherapy for Localized High-Risk Prostate Cancer: The Randomized Phase III NRG Oncology RTOG 0521 Trial,2019-05-10,docetaxel,True,['Sanofi'],1,USA,21,2,0,2,0,0,0,0,0,0,0,0,0,0,0,0
Cyclin E1 Expression and Palbociclib Efficacy in Previously Treated Hormone Receptorâ€“Positive Metastatic Breast Cancer,2019-05-10,palbociclib,True,"['Pfizer', 'Pfizer (I)']",1,United Kingdom,16,14,5,4,0,3,1,1,0,0,1,0,0,0,0,1
Prospective Multicenter Validation of Androgen Receptor Splice Variant 7 and Hormone Therapy Resistance in High-Risk Castration-Resistant Prostate Cancer: The PROPHECY Study,2019-05-01,abiraterone acetate,True,"['Janssen Pharmaceuticals', 'Janssen Oncology', 'Janssen Biotech']",0,USA,27,9,0,6,0,3,1,1,0,0,1,1,0,0,1,1
TBCRC 022: A Phase II Trial of Neratinib and Capecitabine for Patients With Human Epidermal Growth Factor Receptor 2â€“Positive Breast Cancer and Brain Metastases,2019-05-01,neratinib,True,['Puma Biotechnology'],0,USA,31,9,0,5,0,0,1,1,0,0,0,1,0,0,0,0
Phase III Trial of PROSTVAC in Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer,2019-05-01,PROSTVAC,True,"['Bavarian Nordic', 'BN ImmunoTherapeutics']",1,USA,19,6,2,1,0,1,1,1,0,0,0,1,0,0,0,0
Phase IB/II Randomized Study of FOLFIRINOX Plus Pegylated Recombinant Human Hyaluronidase Versus FOLFIRINOX Alone in Patients With Metastatic Pancreatic Adenocarcinoma: SWOG S1313,2019-05-01,pegylated recombinant human hyaluronidase,True,['Halozyme'],0,USA,15,3,0,3,0,1,0,0,0,0,0,0,0,0,0,0
Patient-Centered Preference Assessment to Improve Satisfaction With Care Among Patients With Localized Prostate Cancer: A Randomized Controlled Trial,2019-04-20,,False,[],0,USA,14,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers",2019-04-20,Hu5F9-G4 (5F9),True,"['Forty Seven', 'Patent proposals filed related to using anti-CD47 antibodies as cancer therapy at Forty Seven', 'Inventor on patent developed at Stanford and assigned to Forty Seven', 'Many patents licensed by Stanford to Forty Seven', 'Numerous patents related to CD47 targeting and therapeutics that have been licensed to Forty Seven', 'Stanford/Forty Seven: CD47', 'Inventor on patents generated from Forty Seven', 'Inventor on several patents from Stanford University licensed to Forty Seven']",0,USA,30,19,9,4,0,0,1,1,0,0,0,0,0,0,0,0
First-Line Nivolumab Plus Ipilimumab in Advanced Nonâ€“Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers,2019-04-20,nivolumab,True,['Bristol-Myers Squibb'],1,USA,28,24,8,10,3,4,1,1,0,0,1,1,0,0,0,0
First-Line Treatment of Patients With Indolent Non-Hodgkin Lymphoma or Mantle-Cell Lymphoma With Bendamustine Plus Rituximab Versus R-CHOP or R-CVP: Results of the BRIGHT 5-Year Follow-Up Study,2019-04-20,bendamustine,False,[],1,USA,14,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Conformal Radiation Therapy for Pediatric Ependymoma, Chemotherapy for Incompletely Resected Ependymoma, and Observation for Completely Resected, Supratentorial Ependymoma",2019-04-20,,False,[],0,USA,24,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Evaluation of Intense Androgen Deprivation Before Prostatectomy: A Randomized Phase II Trial of Enzalutamide and Leuprolide With or Without Abiraterone,2019-04-10,enzalutamide,True,['Astellas Pharma'],0,USA,19,5,0,1,0,2,0,1,0,0,0,0,0,0,0,1
Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 Trial,2019-04-10,nivolumab,True,['Bristol-Myers Squibb'],1,France,19,17,3,11,3,5,1,1,0,1,1,0,1,0,1,0
DYNAMO: A Phase II Study of Duvelisib (IPI-145) in Patients With Refractory Indolent Non-Hodgkin Lymphoma,2019-04-10,duvelisib,True,"['Verastem', 'Patent with Verastem', 'Verastem (I)']",1,USA,23,9,3,2,2,1,1,1,0,0,1,0,0,1,0,0
Preoperative Breast Magnetic Resonance Imaging in Women With Local Ductal Carcinoma in Situ to Optimize Surgical Outcomes: Results From the Randomized Phase III Trial IRCIS,2019-04-10,MRI,False,[],0,France,23,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Radiotherapy or Autologous Stem-Cell Transplantation for Primary CNS Lymphoma in Patients 60 Years of Age and Younger: Results of the Intergroup ANOCEF-GOELAMS Randomized Phase II PRECIS Study,2019-04-01,rituximab,True,"['Roche France', 'Roche', 'Roche/Genentech']",0,France,41,8,0,5,0,1,1,0,0,0,1,0,0,0,0,0
"Maintenance Defactinib Versus Placebo After First-Line Chemotherapy in Patients With Merlin-Stratified Pleural Mesothelioma: COMMANDâ€”A Double-Blind, Randomized, Phase II Study",2019-04-01,defactinib,True,['Verastem'],1,United Kingdom,15,3,2,0,0,0,0,0,0,0,0,0,0,0,0,0
Efficacy of Internet-Based Cognitive Behavioral Therapy for Treatment-Induced Menopausal Symptoms in Breast Cancer Survivors: Results of a Randomized Controlled Trial,2019-04-01,,False,[],0,the Netherlands,21,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Hematopoietic Stem-Cell Transplantation Does Not Improve the Poor Outcome of Children With Hypodiploid Acute Lymphoblastic Leukemia: A Report From Childrenâ€™s Oncology Group,2019-04-01,,False,[],0,USA,18,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
West German Study PlanB Trial: Adjuvant Four Cycles of Epirubicin and Cyclophosphamide Plus Docetaxel Versus Six Cycles of Docetaxel and Cyclophosphamide in HER2-Negative Early Breast Cancer,2019-04-01,docetaxel,False,[],0,Germany,21,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Durable Tumor Regression and Overall Survival in Patients With Advanced Merkel Cell Carcinoma Receiving Pembrolizumab as First-Line Therapy,2019-03-20,pembrolizumab,True,"['Merck', 'Merck Sharp & Dohme', 'Merck/Schering Plough']",0,USA,31,14,3,7,1,1,1,1,0,0,1,1,0,0,1,0
TBCRC026: Phase II Trial Correlating Standardized Uptake Value With Pathologic Complete Response to Pertuzumab and Trastuzumab in Breast Cancer,2019-03-20,pertuzumab,True,['Genentech'],0,USA,23,10,0,3,0,3,1,0,0,0,0,0,0,0,0,0
"Buparlisib in Patients With Recurrent Glioblastoma Harboring Phosphatidylinositol 3-Kinase Pathway Activation: An Open-Label, Multicenter, Multi-Arm, Phase II Trial",2019-03-20,buparlisib,True,"['Novartis', 'Novartis Institutes for BioMedical Research']",0,USA,44,9,1,4,0,1,1,0,0,0,0,0,0,0,0,0
Neoplasm Risk Among Individuals With a Pathogenic Germline Variant in DICER1,2019-03-10,,False,[],0,USA,12,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Randomized Phase III Study of Alisertib or Investigatorâ€™s Choice (Selected Single Agent) in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma,2019-03-10,alisertib,True,['Millennium Pharmaceuticals'],1,USA,30,5,2,3,0,1,1,0,0,0,1,0,0,0,1,0
Gemcitabine and Oxaliplatin Chemotherapy or Surveillance in Resected Biliary Tract Cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): A Randomized Phase III Study,2019-03-10,gemcitabine,True,['Eli Lilly'],0,France,24,4,0,1,0,2,0,1,0,0,0,0,0,0,0,1
Combination Lenalidomide and Azacitidine: A Novel Salvage Therapy in Patients Who Relapse After Allogeneic Stem-Cell Transplantation for Acute Myeloid Leukemia,2019-03-01,lenalidomide,True,['Celgene'],0,United Kingdom,14,5,0,0,1,3,1,1,0,0,0,0,1,0,1,1
Randomized Phase II Trial Comparing Site-Specific Treatment Based on Gene Expression Profiling With Carboplatin and Paclitaxel for Patients With Cancer of Unknown Primary Site,2019-03-01,paclitaxel and carboplatin,False,[],0,Japan,21,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Autologous Transplantation, Consolidation, and Maintenance Therapy in Multiple Myeloma: Results of the BMT CTN 0702 Trial",2019-03-01,lenalidomide,True,"['Celgene (I)', 'Celgene']",0,USA,25,14,0,10,2,4,1,1,0,0,1,1,0,1,0,0
Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Nonâ€“Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater,2019-03-01,pembrolizumab,True,"['MSD', 'Merck Serono', 'Merck Sharp & Dohme', 'Merck', 'MSD Oncology']",1,Germany,18,15,4,7,4,6,1,1,0,0,1,1,1,0,0,0
"Nivolumab for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Patients Ineligible for or Having Failed Autologous Transplantation: A Single-Arm, Phase II Study",2019-02-20,nivolumab,True,['Bristol-Myers Squibb'],1,USA,18,12,3,3,1,3,1,0,0,0,0,0,0,0,0,0
Neoadjuvant Degarelix Versus Triptorelin in Premenopausal Patients Who Receive Letrozole for Locally Advanced Endocrine-Responsive Breast Cancer: A Randomized Phase II Trial,2019-02-10,degarelix,True,['Ferring'],1,Italy,20,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Phase I Dose-Escalation Study of Once Weekly or Once Every Two Weeks Administration of High-Dose Sunitinib in Patients With Refractory Solid Tumors,2019-02-10,sunitinib,True,['Pfizer'],0,the Netherlands,9,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Phase I/II Study of Stem-Cell Transplantation Using a Single Cord Blood Unit Expanded Ex Vivo With Nicotinamide,2019-02-10,nicotinamide-expanded umbilical cord blood graft,True,['Gamida Cell'],1,USA,20,6,0,0,0,1,1,0,0,0,0,0,0,0,0,0
"T-Cellâ€“Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028",2019-02-01,pembrolizumab,True,"['Merck', 'Merck Sharp & Dohme', 'MSD', 'Merck Serono']",1,USA,20,17,7,7,0,1,1,1,0,1,1,0,0,0,0,0
Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III Study,2019-02-01,venetoclax,True,['AbbVie'],1,the Netherlands,15,8,1,5,3,5,1,1,0,0,1,1,0,0,0,1
Patient-Reported Outcomes Over 5 Years After Whole- or Partial-Breast Radiotherapy: Longitudinal Analysis of the IMPORT LOW (CRUK/06/003) Phase III Randomized Controlled Trial,2019-02-01,,False,[],0,United Kingdom,9,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Phase I/II Trial to Evaluate the Efficacy and Safety of Nanoparticle Albumin-Bound Paclitaxel in Combination With Gemcitabine in Patients With Pancreatic Cancer and an ECOG Performance Status of 2,2019-01-20,NAB-paclitaxel,True,"['Celgene (I)', 'Celgene']",0,Spain,16,8,0,7,3,3,1,1,0,0,1,1,0,0,0,1
Randomized Phase II Trial of Cisplatin and Etoposide in Combination With Veliparib or Placebo for Extensive-Stage Small-Cell Lung Cancer: ECOG-ACRIN 2511 Study,2019-01-20,veliparib,True,['Abbvie'],0,USA,11,4,0,3,0,0,1,1,0,0,1,1,0,0,0,0
Randomized Phase II Study Evaluating Palbociclib in Addition to Letrozole as Neoadjuvant Therapy in Estrogen Receptorâ€“Positive Early Breast Cancer: PALLET Trial,2019-01-20,palbociclib,True,['Pfizer'],1,United Kingdom,37,21,1,5,4,1,1,1,0,0,0,0,1,0,0,0
Time Interval to Biochemical Failure as a Surrogate End Point in Locally Advanced Prostate Cancer: Analysis of Randomized Trial NRG/RTOG 9202,2019-01-20,androgen deprivation therapy (ADT),False,[],0,USA,12,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Adjuvant Letrozole and Tamoxifen Alone or Sequentially for Postmenopausal Women With Hormone Receptorâ€“Positive Breast Cancer: Long-Term Follow-Up of the BIG 1-98 Trial,2019-01-10,letrozole,True,"['Novartis', 'Novartis (I)']",1,Switzerland,30,20,0,6,0,5,1,1,0,0,1,0,0,0,0,0
Defining Risk Factors for Chemotherapeutic Intervention in Infants With Stage 4S Neuroblastoma: A Report From Childrenâ€™s Oncology Group Study ANBL0531,2019-01-10,,False,[],0,USA,13,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
SELECT: A Phase II Trial of Adjuvant Erlotinib in Patients With Resected Epidermal Growth Factor Receptorâ€“Mutant Nonâ€“Small-Cell Lung Cancer,2019-01-10,erlotinib,True,['Roche'],0,USA,17,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Effect of Pregabalin on Radiotherapy-Related Neuropathic Pain in Patients With Head and Neck Cancer: A Randomized Controlled Trial,2019-01-10,pregabalin,False,[],1,China,19,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Phase II Trial of Trastuzumab and Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2Ã¢â‚¬â€œPositive Salivary Duct Carcinoma,2019-01-10,trastuzumab,False,[],0,Japan,16,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Bladder Preservation With Twice-a-Day Radiation Plus Fluorouracil/Cisplatin or Once Daily Radiation Plus Gemcitabine for Muscle-Invasive Bladder Cancer: NRG/RTOG 0712â€”A Randomized Phase II Trial,2019-01-01,gemcitabine,False,[],0,USA,15,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Long-Term Survival of Patients With Melanoma With Active Brain Metastases Treated With Pembrolizumab on a Phase II Trial,2019-01-01,pembrolizumab,True,"['Merck Sharp & Dohme', 'Merck']",0,USA,17,4,0,1,0,0,1,1,0,0,0,0,0,0,0,0
"Sequential Versus Combination Therapy of Metastatic Colorectal Cancer Using Fluoropyrimidines, Irinotecan, and Bevacizumab: A Randomized, Controlled Studyâ€”XELAVIRI (AIO KRK0110)",2019-01-01,bevacizumab,True,['Roche'],0,Germany,21,10,0,7,2,5,1,1,0,0,0,1,0,0,1,1
Occurrence of Treatment-Related Cardiotoxicity and Its Impact on Outcomes Among Children Treated in the AAML0531 Clinical Trial: A Report From the Childrenâ€™s Oncology Group,2019-01-01,,False,[],0,USA,11,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected BRAF V600â€“Mutant Stage III Melanoma,2018-12-10,dabrafenib plus trametinib,True,['Novartis'],0,USA,23,20,4,14,6,8,1,1,0,0,1,1,0,0,1,1
BRAF Inhibition in BRAFV600-Mutant Gliomas: Results From the VE-BASKET Study,2018-12-10,vemurafenib,True,"['Roche', 'F Hoffmann-La Roche']",0,Canada,21,8,2,4,0,3,0,0,0,0,0,0,0,0,0,0
"Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Urothelial Bladder Carcinoma (PURE-01): An Open-Label, Single-Arm, Phase II Study",2018-12-01,pembrolizumab,True,"['Merck Sharp & Dohme', 'Merck']",0,USA,23,1,0,1,0,1,1,0,0,0,1,0,0,0,1,0
Hydroxycarbamide Plus Aspirin Versus Aspirin Alone in Patients With Essential Thrombocythemia Age 40 to 59 Years Without High-Risk Features,2018-12-01,hydroxycarbamide,False,[],0,France,19,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"First-in-Human Phase I, Dose-Escalation and -Expansion Study of Telisotuzumab Vedotin, an Antibodyâ€“Drug Conjugate Targeting c-Met, in Patients With Advanced Solid Tumors",2018-11-20,telisotuzumab vedotin,True,['AbbVie'],0,USA,15,14,6,2,0,0,1,1,0,0,0,1,0,0,0,0
Multicenter Phase II Study of Lurbinectedin in BRCA-Mutated and Unselected Metastatic Advanced Breast Cancer and Biomarker Assessment Substudy,2018-11-01,lurbinectedin,True,['PharmaMar'],0,USA,24,17,6,2,1,0,1,1,0,0,0,1,0,0,0,0
"Phase Ib/II Study of Capmatinib (INC280) Plus Gefitinib After Failure of Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy in Patients With EGFR-Mutated, MET Factorâ€“Dysregulated Nonâ€“Small-Cell Lung Cancer",2018-11-01,capmatinib,True,"['Novartis', 'Novartis Pharma AG', 'Novartis Pharma']",0,Singapore,17,11,6,3,1,3,0,1,0,0,0,1,0,0,0,1
"Efficacy and Tolerability of First-Line Cetuximab Plus Leucovorin, Fluorouracil, and Oxaliplatin (FOLFOX-4) Versus FOLFOX-4 in Patients With RAS Wild-Type Metastatic Colorectal Cancer: The Open-Label, Randomized, Phase III TAILOR Trial",2018-10-20,cetuximab,True,['Merck Serono'],0,Germany,27,3,3,0,0,0,0,0,0,0,0,0,0,0,0,0
"Multicenter Phase II Study of Sequential Brentuximab Vedotin and Doxorubicin, Vinblastine, and Dacarbazine Chemotherapy for Older Patients With Untreated Classical Hodgkin Lymphoma",2018-10-20,Brentuximab vedotin,True,['Seattle Genetics'],0,USA,11,4,0,3,0,1,1,1,0,0,1,0,0,0,0,0
"Phase Ib Trial With Birabresib, a Small-Molecule Inhibitor of Bromodomain and Extraterminal Proteins, in Patients With Selected Advanced Solid Tumors",2018-10-20,birabresib,True,"['Merck', 'Merck Sharp & Dohme', 'MSD']",0,USA,14,8,3,1,0,3,0,1,0,0,0,0,0,0,0,1
Improved Survival for Children and Young Adults With T-Lineage Acute Lymphoblastic Leukemia: Results From the Childrenâ€™s Oncology Group AALL0434 Methotrexate Randomization,2018-10-10,methotrexate,False,[],0,USA,22,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Randomized Trial of Hypofractionated, Dose-Escalated, Intensity-Modulated Radiation Therapy (IMRT) Versus Conventionally Fractionated IMRT for Localized Prostate Cancer",2018-10-10,,False,[],0,USA,14,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Randomized Trial of Systemic Therapy After Involved-Field Radiotherapy in Patients With Early-Stage Follicular Lymphoma: TROG 99.03,2018-10-10,rituximab,True,['Roche'],0,Canada,12,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0
CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer,2018-10-01,nivolumab,True,"['own patents licensed to Bristol-Myers Squibb (I)', 'Bristol-Myers Squibb', 'Expenses: Bristol-Myers Squibb']",0,USA,16,14,3,9,2,0,1,1,0,0,1,1,0,0,0,0
"First-Line Trastuzumab Plus an Aromatase Inhibitor, With or Without Pertuzumab, in Human Epidermal Growth Factor Receptor 2â€“Positive and Hormone Receptorâ€“Positive Metastatic or Locally Advanced Breast Cancer (PERTAIN): A Randomized, Open-Label Phase II Trial",2018-10-01,pertuzumab,True,['Roche'],0,Switzerland,11,5,2,3,3,4,0,1,0,0,0,1,0,1,0,1
"Addition of Vincristine and Irinotecan to Vincristine, Dactinomycin, and Cyclophosphamide Does Not Improve Outcome for Intermediate-Risk Rhabdomyosarcoma: A Report From the Childrenâ€™s Oncology Group",2018-09-20,,False,[],0,USA,24,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Neoadjuvant Chemoradiotherapy Followed by Surgery Versus Surgery Alone for Locally Advanced Squamous Cell Carcinoma of the Esophagus (NEOCRTEC5010): A Phase III Multicenter, Randomized, Open-Label Clinical Trial",2018-09-20,cisplatin,False,[],0,USA,36,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Ibrutinib Monotherapy in Symptomatic, Treatment-NaÃ¯ve Patients With WaldenstrÃ¶m Macroglobulinemia",2018-09-20,ibrutinib,True,['Pharmacyclics'],0,USA,18,3,0,3,0,0,1,1,0,0,1,1,0,0,0,0
CNS Efficacy of Osimertinib in Patients With T790M-Positive Advanced Nonâ€“Small-Cell Lung Cancer: Data From a Randomized Phase III Trial (AURA3),2018-09-10,osimertinib,True,"['AstraZeneca (I)', 'A straZeneca', 'AstraZeneca']",0,Hong Kong,12,9,6,4,0,4,1,1,0,0,1,1,0,0,1,1
Intensifying Treatment of Childhood B-Lymphoblastic Leukemia With IKZF1 Deletion Reduces Relapse and Improves Overall Survival: Results of Malaysia-Singapore ALL 2010 Study,2018-09-10,imatinib,True,['Novartis'],0,Malaysia,16,1,0,1,0,1,1,0,0,0,1,0,0,0,1,0
CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia,2018-09-10,CPX-351,True,"['Jazz Pharmaceuticals', 'Celator/Jazz Pharmaceuticals']",0,USA,21,12,3,4,0,2,1,1,0,0,1,1,0,0,0,1
Exploratory Analysis of Brigatinib Activity in Patients With Anaplastic Lymphoma Kinase-Positive Nonâ€“Small-Cell Lung Cancer and Brain Metastases in Two Clinical Trials,2018-09-10,brigatinib,True,"['ARIAD', 'ARIAD Pharmaceuticals (I)', 'ARIAD Pharmaceuticals/Takeda', 'Takeda/ARIAD Pharmaceuticals', 'ARIAD Pharmaceuticals']",0,USA,18,11,4,6,2,1,0,1,0,0,0,1,0,0,0,0
Double-Blind Phase III Trial of Adjuvant Chemotherapy With and Without Bevacizumab in Patients With Lymph Nodeâ€“Positive and High-Risk Lymph Nodeâ€“Negative Breast Cancer (E5103),2018-09-01,bevacizumab,True,['Genentech'],0,USA,15,8,0,4,0,1,1,1,0,0,0,0,0,0,0,0
Abiraterone Alone or in Combination With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer With Rising Prostate-Specific Antigen During Enzalutamide Treatment,2018-09-01,enzalutamide,True,"['Astellas Pharma', 'Astellas', 'Astellas Pharma (I)']",0,USA,9,4,0,2,1,2,1,0,0,0,1,0,1,0,1,0
Outcome of Patients With Early-Stage Infradiaphragmatic Hodgkin Lymphoma: A Comprehensive Analysis From the German Hodgkin Study Group,2018-09-01,ABVD and BEACOPP chemotherapy regimens,False,[],0,Czech Republic,17,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Health-Related Quality of Life in Patients With Progressive Midgut Neuroendocrine Tumors Treated With 177Lu-Dotatate in the Phase III NETTER-1 Trial,2018-09-01,177Lu-Dotatate,True,"['Advanced Accelerator Applications', 'Advanced Accelerator Applications International']",0,Netherlands,17,11,3,5,1,0,1,1,0,0,0,0,0,0,0,0
Cisplatin-Based First-Line Treatment of Elderly Patients With Advanced NonÃ¢â‚¬â€œSmall-Cell Lung Cancer: Joint Analysis of MILES-3 and MILES-4 Phase III Trials,2018-09-01,cisplatin,False,[],0,Italy,30,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Sirolimus for Secondary Prevention of Skin Cancer in Kidney Transplant Recipients: 5-Year Results,2018-09-01,sirolimus,True,['Novartis'],0,Switzerland,20,7,0,4,0,2,1,0,0,0,0,0,0,0,0,0
Patient-Reported Toxicity During Pelvic Intensity-Modulated Radiation Therapy: NRG Oncologyâ€“RTOG 1203,2018-08-20,,False,[],0,USA,22,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Ado-Trastuzumab Emtansine for Patients With HER2-Mutant Lung Cancers: Results From a Phase II Basket Trial,2018-08-20,ado-trastuzumab emtansine,True,"['Genentech', 'Roche/Genentech', 'Roche']",0,USA,26,7,0,4,0,0,1,0,0,0,1,0,0,0,0,0
Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study,2018-08-20,enzalutamide,True,"['Astellas Pharma', 'Medivation/Astellas']",0,Italy,31,7,0,5,0,3,0,0,0,0,0,0,0,0,0,0
Intensified Therapy of Acute Lymphoblastic Leukemia in Adults: Report of the Randomized GRAALL-2005 Clinical Trial,2018-08-20,cyclophosphamide,False,[],0,Switzerland,25,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptorâ€“Positive, Human Epidermal Growth Factor Receptor 2â€“Negative Advanced Breast Cancer: MONALEESA-3",2018-08-20,ribociclib,True,['Novartis'],0,Switzerland,21,18,5,10,1,5,1,1,0,0,1,1,0,0,1,1
Managing Cancer and Living Meaningfully (CALM): A Randomized Controlled Trial of a Psychological Intervention for Patients With Advanced Cancer,2018-08-10,,True,[],0,Canada,13,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Face-to-Face and Internet-Based Mindfulness-Based Cognitive Therapy Compared With Treatment as Usual in Reducing Psychological Distress in Patients With Cancer: A Multicenter Randomized Controlled Trial,2018-08-10,,False,[],0,Canada,7,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer",2018-08-10,veliparib,True,"['AbbVie', 'AbbVie Stemcentrx']",0,USA,24,8,0,7,0,1,0,1,0,0,0,1,0,0,0,0
Immunochemotherapy With Obinutuzumab or Rituximab for Previously Untreated Follicular Lymphoma in the GALLIUM Study: Influence of Chemotherapy on Efficacy and Safety,2018-08-10,obinutuzumab,True,"['Roche', 'F. Hoffmann-La Roche', 'Roche (I)']",0,Japan,19,14,6,9,4,4,1,1,0,0,1,1,0,1,1,1
"Ibrutinib as Treatment for Patients With Relapsed/Refractory Follicular Lymphoma: Results From the Open-Label, Multicenter, Phase II DAWN Study",2018-08-10,ibrutinib,True,['Pharmacyclics'],0,France,24,6,0,4,0,1,0,0,0,0,0,0,0,0,0,0
Prophylactic Cranial Irradiation Versus Observation in Radically Treated Stage III Nonâ€“Small-Cell Lung Cancer: A Randomized Phase III NVALT-11/DLCRG-02 Study,2018-08-10,,False,[],0,Belgium,15,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Nonâ€“Small-Cell Lung Cancer and EGFR-Activating Mutations,2018-08-01,dacomitinib,True,['Pfizer'],0,USA,16,8,6,3,0,7,0,1,0,0,0,0,0,0,0,1
"Dasatinib Plus Intensive Chemotherapy in Children, Adolescents, and Young Adults With Philadelphia Chromosomeâ€“Positive Acute Lymphoblastic Leukemia: Results of Childrenâ€™s Oncology Group Trial AALL0622",2018-08-01,Dasatinib,True,['Bristol-Myers Squibb'],0,USA,25,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0
BRCA1/2 Mutations and Bevacizumab in the Neoadjuvant Treatment of Breast Cancer: Response and Prognosis Results in Patients With Triple-Negative Breast Cancer From the GeparQuinto Study,2018-08-01,bevacizumab,True,['Genentech'],0,USA,27,2,0,2,0,0,0,0,0,0,0,0,0,0,0,0
Final Overall Survival Analysis From a Study Comparing First-Line Crizotinib Versus Chemotherapy in ALK-Mutation-Positive Nonâ€“Small-Cell Lung Cancer,2018-08-01,crizotinib,True,['Pfizer'],0,United Kingdom,13,12,4,5,2,6,1,1,0,0,1,1,0,0,1,1
Overall Survival Benefit in Patients With Rituximab-Refractory Indolent Non-Hodgkin Lymphoma Who Received Obinutuzumab Plus Bendamustine Induction and Obinutuzumab Maintenance in the GADOLIN Study,2018-08-01,obinutuzumab,True,['Genentech'],0,Switzerland,17,5,0,4,0,3,1,1,0,0,1,1,0,0,0,1
Loss of Chromosome 18q11.2-q12.1 Is Predictive for Survival in Patients With Metastatic Colorectal Cancer Treated With Bevacizumab,2018-07-10,bevacizumab,True,"['Genentech/Roche', 'Roche Sequencing', 'Roche Diagnostics Nederland B.V.', 'Roche/Genentech', 'Roche']",0,Italy,30,6,0,2,0,1,0,0,0,0,0,0,0,0,0,0
"Positron Emission Tomographyâ€“Guided Therapy of Aggressive Non-Hodgkin Lymphomas (PETAL): A Multicenter, Randomized Phase III Trial",2018-07-10,rituximab,True,['Roche'],0,the Netherlands,46,7,0,4,1,5,1,0,0,0,0,0,0,0,1,0
Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D),2018-07-10,rivaroxaban,True,"['Bayer', 'Bayer AG']",0,Canada,18,11,0,2,0,5,1,1,0,0,0,0,0,0,1,1
Randomized Phase II Trial of Carboplatin-Paclitaxel Versus Carboplatin-Paclitaxel-Trastuzumab in Uterine Serous Carcinomas That Overexpress Human Epidermal Growth Factor Receptor 2/neu,2018-07-10,trastuzumab,True,['Genentech'],0,USA,24,2,0,1,0,0,0,0,0,0,0,0,0,0,0,0
Pomalidomide Plus Low-Dose Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma and Renal Impairment: Results From a Phase II Trial,2018-07-10,pomalidomide,True,"['Celgene (I)', 'Celgene']",0,USA,18,17,5,9,3,8,1,1,0,0,1,1,0,0,1,1
Multicenter Prospective Phase II Trial of Neoadjuvant Dose-Dense Gemcitabine Plus Cisplatin in Patients With Muscle-Invasive Bladder Cancer,2018-07-01,gemcitabine,True,['Eli Lilly'],0,USA,31,2,0,2,0,0,0,1,0,0,0,1,0,0,0,0
Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial,2018-07-01,venetoclax,True,['AbbVie'],0,USA,26,25,8,9,2,5,1,1,0,0,0,0,0,0,1,0
Integration of Clinical Variables for the Prediction of Late Distant Recurrence in Patients With Estrogen Receptorâ€“Positive Breast Cancer Treated With 5 Years of Endocrine Therapy: CTS5,2018-07-01,,False,[],0,Switzerland,8,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Phase III Trial Comparing Intraperitoneal and Intravenous Paclitaxel Plus S-1 Versus Cisplatin Plus S-1 in Patients With Gastric Cancer With Peritoneal Metastasis: PHOENIX-GC Trial,2018-07-01,paclitaxel,False,[],0,Japan,16,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Reducing Body ImageÃ¢â‚¬â€œRelated Distress in Women With Breast Cancer Using a Structured Online Writing Exercise: Results From the My Changed Body Randomized Controlled Trial,2018-07-01,My Changed Body (MyCB),False,[],0,Australia,8,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
SIRveNIB: Selective Internal Radiation Therapy Versus Sorafenib in Asia-Pacific Patients With Hepatocellular Carcinoma,2018-07-01,yttrium-90 resin microspheres,True,"['Sirtex Medical', 'Sirtex Medical Ltd']",0,Australia,42,25,0,4,3,4,1,0,0,0,1,0,1,0,1,0
Patient-Reported Symptoms and Impact of Treatment With Osimertinib Versus Chemotherapy in Advanced Nonâ€“Small-Cell Lung Cancer: The AURA3 Trial,2018-06-20,osimertinib,True,['AstraZeneca'],0,China,5,5,2,2,1,2,1,1,0,0,1,1,0,0,1,1
Bayesian Adaptive Randomization Trial of Passive Scattering Proton Therapy and Intensity-Modulated Photon Radiotherapy for Locally Advanced Nonâ€“Small-Cell Lung Cancer,2018-06-20,Proton therapy,True,['Varian Medical Systems'],0,USA,17,1,0,0,1,1,1,0,0,0,0,0,1,0,1,0
Multicenter Phase IB Trial of Carboxyamidotriazole Orotate and Temozolomide for Recurrent and Newly Diagnosed Glioblastoma and Other Anaplastic Gliomas,2018-06-10,carboxyamidotriazole orotate,True,['Tactical Therapeutics'],0,USA,28,4,1,3,0,0,0,0,0,0,0,0,0,0,0,0
Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Nonâ€“Small-Cell Lung Cancer: Results From the CA209-003 Study,2018-06-10,nivolumab,True,"['Bristol-Myers Squibb (I)', 'Bristol-Myers Squibb', 'Bristol-Myers Squibb/Medarex']",0,USA,15,11,3,7,1,1,1,1,0,0,1,1,0,0,0,0
Alterations in DNA Damage Response and Repair Genes as Potential Marker of Clinical Benefit From PD-1/PD-L1 Blockade in Advanced Urothelial Cancers,2018-06-10,atezolizumab,True,['Genentech'],0,USA,20,5,0,3,0,2,0,1,0,0,0,1,0,0,0,0
Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma,2018-06-10,pembrolizumab,True,"['Merck Serono', 'Merck']",0,USA,20,18,4,9,1,2,1,1,0,0,1,1,0,0,0,0
"Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma",2018-06-10,talimogene laherparepvec,True,['Amgen'],0,USA,18,17,3,10,3,6,1,1,0,0,1,1,0,0,0,1
"Randomized Phase II Trial of Fulvestrant Plus Everolimus or Placebo in Postmenopausal Women With Hormone Receptorâ€“Positive, Human Epidermal Growth Factor Receptor 2â€“Negative Metastatic Breast Cancer Resistant to Aromatase Inhibitor Therapy: Results of PrE0102",2018-06-01,everolimus,True,['Novartis'],0,USA,19,4,0,3,0,1,0,1,0,0,0,1,0,0,0,0
Treatment of Stage IV Favorable Histology Wilms Tumor With Lung Metastases: A Report From the Childrenâ€™s Oncology Group AREN0533 Study,2018-06-01,cyclophosphamide,False,[],0,USA,18,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Phase II Study of Two Weeks on, One Week off Sunitinib Scheduling in Patients With Metastatic Renal Cell Carcinoma",2018-06-01,sunitinib,True,['Pfizer'],0,USA,14,7,0,6,0,1,1,1,0,0,1,1,0,0,0,0
Health-Related Quality-of-Life Analysis From KEYNOTE-045: A Phase III Study of Pembrolizumab Versus Chemotherapy for Previously Treated Advanced Urothelial Cancer,2018-06-01,pembrolizumab,True,"['Merck', 'Merck Serono', 'Merck Sharp & Dohme', 'MSD Oncology']",0,USA,20,18,3,10,1,4,1,1,0,0,0,1,0,0,0,1
Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors,2018-06-01,pembrolizumab,True,"['Merck', 'Merck KGaA']",0,USA,20,3,0,3,0,1,1,0,0,0,1,0,0,0,0,0
"Neoadjuvant Chemotherapy Followed by Radical Surgery Versus Concomitant Chemotherapy and Radiotherapy in Patients With Stage IB2, IIA, or IIB Squamous Cervical Cancer: A Randomized Controlled Trial",2018-06-01,cisplatin,False,[],0,India,20,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Phase I Study of ATR Inhibitor M6620 in Combination With Topotecan in Patients With Advanced Solid Tumors,2018-06-01,M6620,False,[],0,USA,24,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Three Versus 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy for Patients With Stage III Colon Cancer: Disease-Free Survival Results From a Randomized, Open-Label, International Duration Evaluation of Adjuvant (IDEA) France, Phase III Trial",2018-05-20,Oxaliplatin,True,['Sanofi'],0,France,30,6,0,1,1,5,1,1,0,0,0,0,0,1,1,1
FOLFOX or CAPOX in Stage II to III Colon Cancer: Efficacy Results of the Italian Three or Six Colon Adjuvant Trial,2018-05-20,oxaliplatin,True,['Sanofi'],0,Italy,22,3,0,3,1,0,1,0,0,0,1,0,1,0,0,0
Phase III Intergroup Trial of Adjuvant Androgen Deprivation With or Without Mitoxantrone Plus Prednisone in Patients With High-Risk Prostate Cancer After Radical Prostatectomy: SWOG S9921,2018-05-20,mitoxantrone,False,[],0,USA,15,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Phase II Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced Nonâ€“Small-Cell Lung Cancer,2018-05-10,crizotinib,True,['Pfizer'],0,USA,17,8,3,0,0,4,1,1,0,0,0,0,0,0,1,1
Prospective International Randomized Phase II Study of Low-Dose Abiraterone With Food Versus Standard Dose Abiraterone In Castration-Resistant Prostate Cancer,2018-05-10,abiraterone acetate,True,"['Janssen Oncology', 'Janssen']",0,Singapore,15,3,0,0,0,1,1,0,0,0,0,0,0,0,0,0
Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial,2018-05-10,nivolumab,True,['Bristol-Myers Squibb'],0,USA,19,17,3,11,1,9,1,1,0,0,1,0,0,0,0,0
"Antitumor Activity of Nivolumab in Recurrent and Metastatic Nasopharyngeal Carcinoma: An International, Multicenter Study of the Mayo Clinic Phase 2 Consortium (NCI-9742)",2018-05-10,nivolumab,True,"['Bristol-Myers Squibb', 'Bristol-Myers Squibb Eli Lilly']",0,USA,25,7,0,4,1,0,0,1,0,0,0,0,0,0,0,0
Phase I Study of DNX-2401 (Delta-24-RGD) Oncolytic Adenovirus: Replication and Immunotherapeutic Effects in Recurrent Malignant Glioma,2018-05-10,DNX-2401,True,"['DNAtrix', 'MD Anderson and DNAtrix', 'Patent holder on DNAtrix (I)', 'DNAtrix (I)']",0,Spain,23,9,3,7,0,1,0,1,0,0,0,1,0,0,0,0
Concurrent Veliparib With Chest Wall and Nodal Radiotherapy in Patients With Inflammatory or Locoregionally Recurrent Breast Cancer: The TBCRC 024 Phase I Multicenter Study,2018-05-01,Veliparib,True,['AbbVie'],0,USA,13,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0
Pain Management in Cancer Center Inpatients: A Cluster Randomized Trial to Evaluate a Systematic Integrated Approachâ€”The Edinburgh Pain Assessment and Management Tool,2018-05-01,,False,[],0,United Kingdom,7,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Survival Analysis After Neoadjuvant Chemotherapy With Trastuzumab or Lapatinib in Patients With Human Epidermal Growth Factor Receptor 2â€“Positive Breast Cancer in the GeparQuinto (G5) Study (GBG 44),2018-05-01,lapatinib,True,['GlaxoSmithKline'],0,Germany,19,3,0,0,0,1,0,0,0,0,0,0,0,0,0,0
Dasatinib in Pediatric Patients With Chronic Myeloid Leukemia in Chronic Phase: Results From a Phase II Trial,2018-05-01,dasatinib,True,['Bristol-Myers Squibb'],0,European Union,20,8,2,1,0,2,1,1,0,0,0,0,0,0,1,0
Phosphatidylinositol 3-Kinase Î±â€“Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study,2018-05-01,Alpelisib,True,"['Novartis', 'GlaxoSmithKline (now Novartis)']",0,USA,19,17,6,7,0,2,1,1,0,0,1,1,0,0,0,0
"Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Fruquintinib After Two Prior Chemotherapy Regimens in Chinese Patients With Advanced Nonsquamous Nonâ€’Small-Cell Lung Cancer",2018-04-20,fruquintinib,True,"['Hutchison MediPharma', 'Hutchison Medi Pharma']",0,China,16,4,3,0,0,0,1,1,0,1,0,0,0,0,0,0
"Selumetinib in Combination With Dacarbazine in Patients With Metastatic Uveal Melanoma: A Phase III, Multicenter, Randomized Trial (SUMIT)",2018-04-20,selumetinib,True,"['AstraZeneca (I)', 'AstraZeneca']",0,USA,27,14,9,5,0,1,1,1,0,0,1,1,0,0,0,0
Quality of Life During Treatment With Chemohormonal Therapy: Analysis of E3805 Chemohormonal Androgen Ablation Randomized Trial in Prostate Cancer,2018-04-10,docetaxel,True,['Sanofi'],0,USA,12,4,0,3,1,2,1,0,0,0,1,0,0,0,0,0
Efficacy of Chemotherapy for ER-Negative and ER-Positive Isolated Locoregional Recurrence of Breast Cancer: Final Analysis of the CALOR Trial,2018-04-10,chemotherapy,False,[],0,Australia,23,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial,2018-04-10,docetaxel,True,['Sanofi'],0,USA,18,6,0,4,2,3,0,1,0,0,0,1,0,0,0,0
Once-a-Week Versus Once-Every-3-Weeks Cisplatin Chemoradiation for Locally Advanced Head and Neck Cancer: A Phase III Randomized Noninferiority Trial,2018-04-10,cisplatin,False,[],0,India,28,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Placebo-Controlled, Double-Blinded Phase III Study Comparing Dexamethasone on Day 1 With Dexamethasone on Days 1 to 3 With Combined Neurokinin-1 Receptor Antagonist and Palonosetron in High-Emetogenic Chemotherapy",2018-04-01,dexamethasone,False,[],0,Japan,22,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Phase II, Open-Label, Randomized, Multicenter Trial (HERBY) of Bevacizumab in Pediatric Patients With Newly Diagnosed High-Grade Glioma",2018-04-01,bevacizumab,True,['Genentech'],0,USA,20,3,1,2,0,0,0,0,0,0,0,0,0,0,0,0
Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma,2018-04-01,nivolumab,True,['Bristol-Myers Squibb'],0,USA,29,17,3,9,0,7,0,1,0,0,0,1,0,0,0,1
"Phase III, Randomized, Double-Blind Study Comparing the Efficacy, Safety, and Immunogenicity of SB3 (Trastuzumab Biosimilar) and Reference Trastuzumab in Patients Treated With Neoadjuvant Therapy for Human Epidermal Growth Factor Receptor 2â€“Positive Early Breast Cancer",2018-04-01,SB3,True,['Samsung Bioepis'],0,Philippines,17,2,2,0,0,0,0,1,0,1,0,0,0,0,0,0
Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012,2018-04-01,veliparib,True,['AbbVie'],0,USA,25,2,0,1,0,0,0,0,0,0,0,0,0,0,0,0
Selective Inhibition of Nuclear Export With Oral Selinexor for Treatment of Relapsed or Refractory Multiple Myeloma,2018-03-20,selinexor,True,"['Karyopharm Therapeutics', 'Karyopharm Therapeutics patent', 'Karyopharm Therapeutics (I)', 'Karyopharma']",0,USA,32,13,7,3,0,2,1,0,0,0,1,0,0,0,0,0
Enzalutamide for the Treatment of Androgen Receptorâ€“Expressing Triple-Negative Breast Cancer,2018-03-20,enzalutamide,True,"['Medivation', 'Astellas Medivation']",0,USA,20,5,2,1,0,0,1,0,0,0,1,0,0,0,0,0
"Effects of Aerobic and Resistance Exercise on Metabolic Syndrome, Sarcopenic Obesity, and Circulating Biomarkers in Overweight or Obese Survivors of Breast Cancer: A Randomized Controlled Trial",2018-03-20,,False,[],0,USA,10,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Phase I Dose-Escalation Trial of PT2385, a First-in-Class Hypoxia-Inducible Factor-2Î± Antagonist in Patients With Previously Treated Advanced Clear Cell Renal Cell Carcinoma",2018-03-20,PT2385,True,"['Peloton Therapeutics', 'Peloton Therapeutics (I)']",0,USA,12,10,7,2,0,0,1,1,0,0,0,1,0,0,0,0
Osimertinib As First-Line Treatment of EGFR Mutationâ€“Positive Advanced Nonâ€“Small-Cell Lung Cancer,2018-03-20,osimertinib,True,"['AstraZeneca (I)', 'AstraZeneca']",0,USA,16,15,8,6,0,6,1,1,0,0,1,1,0,0,0,0
Quality of Life Outcomes for Cabozantinib Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma: METEOR Phase III Randomized Trial,2018-03-10,cabozantinib,True,['Exelixis'],0,USA,21,13,3,7,0,4,0,1,0,0,0,1,0,0,0,0
"Web-Based Stress Management for Newly Diagnosed Patients With Cancer (STREAM): A Randomized, Wait-List Controlled Intervention Study",2018-03-10,,False,[],0,Switzerland,17,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Restoring Body Image After Cancer (ReBIC): Results of a Randomized Controlled Trial,2018-03-10,,True,[],0,Canada,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Improvement in Overall Survival With Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma",2018-03-10,carfilzomib,True,['Amgen'],0,USA,10,10,2,6,3,2,1,1,0,0,0,1,1,0,0,0
"Phase III, Randomized Study of Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade With Lapatinib Plus Trastuzumab in Combination With an Aromatase Inhibitor in Postmenopausal Women With HER2-Positive, Hormone ReceptorÃ¢â‚¬â€œPositive Metastatic Breast Cancer: ALTERNATIVE",2018-03-10,lapatinib,True,['Puma Biotechnology'],0,USA,15,3,0,2,1,1,1,1,0,0,0,1,1,0,0,0
Improving Breast Cancer Surgical Treatment Decision Making: The iCanDecide Randomized Clinical Trial,2018-03-01,iCanDecide,False,[],0,USA,12,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Continued Excellent Outcomes in Previously Untreated Patients With Follicular Lymphoma After Treatment With CHOP Plus Rituximab or CHOP Plus 131I-Tositumomab: Long-Term Follow-Up of Phase III Randomized Study SWOG-S0016,2018-03-01,rituximab,True,"['Roche/Genentech', 'Genentech', 'Roche']",0,USA,16,7,0,5,0,1,1,1,0,0,0,1,0,0,0,0
Bevacizumab Maintenance Versus No Maintenance During Chemotherapy-Free Intervals in Metastatic Colorectal Cancer: A Randomized Phase III Trial (PRODIGE 9),2018-03-01,bevacizumab,True,"['Roche/Genentech', 'Roche']",0,France,20,12,0,8,3,2,1,1,0,0,0,1,1,0,0,1
Long-Term Outcomes in Patients With BRAF V600â€“Mutant Metastatic Melanoma Who Received Dabrafenib Combined With Trametinib,2018-03-01,dabrafenib,True,['GlaxoSmithKline'],0,USA,19,4,1,1,0,2,0,0,0,0,0,0,0,0,0,0
Quality of Life From Canadian Cancer Trials Group MA.17R: A Randomized Trial of Extending Adjuvant Letrozole to 10 Years,2018-02-20,letrozole,True,['Novartis'],0,Austria,13,3,0,3,0,1,1,0,0,0,1,0,0,0,0,0
"Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study",2018-02-20,pertuzumab,True,"['Roche/Genentech', 'Genentech', 'Genentech Mypath']",0,USA,12,12,3,6,0,2,1,1,0,0,0,1,0,0,0,1
Early Chemotherapy Intensification With Escalated BEACOPP in Patients With Advanced-Stage Hodgkin Lymphoma With a Positive Interim Positron Emission Tomography/Computed Tomography Scan After Two ABVD Cycles: Long-Term Results of the GITIL/FIL HD 0607 Trial,2018-02-10,rituximab,True,['Genentech'],0,Israel,38,1,0,1,0,0,0,1,0,0,0,1,0,0,0,0
"Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Randomized, Multicenter Phase II Trial",2018-02-10,,False,[],0,Belgium,18,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Seven-Month Prostate-Specific Antigen Is Prognostic in Metastatic Hormone-Sensitive Prostate Cancer Treated With Androgen Deprivation With or Without Docetaxel,2018-02-01,docetaxel,True,['Sanofi'],0,USA,19,7,0,4,2,3,0,1,0,0,0,1,0,0,0,0
Phase II Study of Everolimus in Patients With Thymoma and Thymic Carcinoma Previously Treated With Cisplatin-Based Chemotherapy,2018-02-01,everolimus,True,['Novartis'],0,Italy,24,2,0,2,0,0,1,0,0,0,1,0,0,0,0,0
"HALO 202: Randomized Phase II Study of PEGPH20 Plus Nab-Paclitaxel/Gemcitabine Versus Nab-Paclitaxel/Gemcitabine in Patients With Untreated, Metastatic Pancreatic Ductal Adenocarcinoma",2018-02-01,pegvorhyaluronidase alfa,True,['Halozyme Therapeutics'],0,USA,19,12,3,2,0,1,1,1,0,0,1,0,0,0,0,0
"Results of a Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Trifluridine/Tipiracil (TAS-102) Monotherapy in Asian Patients With Previously Treated Metastatic Colorectal Cancer: The TERRA Study ",2018-02-01,trifluridine/tipiracil,True,"['Taiho Pharmaceutical', 'Taiho']",0,Japan,20,5,1,0,0,2,1,0,0,0,0,0,0,0,1,0
Highly Accurate Identification of Cystic Precursor Lesions of Pancreatic Cancer Through Targeted Mass Spectrometry: A Phase IIc Diagnostic Study,2018-02-01,,False,[],0,Norway,5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Randomized, Multicenter, Placebo-Controlled Clinical Trial of Duloxetine Versus Placebo for Aromatase Inhibitorâ€“Associated Arthralgias in Early-Stage Breast Cancer: SWOG S1202",2018-02-01,duloxetine,True,['Eli Lilly'],0,USA,15,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0
"Nivolumab Plus Ipilimumab in Patients With Advanced Melanoma: Updated Survival, Response, and Safety Data in a Phase I Dose-Escalation Study",2018-02-01,nivolumab and ipilimumab,True,"['Bristol-Myers Squibb', 'Bristol-Myers Squibb (I)']",0,USA,12,12,4,7,0,3,1,1,1,0,0,1,0,0,0,0
"Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigatorâ€™s Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial",2018-02-01,nivolumab,True,"['Bristol-Myers Squibb', 'Bristol-Myers Squibb (I)', 'Bristol-Myer Squibb']",0,Austria,23,19,3,12,3,8,1,1,0,0,0,1,0,0,0,1
Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma,2018-01-20,BGJ398,True,['Novartis'],0,USA,29,18,4,7,0,4,0,0,0,0,0,0,0,0,0,0
Effect of Neoadjuvant Chemoradiotherapy on Health-Related Quality of Life in Esophageal or Junctional Cancer: Results From the Randomized CROSS Trial,2018-01-20,carboplatin,False,[],0,the Netherlands,33,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Reduced-Intensity Delayed Intensification in Standard-Risk Pediatric Acute Lymphoblastic Leukemia Defined by Undetectable Minimal Residual Disease: Results of an International Randomized Trial (AIEOP-BFM ALL 2000),2018-01-20,vincristine,True,['TEVA Pharmaceuticals Industries'],0,Switzerland,27,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial,2018-01-20,Bosutinib,True,['Pfizer'],0,France,17,11,2,6,1,4,1,1,0,0,1,1,0,0,0,0
Role of Patient Coping Strategies in Understanding the Effects of Early Palliative Care on Quality of Life and Mood,2018-01-01,,True,[],0,USA,11,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Genotype-Specific Minimal Residual Disease Interpretation Improves Stratification in Pediatric Acute Lymphoblastic Leukemia,2018-01-01,,False,[],0,France,13,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Safety and Antitumor Activity of the Antiâ€“Programmed Death-1 Antibody Pembrolizumab in Patients With Advanced Esophageal Carcinoma,2018-01-01,pembrolizumab,True,"['Merck Sharp & Dohme', 'MSD']",0,France,7,6,3,2,0,1,1,1,0,0,1,1,0,0,0,1
Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600â€“Mutant Anaplastic Thyroid Cancer,2018-01-01,dabrafenib,True,['GlaxoSmithKline'],0,USA,14,4,1,0,0,0,1,0,0,0,0,0,0,0,0,0
"Randomized Trial of ConquerFear: A Novel, Theoretically Based Psychosocial Intervention for Fear of Cancer Recurrence",2017-12-20,,False,[],0,the Netherlands,16,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Safety and Efficacy of Pembrolizumab in Advanced, Programmed Death Ligand 1â€“Positive Cervical Cancer: Results From the Phase Ib KEYNOTE-028 Trial",2017-12-20,pembrolizumab,True,"['Merck', 'Merck Sharp & Dohme', 'Merck KGaA']",0,USA,12,8,2,1,0,1,0,0,0,0,0,0,0,0,0,0
"Prospective, Randomized, Double-Blind, Phase III Clinical Trial of Antiâ€“T-Lymphocyte Globulin to Assess Impact on Chronic Graft-Versus-Host Diseaseâ€“Free Survival in Patients Undergoing HLA-Matched Unrelated Myeloablative Hematopoietic Cell Transplantation",2017-12-20,antithymocyte globulin (ATLG),True,['Neovii Biotech'],0,USA,32,5,1,2,0,0,0,0,0,0,0,0,0,0,0,0
Gefitinib Plus Chemotherapy Versus Chemotherapy in Epidermal Growth Factor Receptor Mutationâ€“Positive Nonâ€“Small-Cell Lung Cancer Resistant to First-Line Gefitinib (IMPRESS): Overall Survival and Biomarker Analyses,2017-12-20,gefitinib,True,['AstraZeneca'],0,France,16,12,4,6,0,7,1,1,0,0,1,1,0,0,1,1
Safety and Antitumor Activity of Pembrolizumab in Patients With Programmed Death-Ligand 1â€“Positive Nasopharyngeal Carcinoma: Results of the KEYNOTE-028 Study,2017-12-20,pembrolizumab,True,"['Merck Serono', 'Merck Sharp & Dohme', 'MSD Relationship', 'Merck']",0,Canada,13,11,3,4,0,4,1,1,0,0,0,0,0,0,1,1
Long-Term Follow-Up of Cardiac Function and Quality of Life for Patients in NSABP Protocol B-31/NRG Oncology: A Randomized Trial Comparing the Safety and Efficacy of Doxorubicin and Cyclophosphamide (AC) Followed by Paclitaxel With AC Followed by Paclitaxel and Trastuzumab in Patients With Node-Positive Breast Cancer With Tumors Overexpressing Human Epidermal Growth Factor Receptor 2,2017-12-10,trastuzumab,True,['Genentech'],0,USA,20,7,0,2,1,1,0,0,0,0,0,0,0,0,0,0
"Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Nonâ€“Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057)",2017-12-10,nivolumab,True,"['Bristol-Myers Squibb', 'Bristol-Myers-Squibb']",0,USA,29,26,4,15,5,10,1,1,0,0,1,1,0,0,0,1
Phosphatidylinositol 3-Kinase Inhibition by Copanlisib in Relapsed or Refractory Indolent Lymphoma,2017-12-10,copanlisib,True,"['Bayer AG', 'Bayer HealthCare Pharmaceuticals']",0,USA,27,20,10,6,1,5,1,1,0,0,1,1,0,0,1,0
Randomized Phase III Trial of Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma,2017-12-10,pazopanib,True,['GlaxoSmithKline'],0,Italy,26,8,0,5,1,4,1,1,0,0,0,0,0,0,0,1
"Cost-Effectiveness Analysis of Monthly Zoledronic Acid, Zoledronic Acid Every 3 Months, and Monthly Denosumab in Women With Breast Cancer and Skeletal Metastases: CALGB 70604 (Alliance)",2017-12-10,zoledronic acid,False,[],0,USA,8,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Randomized Phase III and Extension Studies of Naldemedine in Patients With Opioid-Induced Constipation and Cancer,2017-12-01,naldemedine,True,"['Shionogi', 'Shionogi Pharma']",0,Japan,10,7,3,1,0,2,1,1,0,0,0,0,0,0,0,1
Pembrolizumab in Patients With Extensive-Stage Small-Cell Lung Cancer: Results From the Phase Ib KEYNOTE-028 Study,2017-12-01,pembrolizumab,True,['Merck'],0,USA,8,5,3,0,0,2,1,1,0,0,0,0,0,0,0,1
Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study,2017-12-01,nivolumab,True,"['Bristol-Myers Squibb', 'patents licensed to Bristol-Myers Squibb']",0,USA,15,13,1,9,1,2,1,1,0,0,1,1,0,1,0,1
SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase InhibitorÃ¢â‚¬â€œNaÃƒÂ¯ve Patients With Myelofibrosis,2017-12-01,momelotinib,False,[],0,Spain,14,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Adjuvant Chemoradiotherapy With Epirubicin, Cisplatin, and Fluorouracil Compared With Adjuvant Chemoradiotherapy With Fluorouracil and Leucovorin After Curative Resection of Gastric Cancer: Results From CALGB 80101 (Alliance)",2017-11-10,fluorouracil (FU) and leucovorin (LV),False,[],0,USA,21,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer,2017-11-10,abemaciclib,True,"['Eli Lilly', 'Japan Eli Lilly']",0,Italy,18,12,5,4,1,5,1,1,0,0,1,1,0,0,0,1
Effect of Inpatient Palliative Care During Hematopoietic Stem-Cell Transplant on Psychological Distress 6 Months After Transplant: Results of a Randomized Clinical Trial,2017-11-10,,False,[],0,USA,15,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Phase III, Randomized, Placebo-Controlled, Double-Blind Trial of Motesanib (AMG-706) in Combination With Paclitaxel and Carboplatin in East Asian Patients With Advanced Nonsquamous NonÃ¢â‚¬â€œSmall-Cell Lung Cancer",2017-11-10,motesanib,True,['Amgen'],0,China,19,1,0,0,0,1,1,0,0,0,0,0,0,0,1,0
"Nintedanib Plus Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma: Phase II Results From the Randomized, Placebo-Controlled LUME-Meso Trial",2017-11-01,nintedanib,True,['Boehringer Ingelheim'],0,USA,18,13,4,7,1,3,1,0,0,0,0,0,0,0,0,0
"Obinutuzumab or Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Previously Untreated Diffuse Large B-Cell Lymphoma",2017-11-01,obinutuzumab,True,"['F. Hoffman-La Roche', 'F. Hoffmann-La Roche', 'Roche']",0,USA,21,14,4,7,3,4,1,0,0,0,1,0,1,0,0,0
"Off-the-Shelf Virus-Specific T Cells to Treat BK Virus, Human Herpesvirus 6, Cytomegalovirus, Epstein-Barr Virus, and Adenovirus Infections After Allogeneic Hematopoietic Stem-Cell Transplantation",2017-11-01,virus-specific T cells (VSTs),True,"['Viracyte (I)', 'Viracyte', 'Viracyte (through QB Regulatory)']",0,USA,22,5,0,2,0,0,1,0,0,0,1,0,0,0,0,0
Randomized Phase II Study of R-CHOP With or Without Bortezomib in Previously Untreated Patients With NonÃ¢â‚¬â€œGerminal Center B-CellÃ¢â‚¬â€œLike Diffuse Large B-Cell Lymphoma,2017-11-01,bortezomib,True,"['Millennium/Takeda', 'Takeda']",0,USA,21,3,1,0,0,0,0,0,0,0,0,0,0,0,0,0
"Efficacy of Thalidomide in Preventing Delayed Nausea and Vomiting Induced by Highly Emetogenic Chemotherapy: A Randomized, Multicenter, Double-Blind, Placebo-Controlled Phase III Trial (CLOG1302 study)",2017-11-01,thalidomide,False,[],0,China,32,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
First-in-Human Phase I Study of the Tamoxifen Metabolite Z-Endoxifen in Women With Endocrine-Refractory Metastatic Breast Cancer,2017-10-20,endoxifen,True,['Pfizer'],0,USA,26,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0
Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography After Concurrent Chemoradiotherapy in Locally Advanced Head-and-Neck Squamous Cell Cancer: The ECLYPS Study,2017-10-20,[18F]fluorodeoxyglucose,False,[],0,United Kingdom,18,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Activity of Eribulin in Patients With Advanced Liposarcoma Demonstrated in a Subgroup Analysis From a Randomized Phase III Study of Eribulin Versus Dacarbazine,2017-10-20,eribulin,True,['Eisai'],0,USA,11,9,2,6,1,1,1,1,0,0,1,1,0,0,0,1
"Intravesical rAdâ€“IFNÎ±/Syn3 for Patients With High-Grade, Bacillus Calmette-Guerinâ€“Refractory or Relapsed Nonâ€“Muscle-Invasive Bladder Cancer: A Phase II Randomized Study",2017-10-20,rAdâ€“IFNÎ±/Syn3,True,['FKD Therapies Oy'],0,Finland,24,10,1,4,0,0,0,1,0,0,0,1,0,0,0,0
Phase III Trial of Ipilimumab Combined With Paclitaxel and Carboplatin in Advanced Squamous NonÃ¢â‚¬â€œSmall-Cell Lung Cancer,2017-10-20,ipilimumab,True,"['Bristol-Myers Squibb', 'Bristol-Myers Squibb Japan']",0,USA,22,11,3,6,2,4,0,1,0,0,0,1,0,1,0,0
"Randomized Controlled Trial Testing the Efficacy of Platinum-Free Interval Prolongation in Advanced Ovarian Cancer: The MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG Study",2017-10-10,platinum-based chemotherapy (PBC),False,[],0,Germany,28,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Cabozantinib As Salvage Therapy for Patients With Tyrosine Kinase Inhibitorâ€“Refractory Differentiated Thyroid Cancer: Results of a Multicenter Phase II International Thyroid Oncology Group Trial,2017-10-10,cabozantinib,True,['Exelixis'],0,USA,9,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0
Phase I/II Trial of Labetuzumab Govitecan (Anti-CEACAM5/SN-38 Antibody-Drug Conjugate) in Patients With Refractory or Relapsing Metastatic Colorectal Cancer,2017-10-10,labetuzumab govitecan,True,"['Immunomedics', 'Immunomedics (I)']",0,USA,15,7,4,2,0,0,0,1,0,0,0,0,0,0,0,0
CONKO-005: Adjuvant Chemotherapy With Gemcitabine Plus Erlotinib Versus Gemcitabine Alone in Patients After R0 Resection of Pancreatic Cancer: A Multicenter Randomized Phase III Trial,2017-10-10,erlotinib,True,"['Roche Pharma AG', 'Roche']",0,Germany,21,2,0,1,1,0,0,0,0,0,0,0,0,0,0,0
Treatment of Patients With Metastatic Cancer Using a Major Histocompatibility Complex Class IIÃ¢â‚¬â€œRestricted T-Cell Receptor Targeting the Cancer Germline Antigen MAGE-A3,2017-10-10,MAGE-A3 TCR (chimeric antigen receptor),True,"['The National Cancer Institute has cooperative research and development agreements with Kite Pharma and Lion Biotechnologies', 'Patents held by the National Cancer Institute', 'held by the National Cancer Institute']",0,USA,17,3,0,0,0,0,1,1,0,0,0,0,0,0,0,0
Phase III Study Comparing a Reduced Dose of Cabazitaxel (20 mg/m2) and the Currently Approved Dose (25 mg/m2) in Postdocetaxel Patients With Metastatic Castration-Resistant Prostate Cancerâ€”PROSELICA,2017-10-01,cabazitaxel,True,['Sanofi'],0,USA,14,8,3,4,0,3,1,1,0,0,1,1,0,0,1,1
Targeting ALK With Crizotinib in Pediatric Anaplastic Large Cell Lymphoma and Inflammatory Myofibroblastic Tumor: A Childrenâ€™s Oncology Group Study,2017-10-01,crizotinib,True,['Pfizer'],0,USA,10,2,1,0,0,0,0,0,0,0,0,0,0,0,0,0
Response to Radiotherapy After Breast-Conserving Surgery in Different Breast Cancer Subtypes in the Swedish Breast Cancer Group 91 Radiotherapy Randomized Clinical Trial,2017-10-01,,False,[],0,Sweden,11,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Cabazitaxel Versus Docetaxel As First-Line Therapy for Patients With Metastatic Castration-Resistant Prostate Cancer: A Randomized Phase III Trialâ€”FIRSTANA,2017-10-01,cabazitaxel,True,['Sanofi'],0,USA,16,12,3,7,0,5,1,1,0,0,1,1,0,0,1,0
"Randomized, Noncomparative, Phase II Trial of Early Switch From Docetaxel to Cabazitaxel or Vice Versa, With Integrated Biomarker Analysis, in Men With Chemotherapy-NaÃ¯ve, Metastatic, Castration-Resistant Prostate Cancer",2017-10-01,docetaxel,True,"['Sanofi', 'Sanofi Genzyme Regeneron (I)', 'Sanofi Canada']",0,USA,28,16,3,7,2,5,1,1,0,0,1,0,0,0,1,0
"Phase I Study and Biomarker Analysis of Pyrotinib, a Novel Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Human Epidermal Growth Factor Receptor 2Ã¢â‚¬â€œPositive Metastatic Breast Cancer",2017-09-20,pyrotinib,False,[],0,China,16,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Randomized Phase III Trial of Trastuzumab Plus Capecitabine With or Without Pertuzumab in Patients With Human Epidermal Growth Factor Receptor 2â€“Positive Metastatic Breast Cancer Who Experienced Disease Progression During or After Trastuzumab-Based Therapy,2017-09-10,pertuzumab,True,"['F. Hoffmann-La Roche', 'Roche']",0,USA,11,7,3,2,0,1,1,1,0,0,1,1,0,0,0,1
Arsenic Trioxide Consolidation Allows Anthracycline Dose Reduction for Pediatric Patients With Acute Promyelocytic Leukemia: Report From the Children's Oncology Group Phase III Historically Controlled Trial AAML0631,2017-09-10,arsenic trioxide,False,[],0,USA,11,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen ReceptorÃ¢â‚¬â€œModified T Cells After Failure of Ibrutinib,2017-09-10,anti-CD19 CAR-T cell therapy,True,['Juno Therapeutics'],0,USA,12,6,1,2,0,0,1,1,0,0,1,0,0,0,0,0
"De-Escalation Strategies in Human Epidermal Growth Factor Receptor 2 (HER2)Ã¢â‚¬â€œPositive Early Breast Cancer (BC): Final Analysis of the West German Study Group Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early BC HER2- and Hormone ReceptorÃ¢â‚¬â€œPositive Phase II Randomized TrialÃ¢â‚¬â€Efficacy, Safety, and Predictive Markers for 12 Weeks of Neoadjuvant Trastuzumab Emtansine With or Without Endocrine Therapy (ET) Versus Trastuzumab Plus ET",2017-09-10,T-DM1,True,"['Roche (I)', 'Roche']",0,Germany,21,9,0,7,0,8,1,1,0,0,0,1,0,0,1,1
Biomarker-Based Phase II Trial of Savolitinib in Patients With Advanced Papillary Renal Cell Cancer,2017-09-10,savolitinib,True,['AstraZeneca'],0,France,13,8,5,3,0,1,1,0,0,0,1,0,0,0,0,0
Low-Fat Dietary Pattern and Breast Cancer Mortality in the Womenâ€™s Health Initiative Randomized Controlled Trial,2017-09-01,,False,[],0,USA,17,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2âˆ’ Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy,2017-09-01,abemaciclib,True,['Eli Lilly'],0,Spain,18,10,5,1,0,0,0,1,0,0,0,1,0,0,0,0
Prospective Evaluation of Magnetic Resonance Imaging and [18F]Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography at Diagnosis and Before Maintenance Therapy in Symptomatic Patients With Multiple Myeloma Included in the IFM/DFCI 2009 Trial: Results of the IMAJEM Study,2017-09-01,lenalidomide,True,['Celgene'],0,USA,29,11,0,10,1,7,1,0,0,0,1,0,0,0,1,0
Prospective Randomized Comparison of Idarubicin and High-Dose Daunorubicin in Induction Chemotherapy for Newly Diagnosed Acute Myeloid Leukemia,2017-08-20,idarubicin,False,[],0,Republic of Korea,21,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Efficacy of a Weight Loss Intervention for African American Breast Cancer Survivors,2017-08-20,,False,[],0,San Antonio TX,19,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1â€“Selected Advanced Nonâ€“Small-Cell Lung Cancer (BIRCH),2017-08-20,atezolizumab,True,['Genentech'],0,Japan,28,14,6,6,0,0,1,0,0,0,1,0,0,0,0,0
"Therapy of Advanced Nonâ€“Small-Cell Lung Cancer With an SN-38-Anti-Trop-2 Drug Conjugate, Sacituzumab Govitecan",2017-08-20,sacituzumab govitecan,True,"['Immunomedics', 'Immunomedics (I)']",0,USA,18,9,6,2,0,0,0,0,0,0,0,0,0,0,0,0
Quantitative Assessment of Early [18F]Sodium Fluoride Positron Emission Tomography/Computed Tomography Response to Treatment in Men With Metastatic Prostate Cancer to Bone,2017-08-20,[18F]Sodium Fluoride (NaF),False,[],0,USA,12,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117,2017-08-20,azacitidine,True,['Bristol-Myers Squibb'],0,USA,23,2,0,1,0,0,0,0,0,0,0,0,0,0,0,0
Neurocognitive Functioning of Children Treated for High-Risk B-Acute Lymphoblastic Leukemia Randomly Assigned to Different Methotrexate and Corticosteroid Treatment Strategies: A Report From the Childrenâ€™s Oncology Group,2017-08-10,methotrexate,False,[],0,USA,15,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Adjuvant Cyclophosphamide and Docetaxel With or Without Epirubicin for Early TOP2A-Normal Breast Cancer: DBCG 07-READ, an Open-Label, Phase III, Randomized Trial",2017-08-10,docetaxel,False,[],0,Denmark,19,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CD33 Splicing Polymorphism Determines Gemtuzumab Ozogamicin Response in De Novo Acute Myeloid Leukemia: Report From Randomized Phase III Childrenâ€™s Oncology Group Trial AAML0531,2017-08-10,Gemtuzumab ozogamicin,True,['Pfizer'],0,USA,15,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
Effect of Age on the Efficacy and Safety of Lenvatinib in Radioiodine-Refractory Differentiated Thyroid Cancer in the Phase III SELECT Trial,2017-08-10,lenvatinib,True,['Eisai'],0,USA,5,3,1,2,0,1,1,0,0,0,1,0,0,0,0,0
"Carboplatin and Etoposide With or Without Palifosfamide in Untreated Extensive-Stage Small-Cell Lung Cancer: A Multicenter, Adaptive, Randomized Phase III Study (MATISSE)",2017-08-10,palifosfamide,True,['ZIOPHARM Oncology'],0,Canada,5,2,1,1,0,1,0,0,0,0,0,0,0,0,0,0
Early Responseâ€“Based Therapy Stratification Improves Survival in Adult Early Thymic Precursor Acute Lymphoblastic Leukemia: A Group for Research on Adult Acute Lymphoblastic Leukemia Study,2017-08-10,,False,[],0,Belgium,20,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Open-Label, Multicenter, Phase II Study of Ceritinib in Patients With Nonâ€“Small-Cell Lung Cancer Harboring ROS1 Rearrangement",2017-08-10,ceritinib,False,[],0,USA,19,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Tai Chi Chih Compared With Cognitive Behavioral Therapy for the Treatment of Insomnia in Survivors of Breast Cancer: A Randomized, Partially Blinded, Noninferiority Trial",2017-08-10,,False,[],0,USA,7,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Anthracyclines in Early Breast Cancer: The ABC Trialsâ€”USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG Oncology)",2017-08-10,docetaxel,True,['Sanofi/Genzyme (I)'],0,USA,22,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0
Participant-Reported Symptoms and Their Effect on Long-Term Adherence in the International Breast Cancer Intervention Study I (IBIS I),2017-08-10,tamoxifen,False,[],0,Australia,5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
HELOISE: Phase IIIb Randomized Multicenter Study Comparing Standard-of-Care and Higher-Dose Trastuzumab Regimens Combined With Chemotherapy as First-Line Therapy in Patients With Human Epidermal Growth Factor Receptor 2â€“Positive Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma,2017-08-01,trastuzumab,True,['Genentech'],0,Spain,10,2,2,0,0,0,0,0,0,0,0,0,0,0,0,0
Clinical Impact of the Cell-of-Origin Classification and the MYC/BCL2 Dual Expresser Status in Diffuse Large B-Cell Lymphoma Treated Within Prospective Clinical Trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group ,2017-08-01,rituximab,True,"['Roche (I)', 'Roche']",0,Switzerland,24,8,1,4,0,4,0,0,0,0,0,0,0,0,0,0
Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1â€“Positive Endometrial Cancer: Results From the KEYNOTE-028 Study,2017-08-01,pembrolizumab,True,"['Merck', 'Merck Sharp & Dohme']",0,United Kingdom,14,10,3,2,0,1,1,1,0,0,0,0,0,0,0,1
"Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinaseâ€“Positive Nonâ€“Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial",2017-08-01,brigatinib,True,['ARIAD'],0,USA,20,10,3,4,1,3,0,1,0,0,0,0,0,0,0,1
Long-Term Follow-Up of the Intergroup Exemestane Study,2017-08-01,exemestane,True,['Pfizer'],0,Belgium,21,7,0,3,2,3,0,1,0,0,0,0,0,1,0,1
"Lenalidomide Maintenance Compared With Placebo in Responding Elderly Patients With Diffuse Large B-Cell Lymphoma Treated With First-Line Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone",2017-08-01,lenalidomide,True,['Celgene'],0,Israel,30,13,0,10,1,6,1,1,0,0,1,1,0,0,1,1
"Phase III Randomized, Placebo-Controlled, Double-Blind Trial of Celecoxib in Addition to Standard Chemotherapy for Advanced Nonâ€“Small-Cell Lung Cancer With Cyclooxygenase-2 Overexpression: CALGB 30801 (Alliance)",2017-07-01,celecoxib,True,['Pfizer'],0,USA,19,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Safety and Clinical Activity of the Programmed Death-Ligand 1 Inhibitor Durvalumab in Combination With Poly (ADP-Ribose) Polymerase Inhibitor Olaparib or Vascular Endothelial Growth Factor Receptor 1-3 Inhibitor Cediranib in Women's Cancers: A Dose-Escalation, Phase I Study",2017-07-01,durvalumab,True,['AstraZeneca'],0,USA,19,2,1,1,0,0,0,0,0,0,0,0,0,0,0,0
"Efficacy of Blended Cognitive Behavior Therapy for High Fear of Recurrence in Breast, Prostate, and Colorectal Cancer Survivors: The SWORD Study, a Randomized Controlled Trial",2017-07-01,,False,[],0,Netherlands,5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma,2017-07-01,pembrolizumab,True,"['Merck Sharp & Dohme', 'Merck']",0,USA,18,14,3,8,0,4,1,1,0,0,1,1,0,0,1,0
"Avelumab, an Antiâ€“Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study",2017-07-01,avelumab,True,"['Merck KGaA', 'EMD Serono']",0,Germany,17,8,3,1,0,0,0,1,0,0,0,0,0,0,0,0
Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer,2017-07-01,sacituzumab govitecan,True,"['Immunomedics', 'Coinventorship in patents and patent applications assigned to Immunomedics', 'Immunomedics (I)']",0,USA,22,8,6,1,0,1,0,1,0,0,0,0,0,0,0,0
Dose-Reduced Versus Standard Conditioning Followed by Allogeneic Stem-Cell Transplantation for Patients With Myelodysplastic Syndrome: A Prospective Randomized Phase III Study of the EBMT (RICMAC Trial),2017-07-01,busulfan,False,[],0,the Netherlands,25,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Hypofractionated Postmastectomy Radiation Therapy Is Safe and Effective: First Results From a Prospective Phase II Trial,2017-06-20,,False,[],0,USA,11,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Long-Term Follow-Up of Contemporary Treatment in Early-Stage Hodgkin Lymphoma: Updated Analyses of the German Hodgkin Study Group HD7, HD8, HD10, and HD11 Trials",2017-06-20,ABVD protocol,False,[],0,Germany,12,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Safety and Activity of Varlilumab, a Novel and First-in-Class Agonist Anti-CD27 Antibody, in Patients With Advanced Solid Tumors",2017-06-20,varlilumab,True,"['Celldex Therapeutics', 'CellDex Therapeutics']",0,USA,15,9,4,0,0,0,1,1,0,0,0,0,0,0,0,0
"Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study of Naldemedine for the Treatment of Opioid-Induced Constipation in Patients With Cancer",2017-06-10,naldemedine,True,"['Shionogi & Co', 'Shionogi Pharma', 'Shionogi']",0,Japan,9,5,2,2,0,1,1,1,0,0,0,1,0,0,0,1
"Moderate Hypofractionation in High-Risk, Organ-Confined Prostate Cancer: Final Results of a Phase III Randomized Trial",2017-06-10,,False,[],0,Italy,7,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Final Results of the IELSG-19 Randomized Trial of Mucosa-Associated Lymphoid Tissue Lymphoma: Improved Event-Free and Progression-Free Survival With Rituximab Plus Chlorambucil Versus Either Chlorambucil or Rituximab Monotherapy,2017-06-10,rituximab,True,['Genentech'],0,Belgium,31,4,0,3,0,2,0,0,0,0,0,0,0,0,0,0
Randomized Trial of a Hypofractionated Radiation Regimen for the Treatment of Localized Prostate Cancer,2017-06-10,Radiotherapy,True,['Genesis Cancer Care'],0,France,21,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0
"Randomized Controlled Trial of Survivorship Care Plans Among Low-Income, Predominantly Latina Breast Cancer Survivors",2017-06-01,,False,[],0,USA,5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Randomized Phase II Study Investigating Pazopanib Versus Weekly Paclitaxel in Relapsed or Progressive Urothelial Cancer,2017-06-01,pazopanib,True,['GlaxoSmithKline'],0,United Kingdom,18,1,0,0,0,1,1,0,0,0,0,0,0,0,1,0
"Phase 1 Dose-Escalation Study of Pegylated Arginine Deiminase, Cisplatin, and Pemetrexed in Patients With Argininosuccinate Synthetase 1â€“Deficient Thoracic Cancers",2017-06-01,pegylated arginine deiminase (ADI-PEG 20),True,['Polaris Pharmaceuticals'],0,USA,19,7,5,0,0,0,0,1,0,0,0,0,0,0,0,0
"Complete Hematologic and Molecular Response in Adult Patients With Relapsed/Refractory Philadelphia Chromosomeâ€“Positive B-Precursor Acute Lymphoblastic Leukemia Following Treatment With Blinatumomab: Results From a Phase II, Single-Arm, Multicenter Study",2017-06-01,blinatumomab,True,['Amgen'],0,USA,13,10,2,8,2,5,0,1,0,0,0,1,0,1,0,0
Early Positron Emission Tomography Responseâ€“Adapted Treatment in Stage I and II Hodgkin Lymphoma: Final Results of the Randomized EORTC/LYSA/FIL H10 Trial,2017-06-01,doxorubicin,False,[],0,Denmark,26,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
A Phase II Study of Intermittent Sunitinib in Previously Untreated Patients With Metastatic Renal Cell Carcinoma,2017-06-01,sunitinib,True,['Pfizer'],0,USA,11,6,0,2,3,1,0,1,0,0,0,1,0,0,0,0
Phase III Prospective Randomized Comparison Trial of Depot Octreotide Plus Interferon Alfa-2b Versus Depot Octreotide Plus Bevacizumab in Patients With Advanced Carcinoid Tumors: SWOG S0518,2017-05-20,bevacizumab,True,['Genentech'],0,USA,14,3,0,1,1,0,0,1,0,0,0,1,0,0,0,0
Idarubicin Dose Escalation During Consolidation Therapy for Adult Acute Myeloid Leukemia,2017-05-20,idarubicin,True,['Pfizer'],0,Australia,34,3,0,1,0,1,0,0,0,0,0,0,0,0,0,0
"Ten-Year Progression-Free and Overall Survival in Patients With Unresectable or Metastatic GI Stromal Tumors: Long-Term Analysis of the European Organisation for Research and Treatment of Cancer, Italian Sarcoma Group, and Australasian Gastrointestinal Trials Group Intergroup Phase III Randomized Trial on Imatinib at Two Dose Levels",2017-05-20,imatinib,True,['Novartis'],0,Poland,24,13,0,8,2,10,1,1,0,0,1,1,0,0,1,1
Clinical Activity of the Î³-Secretase Inhibitor PF-03084014 in Adults With Desmoid Tumors (Aggressive Fibromatosis),2017-05-10,PF-03084014,True,['Pfizer'],0,USA,17,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0
"Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study",2017-05-10,pembrolizumab,True,['Merck'],0,USA,18,17,3,6,1,1,1,1,0,0,1,1,0,0,0,0
"Adding Celecoxib With or Without Zoledronic Acid for Hormone-NaÃ¯ve Prostate Cancer: Long-Term Survival Results From an Adaptive, Multiarm, Multistage, Platform, Randomized Controlled Trial",2017-05-10,celecoxib,False,[],0,Switzerland,34,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Three-Year Follow-Up of an Alectinib Phase I/II Study in ALK-Positive Nonâ€“Small-Cell Lung Cancer: AF-001JP,2017-05-10,alectinib,True,['Chugai Pharmaceutical'],0,Japan,17,17,3,3,0,14,1,1,0,0,0,1,0,0,1,1
"Multicenter, Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Pravastatin Added to First-Line Standard Chemotherapy in Small-Cell Lung Cancer (LUNGSTAR)",2017-05-10,pravastatin,False,[],0,United Kingdom,14,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Impact of Diabetes, Insulin, and Metformin Use on the Outcome of Patients With Human Epidermal Growth Factor Receptor 2â€“Positive Primary Breast Cancer: Analysis From the ALTTO Phase III Randomized Trial",2017-05-01,metformin,False,[],0,Ireland,20,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Cardiac Events After Radiation Therapy: Combined Analysis of Prospective Multicenter Trials for Locally Advanced Nonâ€“Small-Cell Lung Cancer,2017-05-01,,False,[],0,USA,15,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Cardiac Toxicity After Radiotherapy for Stage III Nonâ€“Small-Cell Lung Cancer: Pooled Analysis of Dose-Escalation Trials Delivering 70 to 90 Gy,2017-05-01,,False,[],0,USA,13,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
BTKC481S-Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia ,2017-05-01,ibrutinib,True,['Pharmacyclics'],0,USA,32,6,0,4,0,1,0,1,0,0,0,0,0,0,0,0
Phase I Trial of the Human Double Minute 2 Inhibitor MK-8242 in Patients With Advanced Solid Tumors,2017-04-20,MK-8242,True,['Merck Sharp & Dohme'],0,USA,13,10,8,0,0,0,1,1,0,0,0,0,0,0,0,0
Efficacy of Internet-Based Cognitive Behavioral Therapy in Improving Sexual Functioning of Breast Cancer Survivors: Results of a Randomized Controlled Trial,2017-04-20,,False,[],0,the Netherlands,18,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Osimertinib in Pretreated T790M-Positive Advanced Nonâ€“Small-Cell Lung Cancer: AURA Study Phase II Extension Component,2017-04-20,osimertinib,True,"['AstraZeneca (I)', 'AstraZeneca']",0,USA,21,15,4,7,2,4,1,1,0,0,1,1,0,0,1,0
"Italian, Multicenter, Phase III, Randomized Study of Cisplatin Plus Etoposide With or Without Bevacizumab as First-Line Treatment in Extensive-Disease Small-Cell Lung Cancer: The GOIRC-AIFA FARM6PMFJM Trial",2017-04-20,bevacizumab,True,['Roche'],0,Italy,19,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes,2017-04-10,,False,[],0,USA,20,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Reduced and Compressed Cisplatin-Based Chemotherapy in Children and Adolescents With Intermediate-Risk Extracranial Malignant Germ Cell Tumors: A Report From the Childrenâ€™s Oncology Group,2017-04-10,cisplatin,False,[],0,USA,16,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Randomized Phase II Study of Clofarabine-Based Consolidation for Younger Adults With Acute Myeloid Leukemia in First Remission,2017-04-10,clofarabine,True,['Sanofi'],0,France,21,2,0,2,0,2,0,0,0,0,0,0,0,0,0,0
"Cholesterol, Cholesterol-Lowering Medication Use, and Breast Cancer Outcome in the BIG 1-98 Study",2017-04-10,letrozole,True,"['Novartis', 'Novartis (I)']",0,Australia,17,7,0,2,0,1,0,1,0,0,0,0,0,0,0,0
Inhibiting Histone Deacetylase as a Means to Reverse Resistance to Angiogenesis Inhibitors: Phase I Study of Abexinostat Plus Pazopanib in Advanced Solid Tumor Malignancies,2017-04-10,abexinostat,False,[],0,USA,14,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance),2017-04-01,anastrozole,True,['AstraZeneca'],0,USA,31,2,0,1,0,0,1,0,0,0,1,0,0,0,0,0
Tissue Factor As a Predictor of Recurrent Venous Thromboembolism in Malignancy: Biomarker Analyses of the CATCH Trial,2017-04-01,Tinzaparin,True,['LEO Pharma'],0,Canada,7,7,2,3,1,4,1,1,0,0,1,1,0,0,1,1
"Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alphaâ€“Targeting Antibodyâ€“Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study",2017-04-01,mirvetuximab soravtansine,True,['ImmunoGen'],0,USA,9,6,1,2,0,0,1,0,0,0,1,0,0,0,0,0
"Comparative Efficacy and Safety of Adjuvant Letrozole Versus Anastrozole in Postmenopausal Patients With Hormone ReceptorÃ¢â‚¬â€œPositive, Node-Positive Early Breast Cancer: Final Results of the Randomized Phase III Femara Versus Anastrozole Clinical Evaluation (FACE) Trial",2017-04-01,letrozole,True,['Novartis'],0,France,17,13,3,5,1,5,0,1,0,0,0,1,0,0,0,1
Promoting End-of-Life Discussions in Advanced Cancer: Effects of Patient Coaching and Question Prompt Lists,2017-03-10,,False,[],0,Australia,12,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Effects of Early Integrated Palliative Care in Patients With Lung and GI Cancer: A Randomized Clinical Trial,2017-03-10,,False,[],0,USA,16,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Phase III Randomized Study of 4 Weeks of High-Dose Interferon-ÃŽÂ±-2b in Stage T2bNO, T3a-bNO, T4a-bNO, and T1-4N1a-2a (microscopic) Melanoma: A Trial of the Eastern Cooperative Oncology GroupÃ¢â‚¬â€œAmerican College of Radiology Imaging Network Cancer Research Group (E1697)",2017-03-10,interferon alfa-2b,False,"['Merck/Schering-Plough', 'Merck/Schering Plough', 'Merck Sharp & Dohme', 'Merck']",0,Australia,21,8,0,4,3,2,0,1,0,0,0,0,0,0,0,0
Multidisciplinary Approach to Novel Therapies in Cardio-Oncology Research (MANTICORE 101Ã¢â‚¬â€œBreast): A Randomized Trial for the Prevention of Trastuzumab-Associated Cardiotoxicity,2017-03-10,trastuzumab,False,[],0,Canada,14,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Fentanyl Sublingual Tablets Versus Subcutaneous Morphine for the Management of Severe Cancer Pain Episodes in Patients Receiving Opioid Treatment: A Double-Blind, Randomized, Noninferiority Trial",2017-03-01,fentanyl,True,['Mundipharma Pharmaceuticals'],0,Norway,6,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
Impact of a Panel of 88 Single Nucleotide Polymorphisms on the Risk of Breast Cancer in High-Risk Women: Results From Two Randomized Tamoxifen Prevention Trials,2017-03-01,,False,[],0,United Kingdom,12,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Cetuximab Plus Chemoradiotherapy in Immunocompetent Patients With Anal Carcinoma: A Phase II Eastern Cooperative Oncology GroupÃ¢â‚¬â€œAmerican College of Radiology Imaging Network Cancer Research Group Trial (E3205),2017-03-01,cetuximab,True,"['Eli Lilly', 'Eli Lilly/ImClone Systems']",0,USA,15,2,0,2,0,0,0,1,0,0,0,1,0,0,0,0
Cetuximab Plus Chemoradiotherapy for HIV-Associated Anal Carcinoma: A Phase II AIDS Malignancy Consortium Trial,2017-03-01,cetuximab,True,['Eli Lilly'],0,USA,11,1,0,1,0,0,1,0,0,0,1,0,0,0,0,0
Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial,2017-02-20,cabozantinib,True,['Exelixis'],0,USA,13,3,0,3,0,0,1,0,0,0,1,0,0,0,0,0
Factors Associated With Early Discontinuation of Study Treatment in the Mammary Prevention.3 Breast Cancer Chemoprevention Trial,2017-02-20,exemestane,True,['Pfizer'],0,USA,6,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0
Laparoscopy to Predict the Result of Primary Cytoreductive Surgery in Patients With Advanced Ovarian Cancer: A Randomized Controlled Trial,2017-02-20,,False,[],0,Australia,25,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Improved Outcomes With Retinoic Acid and Arsenic Trioxide Compared With Retinoic Acid and Chemotherapy in NonÃ¢â‚¬â€œHigh-Risk Acute Promyelocytic Leukemia: Final Results of the Randomized Italian-German APL0406 Trial,2017-02-20,arsenic trioxide,False,[],0,Italy,45,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: The ORCHARRD Study,2017-02-10,rituximab,True,['Genentech'],0,Switzerland,18,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
"Response to Rituximab Induction Is a Predictive Marker in B-Cell Post-Transplant Lymphoproliferative Disorder and Allows Successful Stratification Into Rituximab or R-CHOP Consolidation in an International, Prospective, Multicenter Phase II Trial",2017-02-10,rituximab,True,['Genentech'],0,Italy,23,2,0,1,0,2,0,0,0,0,0,0,0,0,0,0
E1308: Phase II Trial of Induction Chemotherapy Followed by Reduced-Dose Radiation and Weekly Cetuximab in Patients With HPV-Associated Resectable Squamous Cell Carcinoma of the OropharynxÃ¢â‚¬â€ ECOG-ACRIN Cancer Research Group,2017-02-10,cetuximab,True,['Eli Lilly'],0,USA,17,4,0,3,0,0,0,0,0,0,0,0,0,0,0,0
Results From the Phase III Randomized Trial of Onartuzumab Plus Erlotinib Versus Erlotinib in Previously Treated Stage IIIB or IV Nonâ€“Small-Cell Lung Cancer: METLung,2017-02-01,onartuzumab,True,['Genentech'],0,China,11,10,6,4,2,1,1,1,0,0,1,1,0,1,0,1
Randomized Prospective Biomarker Trial of ERCC1 for Comparing Platinum and Nonplatinum Therapy in Advanced NonÃ¢â‚¬â€œSmall-Cell Lung Cancer: ERCC1 Trial (ET),2017-02-01,cisplatin,False,[],0,United Kingdom,23,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Onartuzumab Plus Bevacizumab Versus Placebo Plus Bevacizumab in Patients With Recurrent Glioblastoma: Efficacy, Safety, and Hepatocyte Growth Factor and O6-Methylguanineâ€“DNA Methyltransferase Biomarker Analyses",2017-01-20,onartuzumab,True,"['Coinventor on several patent applications that have been filed as part of employment with Genentech', 'Genentech']",0,Switzerland,21,8,6,2,0,2,1,1,0,1,1,0,0,0,0,0
Cost-Utility of Stepped Care Targeting Psychological Distress in Patients With Head and Neck or Lung Cancer,2017-01-20,,False,[],0,Netherlands,12,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Mindfulness-Based Cognitive Therapy in Advanced Prostate Cancer: A Randomized Controlled Trial,2017-01-20,,False,[],0,USA,12,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Evaluation of a Web-Based Cognitive Rehabilitation Program in Cancer Survivors Reporting Cognitive Symptoms After Chemotherapy,2017-01-10,,False,[],0,USA,9,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Trastuzumab Emtansine With or Without Pertuzumab Versus Trastuzumab Plus Taxane for Human Epidermal Growth Factor Receptor 2â€“Positive, Advanced Breast Cancer: Primary Results From the Phase III MARIANNE Study",2017-01-10,trastuzumab emtansine (T-DM1),True,"['Genentech', 'Roche/Genentech']",0,United Kingdom,15,5,2,2,0,2,1,0,1,0,0,0,0,0,0,0
"Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study",2017-01-10,BGJ398,True,"['Novartis', 'Novartis (stock options)']",0,Switzerland,27,23,7,8,3,7,1,1,0,0,0,1,0,0,0,1
"Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer",2017-01-01,ipilimumab,True,"['Bristol-Myers Squibb', 'Intellectual property licensed to Bristol-Myers Squibb']",0,the Netherlands,23,13,1,6,0,2,1,1,0,0,0,1,0,0,0,0
"Phase III, Double-Blind, Randomized Trial That Compared Maintenance Lapatinib Versus Placebo After First-Line Chemotherapy in Patients With Human Epidermal Growth Factor Receptor 1/2â€“Positive Metastatic Bladder Cancer",2017-01-01,lapatinib,True,['GlaxoSmithKline'],0,United Kingdom,19,3,0,1,2,3,1,1,0,0,1,0,0,1,1,1
"Telotristat Ethyl, a Tryptophan Hydroxylase Inhibitor for the Treatment of Carcinoid Syndrome",2017-01-01,telotristat ethyl,True,"['Lexicon Pharmaceuticals', 'Lexicon: Inventor on pending US patents regarding methods and compounds for inhibiting tryptophan hydroxylase. Regeneron: Inventor on patent applications unrelated to this study.']",0,Spain,19,15,6,11,0,3,1,1,0,0,1,1,0,0,0,1
"Revised Overall Survival Analysis of a Phase II, Randomized, Double-Blind, Controlled Study of PROSTVAC in Men With Metastatic Castration-Resistant Prostate Cancer",2017-01-01,,False,[],0,USA,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Impact of Intensity-Modulated Radiation Therapy Technique for Locally Advanced NonÃ¢â‚¬â€œSmall-Cell Lung Cancer: A Secondary Analysis of the NRG Oncology RTOG 0617 Randomized Clinical Trial,2017-01-01,IMRT,True,['Varian Medical Systems'],0,Canada,20,4,0,1,1,1,0,1,0,0,0,1,0,0,0,1
Randomized Phase II Trial of Seribantumab in Combination With Paclitaxel in Patients With Advanced Platinum-Resistant or -Refractory Ovarian Cancer,2016-12-20,seribantumab,True,['Merrimack Pharmaceuticals'],0,Belgium,25,8,7,2,0,0,1,0,0,0,0,0,0,0,0,0
Phase II Study of WEE1 Inhibitor AZD1775 Plus Carboplatin in Patients With TP53-Mutated Ovarian Cancer Refractory or Resistant to First-Line Therapy Within 3 Months,2016-12-20,AZD1775,True,['AstraZeneca'],0,USA,13,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Phase I/Phase II Study of Blinatumomab in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia,2016-12-20,blinatumomab,True,"['Amgen Research (Munich) GmbH', 'Amgen']",0,Canada,23,12,2,6,1,3,1,1,0,0,1,1,1,0,1,1
Psychoeducational Intervention to Reduce Fear of Cancer Recurrence in People at High Risk of Developing Another Primary Melanoma: Results of a Randomized Controlled Trial,2016-12-20,,False,[],0,Australia,10,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Phase I Study Evaluating WEE1 Inhibitor AZD1775 As Monotherapy and in Combination With Gemcitabine, Cisplatin, or Carboplatin in Patients With Advanced Solid Tumors",2016-12-20,AZD1775,True,['AstraZeneca'],0,China,16,2,0,0,0,0,0,1,0,0,0,0,0,0,0,0
Pooled Analysis of CNS Response to Alectinib in Two Studies of Pretreated Patients With ALK-Positive Nonâ€“Small-Cell Lung Cancer,2016-12-01,alectinib,True,"['F. Hoffman-La Roche', 'F. Hoffmann-La Roche', 'F. Hoffmann-La Roche (I)', 'Roche']",0,Switzerland,21,10,4,2,0,6,0,0,0,0,0,0,0,0,0,0
Programmed Death-Ligand 1 Expression and Response to the Antiâ€“Programmed Death 1 Antibody Pembrolizumab in Melanoma,2016-12-01,pembrolizumab,True,"['Merck & Co', 'Merck', 'Merck (I)', 'Merck Serono', 'Merck Sharp & Dohme']",0,Australia,24,20,6,8,1,3,1,1,0,0,1,0,0,0,0,0
Pomalidomide for Symptomatic Kaposi's Sarcoma in People With and Without HIV Infection: A Phase I/II Study,2016-12-01,pomalidomide,True,['Celgene'],0,USA,16,4,2,0,0,0,1,1,0,0,0,0,0,0,0,0
Treatment of Children and Adolescents With Metastatic Medulloblastoma and Prognostic Relevance of Clinical and Biologic Parameters,2016-12-01,,False,[],0,USA,26,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Multicenter Phase II Study of Lenalidomide in Relapsed or Recurrent Adult T-Cell Leukemia/Lymphoma: ATLL-002,2016-12-01,lenalidomide,True,"['Celgene', 'Celgene K.K.']",0,Japan,18,12,3,1,2,4,1,1,0,1,0,0,0,0,0,0
"First-in-Class, First-in-Human Phase I Study of Selinexor, a Selective Inhibitor of Nuclear Export, in Patients With Advanced Solid Tumors",2016-12-01,selinexor,True,"['Karyopharm Therapeutics (I)', 'Research Funding Karyopharm Therapeutics', 'Karyopharm Therapeutics']",0,USA,18,15,9,1,0,1,1,1,0,0,0,0,0,0,0,0
"Phase I Study of Selinexor, a Selective Inhibitor of Nuclear Export, in Combination With Fludarabine and Cytarabine, in Pediatric Relapsed or Refractory Acute Leukemia",2016-12-01,selinexor,False,[],0,USA,6,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Randomized Trial Comparing R-CHOP Versus High-Dose Sequential Chemotherapy in High-Risk Patients With Diffuse Large B-Cell Lymphomas,2016-11-20,rituximab,True,['Roche'],0,Italy,34,5,0,0,1,3,0,1,0,0,0,0,0,0,0,1
PANCREOX: A Randomized Phase III Study of Fluorouracil/Leucovorin With or Without Oxaliplatin for Second-Line Advanced Pancreatic Cancer in Patients Who Have Received Gemcitabine-Based Chemotherapy,2016-11-10,oxaliplatin,True,"['Sanofi', 'Sanofi Canada']",0,Canada,14,5,2,2,0,1,0,0,0,0,0,0,0,0,0,0
"Everolimus for the Treatment of Advanced Pancreatic Neuroendocrine Tumors: Overall Survival and Circulating Biomarkers From the Randomized, Phase III RADIANT-3 Study",2016-11-10,Everolimus,True,['Novartis'],0,Sweden,14,10,4,4,2,2,1,1,0,0,1,1,0,1,0,1
Phase II Trial and Correlative Genomic Analysis of Everolimus Plus Bevacizumab in Advanced Nonâ€“Clear Cell Renal Cell Carcinoma,2016-11-10,everolimus,True,['Novartis'],0,USA,18,5,0,4,0,1,1,1,0,0,1,0,0,0,1,0
"Health-Related Quality-of-Life Results From the Open-Label, Randomized, Phase III ASPIRE Trial Evaluating Carfilzomib, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients With Relapsed Multiple Myeloma",2016-11-10,carfilzomib,True,['Amgen'],0,Italy,20,16,3,10,4,6,1,1,0,0,1,1,0,0,0,1
"PICASSO III: A Phase III, Placebo-Controlled Study of Doxorubicin With or Without Palifosfamide in Patients With Metastatic Soft Tissue Sarcoma",2016-11-10,palifosfamide,True,['Threshold Pharmaceuticals'],0,Belgium,21,4,0,2,0,0,0,0,0,0,0,0,0,0,0,0
Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer,2016-11-01,ipilimumab,True,['Bristol-Myers Squibb'],0,United Kingdom,20,15,3,10,3,5,1,1,0,0,1,1,1,0,0,0
"Effect of Interval (7 or 11 weeks) Between Neoadjuvant Radiochemotherapy and Surgery on Complete Pathologic Response in Rectal Cancer: A Multicenter, Randomized, Controlled Trial (GRECCAR-6)",2016-11-01,capecitabine,True,['Roche'],0,France,28,3,0,1,1,0,0,0,0,0,0,0,0,0,0,0
Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure,2016-11-01,pembrolizumab,True,"['Merck (I)', 'Merck']",0,USA,11,8,5,3,0,2,1,1,0,0,1,1,0,0,0,0
"Updated Outcomes and Impact of Age With Lenalidomide and Low-Dose Dexamethasone or Melphalan, Prednisone, and Thalidomide in the Randomized, Phase III FIRST Trial",2016-10-20,lenalidomide,True,"['Celgene', 'Celgene Canada']",0,Greece,29,17,4,8,1,10,1,1,0,0,0,1,0,1,1,1
"Safety, Antitumor Activity, and Immune Activation of Pegylated Recombinant Human Interleukin-10 (AM0010) in Patients With Advanced Solid Tumors",2016-10-10,AM0010,True,['ARMO BioSciences'],0,USA,20,10,5,0,0,0,1,0,0,0,0,0,0,0,0,0
Phase II Weekly Vinblastine for Chemotherapy-NaÃƒÂ¯ve Children With Progressive Low-Grade Glioma: A Canadian Pediatric Brain Tumor Consortium Study,2016-10-10,vinblastine,False,[],0,Canada,23,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Nonâ€“Small-Cell Lung Cancer,2016-10-01,osimertinib,True,['AstraZeneca'],0,Taiwan,9,7,4,3,0,2,1,1,0,0,1,1,0,0,1,0
Low-Dose Oral Cyclophosphamide and Methotrexate Maintenance for Hormone Receptorâ€“Negative Early Breast Cancer: International Breast Cancer Study Group Trial 22-00,2016-10-01,cyclophosphamide,False,[],0,Romania,22,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Efficacy of Mindfulness-Based Cognitive Therapy on Late Post-Treatment Pain in Women Treated for Primary Breast Cancer: A Randomized Controlled Trial,2016-10-01,,False,[],0,Denmark,6,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Randomized Phase II Trial of Gefitinib With and Without Pemetrexed as First-Line Therapy in Patients With Advanced Nonsquamous Nonâ€“Small-Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations,2016-09-20,gefitinib,True,['AstraZeneca'],0,Argentina,12,4,0,2,1,3,0,1,0,0,0,1,0,0,0,1
"Modified FOLFOX6 With or Without Radiation Versus Fluorouracil and Leucovorin With Radiation in Neoadjuvant Treatment of Locally Advanced Rectal Cancer: Initial Results of the Chinese FOWARC Multicenter, Open-Label, Randomized Three-Arm Phase III Trial",2016-09-20,oxaliplatin,False,[],0,China,27,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Bendamustine in Combination With Gemcitabine and Vinorelbine Is an Effective Regimen As Induction Chemotherapy Before Autologous Stem-Cell Transplantation for Relapsed or Refractory Hodgkin Lymphoma: Final Results of a Multicenter Phase II Study,2016-09-20,bendamustine,True,['Mundipharma Pharmaceuticals'],0,Italy,18,2,0,1,0,0,0,0,0,0,0,0,0,0,0,0
Randomized Phase III Study Comparing Gefitinib With Erlotinib in Patients With Previously Treated Advanced Lung Adenocarcinoma: WJOG 5108L,2016-09-20,gefitinib,True,['AstraZeneca'],0,Japan,22,14,0,0,1,13,1,0,0,0,0,0,0,0,1,0
"Phase IB Study of Selinexor, a First-in-Class Inhibitor of Nuclear Export, in Patients With Advanced Refractory Bone or Soft Tissue Sarcoma",2016-09-10,selinexor,True,"['Karyopharm Therapeutics patent', 'Karyopharm Therapeutics (I)', 'Karyopharm Therapeutics patent (I)', 'Karyopharm Therapeutics']",0,USA,25,10,11,1,0,1,1,1,0,0,1,0,0,0,1,0
Gain of 1q As a Prognostic Biomarker in Wilms Tumors (WTs) Treated With Preoperative Chemotherapy in the International Society of Paediatric Oncology (SIOP) WT 2001 Trial: A SIOP Renal Tumours Biology Consortium Study,2016-09-10,,False,['Spago Nanomedical'],0,Sweden,26,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
"Safety and Efficacy of Durvalumab (MEDI4736), an Antiâ€“Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer",2016-09-10,durvalumab,True,['AstraZeneca'],0,USA,19,7,1,2,0,0,1,1,0,0,1,1,0,0,0,0
Phase III Study of Cabozantinib in Previously Treated Metastatic Castration-Resistant Prostate Cancer: COMET-1,2016-09-01,cabozantinib,True,['Exelixis'],0,Australia,26,10,3,3,0,0,1,0,0,0,1,0,0,0,0,0
Continued Risk of Relapse Independent of Treatment Modality in Limited-Stage Diffuse Large B-Cell Lymphoma: Final and Long-Term Analysis of Southwest Oncology Group Study S8736,2016-09-01,rituximab,True,"['Genentech', 'AbbVie/Genentech']",0,USA,7,3,0,3,0,0,0,1,0,0,0,1,0,0,0,0
Nivolumab Monotherapy for First-Line Treatment of Advanced Nonâ€“Small-Cell Lung Cancer,2016-09-01,nivolumab,True,"['Bristol-Myers Squibb (I)', 'Bristol-Myers Squibb']",0,USA,16,14,4,9,0,6,1,1,0,0,1,1,0,0,0,0
Nivolumab in Combination With Platinumâ€Based Doublet Chemotherapy for First-Line Treatment of Advanced Nonâ€“Small-Cell Lung Cancer ,2016-09-01,nivolumab,True,"['Bristol-Myers Squibb (I)', 'Bristol-Myers Squibb']",0,USA,16,14,5,8,0,4,1,1,0,0,0,1,0,0,0,1
Randomized Phase III Study of Lenalidomide Versus Placebo in RBC Transfusion-Dependent Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes and Ineligible for or Refractory to Erythropoiesis-Stimulating Agents,2016-09-01,lenalidomide,True,['Celgene'],0,USA,22,19,6,10,3,10,1,1,0,0,1,0,0,0,1,1
Plasma ESR1 Mutations and the Treatment of Estrogen Receptorâ€“Positive Advanced Breast Cancer,2016-09-01,fulvestrant,True,['AstraZeneca'],0,USA,17,5,0,2,1,0,0,1,0,0,0,1,0,0,0,0
"Outcome of Patients With Recurrent Osteosarcoma Enrolled in Seven Phase II Trials Through Children's Cancer Group, Pediatric Oncology Group, and Children's Oncology Group: Learning From the Past to Move Forward",2016-09-01,granulocyte-macrophage colony-stimulating factor,False,[],0,USA,15,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Multicenter Phase II Study of Whole-Body and Intracranial Activity With Ceritinib in Patients With ALK-Rearranged Nonâ€“Small-Cell Lung Cancer Previously Treated With Chemotherapy and Crizotinib: Results From ASCEND-2,2016-08-20,ceritinib,True,"['Novartis', 'Novartis Pharma AG', 'Novartis Pharma']",0,Boston MA,16,13,5,8,3,4,1,1,0,0,1,1,0,0,1,1
"Phase II Multicenter, Randomized, Double-Blind Controlled Study of Efficacy and Safety of Umbilical Cordâ€“Derived Mesenchymal Stromal Cells in the Prophylaxis of Chronic Graft-Versus-Host Disease After HLA-Haploidentical Stem-Cell Transplantation",2016-08-20,mesenchymal stromal cells (MSCs),False,[],0,USA,18,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Randomized Noninferiority Trial of Telephone Delivery of BRCA1/2 Genetic Counseling Compared With In-Person Counseling: 1-Year Follow-Up,2016-08-20,,False,[],0,USA,14,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Examination of Broad Symptom Improvement Resulting From Mindfulness-Based Stress Reduction in Breast Cancer Survivors: A Randomized Controlled Trial,2016-08-20,,False,[],0,USA,14,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Intracranial Efficacy of Crizotinib Versus Chemotherapy in Patients With Advanced ALK-Positive Nonâ€“Small-Cell Lung Cancer: Results From PROFILE 1014,2016-08-20,crizotinib,True,['Pfizer'],0,China,15,14,5,6,2,7,1,1,0,0,1,1,0,0,0,1
Randomized Phase III Trial of Irinotecan Plus Cisplatin Compared With Paclitaxel Plus Carboplatin As First-Line Chemotherapy for Ovarian Clear Cell Carcinoma: JGOG3017/GCIG Trial,2016-08-20,paclitaxel,False,[],0,United Kingdom,24,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CALGB 80403 (Alliance)/E1206: A Randomized Phase II Study of Three Chemotherapy Regimens Plus Cetuximab in Metastatic Esophageal and Gastroesophageal Junction Cancers,2016-08-10,cetuximab,True,"['Eli Lilly', 'Eli Lilly/ImClone']",0,USA,12,3,0,2,0,0,0,0,0,0,0,0,0,0,0,0
Regorafenib for the Treatment of Advanced Gastric Cancer (INTEGRATE): A Multinational Placebo-Controlled Phase II Trial,2016-08-10,regorafenib,True,"['Bayer HealthCare Pharmaceuticals', 'Bayer Schering Pharma']",0,Canada,21,6,0,4,0,3,1,0,0,0,1,0,0,0,1,0
Phase II Study of Hemithoracic Intensity-Modulated Pleural Radiation Therapy (IMPRINT) As Part of Lung-Sparing Multimodality Therapy in Patients With Malignant Pleural Mesothelioma,2016-08-10,pemetrexed,True,"['Eli Lilly', 'Lilly Oncology']",0,USA,15,3,0,1,0,0,0,1,0,0,0,0,0,0,0,0
Effect of Pathologic Tumor Response and Nodal Status on Survival in the Medical Research Council Adjuvant Gastric Infusional Chemotherapy Trial,2016-08-10,"epirubicin, cisplatin, and fluorouracil (ECF regimen)",False,[],0,the Netherlands,16,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study,2016-08-10,nivolumab,True,"['Bristol-Myers Squibb (I)', 'Bristol-Myers Squibb']",0,USA,23,16,3,6,4,4,1,1,0,0,1,0,0,0,1,0
Lack of Effectiveness of Neutropenic Diet and Social Restrictions as Anti-Infective Measures in Children With Acute Myeloid Leukemia: An Analysis of the AML-BFM 2004 Trial ,2016-08-10,,False,[],0,Canada,8,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Randomized, Double-Blind, Placebo-Controlled Phase III Study of Tasquinimod in Men With Metastatic Castration-Resistant Prostate Cancer",2016-08-01,tasquinimod,True,['Active Biotech'],0,USA,26,6,2,0,0,0,1,0,0,0,0,0,0,0,0,0
"Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanoma",2016-08-01,talimogene laherparepvec,True,"['Biomarker-related patents owned by Amgen', 'Amgen']",0,USA,12,10,6,4,0,2,1,1,0,0,1,1,0,0,0,1
Risk Factors and Outcomes for Patients With Follicular Lymphoma Who Had Histologic Transformation After Response to First-Line Immunochemotherapy in the PRIMA Trial,2016-08-01,rituximab,True,['Genentech'],0,Spain,20,3,0,1,1,2,0,1,0,0,0,0,0,0,0,1
No Evidence for the Benefit of Gonadotropin-Releasing Hormone Agonist in Preserving Ovarian Function and Fertility in Lymphoma Survivors Treated With Chemotherapy: Final Long-Term Report of a Prospective Randomized Trial,2016-08-01,triptorelin,True,['Ferring Pharmaceuticals'],0,Italy,12,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0
Phase III Trial Evaluating Letrozole As First-Line Endocrine Therapy With or Without Bevacizumab for the Treatment of Postmenopausal Women With Hormone Receptorâ€“Positive Advanced-Stage Breast Cancer: CALGB 40503 (Alliance),2016-08-01,bevacizumab,True,['Genentech'],0,USA,15,6,0,3,0,0,1,1,0,0,1,1,0,0,0,0
"Double-Blind, Placebo-Controlled, Randomized Phase III Trial Evaluating Pertuzumab Combined With Chemotherapy for Low Tumor Human Epidermal Growth Factor Receptor 3 mRNAâ€“Expressing Platinum-Resistant Ovarian Cancer (PENELOPE)",2016-07-20,pertuzumab,True,['Genentech'],0,Switzerland,23,3,0,2,0,1,0,0,0,0,0,0,0,0,0,0
Standardized Uptake Decrease on [18F]-Fluorodeoxyglucose Positron Emission Tomography After Neoadjuvant Chemotherapy Is a Prognostic Classifier for Long-Term Outcome After Multimodality Treatment: Secondary Analysis of a Randomized Trial for Resectable Stage IIIA/B Nonâ€“Small-Cell Lung Cancer,2016-07-20,cisplatin,False,[],0,Germany,16,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Treatment Adherence and Its Impact on Disease-Free Survival in the Breast International Group 1-98 Trial of Tamoxifen and Letrozole, Alone and in Sequence",2016-07-20,letrozole,True,"['Novartis', 'Novartis (I)']",0,Hungary,15,4,0,0,0,1,0,1,0,0,0,0,0,0,0,0
"Randomized, Double-Blind, Phase III Trial of Enzastaurin Versus Placebo in Patients Achieving Remission After First-Line Therapy for High-Risk Diffuse Large B-Cell Lymphoma",2016-07-20,enzastaurin,True,['Eli Lilly'],0,China,25,9,5,1,0,0,0,0,0,0,0,0,0,0,0,0
Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study,2016-07-20,pembrolizumab,True,"['Merck (I)', 'Merck & Co.', 'Merck']",0,Belgium,12,9,5,3,0,2,1,0,0,0,1,0,0,0,0,0
"Paclitaxel, Ifosfamide, and Cisplatin Efficacy for First-Line Treatment of Patients With Intermediate- or Poor-Risk Germ Cell Tumors",2016-07-20,paclitaxel,True,['Bristol-Myers Squibb'],0,USA,16,4,0,2,0,0,0,1,0,0,0,0,0,0,0,0
Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-NaÃ¯ve Chronic Myeloid Leukemia Patients Trial,2016-07-10,dasatinib,True,['Bristol-Myers Squibb'],0,Germany,12,11,2,5,1,4,1,1,0,0,1,1,0,0,0,1
Dexamethasone and High-Dose Methotrexate Improve Outcome for Children and Young Adults With High-Risk B-Acute Lymphoblastic Leukemia: A Report From Childrenâ€™s Oncology Group Study AALL0232,2016-07-10,methotrexate,False,[],0,USA,20,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Randomized Phase III Noninferiority Study Comparing Two Radiotherapy Fractionation Schedules in Patients With Low-Risk Prostate Cancer,2016-07-10,,False,[],0,USA,19,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
West German Study Group Phase III PlanB Trial: First Prospective Outcome Data for the 21-Gene Recurrence Score Assay and Concordance of Prognostic Markers by Central and Local Pathology Assessment,2016-07-10,21-gene Recurrence Score (Oncotype DX) assay,True,"['Genomic Health', 'Genomic Health (I)', 'Renal prognostic signature developed at Genomic Health']",0,USA,21,10,2,7,1,3,1,1,0,0,1,1,0,0,0,0
"Randomized, Prospective Evaluation Comparing Intensity of Lymphodepletion Before Adoptive Transfer of Tumor-Infiltrating Lymphocytes for Patients With Metastatic Melanoma",2016-07-10,,False,[],0,USA,25,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Randomized Phase II Evaluation of Bevacizumab Versus Bevacizumab Plus Fosbretabulin in Recurrent Ovarian, Tubal, or Peritoneal Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study",2016-07-01,fosbretabulin tromethamine,True,['OXiGENE'],0,USA,11,1,0,1,0,0,1,0,0,0,1,0,0,0,0,0
Randomized Phase II Study of Trabectedin and Doxorubicin Compared With Doxorubicin Alone as First-Line Treatment in Patients With Advanced Soft Tissue Sarcomas: A Spanish Group for Research on Sarcoma Study,2016-07-01,trabectedin,True,"['Plitidepsin (PharmaMar)', 'PharmaMar']",0,Spain,24,6,0,1,2,2,1,1,0,0,1,0,1,0,0,0
"Hydrocortisone as an Intervention for Dexamethasone-Induced Adverse Effects in Pediatric Patients With Acute Lymphoblastic Leukemia: Results of a Double-Blind, Randomized Controlled Trial",2016-07-01,dexamethasone,False,[],0,the Netherlands,12,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"A Randomized, Double-Blind, Placebo-Controlled, Phase III Study to Assess Efficacy and Safety of Weekly Farletuzumab in Combination With Carboplatin and Taxane in Patients With Ovarian Cancer in First Platinum-Sensitive Relapse",2016-07-01,farletuzumab,True,['Morphotek'],0,USA,15,6,4,2,0,0,0,1,0,0,0,1,0,0,0,0
Two Years of Adjuvant Tamoxifen Provides a Survival Benefit Compared With No Systemic Treatment in Premenopausal Patients With Primary Breast Cancer: Long-Term Follow-Up (> 25 years) of the Phase III SBII:2pre Trial,2016-07-01,tamoxifen,True,['AstraZeneca'],0,Sweden,6,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
Response to Cetuximab With or Without Irinotecan in Patients With Refractory Metastatic Colorectal Cancer Harboring the KRAS G13D Mutation: Australasian Gastro-Intestinal Trials Group ICECREAM Study,2016-07-01,cetuximab,True,"['Merck KGaA', 'Merck', 'Merck Serono', 'Merck-Serono']",0,United Kingdom,23,14,0,9,1,3,1,1,0,0,0,0,0,0,0,0
"Bortezomib, Doxorubicin, Cyclophosphamide, Dexamethasone Induction Followed by Stem Cell Transplantation for Primary Plasma Cell Leukemia: A Prospective Phase II Study of the Intergroupe Francophone du MyÃ©lome",2016-06-20,bortezomib,True,['Takeda Pharmaceuticals'],0,France,28,4,0,3,0,1,0,0,0,0,0,0,0,0,0,0
Molecular Alterations and Everolimus Efficacy in Human Epidermal Growth Factor Receptor 2â€“Overexpressing Metastatic Breast Cancers: Combined Exploratory Biomarker Analysis From BOLERO-1 and BOLERO-3,2016-06-20,everolimus,True,['Novartis'],0,USA,16,12,5,3,1,3,1,1,0,0,0,1,0,0,0,1
Afatinib Activity in Platinum-Refractory Metastatic Urothelial Carcinoma in Patients With ERBB Alterations,2016-06-20,afatinib,True,['Boehringer Ingelheim'],0,USA,10,2,0,0,0,0,0,1,0,0,0,0,0,0,0,0
Enzalutamide Versus Bicalutamide in Castration-Resistant Prostate Cancer: The STRIVE Trial,2016-06-20,enzalutamide,True,['Astellas Pharma'],0,USA,12,8,2,4,2,1,1,1,0,0,1,1,0,0,0,0
"Eight Cycles of ABVD Versus Four Cycles of BEACOPPescalated Plus Four Cycles of BEACOPPbaseline in Stage III to IV, International Prognostic Score â‰¥ 3, High-Risk Hodgkin Lymphoma: First Results of the Phase III EORTC 20012 Intergroup Trial",2016-06-10,"ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine)",False,[],0,Spain,20,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Phase II Randomized Preoperative Window-of-Opportunity Study of the PI3K Inhibitor Pictilisib Plus Anastrozole Compared With Anastrozole Alone in Patients With Estrogen Receptorâ€“Positive Breast Cancer,2016-06-10,pictilisib,True,"['Genentech', 'Genentech (I)']",0,USA,26,6,5,1,1,0,1,0,1,0,0,0,0,0,0,0
US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim FluorodeoxyglucoseÃ¢â‚¬â€œPositron Emission Tomography Imaging: Southwest Oncology Group S0816,2016-06-10,fluorodeoxyglucose F 18,False,[],0,USA,25,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Randomized Trial of Hepatic Artery Embolization for Hepatocellular Carcinoma Using Doxorubicin-Eluting Microspheres Compared With Embolization With Microspheres Alone,2016-06-10,doxorubicin-eluting microspheres,True,['Sirtex Medical'],0,USA,20,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Controlled, Randomized, Open-Label Trial of Risk-Stratified Corticosteroid Prevention of Acute Graft-Versus-Host Disease After Haploidentical Transplantation",2016-06-01,corticosteroids,False,[],0,China,14,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Randomized Controlled Trial of Family Therapy in Advanced Cancer Continued Into Bereavement,2016-06-01,,False,[],0,Australia,9,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
A Randomized Phase II Trial of Short-Course Androgen Deprivation Therapy With or Without Bevacizumab for Patients With Recurrent Prostate Cancer After Definitive Local Therapy,2016-06-01,bevacizumab,True,['Genentech'],0,USA,14,4,0,2,1,0,0,1,0,0,0,0,0,0,0,0
Default Options: Opportunities to Improve Quality and Value in Oncology,2016-06-01,,False,[],0,USA,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Phase I Study of LY2606368, a Checkpoint Kinase 1 Inhibitor, in Patients With Advanced Cancer",2016-05-20,LY2606368,True,"['Eli Lilly (I)', 'Eli Lilly']",0,USA,16,5,5,0,0,0,0,0,0,0,0,0,0,0,0,0
Acupuncture As an Integrative Approach for the Treatment of Hot Flashes in Women With Breast Cancer: A Prospective Multicenter Randomized Controlled Trial (AcCliMaT),2016-05-20,,False,[],0,Italy,14,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Association of Vitamin D Levels With Outcome in Patients With Melanoma After Adjustment For C-Reactive Protein,2016-05-20,vitamin D,False,[],0,USA,18,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Phase II Trial of Temsirolimus for Relapsed/Refractory Primary CNS Lymphoma,2016-05-20,temsirolimus,True,['Pfizer'],0,Germany,12,4,0,2,0,1,1,1,0,0,0,1,0,0,0,0
Short Androgen Suppression and Radiation Dose Escalation for Intermediate- and High-Risk Localized Prostate Cancer: Results of EORTC Trial 22991,2016-05-20,luteinizing hormoneâ€“releasing hormone agonist,True,['Ipsen'],0,Egypt,22,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
SIRFLOX: Randomized Phase III Trial Comparing First-Line mFOLFOX6 (Plus or Minus Bevacizumab) Versus mFOLFOX6 (Plus or Minus Bevacizumab) Plus Selective Internal Radiation Therapy in Patients With Metastatic Colorectal Cancer,2016-05-20,yttrium-90 resin microspheres,True,['Sirtex'],0,France,30,13,2,6,2,7,1,1,0,0,1,0,0,0,1,1
Adjuvant Tamoxifen Plus Ovarian Function Suppression Versus Tamoxifen Alone in Premenopausal Women With Early Breast Cancer: Patient-Reported Outcomes in the Suppression of Ovarian Function Trial,2016-05-10,tamoxifen,False,[],0,Sweden,27,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Efficacy and Biomarker Study of Bevacizumab for Hearing Loss Resulting From Neurofibromatosis Type 2â€“Associated Vestibular Schwannomas,2016-05-10,bevacizumab,True,"['Roche', 'Roche Norway']",0,USA,16,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
Bevacizumab Plus Irinotecan Versus Temozolomide in Newly Diagnosed O6-Methylguanineâ€“DNA Methyltransferase Nonmethylated Glioblastoma: The Randomized GLARIUS Trial,2016-05-10,bevacizumab,True,"['Bureau: Roche', 'F. Hoffmann-La Roche', 'Roche Pharma AG', 'Roche']",0,Germany,38,17,2,10,3,9,1,1,0,0,1,1,1,0,1,1
"Randomized Open-Label Phase II Trial of Apitolisib (GDC-0980), a Novel Inhibitor of the PI3K/Mammalian Target of Rapamycin Pathway, Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma",2016-05-10,apitolisib,True,['Genentech'],0,Germany,21,13,9,1,0,1,0,1,0,0,0,0,0,0,0,0
Incidence and Predictive Factors for Recovery of Ovarian Function in Amenorrheic Women in Their 40s Treated With Letrozole,2016-05-10,letrozole,True,['Novartis'],0,USA,14,2,0,1,1,1,0,1,0,0,0,1,0,0,0,0
Twelve-Month Estrogen Levels in Premenopausal Women With Hormone Receptorâ€“Positive Breast Cancer Receiving Adjuvant Triptorelin Plus Exemestane or Tamoxifen in the Suppression of Ovarian Function Trial (SOFT): The SOFT-EST Substudy,2016-05-10,triptorelin,False,[],0,Hungary,20,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Phase I and II Study of Induction Chemotherapy With Methotrexate, Rituximab, and Temozolomide, Followed By Whole-Brain Radiotherapy and Postirradiation Temozolomide for Primary CNS Lymphoma: NRG Oncology RTOG 0227",2016-05-10,temozolomide,False,[],0,USA,14,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment,2016-05-01,bortezomib,True,['Takeda Pharmaceuticals'],0,Spain,21,8,0,3,1,3,0,1,0,0,0,0,0,0,0,1
Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab,2016-05-01,pembrolizumab,True,"['Merck (I)', 'Merck Serono', 'Merck Sharp & Dohme', 'Merck']",0,USA,21,18,6,8,0,2,1,1,0,0,1,1,0,0,0,0
"Docetaxel As Monotherapy or Combined With Ramucirumab or Icrucumab in Second-Line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma: An Open-Label, Three-Arm, Randomized Controlled Phase II Trial",2016-05-01,ramucirumab,True,"['Eli Lilly/ImClone', 'Eli Lilly']",0,USA,22,11,6,1,0,1,1,1,0,0,0,1,0,0,1,0
"Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction",2016-05-01,apatinib,True,['Jiangsu Hengrui Medicine'],0,China,34,1,1,1,1,1,0,0,0,0,0,0,0,0,0,0
Use of a Comprehensive Geriatric Assessment for the Management of Elderly Patients With Advanced Nonâ€“Small-Cell Lung Cancer: The Phase III Randomized ESOGIA-GFPC-GECP 08-02 Study,2016-05-01,carboplatin,False,[],0,Spain,23,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Phase II Study of Autologous Monocyte-Derived mRNA Electroporated Dendritic Cells (TriMixDC-MEL) Plus Ipilimumab in Patients With Pretreated Advanced Melanoma,2016-04-20,ipilimumab,True,['Bristol-Myers Squibb'],0,the Netherlands,8,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1
Morbidity and Mortality of Laparoscopic Versus Open D2 Distal Gastrectomy for Advanced Gastric Cancer: A Randomized Controlled Trial,2016-04-20,,False,[],0,China,26,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Interim Positron Emission Tomography Responseâ€“Adapted Therapy in Advanced-Stage Hodgkin Lymphoma: Final Results of the Phase II Part of the HD0801 Study,2016-04-20,"ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine)",False,[],0,Italy,28,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Phase I Study of the Aurora A Kinase Inhibitor Alisertib in Combination With Irinotecan and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma: A NANT (New Approaches to Neuroblastoma Therapy) Trial,2016-04-20,alisertib,True,['Millennium Pharmaceuticals'],0,USA,19,4,0,0,0,0,1,0,0,0,0,0,0,0,0,0
Influence of the Acidic Beverage Cola on the Absorption of Erlotinib in Patients With Nonâ€“Small-Cell Lung Cancer,2016-04-20,erlotinib,True,"['Roche', 'Roche Pharma']",0,the Netherlands,13,5,0,2,1,1,1,1,0,0,0,0,0,0,0,0
"A Randomized, Open-Label, Multicenter, Phase III Study of Epoetin Alfa Versus Best Standard of Care in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy",2016-04-10,epoetin alfa,True,['Amgen'],0,USA,23,1,0,1,0,0,1,0,0,0,1,0,0,0,0,0
Long-Term Results of the HD2000 Trial Comparing ABVD Versus BEACOPP Versus COPP-EBV-CAD in Untreated Patients With Advanced Hodgkin Lymphoma: A Study by Fondazione Italiana Linfomi,2016-04-10,,False,[],0,Italy,16,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I Study,2016-04-01,blinatumomab,True,"['Amgen Research (Munich)', 'Executive Director at Amgen Research (Munich)', 'Amgen']",0,USA,24,14,7,4,0,5,1,1,0,0,0,1,0,0,0,1
First-in-Human Phase I/II Study of NEOD001 in Patients With Light Chain Amyloidosis and Persistent Organ Dysfunction,2016-04-01,NEOD001,True,"['Prothena Therapeutics', 'Prothena Corporation', 'Prothena Biosciences']",0,USA,14,12,4,7,0,1,1,1,0,0,1,1,0,0,1,0
Final Results of the Sunbelt Melanoma Trial: A Multi-Institutional Prospective Randomized Phase III Study Evaluating the Role of Adjuvant High-Dose Interferon Alfa-2b and Completion Lymph Node Dissection for Patients Staged by Sentinel Lymph Node Biopsy,2016-04-01,interferon alfa-2b,True,['Merck'],0,USA,17,2,0,2,1,1,0,0,0,0,0,0,0,0,0,0
Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2Ã¢â‚¬â€œPositive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial,2016-04-01,lapatinib,True,['GlaxoSmithKline'],0,USA,35,13,1,2,0,3,0,0,0,0,0,0,0,0,0,0
Translational Breast Cancer Research Consortium (TBCRC) 022: A Phase II Trial of Neratinib for Patients With Human Epidermal Growth Factor Receptor 2â€“Positive Breast Cancer and Brain Metastases,2016-03-20,neratinib,True,['Puma Biotechnology'],0,USA,24,4,0,0,0,0,1,0,0,0,0,0,0,0,0,0
Gemtuzumab Ozogamicin Versus Best Supportive Care in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Unsuitable for Intensive Chemotherapy: Results of the Randomized Phase III EORTC-GIMEMA AML-19 Trial,2016-03-20,gemtuzumab ozogamicin,True,['Pfizer'],0,the Netherlands,24,2,0,2,1,1,0,0,0,0,0,0,0,0,0,0
PROCLAIM: Randomized Phase III Trial of Pemetrexed-Cisplatin or Etoposide-Cisplatin Plus Thoracic Radiation Therapy Followed by Consolidation Chemotherapy in Locally Advanced Nonsquamous Nonâ€“Small-Cell Lung Cancer,2016-03-20,pemetrexed,True,"['Eli Lilly', 'Lilly Oncology']",0,France,21,15,6,7,2,5,1,1,0,0,0,1,0,0,0,0
Cost-Effectiveness of Pertuzumab in Human Epidermal Growth Factor Receptor 2Ã¢â‚¬â€œPositive Metastatic Breast Cancer,2016-03-20,pertuzumab,False,[],0,Stanford CA,10,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Overall Survival and Durable Responses in Patients With BRAF V600â€“Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib,2016-03-10,dabrafenib and trametinib,True,['GlaxoSmithKline'],0,USA,26,17,4,4,0,2,1,1,0,0,1,1,0,0,0,0
"Atezolizumab, an Antiâ€“Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study",2016-03-10,atezolizumab,False,[],0,United Kingdom,14,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Cardioprotection and Safety of Dexrazoxane in Patients Treated for Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Advanced-Stage Lymphoblastic Non-Hodgkin Lymphoma: A Report of the Childrenâ€™s Oncology Group Randomized Trial Pediatric Oncology Group 9404,2016-03-10,dexrazoxane,True,['Clinigen Group'],0,USA,11,1,0,1,0,0,0,1,0,0,0,1,0,0,0,0
Pan Canadian Rash Trial: A Randomized Phase III Trial Evaluating the Impact of a Prophylactic Skin Treatment Regimen on Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitorâ€“Induced Skin Toxicities in Patients With Metastatic Lung Cancer,2016-03-10,erlotinib,True,"['Roche Canada', 'Roche']",0,Canada,14,4,0,2,0,2,1,1,0,0,0,1,0,0,1,0
Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial,2016-03-10,trabectedin,True,['Eisai'],0,USA,19,3,0,1,0,0,0,1,0,0,0,0,0,0,0,0
CD33 Expression and Its Association With Gemtuzumab Ozogamicin Response: Results From the Randomized Phase III Childrenâ€™s Oncology Group Trial AAML0531,2016-03-01,gemtuzumab ozogamicin,True,['Pfizer'],0,USA,10,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
Volasertib Versus Chemotherapy in Platinum-Resistant or -Refractory Ovarian Cancer: A Randomized Phase II Groupe des Investigateurs Nationaux pour l'Etude des Cancers de l'Ovaire Study,2016-03-01,volasertib,True,['Boehringer Ingelheim'],0,Germany,21,6,5,2,1,1,0,0,0,0,0,0,0,0,0,0
"Randomized Trial Comparing Telephone Versus In-Person Weight Loss Counseling on Body Composition and Circulating Biomarkers in Women Treated for Breast Cancer: The Lifestyle, Exercise, and Nutrition (LEAN) Study",2016-03-01,,True,[],0,USA,9,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Radiotherapy With 4 Gy Ã— 5 Versus 3 Gy Ã— 10 for Metastatic Epidural Spinal Cord Compression: Final Results of the SCORE-2 Trial (ARO 2009/01),2016-02-20,,False,[],0,USA,16,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Pediatric-Like Acute Lymphoblastic Leukemia Therapy in Adults With Lymphoblastic Lymphoma: The GRAALL-LYSA LL03 Study,2016-02-20,,False,[],0,Belgium,23,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Randomized Double-Blind Trial of Pregabalin Versus Placebo in Conjunction With Palliative Radiotherapy for Cancer-Induced Bone Pain,2016-02-20,pregabalin,True,['Pfizer'],0,Norway,8,2,0,0,1,0,1,1,0,0,0,0,0,1,0,0
Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled Trial,2016-02-20,,False,[],0,USA,18,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib",2016-02-20,trastuzumab,True,"['Genentech Roche', 'Genentech/Roche', 'Genentech', 'Roche/Genentech']",0,United Kingdom,18,5,0,2,0,0,1,1,0,0,0,1,0,0,0,0
Rituximab Maintenance for a Maximum of 5 Years After Single-Agent Rituximab Induction in Follicular Lymphoma: Results of the Randomized Controlled Phase III Trial SAKK 35/03,2016-02-10,rituximab,True,['Roche'],0,South Africa,19,6,0,4,0,3,1,1,0,0,1,1,0,0,1,1
Randomized Phase III Trial of Standard Therapy Plus Low Molecular Weight Heparin in Patients With Lung Cancer: FRAGMATIC Trial,2016-02-10,LMWH,True,['Leo Pharma'],0,Ireland,16,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0
Randomized Trial of a Web-Based Intervention to Address Barriers to Clinical Trials,2016-02-10,,False,[],0,USA,20,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Multi-Institutional Phase II Study of High-Dose Hypofractionated Proton Beam Therapy in Patients With Localized, Unresectable Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma",2016-02-10,proton beam therapy,False,[],0,USA,24,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Cetuximab and Radiotherapy Versus Cisplatin and Radiotherapy for Locally Advanced Head and Neck Cancer: A Randomized Phase II Trial,2016-02-10,cisplatin,False,[],0,Italy,19,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Randomized Trial of Low-Dose Morphine Versus Weak Opioids in Moderate Cancer Pain,2016-02-10,morphine,False,[],0,USA,16,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2â€“Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiCâ€”A Randomized Phase III Trial",2016-02-10,lapatinib,True,['GlaxoSmithKline'],0,USA,24,9,4,2,0,1,1,0,0,0,0,0,0,0,0,0
"Correlative Analysis of Genetic Alterations and Everolimus Benefit in Hormone Receptorâ€“Positive, Human Epidermal Growth Factor Receptor 2â€“Negative Advanced Breast Cancer: Results From BOLERO-2",2016-02-10,everolimus,True,"['Novartis', 'Novartis Institute of Biomedical Research', 'Novartis Institute for BioMedical Research', 'Novartis Pharmaceuticals']",0,USA,25,20,9,7,1,3,1,1,0,0,1,1,0,0,0,0
Upfront Genotyping of DPYD*2A to Individualize Fluoropyrimidine Therapy: A Safety and Cost Analysis,2016-01-20,fluorouracil,False,[],0,the Netherlands,12,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Evaluating Intermittent Androgen-Deprivation Therapy Phase III Clinical Trials: The Devil Is in the Details,2016-01-20,,False,[],0,USA,5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Adjuvant Imatinib for High-Risk GI Stromal Tumor: Analysis of a Randomized Trial,2016-01-20,imatinib,True,"['Novartis', 'Novartis (I)']",0,Germany,19,7,0,4,0,6,0,1,0,0,0,1,0,0,0,1
Anastrozole-Induced Carpal Tunnel Syndrome: Results From the International Breast Cancer Intervention Study II Prevention Trial,2016-01-10,anastrozole,True,['AstraZeneca'],0,Australia,5,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0
"Intensive Multiagent Therapy, Including Dose-Compressed Cycles of Ifosfamide/Etoposide and Vincristine/Doxorubicin/Cyclophosphamide, Irinotecan, and Radiation, in Patients With High-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group",2016-01-10,irinotecan,True,['Pfizer'],0,USA,9,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0
"Time to Definitive Failure to the First Tyrosine Kinase Inhibitor in Localized GI Stromal Tumors Treated With Imatinib As an Adjuvant: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Intergroup Randomized Trial in Collaboration With the Australasian Gastro-Intestinal Trials Group, UNICANCER, French Sarcoma Group, Italian Sarcoma Group, and Spanish Group for Research on Sarcomas",2015-12-20,imatinib,True,['Novartis'],0,Belgium,22,9,0,5,2,8,1,1,0,0,1,1,0,0,1,1
"Randomized Phase Ib/II Study of Gemcitabine Plus Placebo or Vismodegib, a Hedgehog Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer",2015-12-20,vismodegib,True,"['Genentech/Roche', 'Genentech', 'Roche/Genentech', 'Roche']",0,USA,24,9,2,6,2,4,1,1,0,0,1,1,0,0,1,0
"Postoperative Adjuvant Lapatinib and Concurrent Chemoradiotherapy Followed by Maintenance Lapatinib Monotherapy in High-Risk Patients With Resected Squamous Cell Carcinoma of the Head and Neck: A Phase III, Randomized, Double-Blind, Placebo-Controlled Study",2015-12-10,lapatinib,True,"['GlaxoSmithKline', 'GlaxoSmithKline Biologicals', 'GlaxoSmithKline Oncology']",0,Switzerland,25,11,9,0,0,0,0,0,0,0,0,0,0,0,0,0
Phase III Study of Surgery Versus Definitive Concurrent Chemoradiotherapy Boost in Patients With Resectable Stage IIIA(N2) and Selected IIIB Nonâ€“Small-Cell Lung Cancer After Induction Chemotherapy and Concurrent Chemoradiotherapy (ESPATUE),2015-12-10,cisplatin,False,[],0,the Netherlands,22,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Randomized Comparison of Surveillance Intervals in Familial Colorectal Cancer,2015-12-10,,False,[],0,the Netherlands,27,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Phase II Study of Allogeneic Transplantation for Older Patients With Acute Myeloid Leukemia in First Complete Remission Using a Reduced-Intensity Conditioning Regimen: Results From Cancer and Leukemia Group B 100103 (Alliance for Clinical Trials in Oncology)/Blood and Marrow Transplant Clinical Trial Network 0502,2015-12-10,,False,[],0,USA,20,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study",2015-12-10,oxaliplatin,True,['Sanofi'],0,Germany,25,6,0,5,0,3,1,1,0,0,1,1,0,0,1,1
Acute Toxicity and Quality of Life After Dose-Intensified Salvage Radiation Therapy for Biochemically Recurrent Prostate Cancer After Prostatectomy: First Results of the Randomized Trial SAKK 09/10,2015-12-10,,False,[],0,Belgium,24,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Adjuvant Hormone Therapy May Improve Survival in Epithelial Ovarian Cancer: Results of the AHT Randomized Trial,2015-12-10,hormone-replacement therapy (HRT),False,[],0,Hungary,12,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
International Atomic Energy Agency Randomized Phase III Study of Radiation Therapy in Elderly and/or Frail Patients With Newly Diagnosed Glioblastoma Multiforme,2015-12-10,,False,[],0,Austria,14,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Clinical Utility of Metrics Based on Tumor Measurements in Phase II Trials to Predict Overall Survival Outcomes in Phase III Trials by Using Resampling Methods,2015-12-01,,False,[],0,Belgium,6,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Intermittent High-Dose Intravenous Interferon Alfa-2b for Adjuvant Treatment of Stage III Melanoma: Final Analysis of a Randomized Phase III Dermatologic Cooperative Oncology Group Trial,2015-12-01,interferon alfa-2b,True,"['Merck', 'Merck Serono', 'Merck Sharp & Dohme']",0,Switzerland,21,13,0,8,0,9,1,1,0,0,1,0,0,0,1,1
Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer,2015-12-01,vemurafenib,True,"['Roche', 'Roche/Genentech']",0,Australia,17,4,0,2,0,1,1,1,0,0,1,1,0,0,0,0
Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600â€“Mutant Colorectal Cancer,2015-12-01,dabrafenib,True,['GlaxoSmithKline'],0,USA,20,16,7,2,1,1,1,1,0,0,0,1,0,0,1,0
"Safety and Antitumor Activity of Antiâ€“PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer",2015-12-01,nivolumab,True,['Bristol-Myers Squibb'],0,Japan,21,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
"Randomized, Double-Blind, Phase II Study of Ruxolitinib or Placebo in Combination With Capecitabine in Patients With Metastatic Pancreatic Cancer for Whom Therapy With Gemcitabine Has Failed",2015-12-01,ruxolitinib,True,['Incyte Corporation'],0,USA,17,17,6,1,0,0,1,1,0,1,1,0,0,0,0,0
Double-Blind Phase III Randomized Trial of the Antiprogestin Agent Mifepristone in the Treatment of Unresectable Meningioma: SWOG S9005,2015-12-01,mifepristone,False,[],0,USA,13,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Effect of Granulocyte-Macrophage Colony-Stimulating Factor on Prevention and Treatment of Invasive Fungal Disease in Recipients of Allogeneic Stem-Cell Transplantation: A Prospective Multicenter Randomized Phase IV Trial,2015-12-01,GM-CSF,False,[],0,China,11,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Randomized, Placebo-Controlled, Phase III Trial of Yeast-Derived Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Versus Peptide Vaccination Versus GM-CSF Plus Peptide Vaccination Versus Placebo in Patients With No Evidence of Disease After Complete Surgical Resection of Locally Advanced and/or Stage IV Melanoma: A Trial of the Eastern Cooperative Oncology GroupÃ¢â‚¬â€œAmerican College of Radiology Imaging Network Cancer Research Group (E4697)",2015-12-01,granulocyte-macrophage colony-stimulating factor (GM-CSF),True,['Amgen'],0,USA,11,5,0,3,0,0,1,0,0,0,0,0,0,0,0,0
"Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA NonÃ¢â‚¬â€œSmall-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial",2015-12-01,erlotinib,False,[],0,Canada,16,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Computerized Cognitive Training for Amelioration of Cognitive Late Effects Among Childhood Cancer Survivors: A Randomized Controlled Trial,2015-11-20,computerized cognitive training program,False,[],0,USA,12,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Randomized Multicenter Phase II Study of Modified Docetaxel, Cisplatin, and Fluorouracil (DCF) Versus DCF Plus Growth Factor Support in Patients With Metastatic Gastric Adenocarcinoma: A Study of the US Gastric Cancer Consortium",2015-11-20,docetaxel,True,['sanofi-aventis'],0,USA,13,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0
Surgical Excision Without Radiation for Ductal Carcinoma in Situ of the Breast: 12-Year Results From the ECOG-ACRIN E5194 Study,2015-11-20,tamoxifen,False,[],0,USA,12,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Randomized, Double-Blind Phase II Trial With Prospective Classification by ATM Protein Level to Evaluate the Efficacy and Tolerability of Olaparib Plus Paclitaxel in Patients With Recurrent or Metastatic Gastric Cancer",2015-11-20,olaparib,True,['AstraZeneca'],0,China,16,11,5,1,0,1,1,0,0,0,1,0,0,0,1,0
"Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma",2015-11-20,,False,[],0,France,27,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Community-Based Phase IIIB Trial of Three UPFRONT Bortezomib-Based Myeloma Regimens,2015-11-20,bortezomib,True,"['Takeda Pharmaceuticals', 'a wholly owned subsidiary of Takeda Pharmaceutical', 'Takeda Pharmaceutical']",0,USA,15,7,3,0,0,0,1,0,0,0,0,0,0,0,0,0
High Doses of Antimetabolites Followed by High-Dose Sequential Chemoimmunotherapy and Autologous Stem-Cell Transplantation in Patients With Systemic B-Cell Lymphoma and Secondary CNS Involvement: Final Results of a Multicenter Phase II Trial,2015-11-20,rituximab,False,[],0,Italy,18,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Epirubicin Plus Cyclophosphamide Followed by Docetaxel Versus Epirubicin Plus Docetaxel Followed by Capecitabine As Adjuvant Therapy for Node-Positive Early Breast Cancer: Results From the GEICAM/2003-10 Study,2015-11-10,capecitabine,True,"['Roche', 'Roche (I)']",0,Spain,30,7,0,4,2,3,1,0,0,0,1,0,0,0,0,0
Fulvestrant 500 mg Versus Anastrozole 1 mg for the First-Line Treatment of Advanced Breast Cancer: Overall Survival Analysis From the Phase II FIRST Study,2015-11-10,fulvestrant,True,['AstraZeneca'],0,Poland,8,6,2,3,0,2,1,1,0,0,1,1,0,0,0,1
Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer: Final Results of the NO16968 Randomized Controlled Phase III Trial,2015-11-10,capecitabine,True,"['Roche', 'Hoffmann-La Roche (non-voting stock)']",0,USA,10,8,1,3,1,3,0,0,0,0,0,0,0,0,0,0
"Bevacizumab Combined With Weekly Paclitaxel, Pegylated Liposomal Doxorubicin, or Topotecan in Platinum-Resistant Recurrent Ovarian Cancer: Analysis by Chemotherapy Cohort of the Randomized Phase III AURELIA Trial",2015-11-10,,False,[],1,Spain,11,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Impact of Subsequent Therapies on Outcome of the FIRE-3/AIO KRK0306 Trial: First-Line Therapy With FOLFIRI Plus Cetuximab or Bevacizumab in Patients With KRAS Wild-Type Tumors in Metastatic Colorectal Cancer,2015-11-10,cetuximab,True,"['Eli Lilly/ImClone', 'Eli Lilly']",0,Austria,19,3,0,2,0,3,0,1,0,0,0,1,0,0,0,1
Results of a Phase II Trial of Brentuximab Vedotin for CD30+ Cutaneous T-Cell Lymphoma and Lymphomatoid Papulosis,2015-11-10,brentuximab vedotin,True,"['Seattle Genetics', 'Seattle Genetics (I)']",0,USA,6,2,0,2,0,0,1,0,0,0,1,0,0,0,0,0
Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and SÃ©zary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project,2015-11-10,brentuximab vedotin,True,['Seattle Genetics'],0,USA,17,3,0,2,0,0,1,1,0,0,1,1,0,0,0,0
Feasibility of Preoperative Chemotherapy With or Without Radiation Therapy in Localized Soft Tissue Sarcomas of Limbs and Superficial Trunk in the Italian Sarcoma Group/Grupo EspaÃ±ol de InvestigaciÃ³n en Sarcomas Randomized Clinical Trial: Three Versus Five Cycles of Full-Dose Epirubicin Plus Ifosfamide,2015-11-01,epirubicin,False,[],0,Spain,16,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Impact of an Automatically Generated Cancer Survivorship Care Plan on Patient-Reported Outcomes in Routine Clinical Practice: Longitudinal Outcomes of a Pragmatic, Cluster Randomized Trial",2015-11-01,,False,[],0,the Netherlands,18,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Randomized Trial of Lenalidomide Alone Versus Lenalidomide Plus Rituximab in Patients With Recurrent Follicular Lymphoma: CALGB 50401 (Alliance),2015-11-01,lenalidomide,True,['Celgene'],0,USA,9,5,0,3,0,0,1,1,0,0,1,1,0,0,0,0
Electronic Trigger-Based Intervention to Reduce Delays in Diagnostic Evaluation for Cancer: A Cluster Randomized Controlled Trial,2015-11-01,,True,[],0,USA,6,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Coffee Intake, Recurrence, and Mortality in Stage III Colon Cancer: Results From CALGB 89803 (Alliance)",2015-11-01,,False,[],0,USA,21,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Obesity, Aspirin, and Risk of Colorectal Cancer in Carriers of Hereditary Colorectal Cancer: A Prospective Investigation in the CAPP2 Study",2015-11-01,aspirin,False,[],0,the Netherlands,25,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Randomized Phase II Trial of Ridaforolimus in Advanced Endometrial Carcinoma,2015-11-01,ridaforolimus,True,['ARIAD Pharmaceuticals'],0,USA,11,2,2,0,0,0,0,1,0,1,0,0,0,0,0,0
Electroacupuncture Versus Gabapentin for Hot Flashes Among Breast Cancer Survivors: A Randomized Placebo-Controlled Trial,2015-11-01,gabapentin,False,[],0,USA,6,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Phase I Dose-Escalation Study of JNJ-42756493, an Oral Panâ€“Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors",2015-10-20,erdafitinib,True,"['Janssen Pharmaceutical Companies of Johnson & Johnson', 'Janssen']",0,Belgium,19,10,6,4,0,1,0,1,0,0,0,1,0,0,0,1
"Trebananib (AMG 386) in Combination With Sunitinib in Patients With Metastatic Renal Cell Cancer: An Open-Label, Multicenter, Phase II Study",2015-10-20,trebananib,True,['Amgen'],0,USA,12,7,3,1,0,0,1,1,0,0,1,0,0,0,0,0
Continuous Therapy Versus Fixed Duration of Therapy in Patients With Newly Diagnosed Multiple Myeloma,2015-10-20,,False,[],0,Greece,28,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Randomized Phase II Trial Comparing Obinutuzumab (GA101) With Rituximab in Patients With Relapsed CD20+ Indolent B-Cell Non-Hodgkin Lymphoma: Final Analysis of the GAUSS Study,2015-10-20,obinutuzumab,True,"['Genentech/Roche', 'Genentech', 'F. Hoffmann-LaRoche', 'Roche/Genentech', 'Roche']",0,USA,20,11,3,2,0,3,1,1,0,0,1,0,0,0,1,0
Clinical Course of Oxaliplatin-Induced Neuropathy: Results From the Randomized Phase III Trial N08CB (Alliance),2015-10-20,oxaliplatin,True,['Sanofi'],0,USA,13,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
A Practical Solution for Dyspareunia in Breast Cancer Survivors: A Randomized Controlled Trial,2015-10-20,lidocaine,False,[],0,USA,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Phase I Study of Single-Agent AZD1775 (MK-1775), a Wee1 Kinase Inhibitor, in Patients With Refractory Solid Tumors",2015-10-20,AZD1775,True,['Merck'],0,USA,10,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0
Axillary Ultrasound After Neoadjuvant Chemotherapy and Its Impact on Sentinel Lymph Node Surgery: Results From the American College of Surgeons Oncology Group Z1071 Trial (Alliance),2015-10-20,,False,[],0,USA,8,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Results of the Exercise and Nutrition to Enhance Recovery and Good Health for You (ENERGY) Trial: A Behavioral Weight Loss Intervention in Overweight or Obese Breast Cancer Survivors,2015-10-01,,False,[],0,USA,15,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Effects of Music Therapy on Anesthesia Requirements and Anxiety in Women Undergoing Ambulatory Breast Surgery for Cancer Diagnosis and Treatment: A Randomized Controlled Trial,2015-10-01,,False,[],0,USA,5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Phase III Trial to Compare Adjuvant Chemotherapy With Capecitabine and Cisplatin Versus Concurrent Chemoradiotherapy in Gastric Cancer: Final Report of the Adjuvant Chemoradiotherapy in Stomach Tumors Trial, Including Survival and Subset Analyses",2015-10-01,capecitabine,False,[],0,South Korea,17,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Quality of Life and Cost-Effectiveness Assessment of Radioiodine Ablation Strategies in Patients With Thyroid Cancer: Results From the Randomized Phase III ESTIMABL Trial,2015-09-10,recombinant human TSH,True,['Genzyme'],0,France,21,6,0,2,0,4,0,1,0,0,0,1,0,0,0,1
Paclitaxel Given Once Per Week With or Without Bevacizumab in Patients With Advanced Angiosarcoma: A Randomized Phase II Trial,2015-09-01,bevacizumab,True,['Genentech'],0,France,20,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Relative Effectiveness of Letrozole Compared With Tamoxifen for Patients With Lobular Carcinoma in the BIG 1-98 Trial,2015-09-01,letrozole,True,"['Novartis', 'Novartis (I)']",0,Australia,15,6,0,0,1,1,0,0,0,0,0,0,0,0,0,0
Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma,2015-09-01,talimogene laherparepvec,True,"['Amgen (Consultant)', 'Amgen']",0,USA,29,21,6,10,2,5,1,1,0,1,1,1,0,0,1,0
BREATH: Web-Based Self-Management for Psychological Adjustment After Primary Breast CancerÃ¢â‚¬â€Results of a Multicenter Randomized Controlled Trial,2015-09-01,,False,[],0,the Netherlands,6,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Phase II Study of Lapatinib in Combination With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2â€“Positive Metastatic Breast Cancer: Clinical Outcomes and Predictive Value of Early [18F]Fluorodeoxyglucose Positron Emission Tomography Imaging (TBCRC 003),2015-08-20,trastuzumab,True,"['Genentech/Roche', 'Genentech']",0,USA,18,6,0,2,0,0,1,0,0,0,1,0,0,0,0,0
Vismodegib Exerts Targeted Efficacy Against Recurrent Sonic Hedgehogâ€“Subgroup Medulloblastoma: Results From Phase II Pediatric Brain Tumor Consortium Studies PBTC-025B and PBTC-032,2015-08-20,vismodegib,True,['Genentech'],0,USA,23,5,0,1,0,1,0,1,0,0,0,0,0,0,0,0
"Phase III Multinational, Randomized, Double-Blind, Placebo-Controlled Study of Tivantinib (ARQ 197) Plus Erlotinib Versus Erlotinib Alone in Previously Treated Patients With Locally Advanced or Metastatic Nonsquamous Nonâ€“Small-Cell Lung Cancer",2015-08-20,tivantinib,True,['ArQule'],0,USA,19,3,1,0,0,0,0,1,0,1,0,0,0,0,0,0
Multinational Randomized Phase III Trial With or Without Consolidation Chemotherapy Using Docetaxel and Cisplatin After Concurrent Chemoradiation in Inoperable Stage III Nonâ€“Small-Cell Lung Cancer: KCSG-LU05-04,2015-08-20,docetaxel,True,['Sanofi'],0,China,23,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0
Phase I Imaging and Pharmacodynamic Trial of CS-1008 in Patients With Metastatic Colorectal Cancer,2015-08-20,tigatuzumab,True,['Daiichi Sankyo'],0,USA,22,10,8,0,0,0,1,1,1,0,0,0,0,0,0,0
Late Mortality After Dexrazoxane Treatment: A Report From the Children's Oncology Group,2015-08-20,dexrazoxane,True,['Clinigen Group'],0,USA,12,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
SWOG S0809: A Phase II Intergroup Trial of Adjuvant Capecitabine and Gemcitabine Followed by Radiotherapy and Concurrent Capecitabine in Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma,2015-08-20,gemcitabine,False,[],0,USA,13,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study,2015-08-10,belinostat,True,['Spectrum Pharmaceuticals'],0,USA,17,8,3,4,0,1,1,1,0,0,1,1,0,0,0,0
Pemetrexed Plus Cisplatin Versus Gemcitabine Plus Cisplatin According to Thymidylate Synthase Expression in Nonsquamous Nonâ€“Small-Cell Lung Cancer: A Biomarker-Stratified Randomized Phase II Trial,2015-08-01,pemetrexed,True,['Eli Lilly'],0,USA,8,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
Mapisal Versus Urea Cream as Prophylaxis for Capecitabine-Associated Hand-Foot Syndrome: A Randomized Phase III Trial of the AIO Quality of Life Working Group,2015-08-01,capecitabine,True,['Roche'],0,Germany,12,2,0,1,0,2,1,0,0,0,1,0,0,0,1,0
Impact of Bleomycin and Vincristine Dose Reductions in Patients With Advanced Hodgkin Lymphoma Treated With BEACOPP: An Analysis of the German Hodgkin Study Group HD12 and HD15 Trials,2015-08-01,bleomycin,False,[],0,Germany,9,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Phase II Trial Assessing the Ability of Neoadjuvant Chemotherapy With or Without Second-Look Surgery to Eliminate Measurable Disease for Nongerminomatous Germ Cell Tumors: A Children's Oncology Group Study,2015-08-01,carboplatin,False,[],0,USA,11,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Phase II Intergroup Trial of Alisertib in Relapsed and Refractory Peripheral T-Cell Lymphoma and Transformed Mycosis Fungoides: SWOG 1108,2015-07-20,alisertib,True,['Millennium'],0,USA,16,5,0,3,0,1,1,1,0,0,1,0,0,0,0,0
"BEST: A Randomized Phase II Study of Vascular Endothelial Growth Factor, RAF Kinase, and Mammalian Target of Rapamycin Combination Targeted Therapy With Bevacizumab, Sorafenib, and Temsirolimus in Advanced Renal Cell Carcinomaâ€”A Trial of the ECOGâ€“ACRIN Cancer Research Group (E2804)",2015-07-20,bevacizumab,True,"['Genentech/Roche', 'Genentech']",0,USA,9,5,0,4,1,0,1,0,0,0,1,0,0,0,0,0
Long-Term Follow-Up of the E1199 Phase III Trial Evaluating the Role of Taxane and Schedule in Operable Breast Cancer,2015-07-20,paclitaxel,False,[],0,USA,10,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Randomized Phase III Trial of Paclitaxel Once Per Week Compared With Nanoparticle Albumin-Bound Nab-Paclitaxel Once Per Week or Ixabepilone With Bevacizumab As First-Line Chemotherapy for Locally Recurrent or Metastatic Breast Cancer: CALGB 40502/NCCTG N063H (Alliance),2015-07-20,nab-paclitaxel,True,['Celgene'],0,USA,13,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
"Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial",2015-07-10,pegylated interferon alfa-2b,True,"['Merck', 'Merck Sharp & Dohme']",0,Belgium,49,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Significant Reduction of Late Toxicities in Patients With Extremity Sarcoma Treated With Image-Guided Radiation Therapy to a Reduced Target Volume: Results of Radiation Therapy Oncology Group RTOG-0630 Trial,2015-07-10,image-guided radiation therapy (IGRT),False,[],0,USA,15,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Health-Related Quality of Life in a Randomized Phase III Study of Bevacizumab, Temozolomide, and Radiotherapy in Newly Diagnosed Glioblastoma",2015-07-01,bevacizumab,True,"['Genentech/Roche', 'F. Hofmann-La Roche', 'F. Hoffmann-La Roche/Genentech', 'F. Hoffmann-La Roche', 'F. Hoffmann-La Roche (I)', 'Roche']",0,France,12,12,3,8,1,3,1,1,0,0,1,1,0,1,0,1
Impact of Radiotherapy When Added to Androgen-Deprivation Therapy for Locally Advanced Prostate Cancer: Long-Term Quality-of-Life Outcomes From the NCIC CTG PR3/MRC PR07 Randomized Trial,2015-07-01,androgen-deprivation therapy (ADT),False,[],0,United Kingdom,14,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"BEYOND: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of First-Line Carboplatin/Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients With Advanced or Recurrent Nonsquamous Nonâ€“Small-Cell Lung Cancer",2015-07-01,bevacizumab,True,"['F. Hoffmann-La Roche', 'Roche (China) Holding']",0,China,19,6,2,0,0,4,1,1,0,1,0,0,0,0,1,0
Weight Lifting and Physical Function Among Survivors of Breast Cancer: A Post Hoc Analysis of a Randomized Controlled Trial,2015-07-01,,True,[],0,USA,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Paclitaxel Plus Carboplatin Versus Paclitaxel Plus Cisplatin in Metastatic or Recurrent Cervical Cancer: The Open-Label Randomized Phase III Trial JCOG0505,2015-07-01,cisplatin,False,[],0,Japan,11,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Final Report of the Intergroup Randomized Study of Combined Androgen-Deprivation Therapy Plus Radiotherapy Versus Androgen-Deprivation Therapy Alone in Locally Advanced Prostate Cancer,2015-07-01,,False,[],0,USA,23,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Efficacy of Prophylactic Lowâ€“Molecular Weight Heparin for Ambulatory Patients With Advanced Pancreatic Cancer: Outcomes From the CONKO-004 Trial,2015-06-20,enoxaparin,False,[],0,Germany,15,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Identification of a Low-Risk Luminal A Breast Cancer Cohort That May Not Benefit From Breast Radiotherapy,2015-06-20,tamoxifen,False,['NanoString Technologies'],0,Canada,14,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Overall Survival and Long-Term Safety of Nivolumab (Antiâ€“Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Nonâ€“Small-Cell Lung Cancer",2015-06-20,nivolumab,True,"['Bristol-Myers Squibb', 'Bristol-Myers Squibb (I)', 'Bristol-Myers Squibb (former)', 'Bristol-Myers Squibb/Medarex']",0,USA,29,21,7,9,1,3,1,1,0,0,1,1,0,0,1,0
"Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab",2015-06-20,nivolumab,True,"['Bristol-Myers Squibb', 'Bristol-Myers Squibb (I)', 'Bristol-Myer Squibb', 'Bristol-Myers Squibb/Medarex']",0,USA,21,20,5,6,1,2,1,1,0,0,1,0,0,0,0,1
Randomized Multicenter Placebo-Controlled Trial of Omega-3 Fatty Acids for the Control of Aromatase Inhibitorâ€“Induced Musculoskeletal Pain: SWOG S0927,2015-06-10,omega-3 fatty acids,False,[],0,USA,13,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Effect of Low-Intensity Physical Activity and Moderate- to High-Intensity Physical Exercise During Adjuvant Chemotherapy on Physical Fitness, Fatigue, and Chemotherapy Completion Rates: Results of the PACES Randomized Clinical Trial",2015-06-10,,False,[],0,the Netherlands,18,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Symptoms and Distress in Children With Advanced Cancer: Prospective Patient-Reported Outcomes From the PediQUEST Study,2015-06-10,,False,[],0,Argentina,9,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Randomized Phase III Trial Comparing ABVD Plus Radiotherapy With the Stanford V Regimen in Patients With Stages I or II Locally Extensive, Bulky Mediastinal Hodgkin Lymphoma: A Subset Analysis of the North American Intergroup E2496 Trial",2015-06-10,ABVD chemotherapy regimen,False,[],0,USA,18,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Phase II Study of Gemcitabine, Carboplatin, and Iniparib As Neoadjuvant Therapy for Triple-Negative and BRCA1/2 Mutationâ€“Associated Breast Cancer With Assessment of a Tumor-Based Measure of Genomic Instability: PrECOG 0105",2015-06-10,iniparib,True,['sanofi-aventis'],0,USA,21,4,0,0,0,0,1,1,0,0,0,0,0,0,0,0
TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer,2015-06-10,cisplatin,False,[],0,USA,19,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Donepezil for Irradiated Brain Tumor Survivors: A Phase III Randomized Placebo-Controlled Clinical Trial,2015-05-20,donepezil,False,['Astellas Pharma'],0,USA,13,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0
Phase I/II Study of HSP90 Inhibitor AUY922 and Erlotinib for EGFR-Mutant Lung Cancer With Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors,2015-05-20,AUY922,True,['Novartis'],0,USA,8,3,0,2,0,0,1,1,0,0,0,1,0,0,0,0
"Chemotherapy With or Without Maintenance Sunitinib for Untreated Extensive-Stage Small-Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase II Studyâ€”CALGB 30504 (Alliance)",2015-05-20,sunitinib,True,['Pfizer'],0,USA,12,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Human Epidermal Growth Factor Receptor 2 (HER2) Ã¢â‚¬â€œSpecific Chimeric Antigen ReceptorÃ¢â‚¬â€œModified T Cells for the Immunotherapy of HER2-Positive Sarcoma,2015-05-20,HER2-CAR T cells,False,[],0,Germany,26,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
SWOG S0925: A Randomized Phase II Study of Androgen Deprivation Combined With Cixutumumab Versus Androgen Deprivation Alone in Patients With New Metastatic Hormone-Sensitive Prostate Cancer,2015-05-10,Cixutumumab,True,"['Eli Lilly', 'ImClone Systems', 'Eli Lilly/ImClone Systems']",0,USA,19,4,0,1,0,1,1,0,0,0,0,0,0,0,0,0
Lapatinib or Trastuzumab Plus Taxane Therapy for Human Epidermal Growth Factor Receptor 2â€“Positive Advanced Breast Cancer: Final Results of NCIC CTG MA.31,2015-05-10,lapatinib,True,['GlaxoSmithKline'],0,Brazil,27,7,2,3,1,2,1,0,0,0,1,0,0,0,0,0
Multicenter Phase II Trial of Temsirolimus and Bevacizumab in Pancreatic Neuroendocrine Tumors,2015-05-10,temsirolimus,True,['Pfizer'],0,USA,11,4,0,1,0,1,1,1,0,0,1,0,0,0,0,0
EMERGE: A Randomized Phase II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Advanced Glycoprotein NMBÃ¢â‚¬â€œExpressing Breast Cancer,2015-05-10,Glembatumumab vedotin,False,[],0,USA,20,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"CEREBEL (EGF111438): A Phase III, Randomized, Open-Label Study of Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in Patients With Human Epidermal Growth Factor Receptor 2Ã¢â‚¬â€œPositive Metastatic Breast Cancer",2015-05-10,lapatinib,False,[],0,USA,21,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Low Serum Vitamin D Levels Are Associated With Inferior Survival in Follicular Lymphoma: A Prospective Evaluation in SWOG and LYSA Studies,2015-05-01,rituximab,True,"['Genentech', 'Roche/Genentech']",0,USA,15,5,0,2,0,2,0,1,0,0,0,0,0,0,0,0
Early Versus Delayed Initiation of Concurrent Palliative Oncology Care: Patient Outcomes in the ENABLE III Randomized Controlled Trial,2015-05-01,,False,[],0,USA,12,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Benefits of Early Versus Delayed Palliative Care to Informal Family Caregivers of Patients With Advanced Cancer: Outcomes From the ENABLE III Randomized Controlled Trial,2015-05-01,,False,[],0,USA,12,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Randomized Phase II Trial of Gemcitabine Plus TH-302 Versus Gemcitabine in Patients With Advanced Pancreatic Cancer,2015-05-01,TH-302,True,['Threshold Pharmaceuticals'],0,USA,17,7,2,1,0,0,0,1,0,0,0,0,0,0,0,0
Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial,2015-05-01,nivolumab,True,['Bristol-Myers Squibb'],0,USA,15,1,0,1,0,0,1,1,0,0,1,1,0,0,0,0
Circulating Tumor Cell Biomarker Panel As an Individual-Level Surrogate for Survival in Metastatic Castration-Resistant Prostate Cancer,2015-04-20,abiraterone acetate,False,[],0,Belgium,16,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Radiographic Progression-Free Survival As a Response Biomarker in Metastatic Castration-Resistant Prostate Cancer: COU-AA-302 Results,2015-04-20,abiraterone,True,"['Janssen Pharmaceuticals', 'Janssen Pharmaceuticals (U)']",0,Belgium,18,11,6,4,0,1,1,1,1,0,0,0,0,0,0,0
Safety and Survival With GVAX Pancreas Prime and Listeria Monocytogenesâ€“Expressing Mesothelin (CRS-207) Boost Vaccines for Metastatic Pancreatic Cancer,2015-04-20,GVAX pancreas,True,"['Aduro BioTech', 'Through licensing agreement between Aduro BioTech and Johns Hopkins University']",0,USA,22,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0
PIK3CA Mutations Are Associated With Decreased Benefit to Neoadjuvant Human Epidermal Growth Factor Receptor 2â€“Targeted Therapies in Breast Cancer,2015-04-20,trastuzumab,True,"['Genentech', 'Roche-Genentech']",0,USA,21,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
Stem-Cell Transplantation in Children With Acute Lymphoblastic Leukemia: A Prospective International Multicenter Trial Comparing Sibling Donors With Matched Unrelated Donorsâ€”The ALL-SCT-BFM-2003 Trial,2015-04-10,,False,[],0,Switzerland,23,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Phase III Open-Label Randomized Study of Cytarabine in Combination With Amonafide L-Malate or Daunorubicin As Induction Therapy for Patients With Secondary Acute Myeloid Leukemia,2015-04-10,amonafide L-malate,True,"['Antisoma (employee and stock owner 4 years ago', 'Antisoma']",0,USA,22,3,0,2,0,0,1,0,0,0,1,0,0,0,0,0
Inherited NUDT15 Variant Is a Genetic Determinant of Mercaptopurine Intolerance in Children With Acute Lymphoblastic Leukemia,2015-04-10,mercaptopurine,False,[],0,USA,15,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Monitoring of Minimal Residual Disease After Allogeneic Stem-Cell Transplantation in Relapsed Childhood Acute Lymphoblastic Leukemia Allows for the Identification of Impending Relapse: Results of the ALL-BFM-SCT 2003 Trial,2015-04-10,,False,[],0,Austria,18,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Nadir Testosterone Within First Year of Androgen-Deprivation Therapy (ADT) Predicts for Time to Castration-Resistant Progression: A Secondary Analysis of the PR-7 Trial of Intermittent Versus Continuous ADT,2015-04-01,,False,[],0,USA,11,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Five-Year Survival Rates for Treatment-Naive Patients With Advanced Melanoma Who Received Ipilimumab Plus Dacarbazine in a Phase III Trial,2015-04-01,ipilimumab,True,['Bristol-Myers Squibb'],0,USA,12,9,2,7,1,4,1,1,0,0,1,1,0,0,1,0
Feasibility and Cardiac Safety of Trastuzumab Emtansine After Anthracycline-Based Chemotherapy As (neo)Adjuvant Therapy for Human Epidermal Growth Factor Receptor 2â€“Positive Early-Stage Breast Cancer,2015-04-01,trastuzumab emtansine (T-DM1),True,"['Genentech/Roche', 'Genentech', 'Roche/Genentech', 'Roche']",0,USA,11,10,2,2,1,2,1,1,0,0,0,1,0,0,0,0
Psychosocial Telephone Counseling for Survivors of Cervical Cancer: Results of a Randomized Biobehavioral Trial,2015-04-01,,True,[],0,USA,6,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Randomized Phase III Trial of Gemcitabine Plus Docetaxel Plus Bevacizumab or Placebo As First-Line Treatment for Metastatic Uterine Leiomyosarcoma: An NRG Oncology/Gynecologic Oncology Group Study,2015-04-01,bevacizumab,True,['Genentech'],0,USA,7,2,0,1,0,1,0,0,0,0,0,0,0,0,0,0
Randomized Exercise Trial of Aromatase Inhibitorâ€“Induced Arthralgia in Breast Cancer Survivors,2015-04-01,aromatase inhibitors,False,[],0,USA,16,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Phase III Trial Evaluating the Addition of Bevacizumab to Endocrine Therapy As First-Line Treatment for Advanced Breast Cancer: The Letrozole/Fulvestrant and Avastin (LEA) Study,2015-03-20,bevacizumab,True,"['Roche (I)', 'Roche/Genentech', 'Roche']",0,Germany,19,6,0,4,0,4,1,0,0,0,1,0,0,0,1,0
"Molecular Profiling and Targeted Therapy for Advanced Thoracic Malignancies: A Biomarker-Derived, Multiarm, Multihistology Phase II Basket Trial",2015-03-20,erlotinib,True,"['Genentech', 'Genentech/Roche', 'Roche/Genentech']",0,USA,25,3,1,2,2,3,1,0,0,0,1,0,1,0,1,0
Phase I Dose-Escalation Trial of Checkpoint Kinase 1 Inhibitor MK-8776 As Monotherapy and in Combination With Gemcitabine in Patients With Advanced Solid Tumors,2015-03-20,MK-8776,True,['Merck'],0,USA,18,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0
Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2â€“Positive and Triple-Negative Primary Breast Cancers,2015-03-20,carboplatin,False,[],0,France,30,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Symptomatic Toxicities Experienced During Anticancer Treatment: Agreement Between Patient and Physician Reporting in Three Randomized Trials,2015-03-10,,False,[],0,Canada,20,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Transfer of Communication Skills to the Workplace: Impact of a 38-Hour Communication Skills Training Program Designed for Radiotherapy Teams,2015-03-10,,True,[],0,Belgium,15,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Phase II Study of Everolimus and Letrozole in Patients With Recurrent Endometrial Carcinoma,2015-03-10,everolimus,True,['Novartis'],0,USA,13,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0
"Prediction of Late Distant Recurrence After 5 Years of Endocrine Treatment: A Combined Analysis of Patients From the Austrian Breast and Colorectal Cancer Study Group 8 and Arimidex, Tamoxifen Alone or in Combination Randomized Trials Using the PAM50 Risk of Recurrence Score",2015-03-10,ROR score,True,"['NanoString Technologies (U)', 'NanoString Technologies']",0,USA,11,8,2,5,0,1,1,0,1,0,0,0,0,0,0,0
Randomized Controlled Trial of the Prophylactic Effect of Urea-Based Cream on Sorafenib-Associated Hand-Foot Skin Reactions in Patients With Advanced Hepatocellular Carcinoma,2015-03-10,sorafenib,False,[],0,China,16,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Meaning-Centered Group Psychotherapy: An Effective Intervention for Improving Psychological Well-Being in Patients With Advanced Cancer,2015-03-01,,False,[],0,USA,6,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Phase III, Randomized, Double-Blind, Multicenter Trial Comparing Orteronel (TAK-700) Plus Prednisone With Placebo Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer That Has Progressed During or After Docetaxel-Based Therapy: ELM-PC 5",2015-03-01,Orteronel,True,['Millennium Pharmaceuticals'],0,Spain,20,1,0,1,0,0,1,1,0,0,1,1,0,0,0,0
RTOG 9804: A Prospective Randomized Trial for Good-Risk Ductal Carcinoma In Situ Comparing Radiotherapy With Observation,2015-03-01,tamoxifen,False,[],0,Canada,21,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Fluorouracil, Leucovorin, and Irinotecan Plus Cetuximab Treatment and RAS Mutations in Colorectal Cancer",2015-03-01,cetuximab,True,['Merck KGaA'],0,Italy,11,1,0,1,0,1,1,1,0,0,1,1,0,0,1,1
Anxiety and Health-Related Quality of Life Among Patients With Lowâ€“Tumor Burden Non-Hodgkin Lymphoma Randomly Assigned to Two Different Rituximab Dosing Regimens: Results From ECOG Trial E4402 (RESORT),2015-03-01,rituximab,True,['Genentech/Roche'],0,Canada,15,1,0,1,0,0,1,1,0,0,1,1,0,0,0,0
Phase I Study of 30-Minute Infusion of Carfilzomib As Single Agent or in Combination With Low-Dose Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma,2015-03-01,carfilzomib,True,"['Proteolix/Onyx Pharmaceuticals', 'Onyx Pharmaceuticals']",0,USA,10,6,3,2,0,2,1,1,1,0,0,0,0,0,0,0
Genomic Analysis Reveals That Immune Function Genes Are Strongly Linked to Clinical Outcome in the North Central Cancer Treatment Group N9831 Adjuvant Trastuzumab Trial,2015-03-01,trastuzumab,False,[],0,USA,19,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Phase III Open-Label Randomized Study of Eribulin Mesylate Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane,2015-02-20,eribulin,True,"['Eisai', 'Eisai (U)']",0,Spain,10,8,2,4,0,4,1,1,1,0,0,0,0,0,0,0
Utility of Early Screening Magnetic Resonance Imaging for Extensive Hip Osteonecrosis in Pediatric Patients Treated With Glucocorticoids,2015-02-20,,False,[],0,USA,17,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Randomized Phase III Trial Comparing Weekly Docetaxel Plus Cisplatin Versus Docetaxel Monotherapy Every 3 Weeks in Elderly Patients With Advanced Nonâ€“Small-Cell Lung Cancer: The Intergroup Trial JCOG0803/WJOG4307L,2015-02-20,docetaxel,True,['sanofi-aventis'],0,Japan,20,2,0,0,0,2,1,0,0,0,0,0,0,0,1,0
"SEARCH: A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Sorafenib Plus Erlotinib in Patients With Advanced Hepatocellular Carcinoma",2015-02-20,sorafenib,True,"['Bayer', 'Bayer Pharmaceuticals']",0,Republic of Korea,14,12,3,5,0,6,1,1,1,0,0,0,0,0,0,0
Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma and Indolent B-Cell Malignancies Can Be Effectively Treated With Autologous T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor,2015-02-20,anti-CD19 chimeric antigen receptor (CAR) T cells,True,"['Kite Pharma', 'Kite Pharma (U)']",0,USA,26,1,0,1,0,0,1,1,0,0,1,0,0,0,0,0
Randomized Phase II Study of Carboplatin and Paclitaxel With Either Linifanib or Placebo for Advanced Nonsquamous Nonâ€“Small-Cell Lung Cancer,2015-02-10,linifanib,True,['AbbVie'],0,USA,21,9,7,2,0,0,1,0,1,0,0,0,0,0,0,0
Phase II Study of Paclitaxel Given Once per Week Along With Trastuzumab and Pertuzumab in Patients With Human Epidermal Growth Factor Receptor 2â€“Positive Metastatic Breast Cancer,2015-02-10,pertuzumab,False,[],0,USA,20,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Reproducible and Sustained Efficacy of Targeted Therapy With Vemurafenib in Patients With BRAFV600E-Mutated Erdheim-Chester Disease,2015-02-10,vemurafenib,True,['Roche'],0,France,21,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0
Duration of Androgen Suppression Before Radiotherapy for Localized Prostate Cancer: Radiation Therapy Oncology Group Randomized Clinical Trial 9910,2015-02-01,androgen suppression therapy,False,[],0,Canada,16,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Treatment-Associated Musculoskeletal and Vasomotor Symptoms and Relapse-Free Survival in the NCIC CTG MA.27 Adjuvant Breast Cancer Aromatase Inhibitor Trial,2015-01-20,exemestane,False,[],0,Brazil,14,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Sentinel Node Biopsy After Neoadjuvant Chemotherapy in Biopsy-Proven Node-Positive Breast Cancer: The SN FNAC Study,2015-01-20,,False,[],0,USA,19,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Should the Results of the New EPOC Trial Change Practice in the Management of Patients With Resectable Metastatic Colorectal Cancer Confined to the Liver?,2015-01-20,,False,[],1,France,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline BRCA1/2 Mutation,2015-01-20,olaparib,True,['AstraZeneca'],0,USA,16,14,2,2,0,1,1,1,1,0,0,0,0,0,0,0
Lenalidomide Combined With R-CHOP Overcomes Negative Prognostic Impact of Nonâ€“Germinal Center B-Cell Phenotype in Newly Diagnosed Diffuse Large B-Cell Lymphoma: A Phase II Study,2015-01-20,lenalidomide,True,"['Celgene', 'Celgene (U)']",0,USA,16,5,0,3,0,0,1,1,0,0,1,0,0,0,0,0
Institutional Clinical Trial Accrual Volume and Survival of Patients With Head and Neck Cancer,2015-01-10,cisplatin,False,[],0,USA,15,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Randomized Placebo-Controlled Trial of Cognitive Behavioral Therapy and Armodafinil for Insomnia After Cancer Treatment,2015-01-10,armodafinil,False,[],0,Canada,9,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Primary Results of ROSE/TRIO-12, a Randomized Placebo-Controlled Phase III Trial Evaluating the Addition of Ramucirumab to First-Line Docetaxel Chemotherapy in Metastatic Breast Cancer",2015-01-10,ramucirumab,False,[],0,USA,20,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Linifanib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: Results of a Randomized Phase III Trial,2015-01-10,sorafenib,True,['Bayer'],0,Egypt,17,3,0,2,0,2,0,0,0,0,0,0,0,0,0,0
"Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of the Efficacy and Safety of Apricoxib in Combination With Either Docetaxel or Pemetrexed in Patients With Biomarker-Selected NonÃ¢â‚¬â€œSmall-Cell Lung Cancer",2015-01-10,apricoxib,True,['Tragara Pharmaceuticals'],0,USA,15,2,0,0,0,0,0,1,0,0,0,0,0,0,0,0
SWOG S0221: A Phase III Trial Comparing Chemotherapy Schedules in High-Risk Early-Stage Breast Cancer,2015-01-01,paclitaxel,False,[],0,USA,20,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Impact of the Addition of Carboplatin and/or Bevacizumab to Neoadjuvant Once-per-Week Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide on Pathologic Complete Response Rates in Stage II to III Triple-Negative Breast Cancer: CALGB 40603 (Alliance),2015-01-01,bevacizumab,True,['Genentech/Roche'],0,USA,17,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0
"Redistribution, Hyperproliferation, Activation of Natural Killer Cells and CD8 T Cells, and Cytokine Production During First-in-Human Clinical Trial of Recombinant Human Interleukin-15 in Patients With Cancer",2015-01-01,recombinant human IL-15 (rhIL-15),False,[],0,USA,23,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Comparing Standard Versus Prosocial Internet Support Groups for Patients With Breast Cancer: A Randomized Controlled Trial of the Helper Therapy Principle,2014-12-20,,True,[],0,USA,6,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
First-in-Human Phase I Study of the Liposomal RNA Interference Therapeutic Atu027 in Patients With Advanced Solid Tumors,2014-12-20,Atu027,True,['Silence Therapeutics'],0,Germany,11,7,6,1,0,1,1,0,1,0,0,0,0,0,0,0
Impact of Spin in the Abstracts of Articles Reporting Results of Randomized Controlled Trials in the Field of Cancer: The SPIIN Randomized Controlled Trial,2014-12-20,,False,[],0,USA,6,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Randomized Controlled Trial of a Telephone-Based Peer-Support Program for Women Carrying a BRCA1 or BRCA2 Mutation: Impact on Psychological Distress,2014-12-20,,False,[],0,Australia,9,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Optimization of Rituximab for the Treatment of Diffuse Large B-Cell Lymphoma (II): Extended Rituximab Exposure Time in the SMARTE-R-CHOP-14 Trial of the German High-Grade Non-Hodgkin Lymphoma Study Group,2014-12-20,rituximab,True,['Roche'],0,Germany,17,5,0,4,0,4,1,1,0,0,1,0,0,0,0,0
Phase II Trial of the Anti-CD19 Bispecific T Cellâ€“Engager Blinatumomab Shows Hematologic and Molecular Remissions in Patients With Relapsed or Refractory B-Precursor Acute Lymphoblastic Leukemia,2014-12-20,blinatumomab,True,"['Amgen (U)', 'Amgen']",0,USA,20,11,5,6,0,4,1,1,1,0,0,0,0,0,0,0
Can Urinary PCA3 Supplement PSA in the Early Detection of Prostate Cancer?,2014-12-20,PCA3 assay,True,['Gen-Probe'],0,USA,19,1,0,1,0,0,1,0,0,0,1,0,0,0,0,0
Young Patients With Nonâ€“Germinal Center B-Cellâ€“Like Diffuse Large B-Cell Lymphoma Benefit From Intensified Chemotherapy With ACVBP Plus Rituximab Compared With CHOP Plus Rituximab: Analysis of Data From the Groupe d'Etudes des Lymphomes de l'Adulte/Lymphoma Study Association Phase III Trial LNH 03-2B,2014-12-10,rituximab,True,"['Roche/Genentech', 'Roche']",0,France,22,7,0,6,0,4,0,1,0,0,0,0,0,0,0,0
Increasing Cardiomyopathy Screening in At-Risk Adult Survivors of Pediatric Malignancies: A Randomized Controlled Trial,2014-12-10,,False,[],0,USA,10,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Phase III Comparison of Tamoxifen Versus Tamoxifen Plus Ovarian Function Suppression in Premenopausal Women With Node-Negative, Hormone Receptorâ€“Positive Breast Cancer (E-3193, INT-0142): A Trial of the Eastern Cooperative Oncology Group",2014-12-10,tamoxifen,False,[],0,USA,12,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
p16 Protein Expression and Human Papillomavirus Status As Prognostic Biomarkers of Nonoropharyngeal Head and Neck Squamous Cell Carcinoma,2014-12-10,,False,[],0,USA,14,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Randomized Phase III Trial of Amrubicin Versus Topotecan As Second-Line Treatment for Patients With Small-Cell Lung Cancer,2014-12-10,amrubicin,True,"['Celgene', 'Celgene (U)']",0,USA,19,7,2,3,0,3,1,1,1,0,0,0,0,0,0,0
"Endocrine Therapy With or Without Inhibition of Epidermal Growth Factor Receptor and Human Epidermal Growth Factor Receptor 2: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Fulvestrant With or Without Lapatinib for Postmenopausal Women With Hormone ReceptorÃ¢â‚¬â€œPositive Advanced Breast CancerÃ¢â‚¬â€CALGB 40302 (Alliance)",2014-12-10,lapatinib,False,[],0,USA,10,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Clinical Outcome With Correlation to Disseminated Tumor Cell (DTC) Status After DTC-Guided Secondary Adjuvant Treatment With Docetaxel in Early Breast Cancer,2014-12-01,docetaxel,False,[],0,Norway,15,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Phase III Study of Iniparib Plus Gemcitabine and Carboplatin Versus Gemcitabine and Carboplatin in Patients With Metastatic Triple-Negative Breast Cancer,2014-12-01,iniparib,True,['Sanofi'],0,USA,17,6,2,1,0,0,0,0,0,0,0,0,0,0,0,0
Impact of Reirradiation of Painful Osseous Metastases on Quality of Life and Function: A Secondary Analysis of the NCIC CTG SC.20 Randomized Trial,2014-12-01,,False,[],0,USA,16,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Phase II Trial of Stereotactic Body Radiation Therapy Combined With Erlotinib for Patients With Limited but Progressive Metastatic Nonâ€“Small-Cell Lung Cancer,2014-12-01,erlotinib,True,['OSI Pharmaceuticals'],0,USA,15,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0
Preservation of Memory With Conformal Avoidance of the Hippocampal Neural Stem-Cell Compartment During Whole-Brain Radiotherapy for Brain Metastases (RTOG 0933): A Phase II Multi-Institutional Trial,2014-12-01,,False,[],0,USA,17,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Pharmacokinetic and Pharmacodynamic Properties of Calaspargase Pegol Escherichia coli L-Asparaginase in the Treatment of Patients With Acute Lymphoblastic Leukemia: Results From Children's Oncology Group Study AALL07P4,2014-12-01,calaspargase pegol,True,['Jazz Pharmaceuticals'],0,USA,19,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0
Extended Progression-Free Survival in Two Patients With Alveolar Soft Part Sarcoma Exposed to Tivantinib,2014-12-01,,False,[],0,USA,5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Randomized Phase III Trial to Test Accelerated Versus Standard Fractionation in Combination With Concurrent Cisplatin for Head and Neck Carcinomas in the Radiation Therapy Oncology Group 0129 Trial: Long-Term Report of Efficacy and Toxicity,2014-12-01,cisplatin,False,[],0,USA,18,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Preliminary Results of a Phase II Trial of Proton Radiotherapy for Pediatric Rhabdomyosarcoma,2014-11-20,proton radiotherapy,True,"['ProCure (U)', 'ProCure']",0,USA,12,1,0,1,0,0,1,1,0,0,1,0,0,0,0,0
Trastuzumab Plus Adjuvant Chemotherapy for Human Epidermal Growth Factor Receptor 2â€“Positive Breast Cancer: Planned Joint Analysis of Overall Survival From NSABP B-31 and NCCTG N9831,2014-11-20,trastuzumab,True,"['Genentech/Roche (U)', 'Genentech', 'Genentech/Roche', 'Genetech/Roche (U)', 'Roche', 'Genentech (U)']",0,USA,16,8,0,5,0,3,1,1,0,0,1,0,0,0,0,0
"Biomarker Analyses in CLEOPATRA: A Phase III, Placebo-Controlled Study of Pertuzumab in Human Epidermal Growth Factor Receptor 2â€“Positive, First-Line Metastatic Breast Cancer",2014-11-20,pertuzumab,True,"['Genentech/Roche', 'Genentech', 'Genentech/Roche (U)']",0,USA,7,2,0,2,0,0,0,0,0,0,0,0,0,0,0,0
"Southwest Oncology Group S0008: A Phase III Trial of High-Dose Interferon Alfa-2b Versus Cisplatin, Vinblastine, and Dacarbazine, Plus Interleukin-2 and Interferon in Patients With High-Risk Melanomaâ€”An Intergroup Study of Cancer and Leukemia Group B, Children's Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group",2014-11-20,interferon alfa-2b,True,['Schering-Plough'],0,USA,14,2,0,1,0,0,0,0,0,0,0,0,0,0,0,0
Intense Androgen-Deprivation Therapy With Abiraterone Acetate Plus Leuprolide Acetate in Patients With Localized High-Risk Prostate Cancer: Results of a Randomized Phase II Neoadjuvant Study,2014-11-20,abiraterone acetate,True,['Janssen Pharmaceuticals'],0,USA,28,13,5,4,0,3,1,1,1,0,0,0,0,0,0,0
Tamibarotene As Maintenance Therapy for Acute Promyelocytic Leukemia: Results From a Randomized Controlled Trial,2014-11-20,tamibarotene,False,[],0,Japan,21,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Combined BRAF (Dabrafenib) and MEK Inhibition (Trametinib) in Patients With BRAFV600-Mutant Melanoma Experiencing Progression With Single-Agent BRAF Inhibitor,2014-11-20,dabrafenib and trametinib,True,['GlaxoSmithKline'],0,USA,27,1,0,0,0,1,1,1,0,0,0,0,0,0,1,1
Effect of Radiotherapy After Breast-Conserving Surgery for Ductal Carcinoma in Situ: 20 Years Follow-Up in the Randomized SweDCIS Trial,2014-11-10,radiotherapy,False,[],0,United Kingdom,12,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Dose-Intensive Response-Based Chemotherapy and Radiation Therapy for Children and Adolescents With Newly Diagnosed Intermediate-Risk Hodgkin Lymphoma: A Report From the Children's Oncology Group Study AHOD0031,2014-11-10,doxorubicin,False,[],0,USA,14,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Safety and Efficacy of Neratinib in Combination With Capecitabine in Patients With Metastatic Human Epidermal Growth Factor Receptor 2â€“Positive Breast Cancer,2014-11-10,neratinib,True,['Puma Biotechnology'],0,South Korea,13,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
Phase I/II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Patients With Locally Advanced or Metastatic Breast Cancer,2014-11-10,glembatumumab vedotin,True,['Celldex Therapeutics'],0,USA,13,8,5,0,0,0,1,1,1,0,0,0,0,0,0,0
Phase I/II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Patients With Advanced Melanoma,2014-11-10,glembatumumab vedotin,True,"['Celldex Therapeutics', 'former employee of CuraGen (now Celldex Therapeutics)', 'Celldex Therapeutics (U)']",0,USA,13,6,4,2,0,0,1,1,1,0,0,0,0,0,0,0
Optimal Duration of Low Molecular Weight Heparin for the Treatment of Cancer-Related Deep Vein Thrombosis: The Cancer-DACUS Study,2014-11-10,low molecular weight heparin,False,[],0,Italy,23,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Prospective, Randomized, Multicenter, Phase III Study of Fluorouracil, Leucovorin, and Irinotecan Versus Epirubicin, Cisplatin, and Capecitabine in Advanced Gastric Adenocarcinoma: A French Intergroup (FÃ©dÃ©ration Francophone de CancÃ©rologie Digestive, FÃ©dÃ©ration Nationale des Centres de Lutte Contre le Cancer, and Groupe CoopÃ©rateur Multidisciplinaire en Oncologie) Study",2014-11-01,irinotecan,False,[],0,France,17,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Postinduction Minimal Residual Disease Monitoring by Polymerase Chain Reaction in Children With Acute Lymphoblastic Leukemia,2014-11-01,,False,[],0,Italy,11,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Four-Week Prevalence of Mental Disorders in Patients With Cancer Across Major Tumor Entities,2014-11-01,,False,[],0,Germany,17,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Shorter-Duration Therapy Using Vincristine, Dactinomycin, and Lower-Dose Cyclophosphamide With or Without Radiotherapy for Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma: A Report From the Soft Tissue Sarcoma Committee of the Children's Oncology Group",2014-11-01,vincristine,False,[],0,USA,10,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Circulating Tumor Cells and Response to Chemotherapy in Metastatic Breast Cancer: SWOG S0500,2014-11-01,CellSearch System,True,"['Veridex', 'Veridex/Janssen Diagnostics']",0,USA,14,2,0,0,0,1,0,0,0,0,0,0,0,0,0,0
Multi-Institutional Study of Post-Transplantation Cyclophosphamide As Single-Agent Graft-Versus-Host Disease Prophylaxis After Allogeneic Bone Marrow Transplantation Using Myeloablative Busulfan and Fludarabine Conditioning,2014-11-01,busulfan,False,[],0,USA,12,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Randomized Comparison of Gemcitabine, Dexamethasone, and Cisplatin Versus Dexamethasone, Cytarabine, and Cisplatin Chemotherapy Before Autologous Stem-Cell Transplantation for Relapsed and Refractory Aggressive Lymphomas: NCIC-CTG LY.12",2014-11-01,gemcitabine,True,['Eli Lilly'],0,Italy,23,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
Randomized Phase III Trial of Retinoic Acid and Arsenic Trioxide Versus Retinoic Acid and Chemotherapy in Patients With Acute Promyelocytic Leukemia: Health-Related Quality-of-Life Outcomes,2014-10-20,arsenic trioxide,False,[],0,Germany,19,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Cabozantinib in Chemotherapy-Pretreated Metastatic Castration-Resistant Prostate Cancer: Results of a Phase II Nonrandomized Expansion Study,2014-10-20,cabozantinib,True,"['Exelixis', 'Exelixis (U)']",0,United Kingdom,21,17,3,12,0,2,0,0,0,0,0,0,0,0,0,0
Incorporation of Pazopanib in Maintenance Therapy of Ovarian Cancer,2014-10-20,pazopanib,True,"['GlaxoSmithKline', 'GlaxoSmithKline Japan']",0,USA,35,10,3,6,0,2,1,0,1,0,0,0,0,0,0,0
"Aprepitant, Granisetron, and Dexamethasone for Prevention of Chemotherapy-Induced Nausea and Vomiting After High-Dose Melphalan in Autologous Transplantation for Multiple Myeloma: Results of a Randomized, Placebo-Controlled Phase III Trial",2014-10-20,aprepitant,True,['Merck Sharp & Dohme'],0,Germany,12,5,0,2,0,4,0,1,0,0,0,0,0,0,0,0
Human Papillomavirus and Overall Survival After Progression of Oropharyngeal Squamous Cell Carcinoma,2014-10-20,,False,[],0,Canada,13,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Pathologic Findings at Risk-Reducing Salpingo-Oophorectomy: Primary Results From Gynecologic Oncology Group Trial GOG-0199,2014-10-10,,False,[],0,USA,22,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Phase II Study of the Safety and Antitumor Activity of the Hypoxia-Activated Prodrug TH-302 in Combination With Doxorubicin in Patients With Advanced Soft Tissue Sarcoma,2014-10-10,TH-302,True,['Threshold Pharmaceuticals'],0,USA,10,4,1,1,0,1,1,1,1,0,0,0,0,0,0,0
Vitamin D Deficiency Impairs Rituximab-Mediated Cellular Cytotoxicity and Outcome of Patients With Diffuse Large B-Cell Lymphoma Treated With but Not Without Rituximab,2014-10-10,rituximab,True,['Roche'],0,Germany,10,1,0,1,0,0,1,1,0,0,1,0,0,0,0,0
"Efficacy of Methylprednisolone on Pain, Fatigue, and Appetite Loss in Patients With Advanced Cancer Using Opioids: A Randomized, Placebo-Controlled, Double-Blind Trial",2014-10-10,methylprednisolone,False,[],0,United Kingdom,7,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Rituximab Extended Schedule or Re-Treatment Trial for Lowâ€“Tumor Burden Follicular Lymphoma: Eastern Cooperative Oncology Group Protocol E4402,2014-10-01,rituximab,True,['Genentech'],0,USA,15,1,1,0,0,0,1,1,1,1,0,0,0,0,0,0
Brentuximab Vedotin in the Front-Line Treatment of Patients With CD30+ Peripheral T-Cell Lymphomas: Results of a Phase I Study,2014-10-01,brentuximab vedotin,True,"['Seattle Genetics', 'Seattle Genetics (U)']",0,United Kingdom,12,11,1,9,0,6,0,1,0,0,0,0,0,0,0,0
"Phase I Dose-Escalation Study of LCL161, an Oral Inhibitor of Apoptosis Proteins Inhibitor, in Patients With Advanced Solid Tumors",2014-10-01,LCL161,True,"['Novartis Pharmaceuticals Corp', 'Novartis']",0,USA,7,7,4,3,0,1,1,0,1,0,0,0,0,0,0,0
Randomized Phase III Trial of Concurrent Accelerated Radiation Plus Cisplatin With or Without Cetuximab for Stage III to IV Head and Neck Carcinoma: RTOG 0522,2014-09-20,cetuximab,True,['ImClone Systems'],0,Canada,20,2,0,1,0,1,1,0,0,0,1,0,0,0,0,0
"Effect of Routine Assessment of Specific Psychosocial Problems on Personalized Communication, Counselors' Awareness, and Distress Levels in Cancer Genetic Counseling Practice: A Randomized Controlled Trial",2014-09-20,,False,[],0,the Netherlands,8,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Gemtuzumab Ozogamicin in Children and Adolescents With De Novo Acute Myeloid Leukemia Improves Event-Free Survival by Reducing Relapse Risk: Results From the Randomized Phase III Children's Oncology Group Trial AAML0531,2014-09-20,gemtuzumab ozogamicin,False,[],0,Canada,15,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Pemetrexed and Cisplatin for the Treatment of Advanced, Persistent, or Recurrent Carcinoma of the Cervix: A Limited Access Phase II Trial of the Gynecologic Oncology Group",2014-09-01,pemetrexed,False,[],0,USA,8,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Can Patient Navigation Improve Receipt of Recommended Breast Cancer Care? Evidence From the National Patient Navigation Research Program,2014-09-01,antiestrogen therapy (general),False,[],0,USA,11,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Phase II Randomized Trial Comparing Sequential First-Line Everolimus and Second-Line Sunitinib Versus First-Line Sunitinib and Second-Line Everolimus in Patients With Metastatic Renal Cell Carcinoma,2014-09-01,everolimus,True,"['Novartis', 'Novartis (U)']",0,Switzerland,23,14,5,5,0,4,1,0,1,0,0,0,0,0,0,0
Phase III Randomized Trial of Induction Chemotherapy in Patients With N2 or N3 Locally Advanced Head and Neck Cancer,2014-09-01,docetaxel,True,['sanofi-aventis'],0,France,21,2,0,0,0,0,0,1,0,0,0,0,0,0,0,0
"Front-Line Transplantation Program With Lenalidomide, Bortezomib, and Dexamethasone Combination As Induction and Consolidation Followed by Lenalidomide Maintenance in Patients With Multiple Myeloma: A Phase II Study by the Intergroupe Francophone du MyÃ©lome",2014-09-01,lenalidomide,True,['Celgene'],0,France,21,13,0,6,0,12,1,1,0,0,1,0,0,0,0,0
Postoperative Chemoradiotherapy and Cetuximab for High-Risk Squamous Cell Carcinoma of the Head and Neck: Radiation Therapy Oncology Group RTOG-0234,2014-08-10,cetuximab,True,"['Bristol-Myers Squibb', 'Bristol-Myers Squibb (U)']",0,USA,13,2,0,2,0,1,0,1,0,0,0,0,0,0,0,0
"Southwest Oncology Group S0802: A Randomized, Phase II Trial of Weekly Topotecan With and Without Ziv-Aflibercept in Patients With Platinum-Treated Small-Cell Lung Cancer",2014-08-10,ziv-aflibercept,True,['sanofi-aventis'],0,USA,10,1,0,0,0,1,1,1,0,0,0,0,0,0,1,1
Safety and Efficacy of Aerobic Training in Patients With Cancer Who Have Heart Failure: An Analysis of the HF-ACTION Randomized Trial,2014-08-10,,False,[],0,USA,8,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Cyclophosphamide Compared With Ifosfamide in Consolidation Treatment of Standard-Risk Ewing Sarcoma: Results of the Randomized Noninferiority Euro-EWING99-R1 Trial,2014-08-10,cyclophosphamide,False,[],0,Sweden,18,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Impact of Brachytherapy on Local Recurrence Rates After Sublobar Resection: Results From ACOSOG Z4032 (Alliance), a Phase III Randomized Trial for High-Risk Operable Nonâ€“Small-Cell Lung Cancer",2014-08-10,brachytherapy,False,['SPEC'],0,USA,13,1,0,1,0,0,1,1,0,0,1,0,0,0,0,0
"Second-Line Oxaliplatin, Folinic Acid, and Fluorouracil Versus Folinic Acid and Fluorouracil Alone for Gemcitabine-Refractory Pancreatic Cancer: Outcomes From the CONKO-003 Trial",2014-08-10,oxaliplatin,False,[],0,Germany,14,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Surgery Alone Versus Chemoradiotherapy Followed by Surgery for Stage I and II Esophageal Cancer: Final Analysis of Randomized Controlled Phase III Trial FFCD 9901,2014-08-10,cisplatin,False,[],0,France,15,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Comparison of Doxorubicin and Cyclophosphamide Versus Single-Agent Paclitaxel As Adjuvant Therapy for Breast Cancer in Women With 0 to 3 Positive Axillary Nodes: CALGB 40101 (Alliance),2014-08-01,paclitaxel,True,['Bristol-Meyer Squibb'],0,USA,15,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Prospective Validation of HLA-DRB1*07:01 Allele Carriage As a Predictive Risk Factor for Lapatinib-Induced Liver Injury,2014-08-01,lapatinib,True,['GlaxoSmithKline'],0,USA,11,6,5,1,0,0,1,1,1,0,0,0,0,0,0,0
Improved Survival After Transplantation of More Donor Plasmacytoid Dendritic or NaÃƒÂ¯ve T Cells From Unrelated-Donor Marrow Grafts: Results From BMTCTN 0201,2014-08-01,,False,[],0,USA,16,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Dose-Finding and Pharmacokinetic Study to Optimize the Dosing of Irinotecan According to the UGT1A1 Genotype of Patients With Cancer,2014-08-01,irinotecan,False,[],0,USA,14,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Randomized Trial of a Telephone-Based Weight Loss Intervention in Postmenopausal Women With Breast Cancer Receiving Letrozole: The LISA Trial,2014-07-20,letrozole,True,['Novartis'],0,USA,12,2,0,0,0,1,0,1,0,0,0,0,0,0,0,0
"PEAK: A Randomized, Multicenter Phase II Study of Panitumumab Plus Modified Fluorouracil, Leucovorin, and Oxaliplatin (mFOLFOX6) or Bevacizumab Plus mFOLFOX6 in Patients With Previously Untreated, Unresectable, Wild-Type KRAS Exon 2 Metastatic Colorectal Cancer",2014-07-20,panitumumab,True,['Amgen'],0,USA,9,8,3,4,0,3,1,1,1,0,0,0,0,0,0,0
Effect of Communication Skills Training Program for Oncologists Based on Patient Preferences for Communication When Receiving Bad News: A Randomized Controlled Trial,2014-07-10,,False,[],0,Japan,6,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Trastuzumab-Associated Cardiac Events at 8 Years of Median Follow-Up in the Herceptin Adjuvant Trial (BIG 1-01),2014-07-10,trastuzumab,True,"['Roche', 'F. Hoffmann La Roche']",0,USA,18,13,1,7,0,7,1,1,1,0,0,0,0,0,0,0
"Randomized, Phase III Trial of First-Line Figitumumab in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone in Patients With Advanced Nonâ€“Small-Cell Lung Cancer",2014-07-01,figitumumab,True,"['Pfizer (U)', 'Pfizer']",0,China,10,5,2,3,0,1,1,0,1,0,0,0,0,0,0,0
"Lapatinib Plus Paclitaxel Versus Paclitaxel Alone in the Second-Line Treatment of HER2-Amplified Advanced Gastric Cancer in Asian Populations: TyTANâ€”A Randomized, Phase III Study",2014-07-01,lapatinib,True,['GlaxoSmithKline'],0,Taiwan,19,5,2,2,0,2,1,1,1,0,0,0,0,0,0,0
Antigen-Specific Immune Responses and Clinical Outcome After Vaccination With Glioma-Associated Antigen Peptides and Polyinosinic-Polycytidylic Acid Stabilized by Lysine and Carboxymethylcellulose in Children With Newly Diagnosed Malignant Brainstem and Nonbrainstem Gliomas,2014-07-01,GAA peptide vaccination (cancer vaccine targeting specific antigens),False,[],0,USA,10,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
International Randomized Phase III Study of Elacytarabine Versus Investigator Choice in Patients With Relapsed/Refractory Acute Myeloid Leukemia,2014-06-20,elacytarabine,True,['Clavis Pharma'],0,Norway,16,6,3,3,0,1,1,1,1,0,0,0,0,0,0,0
Randomized Phase III Trial of Erlotinib Versus Docetaxel As Second- or Third-Line Therapy in Patients With Advanced Nonâ€“Small-Cell Lung Cancer: Docetaxel and Erlotinib Lung Cancer Trial (DELTA),2014-06-20,erlotinib,False,[],0,Japan,19,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Neoadjuvant Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin With Pegfilgrastim Support in Muscle-Invasive Urothelial Cancer: Pathologic, Radiologic, and Biomarker Correlates",2014-06-20,pegfilgrastim,True,['Amgen'],0,USA,19,2,0,0,0,0,1,1,0,0,0,0,0,0,0,0
"Accelerated Methotrexate, Vinblastine, Doxorubicin, and Cisplatin Is Safe, Effective, and Efficient Neoadjuvant Treatment for Muscle-Invasive Bladder Cancer: Results of a Multicenter Phase II Study With Molecular Correlates of Response and Toxicity",2014-06-20,Cisplatin,False,[],0,USA,20,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Capecitabine and Oxaliplatin in the Preoperative Multimodality Treatment of Rectal Cancer: Surgical End Points From National Surgical Adjuvant Breast and Bowel Project Trial R-04,2014-06-20,capecitabine,False,[],0,Saudi Arabia,26,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Modafinil for the Treatment of Fatigue in Lung Cancer: Results of a Placebo-Controlled, Double-Blind, Randomized Trial",2014-06-20,modafinil,False,[],0,United Kingdom,11,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Comparison of Subcutaneous Versus Intravenous Administration of Rituximab As Maintenance Treatment for Follicular Lymphoma: Results From a Two-Stage, Phase IB Study",2014-06-10,rituximab,True,"['F. Hoffman-La Roche', 'F. Hoffmann-La Roche', 'Roche']",0,Russia,17,12,5,5,0,5,1,1,1,0,0,0,0,0,0,0
Triple Intrathecal Therapy Alone With Omission of Cranial Radiation in Children With Acute Lymphoblastic Leukemia,2014-06-10,,False,[],0,Taiwan,7,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Assessment of Tumor Size Reduction Improves Outcome Prediction of Positron Emission Tomography/Computed Tomography After Chemotherapy in Advanced-Stage Hodgkin Lymphoma,2014-06-10,fluorodeoxyglucose (FDG),False,[],0,Germany,19,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
[18F]Fluorodeoxyglucose Positron Emission Tomography Predicts Survival After Chemoimmunotherapy for Primary Mediastinal Large B-Cell Lymphoma: Results of the International Extranodal Lymphoma Study Group IELSG-26 Study,2014-06-10,rituximab,True,['Roche'],0,Spain,20,3,0,1,0,3,1,0,0,0,1,0,0,0,0,0
Multicenter Randomized Controlled Trial of Conventional Versus Laparoscopic Surgery for Colorectal Cancer Within an Enhanced Recovery Programme: EnROL,2014-06-10,,False,[],0,United Kingdom,7,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Active Idiotypic Vaccination Versus Control Immunotherapy for Follicular Lymphoma,2014-06-10,MyVax,True,['Genitope'],0,USA,26,4,1,0,0,0,1,1,1,0,0,0,0,0,0,0
Tumor Regression Grading After Preoperative Chemoradiotherapy for Locally Advanced Rectal Carcinoma Revisited: Updated Results of the CAO/ARO/AIO-94 Trial,2014-05-20,,False,[],0,Austria,14,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Treatment of High-Risk Philadelphia Chromosomeâ€“Negative Acute Lymphoblastic Leukemia in Adolescents and Adults According to Early Cytologic Response and Minimal Residual Disease After Consolidation Assessed by Flow Cytometry: Final Results of the PETHEMA ALL-AR-03 Trial,2014-05-20,,False,[],0,Spain,25,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Doxepin Rinse Versus Placebo in the Treatment of Acute Oral Mucositis Pain in Patients Receiving Head and Neck Radiotherapy With or Without Chemotherapy: A Phase III, Randomized, Double-Blind Trial (NCCTG-N09C6 [Alliance])",2014-05-20,doxepin,False,[],0,USA,13,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Combined Molecular and Clinical Prognostic Index for Relapse and Survival in Cytogenetically Normal Acute Myeloid Leukemia,2014-05-20,,False,[],0,New Zealand,26,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Pathologic and Molecular Features Correlate With Long-Term Outcome After Adjuvant Therapy of Resected Primary GI Stromal Tumor: The ACOSOG Z9001 Trial,2014-05-20,imatinib,False,[],0,USA,15,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Results of a Multicenter, Controlled, Randomized Clinical Trial Evaluating the Combination of Piperacillin/Tazobactam and Tigecycline in High-Risk Hematologic Patients With Cancer With Febrile Neutropenia",2014-05-10,tigecycline,True,['Pfizer'],0,Roma,26,2,0,0,0,1,1,1,0,0,0,0,0,0,1,0
"Phase IIa Trial of Trastuzumab Emtansine With Pertuzumab for Patients With Human Epidermal Growth Factor Receptor 2â€“Positive, Locally Advanced, or Metastatic Breast Cancer",2014-05-10,trastuzumab emtansine (T-DM1),True,"['Genentech/Roche', 'Genentech', 'F. Hoffmann-La Roche', 'Roche']",0,Switzerland,12,11,3,6,0,5,1,0,1,0,0,0,0,0,0,0
"Quality of Life in MAP.3 (Mammary Prevention 3): A Randomized, Placebo-Controlled Trial Evaluating Exemestane for Prevention of Breast Cancer",2014-05-10,exemestane,True,"['Pfizer', 'Pfizer (funds donated to education fund)']",0,USA,27,4,0,1,0,2,1,1,0,0,1,0,0,0,0,0
Phase I Dose-Escalation Study of 5-Day Intermittent Oral Lapatinib Therapy in Patients With Human Epidermal Growth Factor Receptor 2â€“Overexpressing Breast Cancer,2014-05-10,lapatinib,True,['GlaxoSmithKline'],0,USA,11,4,1,0,0,1,1,0,1,0,0,0,0,0,0,0
"Randomized, Controlled, Double-Blind, Cross-Over Trial Assessing Treatment Preference for Pazopanib Versus Sunitinib in Patients With Metastatic Renal Cell Carcinoma: PISCES Study",2014-05-10,pazopanib,True,['GlaxoSmithKline'],0,USA,17,15,4,8,0,9,1,1,1,0,0,0,0,0,0,0
"Phase I Trial of a Novel Anti-GD2 Monoclonal Antibody, Hu14.18K322A, Designed to Decrease Toxicity in Children With Refractory or Recurrent Neuroblastoma",2014-05-10,hu14.18K322A,False,[],0,Germany,20,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Patient-Reported Outcome Results From the Open-Label Phase III AURELIA Trial Evaluating Bevacizumab-Containing Therapy for Platinum-Resistant Ovarian Cancer,2014-05-01,bevacizumab,True,"['F. Hoffman-La Roche', 'Roche', 'F. Hoffmann-La Roche']",0,Switzerland,15,11,3,5,0,6,1,1,1,0,0,0,0,0,0,0
Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial,2014-05-01,bevacizumab,True,"['Roche', 'F. Hoffmann-La Roche']",0,Switzerland,17,12,1,6,0,5,1,1,1,0,0,0,0,0,0,0
Prolonged Administration of Azacitidine With or Without Entinostat for Myelodysplastic Syndrome and Acute Myeloid Leukemia With Myelodysplasia-Related Changes: Results of the US Leukemia Intergroup Trial E1905,2014-04-20,azacitidine,True,['Celgene'],0,USA,18,3,0,3,0,1,1,1,0,0,1,0,0,0,0,0
Metastatic Neuroblastoma Confined to Distant Lymph Nodes (stage 4N) Predicts Outcome in Patients With Stage 4 Disease: A Study From the International Neuroblastoma Risk Group Database,2014-04-20,,False,[],0,Austria,13,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Stand Up to Cancer Phase Ib Study of Pan-Phosphoinositide-3-Kinase Inhibitor Buparlisib With Letrozole in Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer,2014-04-20,buparlisib,True,"['Novartis (U)', 'Novartis']",0,USA,13,4,0,3,0,0,1,1,0,0,1,0,0,0,0,0
Phase III Study Comparing Amrubicin Plus Cisplatin With Irinotecan Plus Cisplatin in the Treatment of Extensive-Disease Small-Cell Lung Cancer: JCOG 0509,2014-04-20,amrubicin,True,['Daiichi Sankyo'],0,Japan,18,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
Customized Adjuvant Phase II Trial in Patients With Nonâ€“Small-Cell Lung Cancer: IFCT-0801 TASTE,2014-04-20,erlotinib,True,['Roche'],0,France,19,8,0,5,0,6,1,0,0,0,1,0,0,0,0,0
Rituximab Plus Chlorambucil As First-Line Treatment for Chronic Lymphocytic Leukemia: Final Analysis of an Open-Label Phase II Study,2014-04-20,rituximab,True,"['Roche/Genentech', 'Roche', 'F. Hoffmann-La Roche', 'Roche (U)']",0,Switzerland,16,11,1,5,0,8,1,1,1,0,0,0,0,0,0,0
Risk Factors for GI Adverse Events in a Phase III Randomized Trial of Bevacizumab in First-Line Therapy of Advanced Ovarian Cancer: A Gynecologic Oncology Group Study,2014-04-20,bevacizumab,False,[],0,USA,14,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Omitting Radiotherapy in Early Positron Emission Tomographyâ€“Negative Stage I/II Hodgkin Lymphoma Is Associated With an Increased Risk of Early Relapse: Clinical Results of the Preplanned Interim Analysis of the Randomized EORTC/LYSA/FIL H10 Trial,2014-04-20,doxorubicin,False,[],0,Denmark,29,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Multicenter Phase II Study of Mogamulizumab (KW-0761), a Defucosylated Anti-CC Chemokine Receptor 4 Antibody, in Patients With Relapsed Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma",2014-04-10,mogamulizumab,True,['Kyowa Hakko Kirin'],0,Japan,19,14,1,8,0,2,1,1,1,0,0,0,0,0,0,0
Circulating Tumor Cell Counts Are Prognostic of Overall Survival in SWOG S0421: A Phase III Trial of Docetaxel With or Without Atrasentan for Metastatic Castration-Resistant Prostate Cancer,2014-04-10,docetaxel,False,[],0,USA,20,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Improving the Care of Children With Advanced Cancer by Using an Electronic Patient-Reported Feedback Intervention: Results From the PediQUEST Randomized Controlled Trial,2014-04-10,,False,[],0,USA,9,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Randomized Controlled Trial of Early Zoledronic Acid in Men With Castration-Sensitive Prostate Cancer and Bone Metastases: Results of CALGB 90202 (Alliance),2014-04-10,zoledronic acid,True,['Novartis'],0,Canada,15,3,0,3,0,0,0,0,0,0,0,0,0,0,0,0
Role of Radiotherapy to Bulky Disease in Elderly Patients With Aggressive B-Cell Lymphoma,2014-04-10,rituximab,True,['Roche'],0,Germany,14,4,0,2,0,3,1,1,0,0,1,0,0,0,0,0
"Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab",2014-04-01,nivolumab,True,"['Bristol-Myers Squibb', 'Bristol-Myers Squibb (U)', 'Bristol-Myers Squibb (Speakers Bureau)']",0,USA,21,15,3,9,0,2,0,1,0,0,0,0,0,0,0,0
"Randomized, Controlled Trial of Yoga in Women With Breast Cancer Undergoing Radiotherapy",2014-04-01,,False,[],0,Germany,16,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Double-Blind, Placebo-Controlled, Multicenter, Randomized, Phase IIB Neoadjuvant Study of Letrozole-Lapatinib in Postmenopausal Hormone Receptorâ€“Positive, Human Epidermal Growth Factor Receptor 2â€“Negative, Operable Breast Cancer",2014-04-01,lapatinib,True,['GlaxoSmithKline'],0,United Kingdom,20,7,3,2,0,3,1,1,1,0,0,0,0,0,0,0
Event-Free Survival at 24 Months Is a Robust End Point for Disease-Related Outcome in Diffuse Large B-Cell Lymphoma Treated With Immunochemotherapy,2014-04-01,rituximab,True,['Roche'],0,USA,23,1,0,1,0,0,1,0,0,0,1,0,0,0,0,0
Randomized Phase III Trial Exploring the Use of Long-Acting Release Octreotide in the Prevention of Chemotherapy-Induced Diarrhea in Patients With Colorectal Cancer: The LARCID Trial,2014-04-01,octreotide,True,['Novartis'],0,USA,13,6,3,1,0,1,1,1,1,0,0,0,0,0,0,0
"Yoga's Impact on Inflammation, Mood, and Fatigue in Breast Cancer Survivors: A Randomized Controlled Trial",2014-04-01,,False,[],0,USA,10,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Phase III Randomized, Placebo-Controlled, Double-Blind Study of Intravenous Calcium and Magnesium to Prevent Oxaliplatin-Induced Sensory Neurotoxicity (N08CB/Alliance)",2014-04-01,oxaliplatin,True,['sanofi-aventis'],0,USA,10,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0
Pharmacokinetics-Based Integration of Multiple Doses of Intravenous Pegaspargase in a Pediatric Regimen for Adults With Newly Diagnosed Acute Lymphoblastic Leukemia,2014-03-20,pegaspargase,True,['Sigma Tau Pharmaceuticals'],0,USA,12,1,0,0,0,1,1,1,0,0,0,0,0,0,1,0
Mature Results of a Phase II Study of Rituximab Therapy for Nodular Lymphocyteâ€“Predominant Hodgkin Lymphoma,2014-03-20,rituximab,True,"['Genentech', 'Genentech (U)']",0,USA,7,2,1,1,0,0,1,0,1,0,0,0,0,0,0,0
"Benefit From Procarbazine, Lomustine, and Vincristine in Oligodendroglial Tumors Is Associated With Mutation of IDH",2014-03-10,"procarbazine, lomustine, vincristine (PCV regimen)",False,[],0,USA,13,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Sector Resection With or Without Postoperative Radiotherapy for Stage I Breast Cancer: 20-Year Results of a Randomized Trial,2014-03-10,radiotherapy,False,[],0,USA,6,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Sustained Complete Responses in Patients With Lymphoma Receiving Autologous Cytotoxic T Lymphocytes Targeting Epstein-Barr Virus Latent Membrane Proteins,2014-03-10,Autologous T Cells specific for LMP2 and Î”LMP1,True,"['Cellmedica', 'Cellmedica (U)']",0,USA,20,4,0,4,0,2,1,0,0,0,1,0,0,0,0,0
Randomized Phase III Trial of Temsirolimus Versus Sorafenib As Second-Line Therapy After Sunitinib in Patients With Metastatic Renal Cell Carcinoma,2014-03-10,temsirolimus,True,['Pfizer'],0,USA,11,8,4,4,0,3,1,1,1,0,0,0,0,0,0,0
Randomized Phase III Trial of Temsirolimus and Bevacizumab Versus Interferon Alfa and Bevacizumab in Metastatic Renal Cell Carcinoma: INTORACT Trial,2014-03-10,temsirolimus,True,['Pfizer'],0,France,7,7,4,3,0,1,1,1,1,0,0,0,0,0,0,0
"Open-Label, Exploratory Phase II Trial of Oral Itraconazole for the Treatment of Basal Cell Carcinoma",2014-03-10,itraconazole,False,[],0,Chile,11,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Randomized Controlled Trial of Expressive Writing for Patients With Renal Cell Carcinoma,2014-03-01,,False,[],0,USA,9,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Bortezomib-Melphalan-Prednisone-Thalidomide Followed by Maintenance With Bortezomib-Thalidomide Compared With Bortezomib-Melphalan-Prednisone for Initial Treatment of Multiple Myeloma: Updated Follow-Up and Improved Survival,2014-03-01,bortezomib,True,['Millennium Pharmaceuticals'],0,Italy,30,2,0,2,0,1,1,0,0,0,1,0,0,0,0,0
Randomized Noninferiority Trial of Telephone Versus In-Person Genetic Counseling for Hereditary Breast and Ovarian Cancer,2014-03-01,,False,[],0,USA,20,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Telehealth Personalized Cancer Risk Communication to Motivate Colonoscopy in Relatives of Patients With Colorectal Cancer: The Family CARE Randomized Controlled Trial,2014-03-01,,False,[],0,USA,19,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Concomitant Cisplatin Plus Radiotherapy and Highâ€“Dose-Rate Brachytherapy Versus Radiotherapy Alone for Stage IIIB Epidermoid Cervical Cancer: A Randomized Controlled Trial,2014-02-20,cisplatin,False,[],0,Brazil,6,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Neoadjuvant Chemotherapy Without Routine Use of Radiation Therapy for Patients With Locally Advanced Rectal Cancer: A Pilot Trial,2014-02-20,bevacizumab,True,['Genentech'],0,USA,13,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0
Randomized Controlled Trial of a Cognitive-Behavioral Therapy Plus Hypnosis Intervention to Control Fatigue in Patients Undergoing Radiotherapy for Breast Cancer,2014-02-20,,False,[],0,USA,8,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Effect of the Addition of Chemotherapy to Radiotherapy on Cognitive Function in Patients With Low-Grade Glioma: Secondary Analysis of RTOG 98-02,2014-02-20,procarbazine,False,[],0,USA,11,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Optimal Duration and Timing of Adjuvant Chemotherapy After Definitive Surgery for Ductal Adenocarcinoma of the Pancreas: Ongoing Lessons From the ESPAC-3 Study,2014-02-20,gemcitabine,False,[],0,Sweden,28,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Patterns of Recurrence After Surgery Alone Versus Preoperative Chemoradiotherapy and Surgery in the CROSS Trials,2014-02-10,paclitaxel,False,[],0,the Netherlands,14,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Mindfulness-Based Stress Reduction Compared With Cognitive Behavioral Therapy for the Treatment of Insomnia Comorbid With Cancer: A Randomized, Partially Blinded, Noninferiority Trial",2014-02-10,,False,[],0,Canada,6,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Phase II Trial of Imatinib in AIDS-Associated Kaposi's Sarcoma: AIDS Malignancy Consortium Protocol 042,2014-02-10,imatinib,True,['Novartis'],0,USA,11,2,0,0,0,0,1,1,0,0,0,0,0,0,0,0
"Deep Molecular Response Is Reached by the Majority of Patients Treated With Imatinib, Predicts Survival, and Is Achieved More Quickly by Optimized High-Dose Imatinib: Results From the Randomized CML-Study IV",2014-02-10,imatinib,True,"['Novartis', 'Novartis Pharma']",0,Switzerland,32,13,0,3,0,9,0,1,0,0,0,0,0,0,0,0
"Phase III Randomized Trial of Weekly Cisplatin and Irradiation Versus Cisplatin and Tirapazamine and Irradiation in Stages IB2, IIA, IIB, IIIB, and IVA Cervical Carcinoma Limited to the Pelvis: A Gynecologic Oncology Group Study",2014-02-10,tirapazamine,False,[],0,USA,12,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Randomized Phase III Study of Erlotinib Versus Observation in Patients With No Evidence of Disease Progression After First-Line Platin-Based Chemotherapy for Ovarian Carcinoma: A European Organisation for Research and Treatment of Cancer-Gynaecological Cancer Group, and Gynecologic Cancer Intergroup Study",2014-02-01,erlotinib,True,['Roche'],0,Spain,21,6,0,5,0,2,1,0,0,0,1,0,0,0,0,0
Allogeneic Transplantation Versus Chemotherapy as Postremission Therapy for Acute Myeloid Leukemia: A Prospective Matched Pairs Analysis,2014-02-01,,False,[],0,Germany,22,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Determinants of Pain Severity Changes in Ambulatory Patients With Cancer: An Analysis From Eastern Cooperative Oncology Group Trial E2Z02,2014-02-01,,False,[],0,USA,7,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"De Novo Treatment of Diffuse Large B-Cell Lymphoma With Rituximab, Cyclophosphamide, Vincristine, Gemcitabine, and Prednisolone in Patients With Cardiac Comorbidity: A United Kingdom National Cancer Research Institute Trial",2014-02-01,R-GCVP,True,['Roche'],0,United Kingdom,12,3,0,1,0,1,1,1,0,0,1,0,0,0,0,0
Electronic Self-Report Assessment for Cancer and Self-Care Support: Results of a Multicenter Randomized Trial,2014-01-20,,False,[],0,USA,12,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Intensive Chemotherapy for Childhood Acute Lymphoblastic Leukemia: Results of the Randomized Intercontinental Trial ALL IC-BFM 2002,2014-01-20,,False,[],0,Italy,24,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Phase II Pilot Study of Intravenous High-Dose Interferon With or Without Maintenance Treatment in Melanoma at High Risk of Recurrence,2014-01-20,interferon alfa-2b,True,['Schering-Plough'],0,United Kingdom,12,2,0,0,0,2,0,0,0,0,0,0,0,0,0,0
Targeted Androgen Pathway Suppression in Localized Prostate Cancer: A Pilot Study,2014-01-20,dutasteride,True,['GlaxoSmithKline'],0,USA,17,3,0,0,0,0,0,1,0,0,0,0,0,0,0,0
Fractionated 90Y-Ibritumomab Tiuxetan Radioimmunotherapy As an Initial Therapy of Follicular Lymphoma: An International Phase II Study in Patients Requiring Treatment According to GELF/BNLI Criteria,2014-01-20,90Y-ibritumomab tiuxetan,True,['Spectrum Pharmaceuticals'],0,France,17,2,0,1,0,2,0,0,0,0,0,0,0,0,0,0
TMPRSS2:ERG Gene Fusion Predicts Subsequent Detection of Prostate Cancer in Patients With High-Grade Prostatic Intraepithelial Neoplasia,2014-01-20,toremifene,True,['GTx'],0,USA,8,4,4,0,0,0,1,0,1,0,0,0,0,0,0,0
High-Dose Cytarabine in Induction Treatment Improves the Outcome of Adult Patients Younger Than Age 46 Years With Acute Myeloid Leukemia: Results of the EORTC-GIMEMA AML-12 Trial,2014-01-20,Cytarabine,False,[],0,Portugal,41,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Randomized, Placebo-Controlled, Phase III Trial of Sunitinib Plus Prednisone Versus Prednisone Alone in Progressive, Metastatic, Castration-Resistant Prostate Cancer",2014-01-10,sunitinib,True,"['Pfizer (U)', 'Pfizer']",0,Italy,21,13,5,4,0,4,0,0,0,0,0,0,0,0,0,0
Aprepitant Versus Dexamethasone for Preventing Chemotherapy-Induced Delayed Emesis in Patients With Breast Cancer: A Randomized Double-Blind Study,2014-01-10,aprepitant,True,['Merck Sharp & Dohme'],0,Italy,5,1,0,1,0,1,1,1,0,0,1,0,0,0,0,0
Phase I Study of Neratinib in Combination With Temsirolimus in Patients With Human Epidermal Growth Factor Receptor 2Ã¢â‚¬â€œDependent and Other Solid Tumors,2014-01-10,temsirolimus,True,['Pfizer'],0,USA,15,8,2,2,0,1,1,1,1,0,0,0,0,0,0,0
"Nurse Navigators in Early Cancer Care: A Randomized, Controlled Trial",2014-01-01,,False,[],0,USA,8,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Preoperative Magnetic Resonance Imaging Assessment of Circumferential Resection Margin Predicts Disease-Free Survival and Local Recurrence: 5-Year Follow-Up Results of the MERCURY Study,2014-01-01,,False,[],0,Sweden,9,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Phase II Study of Alisertib, a Selective Aurora A Kinase Inhibitor, in Relapsed and Refractory Aggressive B- and T-Cell Non-Hodgkin Lymphomas",2014-01-01,alisertib,True,['Millennium Pharmaceuticals'],0,USA,13,7,4,0,0,1,1,1,1,0,0,0,0,0,0,0
"Pattern of Rash, Diarrhea, and Hepatic Toxicities Secondary to Lapatinib and Their Association With Age and Response to Neoadjuvant Therapy: Analysis From the NeoALTTO Trial",2013-12-20,lapatinib,True,['GlaxoSmithKline'],0,South Africa,18,7,1,2,0,0,1,1,1,0,0,0,0,0,0,0
Randomized Controlled Trial of Intensity-Modulated Radiotherapy for Early Breast Cancer: 5-Year Results Confirm Superior Overall Cosmesis,2013-12-20,intensity-modulated radiotherapy,False,[],0,United Kingdom,12,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Randomized, Open-Label, Phase III Study Comparing Irinotecan With Paclitaxel in Patients With Advanced Gastric Cancer Without Severe Peritoneal Metastasis After Failure of Prior Combination Chemotherapy Using Fluoropyrimidine Plus Platinum: WJOG 4007 Trial",2013-12-10,paclitaxel,True,['Bristol-Myers Squibb'],0,Japan,20,2,0,0,0,2,1,0,0,0,0,0,0,0,1,0
Sibling Donor and Recipient Immune Modulation With Atorvastatin for the Prophylaxis of Acute Graft-Versus-Host Disease,2013-12-10,Atorvastatin,False,[],0,USA,11,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
PRECEDENT: A Randomized Phase II Trial Comparing Vintafolide (EC145) and Pegylated Liposomal Doxorubicin (PLD) in Combination Versus PLD Alone in Patients With Platinum-Resistant Ovarian Cancer,2013-12-10,vintafolide,True,['Endocyte'],0,USA,20,16,2,5,0,2,1,1,1,0,0,0,0,0,0,0
Sequential Combination of Gemtuzumab Ozogamicin and Standard Chemotherapy in Older Patients With Newly Diagnosed Acute Myeloid Leukemia: Results of a Randomized Phase III Trial by the EORTC and GIMEMA Consortium (AML-17),2013-12-10,gemtuzumab ozogamicin,True,['Pfizer'],0,Portugal,24,1,0,1,0,1,1,0,0,0,1,0,0,0,0,0
"Randomized, Multicenter, Phase II Study of CO-101 Versus Gemcitabine in Patients With Metastatic Pancreatic Ductal Adenocarcinoma: Including a Prospective Evaluation of the Role of hENT1 in Gemcitabine or CO-101 Sensitivity",2013-12-10,CO-101,True,['Clovis Oncology'],0,Sweden,23,13,7,1,0,1,1,1,1,0,0,0,0,0,0,0
Toward a NOTCH1/FBXW7/RAS/PTENâ€“Based Oncogenetic Risk Classification of Adult T-Cell Acute Lymphoblastic Leukemia: A Group for Research in Adult Acute Lymphoblastic Leukemia Study,2013-12-01,,False,[],0,Belgium,26,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
PointBreak: A Randomized Phase III Study of Pemetrexed Plus Carboplatin and Bevacizumab Followed by Maintenance Pemetrexed and Bevacizumab Versus Paclitaxel Plus Carboplatin and Bevacizumab Followed by Maintenance Bevacizumab in Patients With Stage IIIB or IV Nonsquamous Nonâ€“Small-Cell Lung Cancer,2013-12-01,pemetrexed,True,['Eli Lilly'],0,USA,18,11,6,2,0,3,1,1,1,0,0,0,0,0,0,0
"Safety, Efficacy, and Biomarkers of Nivolumab With Vaccine in Ipilimumab-Refractory or -Naive Melanoma",2013-12-01,nivolumab,True,['Bristol-Myers Squibb'],0,USA,14,4,2,2,0,2,1,1,1,0,0,0,0,0,0,0
Dose-Limiting Toxicity After Hypofractionated Dose-Escalated Radiotherapy in Nonâ€“Small-Cell Lung Cancer,2013-12-01,,False,[],0,Canada,11,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Evaluation of PIK3CA Mutation As a Predictor of Benefit From Nonsteroidal Anti-Inflammatory Drug Therapy in Colorectal Cancer,2013-12-01,aspirin,True,['Bayer'],0,Australia,10,1,0,1,0,1,1,1,0,0,1,0,0,0,0,1
Primary Granulocyte Colony-Stimulating Factor Prophylaxis During the First Two Cycles Only or Throughout All Chemotherapy Cycles in Patients With Breast Cancer at Risk for Febrile Neutropenia,2013-12-01,granulocyte colony-stimulating factor,False,[],0,the Netherlands,20,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Disabling Immune Tolerance by Programmed Death-1 Blockade With Pidilizumab After Autologous Hematopoietic Stem-Cell Transplantation for Diffuse Large B-Cell Lymphoma: Results of an International Phase II Trial,2013-11-20,pidilizumab,True,"['CureTech', 'Cure Tech']",0,USA,24,8,1,3,0,0,1,1,1,0,0,0,0,0,0,0
Oral Tetra-Arsenic Tetra-Sulfide Formula Versus Intravenous Arsenic Trioxide As First-Line Treatment of Acute Promyelocytic Leukemia: A Multicenter Randomized Controlled Trial,2013-11-20,arsenic trioxide,False,[],0,China,9,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Randomized, Double-Blind, Placebo-Controlled, Phase III Chemoprevention Trial of Selenium Supplementation in Patients With Resected Stage I Nonâ€“Small-Cell Lung Cancer: ECOG 5597",2013-11-20,Selenium,False,[],0,Canada,17,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Randomized Phase II Trial of Onartuzumab in Combination With Erlotinib in Patients With Advanced Nonâ€“Small-Cell Lung Cancer,2013-11-10,onartuzumab,True,"['Genentech', 'Genentech (U)']",0,China,20,10,5,5,0,1,1,1,1,0,0,0,0,0,0,0
Net Clinical Benefit Analysis of Radiation Therapy Oncology Group 0525: A Phase III Trial Comparing Conventional Adjuvant Temozolomide With Dose-Intensive Temozolomide in Patients With Newly Diagnosed Glioblastoma,2013-11-10,temozolomide,True,['Merck'],0,USA,12,3,0,2,0,2,1,0,0,0,1,0,0,0,0,0
Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized Phase III Clinical Trial,2013-11-10,temozolomide,True,['Schering-Plough'],0,USA,20,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
Randomized Multicenter Phase II Trial Comparing Two Schedules of Etirinotecan Pegol (NKTR-102) in Women With Recurrent Platinum-Resistant/Refractory Epithelial Ovarian Cancer,2013-11-10,etirinotecan pegol,True,['Nektar Therapeutics'],0,USA,19,8,3,2,0,1,1,1,1,0,0,0,0,0,0,0
Randomized Trial to Assess the Impact of Venlafaxine and Soy Protein on Hot Flashes and Quality of Life in Men With Prostate Cancer,2013-11-10,venlafaxine,False,[],0,USA,11,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Sunitinib Versus Sorafenib in Advanced Hepatocellular Cancer: Results of a Randomized Phase III Trial,2013-11-10,sunitinib,True,"['Pfizer.', 'Pfizer']",0,France,16,7,4,3,0,3,1,1,1,0,0,0,0,0,0,0
Prognostic Relevance of Treatment Response Measured by Flow Cytometric Residual Disease Detection in Older Patients With Acute Myeloid Leukemia,2013-11-10,gemtuzumab ozogamicin,False,[],0,United Kingdom,7,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Breast-Conserving Treatment With or Without Radiotherapy in Ductal Carcinoma In Situ: 15-Year Recurrence Rates and Outcome After a Recurrence, From the EORTC 10853 Randomized Phase III Trial",2013-11-10,,False,[],0,Italy,12,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Interim Cosmetic and Toxicity Results From RAPID: A Randomized Trial of Accelerated Partial Breast Irradiation Using Three-Dimensional Conformal External Beam Radiation Therapy,2013-11-10,,False,[],0,Canada,19,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Prostate-Specific Antigen Changes As Surrogate for Overall Survival in Men With Metastatic Castration-Resistant Prostate Cancer Treated With Second-Line Chemotherapy,2013-11-01,cabazitaxel,True,['sanofi-aventis'],0,USA,8,5,0,2,0,1,1,1,0,0,1,0,0,0,0,0
"Rituximab, Methotrexate, Procarbazine, and Vincristine Followed by Consolidation Reduced-Dose Whole-Brain Radiotherapy and Cytarabine in Newly Diagnosed Primary CNS Lymphoma: Final Results and Long-Term Outcome",2013-11-01,rituximab,True,['Genentech'],0,USA,16,2,0,2,0,0,0,0,0,0,0,0,0,0,0,0
High Prognostic Impact of Flow Cytometric Minimal Residual Disease Detection in Acute Myeloid Leukemia: Data From the HOVON/SAKK AML 42A Study,2013-11-01,,False,[],0,Belgium,36,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Phase II Trial of Palliative Radiotherapy for Hepatocellular Carcinoma and Liver Metastases,2013-11-01,,False,[],0,Canada,12,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Everolimus for Previously Treated Advanced Gastric Cancer: Results of the Randomized, Double-Blind, Phase III GRANITE-1 Study",2013-11-01,everolimus,True,"['Novartis', 'Novartis Pharma AG', 'Novartis Pharmaceuticals', 'Novartis (U)', 'Novartis Pharma KK']",0,Belgium,20,14,6,5,0,4,0,1,0,0,0,0,0,0,0,0
Long-Term Outcomes After Pelvic Radiation for Early-Stage Endometrial Cancer,2013-11-01,,False,[],0,Norway,6,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"ATLAS: Randomized, Double-Blind, Placebo-Controlled, Phase IIIB Trial Comparing Bevacizumab Therapy With or Without Erlotinib, After Completion of Chemotherapy, With Bevacizumab for First-Line Treatment of Advanced NonÃ¢â‚¬â€œSmall-Cell Lung Cancer",2013-11-01,erlotinib,True,['Roche'],0,Taiwan,15,3,0,1,0,2,0,0,0,0,0,0,0,0,0,0
Randomized Trial of Hypofractionated External-Beam Radiotherapy for Prostate Cancer,2013-11-01,Prostate cancer radiation therapy,False,[],0,USA,12,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Denosumab and Bone Metastasisâ€“Free Survival in Men With Nonmetastatic Castration-Resistant Prostate Cancer: Exploratory Analyses by Baseline Prostate-Specific Antigen Doubling Time,2013-10-20,denosumab,True,"['Amgen', 'Amgen (U)']",0,USA,15,11,2,8,0,6,1,1,1,0,0,0,0,0,0,0
Prediction of Survival by [18F]Fluorodeoxyglucose Positron Emission Tomography in Patients With Locally Advanced Nonâ€“Small-Cell Lung Cancer Undergoing Definitive Chemoradiation Therapy: Results of the ACRIN 6668/RTOG 0235 Trial,2013-10-20,[18F]fluorodeoxyglucose,False,[],0,Republic of Korea,19,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Randomized Trial of Decongestive Lymphatic Therapy for the Treatment of Lymphedema in Women With Breast Cancer,2013-10-20,,False,[],0,Canada,13,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Adjuvant Ganglioside GM2-KLH/QS-21 Vaccination Versus Observation After Resection of Primary Tumor > 1.5 mm in Patients With Stage II Melanoma: Results of the EORTC 18961 Randomized Phase III Trial,2013-10-20,GM2-KLH/QS-21 vaccine,True,['GlaxoSmithKline'],0,Canada,17,1,0,1,0,0,1,0,0,0,1,0,0,0,0,0
Tivozanib Versus Sorafenib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma: Results From a Phase III Trial,2013-10-20,tivozanib,True,"['AVEO Pharmaceuticals (U)', 'AVEO Pharmaceuticals']",0,USA,21,9,3,5,0,1,0,1,0,0,0,0,0,0,0,0
Use of Early Tumor Shrinkage to Predict Long-Term Outcome in Metastatic Colorectal Cancer Treated With Cetuximab,2013-10-20,cetuximab,True,['Merck KGaA'],0,Germany,7,2,2,0,0,0,0,0,0,0,0,0,0,0,0,0
Sentinel Node Mapping for Gastric Cancer: A Prospective Multicenter Trial in Japan,2013-10-10,,False,[],0,Japan,20,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Phase Ib Study of Panobinostat and Bortezomib in Relapsed or Relapsed and Refractory Multiple Myeloma,2013-10-10,panobinostat,True,"['Novartis', 'Novartis Pharma AG']",0,Switzerland,14,10,4,4,0,3,1,1,1,0,0,0,0,0,0,0
Prognostic Impact of Deficient DNA Mismatch Repair in Patients With Stage III Colon Cancer From a Randomized Trial of FOLFOX-Based Adjuvant Chemotherapy,2013-10-10,oxaliplatin,False,[],0,USA,10,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Response-Guided Neoadjuvant Chemotherapy for Breast Cancer,2013-10-10,,False,[],0,Switzerland,19,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Are Needs Assessments Cost Effective in Reducing Distress Among Patients With Cancer? A Randomized Controlled Trial Using the Distress Thermometer and Problem List,2013-10-10,,False,[],0,United Kingdom,8,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Cabozantinib in Progressive Medullary Thyroid Cancer,2013-10-10,cabozantinib,True,"['Exelixis', 'Exelixis (U)']",0,USA,19,13,2,6,0,3,1,1,1,0,0,0,0,0,0,0
Single-Agent Lenalidomide in Patients With Mantle-Cell Lymphoma Who Relapsed or Progressed After or Were Refractory to Bortezomib: Phase II MCL-001 (EMERGE) Study,2013-10-10,lenalidomide,True,"['Celgene', 'Celgene (U)']",0,USA,10,7,3,4,0,2,1,1,1,0,0,0,0,0,0,0
Phase I Study of Quizartinib Administered Daily to Patients With Relapsed or Refractory Acute Myeloid Leukemia Irrespective of FMS-Like Tyrosine Kinase 3â€“Internal Tandem Duplication Status,2013-10-10,quizartinib,True,"['Ambit Biosciences (U)', 'Ambit Biosciences']",0,USA,11,6,4,2,0,0,1,0,1,0,0,0,0,0,0,0
Effect of Antiviral Treatment With Nucleotide/Nucleoside Analogs on Postoperative Prognosis of Hepatitis B VirusÃ¢â‚¬â€œRelated Hepatocellular Carcinoma: A Two-Stage Longitudinal Clinical Study,2013-10-10,lamivudine,False,[],0,China,11,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Multicenter Randomized Trial of Centralized Nurse-Led Telephone-Based Care Coordination to Improve Outcomes After Surgical Resection for Colorectal Cancer: The CONNECT Intervention,2013-10-01,,False,[],0,Australia,29,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Phase I Study of ARN-509, a Novel Antiandrogen, in the Treatment of Castration-Resistant Prostate Cancer",2013-10-01,ARN-509,True,"['Aragon Pharmaceuticals (U)', 'Aragon Pharmaceutical', 'Aragon Pharmaceuticals']",0,USA,14,7,4,2,0,0,1,0,1,0,0,0,0,0,0,0
Brivanib in Patients With Advanced Hepatocellular Carcinoma Who Were Intolerant to Sorafenib or for Whom Sorafenib Failed: Results From the Randomized Phase III BRISK-PS Study,2013-10-01,brivanib,True,['Bristol-Myers Squibb'],0,USA,24,13,3,9,0,5,1,1,1,0,0,0,0,0,0,0
"Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL Study",2013-10-01,Brivanib,True,['Bristol-Myers Squibb'],0,Russia,27,9,3,4,0,1,1,1,1,0,0,0,0,0,0,0
German Adjuvant Intergroup Node-Positive Study: A Phase III Trial to Compare Oral Ibandronate Versus Observation in Patients With High-Risk Early Breast Cancer,2013-10-01,ibandronate,True,['Roche'],0,Germany,23,11,0,6,0,10,0,1,0,0,0,0,0,0,0,0
"Randomized, Multicenter, Open-Label Study of Oxaliplatin Plus Fluorouracil/Leucovorin Versus Doxorubicin As Palliative Chemotherapy in Patients With Advanced Hepatocellular Carcinoma From Asia",2013-10-01,FOLFOX4,False,[],0,Taiwan,12,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Gefitinib Versus Placebo in Completely Resected Nonâ€“Small-Cell Lung Cancer: Results of the NCIC CTG BR19 Study,2013-09-20,gefitinib,True,['AstraZeneca'],0,USA,20,7,0,4,0,4,0,1,0,0,0,0,0,0,0,0
Rituximab Maintenance Compared With Observation After Brief First-Line R-FND Chemoimmunotherapy With Rituximab Consolidation in Patients Age Older Than 60 Years With Advanced Follicular Lymphoma: A Phase III Randomized Study by the Fondazione Italiana Linfomi,2013-09-20,rituximab,True,"['Roche', 'Roche S.p.A Italy']",0,Italy,21,9,1,2,0,6,1,1,1,0,0,0,0,0,0,0
Project Connect Online: Randomized Trial of an Internet-Based Program to Chronicle the Cancer Experience and Facilitate Communication,2013-09-20,,False,[],0,USA,5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Optimization of Chemotherapy for Younger Patients With Acute Myeloid Leukemia: Results of the Medical Research Council AML15 Trial,2013-09-20,cytarabine,False,[],0,Denmark,9,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Intrachromosomal Amplification of Chromosome 21 Is Associated With Inferior Outcomes in Children With Acute Lymphoblastic Leukemia Treated in Contemporary Standard-Risk Children's Oncology Group Studies: A Report From the Children's Oncology Group,2013-09-20,,False,[],0,USA,15,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Randomized Controlled Trial of a Structured Intervention to Facilitate End-of-Life Decision Making in Patients With Advanced Cancer,2013-09-20,,False,[],0,Australia,6,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Symptom Control and Quality of Life in LUX-Lung 3: A Phase III Study of Afatinib or Cisplatin/Pemetrexed in Patients With Advanced Lung Adenocarcinoma With EGFR Mutations,2013-09-20,afatinib,True,"['Boehringer Ingelheim (U)', 'Boehringer Ingelheim']",0,USA,12,11,4,6,0,2,1,1,1,0,0,0,0,0,0,0
"LUX-Lung 4: A Phase II Trial of Afatinib in Patients With Advanced Nonâ€“Small-Cell Lung Cancer Who Progressed During Prior Treatment With Erlotinib, Gefitinib, or Both",2013-09-20,afatinib,True,['Boehringer Ingelheim'],0,United Kingdom,15,7,3,2,0,0,1,1,1,0,0,0,0,0,0,0
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations,2013-09-20,afatinib,True,"['Boehringer Ingelheim (U)', 'Boehringer Ingelheim']",0,Germany,20,14,3,7,0,7,1,0,1,0,0,0,0,0,0,0
"Multicenter, Randomized Controlled Trial of Yoga for Sleep Quality Among Cancer Survivors",2013-09-10,,False,[],0,USA,10,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Definitive Results of a Phase III Adjuvant Trial Comparing Three Chemotherapy Regimens in Women With Operable, Node-Positive Breast Cancer: The NSABP B-38 Trial",2013-09-10,gemcitabine,True,['Eli Lilly'],0,USA,20,1,0,1,0,0,1,0,0,0,1,0,0,0,0,0
"Phase III Randomized Trial Comparing the Efficacy of Cediranib As Monotherapy, and in Combination With Lomustine, Versus Lomustine Alone in Patients With Recurrent Glioblastoma",2013-09-10,cediranib,True,"['Astra Zeneca', 'AstraZeneca']",0,the Netherlands,21,10,4,2,0,2,1,1,1,0,0,0,0,0,0,0
"Apatinib for Chemotherapy-Refractory Advanced Metastatic Gastric Cancer: Results From a Randomized, Placebo-Controlled, Parallel-Arm, Phase II Trial",2013-09-10,apatinib,False,[],0,China,18,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Phase II Trial (BREAK-2) of the BRAF Inhibitor Dabrafenib (GSK2118436) in Patients With Metastatic Melanoma,2013-09-10,dabrafenib,True,['GlaxoSmithKline'],0,Australia,20,17,6,9,0,3,1,1,1,0,0,0,0,0,0,0
"Imatinib for Melanomas Harboring Mutationally Activated or Amplified KIT Arising on Mucosal, Acral, and Chronically Sun-Damaged Skin",2013-09-10,imatinib,True,['Novartis'],0,USA,24,12,0,7,0,3,1,0,0,0,1,0,0,0,0,0
Randomized Controlled Trial of Mindfulness-Based Cancer Recovery Versus Supportive Expressive Group Therapy for Distressed Survivors of Breast Cancer (MINDSET),2013-09-01,,False,[],0,Canada,7,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Reduction of Cancer-Related Fatigue With Dexamethasone: A Double-Blind, Randomized, Placebo-Controlled Trial in Patients With Advanced Cancer",2013-09-01,Dexamethasone,False,[],0,USA,14,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Randomized, Phase II, Placebo-Controlled, Double-Blind Study With and Without Enzastaurin in Combination With Paclitaxel and Carboplatin As First-Line Treatment Followed by Maintenance Treatment in Advanced Ovarian Cancer",2013-09-01,enzastaurin,True,['Eli Lilly'],0,USA,12,6,5,0,0,0,1,1,1,0,0,0,0,0,0,0
"Sorafenib in Combination With Intensive Chemotherapy in Elderly Patients With Acute Myeloid Leukemia: Results From a Randomized, Placebo-Controlled Trial",2013-09-01,sorafenib,True,['Bayer'],0,Germany,27,6,0,1,0,2,0,1,0,0,0,0,0,0,0,0
Patterns of Recurrence and Outcome According to Breast Cancer Subtypes in Lymph Nodeâ€“Negative Disease: Results From International Breast Cancer Study Group Trials VIII and IX,2013-09-01,,False,[],0,Portugal,11,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Intensive Chemotherapy and Immunotherapy in Patients With Newly Diagnosed Primary CNS Lymphoma: CALGB 50202 (Alliance 50202),2013-09-01,methotrexate,False,[],0,USA,8,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Molecular Profiling Improves Classification and Prognostication of Nodal Peripheral T-Cell Lymphomas: Results of a Phase III Diagnostic Accuracy Study,2013-08-20,,False,[],0,USA,24,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Prospective Multicenter Study Evaluating the Survival of Patients With Locally Advanced Cervical Cancer Undergoing Laparoscopic Para-Aortic Lymphadenectomy Before Chemoradiotherapy in the Era of Positron Emission Tomography Imaging,2013-08-20,,False,[],0,France,12,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Phase I Pharmacokinetic and Pharmacodynamic Study of Pazopanib in Children With Soft Tissue Sarcoma and Other Refractory Solid Tumors: A Children's Oncology Group Phase I Consortium Report,2013-08-20,pazopanib,True,['GlaxoSmithKline (U)'],0,Canada,12,1,0,1,0,0,1,0,0,0,1,0,0,0,0,0
"Randomized Phase III Trial of Maintenance Bevacizumab With or Without Pemetrexed After First-Line Induction With Bevacizumab, Cisplatin, and Pemetrexed in Advanced Nonsquamous Nonâ€“Small-Cell Lung Cancer: AVAPERL (MO22089)",2013-08-20,pemetrexed,True,"['Eli Lilly (U)', 'Eli Lilly']",0,Switzerland,14,6,0,5,0,2,0,0,0,0,0,0,0,0,0,0
High-Risk Medulloblastoma: A Pediatric Oncology Group Randomized Trial of Chemotherapy Before or After Radiation Therapy (POG 9031),2013-08-10,cisplatin,False,[],0,USA,9,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Phase III Trial of Sunitinib in Combination With Capecitabine Versus Capecitabine Monotherapy for the Treatment of Patients With Pretreated Metastatic Breast Cancer,2013-08-10,sunitinib,True,['Pfizer'],0,USA,22,9,4,4,0,2,1,1,1,0,0,0,0,0,0,0
Obinutuzumab (GA101) Monotherapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma or Mantle-Cell Lymphoma: Results From the Phase II GAUGUIN Study,2013-08-10,obinutuzumab,True,['Roche'],0,United Kingdom,13,10,3,6,0,5,1,1,1,0,0,0,0,0,0,0
Obinutuzumab (GA101) in Patients With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma: Results From the Phase II GAUGUIN Study,2013-08-10,obinutuzumab,True,"['Roche', 'Produits Roche']",0,Switzerland,11,10,3,5,0,4,1,1,1,0,0,0,0,0,0,0
Reducing Treatment Decision Conflict Difficulties in Breast Cancer Surgery: A Randomized Controlled Trial,2013-08-10,,False,[],0,China,6,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
PARAMOUNT: Final Overall Survival Results of the Phase III Study of Maintenance Pemetrexed Versus Placebo Immediately After Induction Treatment With Pemetrexed Plus Cisplatin for Advanced Nonsquamous Nonâ€“Small-Cell Lung Cancer,2013-08-10,pemetrexed,True,['Eli Lilly'],0,the Netherlands,17,12,5,6,0,5,1,1,1,0,0,0,0,0,0,0
Randomized Phase III Trial of Single-Agent Pemetrexed Versus Carboplatin and Pemetrexed in Patients With Advanced Nonâ€“Small-Cell Lung Cancer and Eastern Cooperative Oncology Group Performance Status of 2,2013-08-10,pemetrexed,True,['Eli Lilly'],0,USA,15,4,0,1,0,2,1,1,0,0,1,0,0,0,0,0
Serum Androgens As Prognostic Biomarkers in Castration-Resistant Prostate Cancer: Results From an Analysis of a Randomized Phase III Trial,2013-08-01,abiraterone acetate,True,"['Janssen Pharmaceuticals', 'Janssen Pharmaceuticals Research and Development', 'Janssen Pharmaceuticals (U)']",0,United Kingdom,9,5,3,1,0,1,1,1,1,0,0,0,0,0,0,0
Treatment-Related Mortality in Patients With Advanced-Stage Hodgkin Lymphoma: An Analysis of the German Hodgkin Study Group,2013-08-01,"BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone)",False,[],0,Germany,14,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Randomized Controlled Trial of Entecavir Prophylaxis for Rituximab-Associated Hepatitis B Virus Reactivation in Patients With Lymphoma and Resolved Hepatitis B,2013-08-01,entecavir,False,[],0,Taiwan,12,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Osteonecrosis of the Jaw and Oral Healthâ€“Related Quality of Life After Adjuvant Zoledronic Acid: An Adjuvant Zoledronic Acid to Reduce Recurrence Trial Subprotocol (BIG01/04),2013-07-20,zoledronic acid,True,['Novartis'],0,Australia,14,4,0,3,0,2,1,1,0,0,1,0,0,0,0,0
Use of Allogeneic Hematopoietic Stem-Cell Transplantation Based on Minimal Residual Disease Response Improves Outcomes for Children With Relapsed Acute Lymphoblastic Leukemia in the Intermediate-Risk Group,2013-07-20,,False,[],0,Canada,16,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Effect of Age on Breast Cancer Outcomes in Women With Human Epidermal Growth Factor Receptor 2â€“Positive Breast Cancer: Results From a Herceptin Adjuvant Trial,2013-07-20,trastuzumab,True,"['Genentech (U)', 'Genentech', 'Genentech/Roche (U)']",0,United Kingdom,8,2,0,2,0,0,0,0,0,0,0,0,0,0,0,0
Minimal Residual Disease Assessed by Multiparameter Flow Cytometry in Multiple Myeloma: Impact on Outcome in the Medical Research Council Myeloma IX Study,2013-07-10,thalidomide,True,['Celgene'],0,United Kingdom,15,9,0,5,0,5,1,1,0,0,1,0,0,0,0,0
"Fluorouracil, Doxorubicin, and Cyclophosphamide (FAC) Versus FAC Followed by Weekly Paclitaxel As Adjuvant Therapy for High-Risk, Node-Negative Breast Cancer: Results From the GEICAM/2003-02 Study",2013-07-10,paclitaxel,False,[],0,Spain,30,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Randomized Open-Label Phase II Study of  Decitabine in Patients With Low- or Intermediate-Risk  Myelodysplastic Syndromes,2013-07-10,decitabine,True,['Eisai Pharmaceuticals'],0,USA,13,4,0,1,0,1,1,0,0,0,1,0,0,0,0,0
Randomized Phase II Study of the Antiâ€“Epidermal Growth Factor Receptor Monoclonal Antibody Cetuximab With Cisplatin Versus Cisplatin Alone in Patients With Metastatic Triple-Negative Breast Cancer,2013-07-10,cetuximab,True,['Merck KGaA'],0,Germany,19,3,2,1,0,1,1,1,1,0,0,0,0,0,0,1
Randomized Double-Blind Placebo-Controlled Trial of Acetyl-L-Carnitine for the Prevention of Taxane-Induced Neuropathy in Women Undergoing Adjuvant Breast  Cancer Therapy,2013-07-10,acetyl-L-carnitine,False,[],0,USA,15,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Results of an International Randomized Phase III Trial of the Mammalian Target of Rapamycin Inhibitor Ridaforolimus Versus Placebo to Control Metastatic Sarcomas in Patients After Benefit From Prior Chemotherapy,2013-07-01,ridaforolimus,True,"['ARIAD Pharmaceuticals (U)', 'ARIAD Pharmaceuticals']",0,USA,22,7,2,2,0,2,0,1,0,0,0,0,0,0,0,0
Resolution of Clostridium difficileâ€“Associated Diarrhea in Patients With Cancer Treated With Fidaxomicin or Vancomycin,2013-07-01,fidaxomicin,True,"['Optimer Pharma', 'Optimer', 'Optimer Pharmaceuticals']",0,USA,6,6,2,4,0,4,1,1,1,0,0,0,0,0,0,0
Dasatinib in Children and Adolescents With Relapsed or Refractory Leukemia: Results of the CA180-018 Phase I Dose-Escalation Study of the Innovative Therapies for Children With Cancer Consortium,2013-07-01,Dasatinib,True,['Bristol-Myers Squibb'],0,France,17,7,4,1,0,0,1,1,1,0,0,0,0,0,0,0
Selection of Immunostimulant AS15 for Active Immunization With MAGE-A3 Protein: Results of a Randomized Phase II Study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic Melanoma,2013-07-01,MAGE-A3 protein,True,"['GlaxoSmithKline Biologicals', 'GlaxoSmithKline']",0,Germany,17,11,3,8,0,4,1,1,1,0,0,0,0,0,0,0
Adjuvant MAGE-A3 Immunotherapy in Resected Nonâ€“Small-Cell Lung Cancer: Phase II Randomized Study Results,2013-07-01,Recombinant MAGE-A3 protein immunotherapeutic,True,"['GlaxoSmithKline Biologicals (U)', 'GlaxoSmithKline Biologicals']",0,United Kingdom,19,9,3,3,0,2,1,1,1,0,0,0,0,0,0,0
"Prospective Investigation of Body Mass Index, Colorectal Adenoma, and Colorectal Cancer in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial",2013-07-01,,False,[],0,USA,7,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Predictive Gene Signature in MAGE-A3 Antigen-Specific Cancer Immunotherapy,2013-07-01,MAGE-A3 immunotherapeutic,True,['GlaxoSmithKline Vaccines'],0,France,11,8,7,1,0,0,1,1,1,0,0,0,0,0,0,0
"Phase III Randomized, Placebo-Controlled Study of Cetuximab Plus Brivanib Alaninate Versus Cetuximab Plus Placebo in Patients With Metastatic, Chemotherapy-Refractory, Wild-Type K-RAS Colorectal Carcinoma: The NCIC Clinical Trials Group and AGITG CO.20 Trial",2013-07-01,cetuximab,True,"['Merck Serono', 'Merck Serono (U)']",0,USA,21,5,0,4,0,2,0,0,0,0,0,0,0,0,0,0
Lumpectomy Plus Tamoxifen With or Without Irradiation in Women Age 70 Years or Older With Early Breast Cancer: Long-Term Follow-Up of CALGB 9343,2013-07-01,tamoxifen,False,[],0,USA,11,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Randomized International Phase III Trial of ERCC1 and RRM1 Expressionâ€“Based Chemotherapy Versus Gemcitabine/Carboplatin in Advanced Nonâ€“Small-Cell Lung Cancer,2013-07-01,gemcitabine,True,['Eli Lilly'],0,Germany,17,2,0,1,0,1,1,0,0,0,1,0,0,0,0,0
"Methylphenidate and/or a Nursing Telephone Intervention for Fatigue in Patients With Advanced Cancer: A Randomized, Placebo-Controlled, Phase II Trial",2013-07-01,methylphenidate,False,[],0,Chile,8,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Effects of a Telephone-Delivered Multiple Health Behavior Change Intervention (CanChange) on Health and Behavioral Outcomes in Survivors of Colorectal Cancer: A Randomized Controlled Trial,2013-06-20,,False,[],0,Canada,9,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Cediranib for Metastatic Alveolar Soft Part Sarcoma,2013-06-20,cediranib,False,[],0,USA,14,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Randomized Selection Design Trial Evaluating CD8+-Enriched Versus Unselected Tumor-Infiltrating Lymphocytes for Adoptive Cell Therapy for Patients With Melanoma,2013-06-10,,False,[],0,USA,18,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Randomized Phase II, Double-Blind, Placebo-Controlled Study of Exemestane With or Without Entinostat in Postmenopausal Women With Locally Recurrent or Metastatic Estrogen Receptor-Positive Breast Cancer Progressing on Treatment With a Nonsteroidal Aromatase Inhibitor",2013-06-10,entinostat,True,"['Syndax Pharmaceuticals', 'Syndax Pharmaceuticals (U)']",0,USA,10,4,0,3,0,0,1,1,0,0,1,0,0,0,0,0
Impact of PTEN Protein Expression on Benefit From Adjuvant Trastuzumab in Early-Stage Human Epidermal Growth Factor Receptor 2â€“Positive Breast Cancer in the North Central Cancer Treatment Group N9831 Trial,2013-06-10,trastuzumab,True,"['Genentech', 'Genentech/Roche']",0,USA,15,3,0,1,0,0,1,1,0,0,1,0,0,0,0,0
Pooled Analysis of the Prognostic and Predictive Effects of KRAS Mutation Status and KRAS Mutation Subtype in Early-Stage Resected Nonâ€“Small-Cell Lung Cancer in Four Trials of Adjuvant Chemotherapy,2013-06-10,,False,[],0,USA,21,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
High-Dose Cytarabine Consolidation With or Without Additional Amsacrine and Mitoxantrone in Acute Myeloid Leukemia: Results of the Prospective Randomized AML2003 Trial,2013-06-10,mitoxantrone,True,['Novartis'],0,Czech Republic,22,3,0,0,0,3,0,1,0,0,0,0,0,0,0,0
Multicenter Phase II Study of Bendamustine Plus Rituximab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma,2013-06-10,bendamustine,True,['SymBio Pharmaceuticals'],0,Korea,17,2,0,2,0,0,0,1,0,0,0,0,0,0,0,0
Randomized Phase II Study of Ixabepilone or Paclitaxel Plus Carboplatin in Patients With Nonâ€“Small-Cell Lung Cancer Prospectively Stratified by Beta-3 Tubulin Status,2013-06-01,ixabepilone,True,['Bristol-Myers Squibb'],0,USA,11,7,4,3,0,1,1,1,1,0,0,0,0,0,0,0
"Magnitude of Trastuzumab Benefit in Patients With  HER2-Positive, Invasive Lobular Breast Carcinoma: Results From the HERA Trial",2013-06-01,trastuzumab,True,"['Genentech', 'Roche-Genentech']",0,USA,18,2,0,1,0,1,0,0,0,0,0,0,0,0,0,0
Phase II Trial of the CDK4 Inhibitor PD0332991 in Patients With Advanced CDK4-Amplified Well-Differentiated or Dedifferentiated Liposarcoma,2013-06-01,palbociclib,True,['Pfizer'],0,USA,14,3,0,3,0,0,1,1,0,0,1,1,0,0,0,0
"90Yttrium-Ibritumomab Tiuxetan Consolidation of First Remission in Advanced-Stage Follicular Non-Hodgkin Lymphoma: Updated Results After a Median Follow-Up of 7.3 Years From the International, Randomized, Phase III First-Line Indolent Trial",2013-06-01,90Y-ibritumomab tiuxetan,True,['Spectrum Pharmaceuticals'],0,USA,12,3,1,2,0,1,1,0,1,0,0,0,0,0,0,0
Randomized Trial of Lapatinib Versus Placebo Added to Paclitaxel in the Treatment of Human Epidermal Growth Factor Receptor 2â€“Overexpressing Metastatic Breast Cancer,2013-06-01,lapatinib,True,['GlaxoSmithKline'],0,Peru,17,5,3,0,0,0,1,1,1,0,0,0,0,0,0,0
Randomized Controlled Trial of Cetuximab Plus Chemotherapy for Patients With KRAS Wild-Type Unresectable Colorectal Liver-Limited Metastases,2013-06-01,cetuximab,False,[],0,China,11,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Associations Between Cigarette Smoking Status and Colon Cancer Prognosis Among Participants in North Central Cancer Treatment Group Phase III Trial N0147,2013-06-01,cetuximab,False,[],0,USA,7,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Multicenter Phase II Study of Neoadjuvant Lapatinib and Trastuzumab With Hormonal Therapy and Without Chemotherapy in Patients With Human Epidermal Growth Factor Receptor 2â€“Overexpressing Breast Cancer: TBCRC 006,2013-05-10,lapatinib,True,['GlaxoSmithKline'],0,USA,13,3,0,0,0,0,0,1,0,0,0,0,0,0,0,0
AVEREL: A Randomized Phase III Trial Evaluating Bevacizumab in Combination With Docetaxel and Trastuzumab As First-Line Therapy for HER2-Positive Locally Recurrent/Metastatic Breast Cancer,2013-05-10,bevacizumab,True,"['Roche', 'F. Hoffmann-La Roche']",0,Switzerland,17,9,3,4,0,3,1,1,1,0,0,0,0,0,0,0
"Phase III, Multicenter, Randomized Trial of Maintenance Chemotherapy Versus Observation in Patients With Metastatic Breast Cancer After Achieving Disease Control With Six Cycles of Gemcitabine Plus Paclitaxel As First-Line Chemotherapy: KCSG-BR07-02",2013-05-10,paclitaxel,False,[],0,Korea,19,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Phase III, Randomized, Placebo-Controlled Study of Docetaxel in Combination With Zibotentan in Patients With Metastatic Castration-Resistant Prostate Cancer",2013-05-10,zibotentan,True,['AstraZeneca'],0,USA,10,10,4,5,0,2,1,1,1,0,0,0,0,0,0,0
Pharmacodynamic Effects and Mechanisms of Resistance to Vemurafenib in Patients With Metastatic Melanoma,2013-05-10,vemurafenib,True,"['Roche Genentech', 'Genentech', 'F. Hoffmann-La Roche', 'F. Hoffmann-La Roche/Genentech', 'Roche', 'Roche Diagnostics', 'Roche (U)']",0,USA,29,19,6,12,0,6,1,1,1,0,0,0,0,0,0,0
"Randomized Phase III Study of Gemcitabine Plus S-1, S-1 Alone, or Gemcitabine Alone in Patients With Locally Advanced and Metastatic Pancreatic Cancer in Japan and Taiwan: GEST Study",2013-05-01,S-1,True,"['Taiho Pharmaceutical', 'Taiho Pharmaceutical Co. Ltd', 'Taiho Pharmaceutical (U)']",0,Taiwan,25,22,0,14,0,17,1,1,0,0,1,0,0,0,0,0
Rituximab Purging and/or Maintenance in Patients Undergoing Autologous Transplantation for Relapsed Follicular Lymphoma: A Prospective Randomized Trial From the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation,2013-05-01,rituximab,True,['Roche'],0,Czech Republic,20,10,0,5,0,5,1,1,0,0,1,0,0,0,0,0
"Allogeneic Hematopoietic Cell Transplantation for Fanconi Anemia in Patients With Pretransplantation Cytogenetic Abnormalities, Myelodysplastic Syndrome, or Acute Leukemia",2013-05-01,,False,[],0,United Kingdom,29,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Sequential Phase I and II Trials of Stereotactic Body Radiotherapy for Locally Advanced Hepatocellular Carcinoma,2013-05-01,,False,[],0,Canada,14,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Phase III Randomized Study of Rituximab/Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) Compared With Iodine-131 Tositumomab/BEAM With Autologous Hematopoietic Cell Transplantation for Relapsed Diffuse Large B-Cell Lymphoma: Results From the BMT CTN 0401 Trial",2013-05-01,Rituximab,True,['Genentech'],0,USA,13,3,0,1,0,0,0,1,0,0,0,0,0,0,0,0
R-CVP Versus R-CHOP Versus R-FM for the Initial Treatment of Patients With Advanced-Stage Follicular Lymphoma: Results of the FOLL05 Trial Conducted by the Fondazione Italiana Linfomi,2013-04-20,rituximab,True,['Roche'],0,Italy,20,1,0,1,0,0,1,1,0,0,1,1,0,0,0,0
ABVD in Older Patients With Early-Stage Hodgkin Lymphoma Treated Within the German Hodgkin Study Group HD10 and HD11 Trials,2013-04-20,ABVD,False,[],0,Austria,17,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Abagovomab As Maintenance Therapy in Patients With Epithelial Ovarian Cancer: A Phase III Trial of the AGO OVAR, COGI, GINECO, and GEICOâ€”The MIMOSA Study",2013-04-20,abagovomab,True,['Menarini Ricerche'],0,USA,29,10,5,3,0,0,1,0,1,0,0,0,0,0,0,0
"Phase III Randomized, Placebo-Controlled Trial of Docetaxel With or Without Gefitinib in Recurrent or Metastatic Head and Neck Cancer: An Eastern Cooperative Oncology Group Trial",2013-04-10,gefitinib,True,['AstraZeneca'],0,USA,8,3,0,1,0,1,1,0,0,0,1,0,0,0,0,0
Cisplatin and Radiotherapy With or Without Erlotinib in Locally Advanced Squamous Cell Carcinoma of the Head and Neck: A Randomized Phase II Trial,2013-04-10,erlotinib,True,['OSI Pharmaceuticals'],0,USA,18,2,0,0,0,0,0,1,0,0,0,0,0,0,0,0
Prospective Randomized Phase II Trial of a Single Early Intravesical Instillation of Pirarubicin (THP) in the Prevention of Bladder Recurrence After Nephroureterectomy for Upper Urinary Tract Urothelial Carcinoma: The THP Monotherapy Study Group Trial,2013-04-10,pirarubicin,False,[],0,Japan,23,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Combination of Rituximab, Bendamustine, and Cytarabine for Patients With Mantle-Cell Non-Hodgkin Lymphoma Ineligible for Intensive Regimens or Autologous Transplantation",2013-04-10,rituximab,False,[],0,Italy,11,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Exemestane Versus Anastrozole in Postmenopausal Women With Early Breast Cancer: NCIC CTG MA.27â€”A Randomized Controlled Phase III Trial,2013-04-10,exemestane,True,"['Pfizer (U)', 'Pfizer']",0,Hungary,21,5,0,4,0,1,1,0,0,0,1,0,0,0,0,0
Geriatric Factors Predict Chemotherapy Feasibility: Ancillary Results of FFCD 2001-02 Phase III Study in First-Line Chemotherapy for Metastatic Colorectal Cancer in Elderly Patients,2013-04-10,irinotecan,True,['Pfizer'],0,France,17,4,0,0,0,4,1,1,0,0,0,0,0,0,1,1
Results of a Multicenter Prospective Study on the Postoperative Treatment of Unilateral Retinoblastoma After Primary Enucleation,2013-04-10,thiotepa,False,[],0,CHU Nantes,13,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Effects of Melatonin on Appetite and Other Symptoms in Patients With Advanced Cancer and Cachexia: A Double-Blind Placebo-Controlled Trial,2013-04-01,melatonin,False,[],0,USA,5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Effect of Ruxolitinib Therapy on Myelofibrosis-Related Symptoms and Other Patient-Reported Outcomes in COMFORT-I: A Randomized, Double-Blind, Placebo-Controlled Trial",2013-04-01,ruxolitinib,True,['Incyte'],0,USA,18,16,5,6,0,6,1,1,1,0,0,0,0,0,0,0
Specificity of Problem-Solving Skills Training in Mothers of Children Newly Diagnosed With Cancer: Results of a Multisite Randomized Clinical Trial,2013-04-01,,False,[],0,USA,8,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Two-Year Randomized Controlled Prospective Trial Converting Treatment of Stable Renal Transplant Recipients With Cutaneous Invasive Squamous Cell Carcinomas to Sirolimus,2013-04-01,sirolimus,True,['Pfizer'],0,United Kingdom,7,1,0,0,0,1,1,1,0,0,0,0,0,0,1,1
"Fluorouracil, Leucovorin, and Irinotecan Plus Either Sunitinib or Placebo in Metastatic Colorectal Cancer: A Randomized, Phase III Trial",2013-04-01,sunitinib,True,['Pfizer'],0,Belgium,17,9,6,1,0,1,1,1,1,0,0,0,0,0,0,0
"Final Results of Phase III SYMMETRY Study: Randomized, Double-Blind Trial of Elesclomol Plus Paclitaxel Versus Paclitaxel Alone As Treatment for Chemotherapy-Naive Patients With Advanced Melanoma",2013-03-20,elesclomol,True,['Synta Pharmaceuticals'],0,USA,19,6,3,2,0,0,1,0,1,0,0,0,0,0,0,0
Steroid-Sparing Effect of Corticorelin Acetate in Peritumoral Cerebral Edema Is Associated With Improvement in Steroid-Induced Myopathy,2013-03-20,corticorelin acetate,True,['Celtic Pharma'],0,USA,5,4,1,2,0,0,1,1,1,0,0,0,0,0,0,0
"Oral Antibiotics for Fever in Low-Risk Neutropenic Patients With Cancer: A Double-Blind, Randomized, Multicenter Trial Comparing Single Daily Moxifloxacin With Twice Daily Ciprofloxacin Plus Amoxicillin/Clavulanic Acid Combination Therapyâ€”EORTC Infectious Diseases  Group Trial XV",2013-03-20,moxifloxacin,True,['Bayer HealthCare Pharmaceuticals'],0,Italy,10,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
Postinduction Dexamethasone and Individualized Dosing of Escherichia Coli L-Asparaginase Each Improve Outcome of Children and Adolescents With Newly Diagnosed Acute Lymphoblastic Leukemia: Results From a Randomized Studyâ€”Dana-Farber Cancer Institute ALL Consortium Protocol 00-01,2013-03-20,Escherichia coli L-asparaginase,True,['Sigma-Tau Pharmaceuticals'],0,Canada,19,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Phase II Randomized Study of Trastuzumab Emtansine Versus Trastuzumab Plus Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2Ã¢â‚¬â€œPositive Metastatic Breast Cancer,2013-03-20,trastuzumab emtansine (T-DM1),True,['Roche'],0,USA,12,4,0,0,0,0,0,1,0,0,0,0,0,0,0,0
Randomized Phase III Multi-Institutional Study of TNFerade Biologic With Fluorouracil and Radiotherapy for Locally Advanced Pancreatic Cancer: Final Results,2013-03-01,TNFerade,True,['GenVec'],0,USA,19,1,0,1,0,0,1,1,0,0,1,0,0,0,0,0
Phase II Trial of Erlotinib Plus Concurrent Whole-Brain Radiation Therapy for Patients With Brain Metastases From Nonâ€“Small-Cell Lung Cancer,2013-03-01,erlotinib,True,['Genentech'],0,USA,18,2,0,1,0,2,1,1,0,0,1,0,0,0,0,1
Prognostic and Predictive Value of Tumor-Infiltrating Lymphocytes in a Phase III Randomized Adjuvant Breast Cancer Trial in Node-Positive Breast Cancer Comparing the Addition of Docetaxel to Doxorubicin With Doxorubicin-Based Chemotherapy: BIG 02-98,2013-03-01,doxorubicin,False,[],0,Hungary,16,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Induction Chemotherapy Followed by Either Chemoradiotherapy or Bioradiotherapy for Larynx Preservation: The TREMPLIN Randomized Phase II Study,2013-03-01,cetuximab,True,"['Merck', 'Merck Serono']",0,Belgium,24,3,1,1,0,3,1,1,1,0,0,0,0,0,0,1
Long-Term Results of RTOG 91-11: A Comparison of Three Nonsurgical Treatment Strategies to Preserve the Larynx in Patients With Locally Advanced Larynx Cancer,2013-03-01,cisplatin,False,[],0,USA,14,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Gonadotropin-Releasing Hormone Agonist for the Prevention of Chemotherapy-Induced Ovarian Failure in Patients With Lymphoma: 1-Year Follow-Up of a Prospective Randomized Trial,2013-03-01,triptorelin,True,['Ipsen'],0,Italy,12,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0
Bortezomib Added to Daunorubicin and Cytarabine During Induction Therapy and to Intermediate-Dose Cytarabine for Consolidation in Patients With Previously Untreated Acute Myeloid Leukemia Age 60 to 75 Years: CALGB (Alliance) Study 10502,2013-03-01,bortezomib,False,[],0,USA,16,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Phase II Study of Gemcitabine, Carboplatin, and Bevacizumab in Patients With Advanced Unresectable or Metastatic Urothelial Cancer",2013-02-20,bevacizumab,True,['Genentech'],0,USA,11,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0
Systematic Monitoring and Treatment of Physical Symptoms to Alleviate Fatigue in Patients With Advanced Cancer: A Randomized Controlled Trial,2013-02-20,,False,[],0,the Netherlands,6,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Randomized Phase III Trial of ABVD Versus Stanford V With or Without Radiation Therapy in Locally Extensive and Advanced-Stage Hodgkin Lymphoma: An Intergroup Study Coordinated by the Eastern Cooperative Oncology Group (E2496),2013-02-20,"doxorubicin, bleomycin, vinblastine, dacarbazine",False,[],0,USA,18,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"High-Dose Vincristine Sulfate Liposome Injection for Advanced, Relapsed, and Refractory Adult Philadelphia Chromosomeâ€“Negative Acute Lymphoblastic Leukemia",2013-02-20,vincristine sulfate liposome injection,True,['Talon Therapeutics'],0,Canada,27,17,2,5,0,0,1,1,1,0,0,0,0,0,0,0
"Randomized Phase III Trial of Induction Chemotherapy With Docetaxel, Cisplatin, and Fluorouracil Followed by Surgery Versus Up-Front Surgery in Locally Advanced Resectable Oral Squamous Cell Carcinoma",2013-02-20,docetaxel,True,['sanofi-aventis'],0,USA,26,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0
Randomized Trial of Myeloablative Conditioning Regimens: Busulfan Plus Cyclophosphamide Versus Busulfan Plus Fludarabine,2013-02-20,busulfan,True,['Otsuka'],0,Korea,15,1,0,1,0,0,1,1,0,0,1,1,0,0,0,0
Improved Outcome in Pediatric Relapsed Acute Myeloid Leukemia: Results of a Randomized Trial on Liposomal Daunorubicin by the International BFM Study Group,2013-02-10,liposomal daunorubicin,True,['Galen'],0,Israel,20,2,0,2,0,0,1,1,0,0,1,1,0,0,0,0
Phase III Randomized Clinical Trial Comparing Tremelimumab With Standard-of-Care Chemotherapy in Patients With Advanced Melanoma,2013-02-10,tremelimumab,True,['Pfizer'],0,USA,24,14,4,6,0,2,1,1,1,0,0,0,0,0,0,0
Prostate Cancer Diagnosis Among Men With Isolated High-Grade Intraepithelial Neoplasia Enrolled Onto a 3-Year Prospective Phase III Clinical Trial of Oral Toremifene,2013-02-10,toremifene citrate,True,"['GTx', 'Gtx']",0,USA,6,6,4,2,0,1,1,1,1,0,0,0,0,0,0,0
Safety and Clinical Activity of a Combination Therapy Comprising Two Antibody-Based Targeting Agents for the Treatment of Non-Hodgkin Lymphoma: Results of a Phase I/II Study Evaluating the Immunoconjugate Inotuzumab Ozogamicin With Rituximab,2013-02-10,Inotuzumab ozogamicin,True,['Pfizer'],0,USA,20,12,5,3,0,4,1,1,1,0,0,0,0,0,0,0
Addition of Rituximab to Chlorambucil Produces Superior Event-Free Survival in the Treatment of Patients With Extranodal Marginal-Zone B-Cell Lymphoma: 5-Year Analysis of the IELSG-19 Randomized Study,2013-02-10,rituximab,True,['Genentech'],0,United Kingdom,20,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0
Phase II Study of Lenalidomide and Rituximab As Salvage Therapy for Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia,2013-02-10,lenalidomide,True,['Celgene'],0,USA,9,4,0,3,0,0,1,1,0,0,1,0,0,0,0,0
Radiofrequency Ablation With or Without Transcatheter Arterial Chemoembolization in the Treatment of Hepatocellular Carcinoma: A Prospective Randomized Trial,2013-02-01,,False,[],0,China,9,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Phase II Study of the MEK1/MEK2 Inhibitor Trametinib in Patients With Metastatic BRAF-Mutant Cutaneous Melanoma Previously Treated With or Without a BRAF Inhibitor,2013-02-01,trametinib,True,"['GlaxoSmithKline (U)', 'GlaxoSmithKline']",0,USA,20,17,6,6,0,0,1,1,1,0,0,0,0,0,0,0
Phase II Study of Bendamustine in Relapsed and Refractory Hodgkin Lymphoma,2013-02-01,bendamustine,True,"['Cephalon', 'Cephalon/Teva']",0,USA,13,3,0,1,0,0,0,1,0,0,0,0,0,0,0,0
Persistent Overall Survival Benefit and No Increased Risk of Second Malignancies With Bortezomib-Melphalan-Prednisone Versus Melphalan-Prednisone in Patients With Previously Untreated Multiple Myeloma,2013-02-01,bortezomib,True,['Millennium Pharmaceuticals'],0,United Kingdom,22,8,1,4,0,6,1,0,1,0,0,0,0,0,0,0
Cabozantinib in Patients With Advanced Prostate Cancer: Results of a Phase II Randomized Discontinuation Trial,2013-02-01,cabozantinib,True,"['Exelixis (U)', 'Exelixis']",0,Belgium,21,12,2,7,0,2,0,0,0,0,0,0,0,0,0,0
Phase III Trial of Carboplatin and Paclitaxel With or Without Sorafenib in Metastatic Melanoma,2013-01-20,sorafenib,True,['Onyx Pharmaceuticals'],0,USA,9,1,0,1,0,0,1,0,0,0,1,0,0,0,0,0
Superior Long-Term Outcome With Idarubicin Compared With High-Dose Daunorubicin in Patients With Acute Myeloid Leukemia Age 50 Years and Older,2013-01-20,idarubicin,False,[],0,France,19,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Bevacizumab in Stage II-III Colon Cancer: 5-Year Update of the National Surgical Adjuvant Breast and Bowel Project C-08 Trial ,2013-01-20,bevacizumab,True,"['Genentech', 'Genentech (U)']",0,USA,7,3,0,3,0,0,1,1,0,0,1,1,0,0,0,0
Phase III Randomized Intergroup Trial of CHOP Plus Rituximab Compared With CHOP Chemotherapy Plus 131Iodine-Tositumomab for Previously Untreated Follicular Non-Hodgkin Lymphoma: SWOG S0016,2013-01-20,rituximab,True,"['Roche/Genentech', 'Genentech', 'Roche']",0,USA,15,6,0,5,0,3,1,0,0,0,1,0,0,0,0,0
Randomized Controlled Trial of a Video Decision Support Tool for Cardiopulmonary Resuscitation Decision Making in Advanced Cancer,2013-01-20,,False,[],0,USA,23,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Adjuvant Procarbazine, Lomustine, and Vincristine  Chemotherapy in Newly Diagnosed Anaplastic Oligodendroglioma: Long-Term Follow-Up of EORTC Brain Tumor Group Study 26951",2013-01-20,"PCV chemotherapy (procarbazine, lomustine, vincristine)",False,[],0,Belgium,19,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Intrinsic Molecular Subtypes of Glioma Are Prognostic and Predict Benefit From Adjuvant Procarbazine, Lomustine, and Vincristine Chemotherapy in Combination With Other Prognostic Factors in Anaplastic Oligodendroglial Brain Tumors: A Report From EORTC Study 26951",2013-01-20,"Procarbazine, Lomustine, and Vincristine (PCV)",False,[],0,Belgium,14,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Results of a Randomized Trial of Chlorambucil Versus Fludarabine for Patients With Untreated WaldenstrÃƒÂ¶m Macroglobulinemia, Marginal Zone Lymphoma, or Lymphoplasmacytic Lymphoma",2013-01-20,fludarabine,False,[],0,Australia,21,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
90Yttrium-Ibritumomab-Tiuxetan as First-Line Treatment for Follicular Lymphoma: 30 Months of Follow-Up Data From an International Multicenter Phase II Clinical Trial,2013-01-20,ibritumomab tiuxetan,True,['Bayer Schering Pharma'],0,Sweden,15,3,0,1,0,2,1,1,0,0,1,0,0,0,0,0
Phase III Trial of Chemoradiotherapy for Anaplastic Oligodendroglioma: Long-Term Results of RTOG 9402,2013-01-20,"PCV (procarbazine, lomustine, vincristine)",False,[],0,USA,11,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Randomized Phase III Placebo-Controlled Trial of Letrozole Plus Oral Temsirolimus As First-Line Endocrine Therapy in Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer,2013-01-10,temsirolimus,True,['Wyeth Research'],0,USA,19,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Phase II and Biomarker Study of the Dual MET/VEGFR2 Inhibitor Foretinib in Patients With Papillary Renal Cell Carcinoma,2013-01-10,foretinib,True,['Exelixis'],0,USA,23,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Positron Emission Tomography/Computed Tomography Identification of Clear Cell Renal Cell Carcinoma: Results From the REDECT Trial,2013-01-10,girentuximab,True,"['WILEX (U)', 'WILEX']",0,Germany,11,11,4,4,0,0,1,1,1,0,0,0,0,0,0,0
"Randomized Phase II Study of Bortezomib, Thalidomide, and Dexamethasone With or Without Cyclophosphamide As Induction Therapy in Previously Untreated Multiple Myeloma",2013-01-10,bortezomib,True,['Millennium Pharmaceuticals'],0,Belgium,19,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
Molecular Gene Expression Profiling to Predict the Tissue of Origin and Direct Site-Specific Therapy in Patients With Carcinoma of Unknown Primary Site: A Prospective Trial of the Sarah Cannon Research Institute,2013-01-10,92-gene cancer classification assay,True,['bioTheranostics'],0,USA,7,1,0,0,0,1,1,1,0,0,0,0,0,0,1,0
A European Organisation for Research and Treatment of Cancer Phase III Trial of Adjuvant Whole-Brain Radiotherapy Versus Observation in Patients With One to Three Brain Metastases From Solid Tumors After Surgical Resection or Radiosurgery: Quality-of-Life Results,2013-01-01,,False,[],0,Belgium,18,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Impact of FOLFIRINOX Compared With Gemcitabine on Quality of Life in Patients With Metastatic Pancreatic Cancer: Results From the PRODIGE 4/ACCORD 11 Randomized Trial,2013-01-01,FOLFIRINOX,True,['sanofi-aventis'],0,France,12,2,0,0,0,1,0,1,0,0,0,0,0,0,0,1
Results of Annual Screening in Phase I of the United Kingdom Familial Ovarian Cancer Screening Study Highlight the Need for Strict Adherence to Screening Schedule,2013-01-01,,False,[],0,USA,16,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Parenteral Hydration in Patients With Advanced Cancer: A Multicenter, Double-Blind, Placebo-Controlled Randomized Trial",2013-01-01,,False,[],0,USA,13,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Pegylated Liposomal Doxorubicin, Rituximab, Cyclophosphamide, Vincristine, and Prednisone in AIDS-Related Lymphoma: AIDS Malignancy Consortium Study 047",2013-01-01,pegylated liposomal doxorubicin,False,[],0,USA,14,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Results From a Prospective, Open-Label, Phase II Trial of Bendamustine in Refractory or Relapsed T-Cell Lymphomas: The BENTLY Trial",2013-01-01,bendamustine,True,"['Mundipharma', 'Mundipharma (U)']",0,France,26,4,1,0,0,4,1,1,1,0,0,0,0,0,0,0
Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies,2013-01-01,ibrutinib,True,"['Pharamcyclics', 'Pharamacyclics', 'Pharmacyclics']",0,USA,15,12,5,3,0,0,1,1,1,0,0,0,0,0,0,0
Acupuncture for Cancer-Related Fatigue in Patients With Breast Cancer: A Pragmatic Randomized Controlled Trial,2012-12-20,,False,[],0,United Kingdom,8,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Clinical Outcome of the ACCORD 12/0405 PRODIGE 2 Randomized Trial in Rectal Cancer,2012-12-20,capecitabine,True,['Roche'],0,France,22,4,0,4,0,2,1,0,0,0,1,0,0,0,0,0
Pemetrexed Versus Pemetrexed and Carboplatin As Second-Line Chemotherapy in Advanced Nonâ€“Small-Cell Lung Cancer: Results of the GOIRC 02-2006 Randomized Phase II Study and Pooled Analysis With the NVALT7 Trial,2012-12-20,pemetrexed,True,['Eli Lilly'],0,the Netherlands,25,6,0,0,0,6,1,1,0,0,0,0,0,0,1,1
Rituximab Maintenance Therapy After Autologous Stem-Cell Transplantation in Patients With Relapsed CD20+ Diffuse Large B-Cell Lymphoma: Final Analysis of the Collaborative Trial in Relapsed Aggressive Lymphoma,2012-12-20,rituximab,True,"['Roche', 'Roche Pharma', 'Roche (U)']",0,USA,20,11,0,7,0,8,1,1,0,0,1,0,0,0,0,0
Biallelic ATM Inactivation Significantly Reduces Survival in Patients Treated on the United Kingdom Leukemia Research Fund Chronic Lymphocytic Leukemia 4 Trial,2012-12-20,chlorambucil,False,[],0,United Kingdom,14,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Mammostrat As an Immunohistochemical Multigene Assay for Prediction of Early Relapse Risk in the Tamoxifen Versus Exemestane Adjuvant Multicenter Trial Pathology Study,2012-12-20,Mammostrat,True,['Clarient'],0,Belgium,16,6,5,1,0,0,1,1,1,0,0,0,0,0,0,0
"Long-Term Update of US GI Intergroup RTOG 98-11 Phase III Trial for Anal Carcinoma: Survival, Relapse, and Colostomy Failure With Concurrent Chemoradiation Involving Fluorouracil/Mitomycin Versus Fluorouracil/Cisplatin",2012-12-10,fluorouracil,False,[],0,USA,11,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Referral Practices of Oncologists to Specialized Palliative Care,2012-12-10,,False,[],0,Canada,6,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Impact of [18F]Fluorodeoxyglucose Positron Emission Tomography Response Evaluation in Patients With Highâ€“Tumor Burden Follicular Lymphoma Treated With Immunochemotherapy: A Prospective Study From the Groupe d'Etudes des Lymphomes de l'Adulte and GOELAMS,2012-12-10,rituximab,True,['Roche'],0,Italy,20,1,0,0,0,1,1,1,0,0,0,0,0,0,1,1
Initial Molecular Response at 3 Months May Predict Both Response and Event-Free Survival at 24 Months in Imatinib-Resistant or -Intolerant Patients With Philadelphia Chromosomeâ€“Positive Chronic Myeloid Leukemia in Chronic Phase Treated With Nilotinib,2012-12-10,nilotinib,True,['Novartis'],0,Germany,13,13,3,8,0,7,1,1,1,0,0,0,0,0,0,0
"Symptomatic Treatment With Lanreotide Microparticles in Inoperable Bowel Obstruction Resulting From Peritoneal Carcinomatosis: A Randomized, Double-Blind, Placebo-Controlled Phase III Study",2012-12-10,lanreotide,True,['Ipsen'],0,France,10,3,2,0,0,1,1,1,1,0,0,0,0,0,0,1
Research Participants' High Expectations of Benefit in Early-Phase Oncology Trials: Are We Asking the Right Question?,2012-12-10,,False,[],0,USA,8,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Randomized Controlled Trial of Interval-Compressed Chemotherapy for the Treatment of Localized Ewing Sarcoma: A Report From the Children's Oncology Group,2012-11-20,vincristine,False,[],0,USA,11,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Prospective International Multicenter Phase II Trial of Intravenous Pegylated Liposomal Doxorubicin Monochemotherapy in Patients With Stage IIB, IVA, or IVB Advanced Mycosis Fungoides: Final Results From EORTC 21012",2012-11-20,pegylated liposomal doxorubicin,True,['Johnson & Johnson (U)'],0,France,13,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
HLA-Mismatched Stem-Cell Microtransplantation As Postremission Therapy for Acute Myeloid Leukemia:  Long-Term Follow-Up,2012-11-20,,False,[],0,China,21,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Efficacy of Cognitive Behavioral Therapy and Physical Exercise in Alleviating Treatment-Induced Menopausal Symptoms in Patients With Breast Cancer: Results of a Randomized, Controlled, Multicenter Trial",2012-11-20,,False,[],0,United Kingdom,21,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Open-Label, Multicenter, Randomized Phase III Trial of Adjuvant Chemoradiation Plus Interferon Alfa-2b Versus Fluorouracil and Folinic Acid for Patients With Resected Pancreatic Adenocarcinoma",2012-11-20,interferon alfa-2b,False,[],0,Italy,13,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Phase I Study of a Novel Oral Janus Kinase 2 Inhibitor, SB1518, in Patients With Relapsed Lymphoma: Evidence of Clinical and Biologic Activity in Multiple Lymphoma Subtypes",2012-11-20,SB1518,True,"['S*Bio Pte Ltd', 'S*Bio Pte Ltd (U)']",0,Singapore,15,2,2,0,0,0,1,0,1,0,0,0,0,0,0,0
Phase I Trial and Pharmacokinetic Study of Lexatumumab in Pediatric Patients With Solid Tumors,2012-11-20,lexatumumab,False,[],0,USA,14,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Stage-Adapted Treatment of HIV-Associated Hodgkin Lymphoma: Results of a Prospective Multicenter Study,2012-11-20,doxorubicin,False,[],0,Germany,19,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Six Cycles of Doxorubicin and Cyclophosphamide or Paclitaxel Are Not Superior to Four Cycles As Adjuvant Chemotherapy for Breast Cancer in Women With Zero to Three Positive Axillary Nodes: Cancer and Leukemia Group B 40101,2012-11-20,paclitaxel,False,[],0,USA,15,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Incorporating Bevacizumab and Erlotinib in the Combined-Modality Treatment of Stage III Nonâ€“Small-Cell Lung Cancer: Results of a Phase I/II Trial,2012-11-10,bevacizumab,True,['Genentech'],0,USA,11,3,0,1,0,1,1,1,0,0,1,0,0,0,0,0
Obesity and Risk of Recurrence or Death After Adjuvant Endocrine Therapy With Letrozole or Tamoxifen in the Breast International Group 1-98 Trial,2012-11-10,letrozole,True,['Novartis'],0,United Kingdom,17,5,0,0,0,2,1,1,0,0,0,0,0,0,0,0
Phase I Study of Folate Conjugate EC145 (Vintafolide) in Patients With Refractory Solid Tumors,2012-11-10,vintafolide,True,"['Endocyte', 'Endocyte (U)']",0,USA,13,7,4,3,0,0,1,1,1,0,0,0,0,0,0,0
Estrogen Plus Progestin and Colorectal Cancer Incidence and Mortality,2012-11-10,conjugated equine estrogen (CEE) and medroxyprogesterone acetate (MPA),True,['Wyeth Ayerst'],0,USA,9,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
"Randomized, Double-Blind, Placebo-Controlled, Phase III Cross-Over Study Evaluating the Oral Neurokinin-1 Antagonist Aprepitant in Combination With a 5HT3 Receptor Antagonist and Dexamethasone in Patients With Germ Cell Tumors Receiving 5-Day Cisplatin Combination Chemotherapy Regimens: A Hoosier Oncology Group Study",2012-11-10,aprepitant,False,[],0,USA,6,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Addition of Gemtuzumab Ozogamicin to Induction Chemotherapy Improves Survival in Older Patients With Acute Myeloid Leukemia,2012-11-10,gemtuzumab ozogamicin,True,['Pfizer'],0,Denmark,12,1,0,1,0,0,1,0,0,0,1,0,0,0,0,0
Randomized Trial of Short-Course Radiotherapy Versus Long-Course Chemoradiation Comparing Rates of Local Recurrence in Patients With T3 Rectal Cancer: Trans-Tasman Radiation Oncology Group Trial 01.04,2012-11-01,fluorouracil,False,[],0,New Zealand,15,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Long-Term Results of the Randomized Phase III Trial EORTC 18991 of Adjuvant Therapy With Pegylated Interferon Alfa-2b Versus Observation in Resected Stage III Melanoma,2012-11-01,peginterferon alfa-2b,True,"['Merck', 'MSD']",0,Canada,15,4,0,4,0,2,1,0,0,0,1,0,0,0,0,0
Association Between Circulating Tumor Cells and Prognosis in Patients With Stage III Melanoma With Sentinel Lymph Node Metastasis in a Phase III International Multicenter Trial,2012-11-01,,False,['NANT'],0,USA,10,1,0,0,0,1,1,1,0,0,0,0,0,0,1,1
"L-Carnitine Supplementation for the Management of Fatigue in Patients With Cancer: An Eastern Cooperative Oncology Group Phase III, Randomized, Double-Blind, Placebo-Controlled Trial",2012-11-01,L-Carnitine,False,[],0,USA,6,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Seven-Year Follow-Up Assessment of Cardiac Function in NSABP B-31, a Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Paclitaxel (ACP) With ACP Plus Trastuzumab As Adjuvant Therapy for Patients With Node-Positive, Human Epidermal Growth Factor Receptor 2â€“Positive Breast Cancer",2012-11-01,trastuzumab,True,"['Genentech/Roche (U)', 'Genentech', 'Genentech/Roche']",0,USA,21,4,0,3,0,2,1,1,0,0,1,0,0,0,0,0
"Randomized, Open-Label, Phase III Study Comparing Patupilone (EPO906) With Pegylated Liposomal Doxorubicin in Platinum-Refractory or -Resistant Patients With Recurrent Epithelial Ovarian, Primary Fallopian Tube, or Primary Peritoneal Cancer",2012-11-01,patupilone,True,['Novartis Pharmaceuticals'],0,USA,17,6,4,1,0,1,1,1,1,0,0,0,0,0,0,1
Lymphatic Mapping and Sentinel Lymph Node Biopsy in Women With Squamous Cell Carcinoma of the Vulva: A Gynecologic Oncology Group Study,2012-11-01,,False,[],0,USA,17,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Acute Myeloid Leukemia (AML): Different Treatment Strategies Versus a Common Standard Armâ€”Combined Prospective Analysis by the German AML Intergroup,2012-10-10,cytarabine,False,[],0,,24,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Cediranib Plus FOLFOX/CAPOX Versus Placebo Plus FOLFOX/CAPOX in Patients With Previously Untreated Metastatic Colorectal Cancer: A Randomized, Double-Blind, Phase III Study (HORIZON II)",2012-10-10,cediranib,True,['AstraZeneca'],0,United Kingdom,15,8,3,2,0,2,1,0,1,0,0,0,0,0,0,0
"Aflibercept and Docetaxel Versus Docetaxel Alone After Platinum Failure in Patients With Advanced or Metastatic Nonâ€“Small-Cell Lung Cancer: A Randomized, Controlled Phase III Trial",2012-10-10,aflibercept,True,"['sanofi-aventis', 'Sanofi']",0,United Kingdom,14,8,2,3,0,4,1,0,1,0,0,0,0,0,0,0
"Cediranib With mFOLFOX6 Versus Bevacizumab With mFOLFOX6 As First-Line Treatment for Patients With Advanced Colorectal Cancer: A Double-Blind, Randomized Phase III Study (HORIZON III)",2012-10-10,cediranib,True,"['AstraZeneca', 'AstraZeneca (U)']",0,Belgium,15,6,2,2,0,0,1,0,1,0,0,0,0,0,0,0
"Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Toxicity of Subcutaneous Ketamine in the Management of Cancer Pain ",2012-10-10,ketamine,False,[],0,Australia,9,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Neurocognitive Function and CNS Integrity in Adult Survivors of Childhood Hodgkin Lymphoma ,2012-10-10,,False,[],0,USA,11,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Association of KRAS G13D Tumor Mutations With Outcome in Patients With Metastatic Colorectal Cancer Treated With First-Line Chemotherapy With or Without Cetuximab,2012-10-10,cetuximab,True,['Merck KGaA'],0,Germany,6,3,3,0,0,0,1,0,1,0,0,0,0,0,0,0
Bosutinib Versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia: Results From the BELA Trial,2012-10-01,bosutinib,True,"['Pfizer', 'Wyeth Research/Pfizer']",0,Italy,11,7,3,3,0,2,1,0,1,0,0,0,0,0,0,0
"Randomized, Phase III Study of Gemcitabine or Erlotinib Maintenance Therapy Versus Observation, With Predefined Second-Line Treatment, After Cisplatin-Gemcitabine Induction Chemotherapy in Advanced Nonâ€“Small-Cell Lung Cancer",2012-10-01,erlotinib,True,['Roche'],0,Spain,20,11,0,9,0,7,1,0,0,0,1,0,0,0,0,0
"Addition of Aflibercept to Fluorouracil, Leucovorin, and Irinotecan Improves Survival in a Phase III Randomized Trial in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen",2012-10-01,aflibercept,True,['Regeneron Pharmaceuticals'],0,USA,15,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
Phase II Trial of Cetuximab With or Without Paclitaxel in Patients With Advanced Urothelial Tract Carcinoma ,2012-10-01,cetuximab,False,[],0,USA,11,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Interleukin-21 Has Activity in Patients With Metastatic Melanoma: A Phase II Study,2012-09-20,interleukin-21 (IL-21),True,['ZymoGenetics'],0,USA,13,2,0,0,0,0,1,1,0,0,0,0,0,0,0,0
Prevention of Delayed Nausea: A University of Rochester Cancer Center Community Clinical Oncology Program Study of Patients Receiving Chemotherapy,2012-09-20,Palonosetron,True,['Eisai'],0,USA,7,1,0,1,0,0,1,0,0,0,1,0,0,0,0,0
"Randomized Phase II Study of Dacomitinib (PF-00299804), an Irreversible Panâ€“Human Epidermal Growth Factor Receptor Inhibitor, Versus Erlotinib in Patients With Advanced Nonâ€“Small-Cell Lung Cancer",2012-09-20,dacomitinib,True,"['Pfizer', 'Pfizer (immediate family member']",0,Australia,17,12,8,5,0,5,1,1,1,0,0,0,0,0,0,0
Epigenetic Therapy Using Belinostat for Patients With Unresectable Hepatocellular Carcinoma: A Multicenter Phase I/II Study With Biomarker and Pharmacokinetic Analysis of Tumors From Patients in the Mayo Phase II Consortium and the Cancer Therapeutics Research Group,2012-09-20,belinostat,False,[],0,USA,22,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Primary mFOLFOX6 Plus Bevacizumab Without Resection of the Primary Tumor for Patients Presenting With Surgically Unresectable Metastatic Colon Cancer and an Intact Asymptomatic Colon Cancer: Definitive Analysis of NSABP Trial C-10,2012-09-10,bevacizumab,True,['Genentech'],0,USA,13,1,0,1,0,0,1,0,0,0,1,0,0,0,0,0
Bendamustine in Combination With Rituximab for Previously Untreated Patients With Chronic Lymphocytic Leukemia: A Multicenter Phase II Trial of the German Chronic Lymphocytic Leukemia Study Group,2012-09-10,bendamustine,True,"['Mundipharma/Cephalon', 'Cephalon']",0,Germany,23,2,0,2,0,2,0,0,0,0,0,0,0,0,0,0
Bortezomib-Based Graft-Versus-Host Disease Prophylaxis in HLA-Mismatched Unrelated Donor Transplantation,2012-09-10,bortezomib,True,['Millennium Pharmaceuticals'],0,USA,13,1,0,1,0,0,1,1,0,0,1,0,0,0,0,0
Induction Chemotherapy and Conformal Radiation Therapy for Very Young Children With Nonmetastatic Medulloblastoma: Children's Oncology Group Study P9934,2012-09-10,,False,[],0,USA,15,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Hyperfractionated Versus Conventional Radiotherapy Followed by Chemotherapy in Standard-Risk Medulloblastoma: Results From the Randomized Multicenter HIT-SIOP PNET 4 Trial,2012-09-10,cisplatin,False,[],0,Austria,25,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Sarcopenia During Androgen-Deprivation Therapy for Prostate Cancer,2012-09-10,denosumab,True,"['Amgen (U)', 'Amgen']",0,USA,8,8,2,6,0,3,1,1,1,0,0,0,0,0,0,0
Long-Term Results of CCG 5942: A Randomized Comparison of Chemotherapy With and Without Radiotherapy for Children With Hodgkin's Lymphomaâ€”A Report From the Children's Oncology Group,2012-09-10,,False,[],0,USA,10,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"A Phase II Study of Trastuzumab Emtansine in Patients With Human Epidermal Growth Factor Receptor 2â€“Positive Metastatic Breast Cancer Who Were Previously Treated With Trastuzumab, Lapatinib, an Anthracycline, a Taxane, and Capecitabine",2012-09-10,trastuzumab emtansine,True,"['Genentech/Roche (U)', 'Genentech', 'Genentech/Roche', 'Genentech (U)']",0,USA,13,11,5,4,0,1,1,1,1,0,0,0,0,0,0,0
Murine Anti-GD2 Monoclonal Antibody 3F8 Combined With Granulocyte-Macrophage Colony-Stimulating Factor and 13-Cis-Retinoic Acid in High-Risk Patients With Stage 4 Neuroblastoma in First Remission,2012-09-10,3F8,False,[],0,USA,7,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Neuropathy Is Not Associated With Clinical Outcomes in Patients Receiving Adjuvant Taxane-Containing Therapy for Operable Breast Cancer,2012-09-01,paclitaxel,True,['Abraxis'],0,USA,13,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0
"Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Gemcitabine/Cisplatin Alone or With Sorafenib for the First-Line Treatment of Advanced, Nonsquamous Nonâ€“Small-Cell Lung Cancer",2012-09-01,sorafenib,True,['Bayer HealthCare Pharmaceuticals'],0,,19,7,3,2,0,3,1,1,1,0,0,0,0,0,0,0
"IGH@ Translocations, CRLF2 Deregulation, and Microdeletions in Adolescents and Adults With Acute Lymphoblastic Leukemia",2012-09-01,,False,[],0,USA,13,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Randomized Trial of Radiation Therapy Plus Procarbazine, Lomustine, and Vincristine Chemotherapy for Supratentorial Adult Low-Grade Glioma: Initial Results of RTOG 9802",2012-09-01,procarbazine,False,[],0,USA,10,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Phase II Study of Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Immunochemotherapy Followed by Yttrium-90â€“Ibritumomab Tiuxetan in Untreated Mantle-Cell Lymphoma: Eastern Cooperative Oncology Group Study E1499",2012-09-01,ibritumomab tiuxetan,True,['Spectrum Pharmaceuticals'],0,USA,10,2,0,1,0,1,0,0,0,0,0,0,0,0,0,0
Up-Front Autologous Stem-Cell Transplantation in  Peripheral T-Cell Lymphoma: NLG-T-01,2012-09-01,cyclophosphamide,False,[],0,Finland,20,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
RUNX1 Mutations Are Associated With Poor Outcome in Younger and Older Patients With Cytogenetically Normal Acute Myeloid Leukemia and With Distinct Gene and MicroRNA Expression Signatures,2012-09-01,cytarabine,False,[],0,,22,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Bortezomib Induction and Maintenance Treatment in Patients With Newly Diagnosed Multiple Myeloma: Results of the Randomized Phase III HOVON-65/ GMMG-HD4 Trial,2012-08-20,bortezomib,True,['Millennium Pharmaceuticals'],0,,28,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0
Chlamydophila Psittaci Eradication With Doxycycline As First-Line Targeted Therapy for Ocular Adnexae Lymphoma: Final Results of an International Phase II Trial,2012-08-20,doxycycline,False,[],0,Chile,16,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Prospective Study of Bevacizumab Plus Temozolomide in Patients With Advanced Neuroendocrine Tumors,2012-08-20,temozolomide,False,[],0,USA,12,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
First-Line Erlotinib Followed by Second-Line Cisplatin-Gemcitabine Chemotherapy in Advanced Nonâ€“Small-Cell Lung Cancer: The TORCH Randomized Trial,2012-08-20,erlotinib,True,"['F. Hoffman-La Roche', 'Roche']",0,,28,11,0,6,0,10,1,1,0,0,1,0,0,0,0,0
Advance Care Planning in Patients With Cancer Referred to a Phase I Clinical Trials Program: The MD Anderson Cancer Center Experience,2012-08-10,,False,[],0,USA,10,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"International, Randomized, Placebo-Controlled, Double-Blind Phase III Study of Motesanib Plus Carboplatin/Paclitaxel in Patients With Advanced Nonsquamous Nonâ€“Small-Cell Lung Cancer: MONET1",2012-08-10,motesanib,True,['Amgen/Takeda Bio'],0,USA,18,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Randomized Controlled Trial of a Computerized Decision Aid on Adjuvant Radioactive Iodine Treatment for Patients With Early-Stage Papillary Thyroid Cancer,2012-08-10,radioactive iodine (RAI),False,[],0,Canada,16,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Intrapatient Cetuximab Dose Escalation in Metastatic Colorectal Cancer According to the Grade of Early Skin Reactions: The Randomized EVEREST Study,2012-08-10,cetuximab,True,['Merck Serono'],0,Italy,17,5,0,4,0,4,0,1,0,0,0,0,0,0,0,0
Tumor Response and Toxicity of Neoadjuvant Erlotinib in Patients With Early-Stage Nonâ€“Small-Cell Lung Cancer,2012-08-01,erlotinib,True,['Roche'],0,the Netherlands,9,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0
Phase I Multidose-Escalation Study of the Anti-CD19 Maytansinoid Immunoconjugate SAR3419 Administered by Intravenous Infusion Every 3 Weeks to Patients With Relapsed/Refractory B-Cell Lymphoma,2012-08-01,SAR3419,True,"['Sanofi', 'sanofi-aventis', 'sanofi-aventis (U)']",0,USA,14,4,1,2,0,2,0,1,0,0,0,0,0,0,0,0
"Randomized Phase II Trial of Everolimus in Combination With Tamoxifen in Patients With Hormone Receptorâ€“Positive, Human Epidermal Growth Factor Receptor 2â€“Negative Metastatic Breast Cancer With Prior Exposure to Aromatase Inhibitors: A GINECO Study",2012-08-01,everolimus,True,['Novartis'],0,France,14,1,0,1,0,0,1,1,0,0,1,0,0,0,0,0
Overall Survival Benefit With Lapatinib in Combination With Trastuzumab for Patients With Human Epidermal Growth Factor Receptor 2â€“Positive Metastatic Breast Cancer: Final Results From the EGF104900 Study,2012-07-20,lapatinib,True,"['GlaxoSmithKline', 'GlaxoSmithKline (U)']",0,Germany,12,10,3,4,0,4,1,1,1,0,0,0,0,0,0,0
"Multicenter, Randomized, Open-Label, Phase III Trial of Decitabine Versus Patient Choice, With Physician Advice, of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia",2012-07-20,decitabine,True,['Eisai'],0,Australia,18,3,0,1,0,1,0,0,0,0,0,0,0,0,0,0
Randomized Study of Two Chemotherapy Regimens for Treatment of Low-Grade Glioma in Young Children: A Report From the Children's Oncology Group,2012-07-20,carboplatin,False,[],0,USA,13,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
TBCRC 001: Randomized Phase II Study of Cetuximab in Combination With Carboplatin in Stage IV Triple-Negative Breast Cancer,2012-07-20,cetuximab,True,"['Bristol-Myers Squibb', 'Bristol-Myers Squibb (U)']",0,USA,20,7,0,3,0,1,0,1,0,0,0,0,0,0,0,0
Dual Effect of Metformin on Breast Cancer Proliferation in a Randomized Presurgical Trial,2012-07-20,metformin,False,[],0,Italy,19,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Outcome of Children With Metastatic Medulloblastoma Treated With Carboplatin During Craniospinal Radiotherapy: A Children's Oncology Group Phase I/II Study,2012-07-20,carboplatin,False,[],0,USA,14,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Multicenter, Double-Blind, Placebo-Controlled, Randomized Phase II Trial of Gemcitabine/Cisplatin Plus Bevacizumab or Placebo in Patients With Malignant Mesothelioma",2012-07-10,bevacizumab,True,"['Genentech', 'Genentech/Roche']",0,USA,17,12,0,11,0,4,1,1,0,0,1,0,0,0,0,0
Randomized Comparison of Intensified Six-Drug Versus Standard Three-Drug Chemotherapy for High-Risk Nonmetastatic Rhabdomyosarcoma and Other Chemotherapy-Sensitive Childhood Soft Tissue Sarcomas: Long-Term Results From the International Society of Pediatric Oncology MMT95 Study,2012-07-10,ifosfamide,False,[],0,the Netherlands,13,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Effects of a Brief Multimedia Psychoeducational Intervention on the Attitudes and Interest of Patients With Cancer Regarding Clinical Trial Participation: A Multicenter Randomized Controlled Trial,2012-07-10,,False,[],0,USA,17,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Clofarabine Plus Cytarabine Compared With Cytarabine Alone in Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia: Results From the CLASSIC I Trial,2012-07-10,clofarabine,True,['Genzyme'],0,France,23,19,2,10,0,10,1,1,1,0,0,0,0,0,0,0
Superiority of the Triple Combination of Bortezomib-Thalidomide-Dexamethasone Over the Dual Combination of Thalidomide-Dexamethasone in Patients With Multiple Myeloma Progressing or Relapsing After Autologous Transplantation: The MMVAR/IFM 2005-04 Randomized Phase III Trial From the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation,2012-07-10,bortezomib,True,['Millennium Pharmaceuticals'],0,Sweden,30,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
"Cladribine, But Not Fludarabine, Added to Daunorubicin and Cytarabine During Induction Prolongs Survival of Patients With Acute Myeloid Leukemia: A Multicenter, Randomized Phase III Study",2012-07-10,cladribine,False,[],0,Poland,21,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Phase II Trial of Trastuzumab in Combination With Cytotoxic Chemotherapy for Treatment of Metastatic Osteosarcoma With Human Epidermal Growth Factor Receptor 2 Overexpression: A Report From the Children's Oncology Group,2012-07-10,trastuzumab,False,[],0,Canada,16,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Reach Out to Enhance Wellness Home-Based Diet-Exercise Intervention Promotes Reproducible and Sustainable Long-Term Improvements in Health Behaviors, Body Weight, and Physical Functioning in Older, Overweight/Obese Cancer Survivors",2012-07-01,,False,[],0,USA,7,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Reduced-Calorie Dietary Weight Loss, Exercise, and Sex Hormones in Postmenopausal Women: Randomized Controlled Trial",2012-07-01,,False,[],0,USA,14,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Efficacy and Safety of Regorafenib in Patients With Metastatic and/or Unresectable GI Stromal Tumor After Failure of Imatinib and Sunitinib: A Multicenter Phase II Trial,2012-07-01,regorafenib,True,"['Bayer', 'Bayer (U)']",0,USA,17,5,0,0,0,0,0,1,0,0,0,0,0,0,0,0
Updated Analysis of SWOG-Directed Intergroup Study 0116: A Phase III Trial of Adjuvant Radiochemotherapy Versus Observation After Curative Gastric Cancer Resection,2012-07-01,Fluorouracil,False,[],0,Canada,13,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Phase I Pharmacologic and Pharmacodynamic Study of the Gamma Secretase (Notch) Inhibitor MK-0752 in Adult Patients With Advanced Solid Tumors,2012-07-01,MK-0752,True,['Merck'],0,USA,20,15,8,4,0,5,1,1,1,0,0,0,0,0,0,0
"Phase I Study of RO4929097, a Gamma Secretase Inhibitor of Notch Signaling, in Patients With Refractory Metastatic or Locally Advanced Solid Tumors",2012-07-01,RO4929097,True,"['Hoffmann-La Roche AG', 'Hoffmann-La Roche']",0,Germany,20,17,8,0,0,0,1,1,1,0,0,0,0,0,0,0
Minimal Residual DiseaseÃ¢â‚¬â€œGuided Treatment Deintensification for Children With Acute Lymphoblastic Leukemia: Results From the Malaysia-Singapore Acute Lymphoblastic Leukemia 2003 Study,2012-07-01,,False,[],0,Malaysia,14,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study,2012-06-20,brentuximab vedotin,True,['Seattle Genetics'],0,Canada,14,14,3,5,0,3,1,1,1,0,0,0,0,0,0,0
Phase II Trial of Vorinostat With Idarubicin and Cytarabine for Patients With Newly Diagnosed Acute Myelogenous Leukemia or Myelodysplastic Syndrome,2012-06-20,vorinostat,True,['Merck'],0,USA,18,1,0,0,0,1,1,1,0,0,0,0,0,0,1,1
Intracutaneous and Intravesical Immunotherapy With Keyhole Limpet Hemocyanin Compared With Intravesical Mitomycin in Patients With Nonâ€“Muscle-Invasive Bladder Cancer: Results From a Prospective Randomized Phase III Trial,2012-06-20,keyhole limpet hemocyanin,True,['biosyn Arzneimittel GmbH'],0,the Netherlands,5,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0
Panobinostat in Patients With Relapsed/Refractory Hodgkin's Lymphoma After Autologous Stem-Cell Transplantation: Results of a Phase II Study,2012-06-20,panobinostat,True,"['Novartis', 'Novaratis']",0,Germany,13,8,3,3,0,5,1,1,1,0,0,0,0,0,0,0
Randomized Phase II Trial of Erlotinib With and Without Entinostat in Patients With Advanced Nonâ€“Small-Cell Lung Cancer Who Progressed on Prior Chemotherapy,2012-06-20,entinostat,True,['Syndax Pharmaceuticals'],0,USA,9,3,0,2,0,0,0,1,0,0,0,0,0,0,0,0
Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma,2012-06-20,brentuximab vedotin,True,['Seattle Genetics'],0,Germany,18,18,3,7,0,4,1,1,1,0,0,0,0,0,0,0
"Neoadjuvant Chemotherapy With Methotrexate, Cisplatin, and Doxorubicin With or Without Ifosfamide in Nonmetastatic Osteosarcoma of the Extremity: An Italian Sarcoma Group Trial ISG/OS-1",2012-06-10,ifosfamide,False,[],0,Italy,15,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Sunitinib Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Previously Treated Advanced Nonâ€“Small-Cell Lung Cancer: A Phase III Trial,2012-06-10,Sunitinib,True,['Pfizer'],0,USA,20,9,4,5,0,0,1,1,1,0,0,0,0,0,0,0
Deferasirox Reduces Serum Ferritin and Labile Plasma Iron in RBC Transfusionâ€“Dependent Patients With Myelodysplastic Syndrome,2012-06-10,deferasirox,True,"['Novartis', 'Novartis Oncology']",0,USA,9,6,3,1,0,0,1,1,1,0,0,0,0,0,0,0
Randomized Phase II Trial of Erlotinib Alone or With Carboplatin and Paclitaxel in Patients Who Were Never or Light Former Smokers With Advanced Lung Adenocarcinoma: CALGB 30406 Trial,2012-06-10,erlotinib,True,['Roche'],0,USA,12,1,0,1,0,0,1,0,0,0,1,0,0,0,0,0
"Ipilimumab in Combination With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB/IV Nonâ€“Small-Cell Lung Cancer: Results From a Randomized, Double-Blind, Multicenter Phase II Study",2012-06-10,ipilimumab,True,"['Bristol-Myers Squibb', 'Bristol-Myers Squibb (U)']",0,Germany,11,5,2,2,0,0,0,1,0,0,0,0,0,0,0,0
Weekly nab-Paclitaxel in Combination With Carboplatin Versus Solvent-Based Paclitaxel Plus Carboplatin as First-Line Therapy in Patients With Advanced Nonâ€“Small-Cell Lung Cancer: Final Results of a Phase III Trial,2012-06-10,nab-paclitaxel,True,['Celgene'],0,USA,12,11,4,1,0,0,1,1,1,0,0,0,0,0,0,0
"OCEANS: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Chemotherapy With or Without Bevacizumab in Patients With Platinum-Sensitive Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer",2012-06-10,bevacizumab,True,['Genentech'],0,USA,9,4,3,1,0,0,1,0,1,0,0,0,0,0,0,0
Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Biomarker Evaluation From the AVAGAST Randomized Phase III Trial,2012-06-10,bevacizumab,True,"['F. Hoffmann-La Roche', 'F. Hoffmann-La Roche (U)']",0,USA,11,6,3,2,0,1,1,1,1,0,0,0,0,0,0,0
"Clinical Impact of NOTCH1 and/or FBXW7 Mutations, FLASH Deletion, and TCR Status in Pediatric T-Cell Lymphoblastic Lymphoma",2012-06-01,,False,[],0,France,15,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Elotuzumab in Combination With Lenalidomide and Low-Dose Dexamethasone in Relapsed or Refractory Multiple Myeloma,2012-06-01,elotuzumab,True,['Bristol-Myers Squibb'],0,USA,12,3,0,3,0,1,0,0,0,0,0,0,0,0,0,0
Induction Chemotherapy and Dose Intensification of the Radiation Boost in Locally Advanced Anal Canal Carcinoma: Final Analysis of the Randomized UNICANCER ACCORD 03 Trial,2012-06-01,fluorouracil,False,[],0,FÃ©dÃ©ration Nationale des Centres de Lutte Contre le Cancer (UNICANCER),20,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Preoperative Versus Postoperative Chemoradiotherapy for Locally Advanced Rectal Cancer: Results of the German CAO/ARO/AIO-94 Randomized Phase III Trial After a Median Follow-Up of 11 Years,2012-06-01,fluorouracil,False,[],0,Germany,13,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Prevention of Pegfilgrastim-Induced Bone Pain: A Phase III Double-Blind Placebo-Controlled Randomized Clinical Trial of the University of Rochester Cancer Center Clinical Community Oncology Program Research Base,2012-06-01,pegfilgrastim,True,['Amgen Neulasta Bone Pain Advisory Board'],0,USA,7,1,0,1,0,0,1,1,0,0,1,1,0,0,0,0
"Preoperative Chemotherapy Plus Trastuzumab, Lapatinib, or Both in Human Epidermal Growth Factor Receptor 2â€“Positive Operable Breast Cancer: Results of the Randomized Phase II CHER-LOB Study",2012-06-01,trastuzumab,True,['Roche'],0,Germany,21,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0
FACT: An Open-Label Randomized Phase III Study of Fulvestrant and Anastrozole in Combination Compared With Anastrozole Alone As First-Line Therapy for Patients With Receptor-Positive Postmenopausal Breast Cancer,2012-06-01,anastrozole,True,"['AstraZeneca (U)', 'AstraZeneca']",0,United Kingdom,9,4,1,3,0,1,1,0,1,0,0,0,0,0,0,0
Phase I Trial of Anti-CS1 Monoclonal Antibody Elotuzumab in Combination With Bortezomib in the Treatment of Relapsed/Refractory Multiple Myeloma,2012-06-01,elotuzumab,True,"['Bristol-Myers Squibb', 'Bristol-Myers Squibb (U)']",0,USA,10,3,0,3,0,2,0,0,0,0,0,0,0,0,0,0
Outcome After Surgery Alone or With Restricted Use of Chemotherapy for Patients With Low-Risk Neuroblastoma: Results of Children's Oncology Group Study P9641,2012-05-20,,False,[],0,USA,16,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Phase II Study of Ganitumab, a Fully Human Antiâ€“Type-1 Insulin-Like Growth Factor Receptor Antibody, in Patients With Metastatic Ewing Family Tumors or Desmoplastic Small Round Cell Tumors",2012-05-20,ganitumab,True,['Amgen'],0,USA,15,10,7,2,0,0,1,0,1,0,0,0,0,0,0,0
Accelerated Radiotherapy With Carbogen and Nicotinamide for Laryngeal Cancer: Results of a Phase III Randomized Trial,2012-05-20,carbogen,False,[],0,the Netherlands,14,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Phase I Trial of Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox (CAT-8015 or HA22) in Patients With Hairy Cell Leukemia,2012-05-20,moxetumomab pasudotox,True,['MedImmune'],0,Poland,9,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0
"Long-Term Dynamics of Bone Mineral Density During Intermittent Androgen Deprivation for Men With Nonmetastatic, Hormone-Sensitive Prostate Cancer",2012-05-20,leuprolide,False,[],0,USA,9,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Phase III Trial of Cetuximab With Continuous or Intermittent Fluorouracil, Leucovorin, and Oxaliplatin (Nordic FLOX) Versus FLOX Alone in First-Line Treatment of Metastatic Colorectal Cancer: The NORDIC-VII Study",2012-05-20,cetuximab,True,"['Merck Serono', 'Merck Serono (U)']",0,,22,5,0,3,0,0,1,0,0,0,1,0,0,0,0,0
Antitumor Activity and Safety of Tivozanib (AV-951) in a Phase II Randomized Discontinuation Trial in Patients With Renal Cell Carcinoma,2012-05-10,tivozanib,True,['AVEO Pharmaceuticals'],0,India,10,4,4,0,0,0,1,1,1,0,0,0,0,0,0,0
Alemtuzumab in Combination With Methylprednisolone Is a Highly Effective Induction Regimen for Patients With Chronic Lymphocytic Leukemia and Deletion of TP53: Final Results of the National Cancer Research Institute CLL206 Trial,2012-05-10,alemtuzumab,True,['Genzyme'],0,United Kingdom,25,7,0,5,0,4,1,0,0,0,1,0,0,0,0,0
"Multicenter Randomized Phase II Clinical Trial Comparing Neoadjuvant Oxaliplatin, Capecitabine, and Preoperative Radiotherapy With or Without Cetuximab Followed by Total Mesorectal Excision in Patients With High-Risk Rectal Cancer (EXPERT-C)",2012-05-10,cetuximab,True,"['Merck Serono', 'Merck Serono (U)']",0,Sweden,15,2,0,2,0,1,0,0,0,0,0,0,0,0,0,0
Outcome of Acute Promyelocytic Leukemia (APL) in Children and Adolescents: An Analysis in Two Consecutive Trials of the European APL Group,2012-05-10,all-trans-retinoic acid,False,[],0,Spain,19,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Prognostic Index for Acute- and Lymphoma-Type Adult T-Cell Leukemia/Lymphoma,2012-05-10,,False,[],0,Japan,21,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Marked, Homogeneous, and Early [18F]Fluorodeoxyglucoseâ€“Positron Emission Tomography Responses to Vemurafenib in BRAF-Mutant Advanced Melanoma",2012-05-10,vemurafenib,True,"['Roche/Genentech (U)', 'Genentech', 'Roche/Genentech', 'Roche', 'Hoffman-La Roche/Genentech']",0,USA,12,9,1,8,0,3,1,0,1,0,0,0,0,0,0,0
Assessing the Impact of a Cooperative Group Trial on Breast Cancer Care in the Medicare Population,2012-05-10,,False,[],0,USA,7,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Pertuzumab Monotherapy After Trastuzumab-Based Treatment and Subsequent Reintroduction of Trastuzumab: Activity and Tolerability in Patients With Advanced Human Epidermal Growth Factor Receptor 2â€“Positive Breast Cancer,2012-05-10,pertuzumab,True,['Genentech'],0,USA,18,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
"Safety, Pharmacokinetic, and Pharmacodynamic Phase I Dose-Escalation Trial of PF-00562271, an Inhibitor of Focal Adhesion Kinase, in Advanced Solid Tumors",2012-05-01,PF-00562271,True,"['Pfizer', 'Pfizer Oncology', 'Pfizer Global Research and Development']",0,USA,13,10,6,1,0,0,1,1,1,0,0,0,0,0,0,0
"Randomized, Double-Blind, Placebo-Controlled Phase III Trial Comparing Docetaxel and Prednisone With or Without Bevacizumab in Men With Metastatic Castration-Resistant Prostate Cancer: CALGB 90401",2012-05-01,bevacizumab,True,['Genentech'],0,USA,12,5,0,4,0,1,0,0,0,0,0,0,0,0,0,0
Effect of Postdiagnosis Weight Change on Hot Flash Status Among Early-Stage Breast Cancer Survivors,2012-05-01,,False,[],0,USA,10,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Phase II Study of Bevacizumab in Patients With HIV-Associated Kaposi's Sarcoma Receiving Antiretroviral Therapy,2012-05-01,bevacizumab,True,['bevacizumab provided to National Cancer Institute by Genentech under a Cooperative Research and Development Agreement'],0,USA,13,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0
Sorafenib in Combination With Capecitabine: An Oral Regimen for Patients With HER2-Negative Locally Advanced or Metastatic Breast Cancer,2012-05-01,sorafenib,True,['Bayer Pharmaceuticals'],0,,24,2,0,0,0,2,0,0,0,0,0,0,0,0,0,0
"Dual Targeting of the Epidermal Growth Factor Receptor Using the Combination of Cetuximab and Erlotinib: Preclinical Evaluation and Results of the Phase II DUX Study in Chemotherapy-Refractory, Advanced Colorectal Cancer",2012-05-01,cetuximab,True,['Merck Serono (U)'],0,Australia,14,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
Salvage Chemotherapy for Pretreated Gastric Cancer: A Randomized Phase III Trial Comparing Chemotherapy Plus Best Supportive Care With Best Supportive Care Alone,2012-05-01,docetaxel,False,[],0,Korea,16,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Randomized Phase II Trial of Sunitinib on an Intermittent Versus Continuous Dosing Schedule As First-Line Therapy for Advanced Renal Cell Carcinoma,2012-04-20,sunitinib,True,['Pfizer'],0,USA,17,13,6,5,0,1,1,1,1,0,0,0,0,0,0,0
TET2 Mutations in Acute Myeloid Leukemia (AML): Results From a Comprehensive Genetic and Clinical Analysis of the AML Study Group,2012-04-20,,False,[],0,Germany,16,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Depression and Survival in Metastatic Nonâ€“Small-Cell Lung Cancer: Effects of Early Palliative Care,2012-04-20,,False,[],0,USA,9,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Effectiveness of Mindfulness-Based Stress Reduction in Mood, Breast- and Endocrine-Related Quality of Life, and Well-Being in Stage 0 to III Breast Cancer: A Randomized, Controlled Trial",2012-04-20,,False,[],0,United Kingdom,6,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Web-Based Tailored Education Program for Disease-Free Cancer Survivors With Cancer-Related Fatigue: A Randomized Controlled Trial,2012-04-20,,False,[],0,Korea,19,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Phase II Study of Weekly Vinblastine in Recurrent or Refractory Pediatric Low-Grade Glioma,2012-04-20,vinblastine,False,[],0,Australia,16,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Pilot Randomized Controlled Trial of Individual Meaning-Centered Psychotherapy for Patients With Advanced Cancer,2012-04-20,,False,[],0,USA,11,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Prospective Study of 2-[18F]Fluorodeoxyglucose Positron Emission Tomography in the Assessment of Regional Nodal Spread of Disease in Patients With Breast Cancer: An Ontario Clinical Oncology Group Study,2012-04-20,2-[18F]fluorodeoxyglucose (FDG),False,[],0,Canada,15,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Changes in Cardiac Biomarkers During Doxorubicin Treatment of Pediatric Patients With High-Risk Acute Lymphoblastic Leukemia: Associations With Long-Term Echocardiographic Outcomes,2012-04-01,doxorubicin,False,[],0,USA,17,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Randomized Phase III Study Comparing Paclitaxel/Cisplatin/ Gemcitabine and Gemcitabine/Cisplatin in Patients With Locally Advanced or Metastatic Urothelial Cancer Without Prior Systemic Therapy: EORTC Intergroup Study 30987,2012-04-01,paclitaxel,False,[],0,the Netherlands,16,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Vandetanib Versus Placebo in Patients With Advanced Nonâ€“Small-Cell Lung Cancer After Prior Therapy With an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor: A Randomized, Double-Blind Phase III Trial (ZEPHYR)",2012-04-01,vandetanib,True,['AstraZeneca'],0,Germany,10,7,2,2,0,3,1,1,1,0,0,0,0,0,0,0
First-SIGNAL: First-Line Single-Agent Iressa Versus Gemcitabine and Cisplatin Trial in Never-Smokers With Adenocarcinoma of the Lung,2012-04-01,gefitinib,True,['AstraZeneca'],0,Republic of Korea,16,10,0,1,0,2,1,1,0,0,1,0,0,0,0,0
Long-Term Follow-Up of Children Treated for High-Grade Gliomas: Children's Oncology Group L991 Final Study Report,2012-03-20,,False,[],0,USA,10,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"First-Line Treatment of Advanced Breast Cancer With Sunitinib in Combination With Docetaxel Versus Docetaxel Alone: Results of a Prospective, Randomized Phase III Study",2012-03-20,sunitinib,True,['Pfizer'],0,Italy,15,8,3,4,0,4,1,0,1,0,0,0,0,0,0,0
Predictors of Aromatase Inhibitor Discontinuation as a Result of Treatment-Emergent Symptoms in Early-Stage Breast Cancer,2012-03-20,exemestane,True,['Pfizer'],0,USA,13,4,0,0,0,1,0,1,0,0,0,0,0,0,0,0
Phase III Trial Evaluating Weekly Paclitaxel Versus Docetaxel in Combination With Capecitabine in Operable Breast Cancer,2012-03-20,capecitabine,True,['Roche'],0,USA,13,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
Phase II Study of Imatinib in Advanced Chordoma,2012-03-20,imatinib,True,"['Novartis', 'Novartis: travel coverage']",0,Switzerland,15,6,2,2,0,3,1,1,1,0,0,0,0,0,0,0
Minimal Residual Disease Quantification Is an Independent Predictor of Progression-Free and Overall Survival in Chronic Lymphocytic Leukemia: A Multivariate Analysis From the Randomized GCLLSG CLL8 Trial ,2012-03-20,rituximab,True,"['F. Hoffmann-La Roche', 'Travel grants: F. Hoffmann-La Roche']",0,Switzerland,16,13,3,4,0,7,1,1,1,0,0,0,0,0,0,0
Dose-Intensification in Early Unfavorable Hodgkin's Lymphoma: Final Analysis of the German Hodgkin Study Group HD14 Trial,2012-03-20,bleomycin,False,[],0,the Netherlands,18,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Pulmonary Toxicity After Bevacizumab and Concurrent Thoracic Radiotherapy Observed in a Phase I Study for Inoperable Stage III Nonâ€“Small-Cell Lung Cancer,2012-03-10,,False,[],0,the Netherlands,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Defucosylated Anti-CCR4 Monoclonal Antibody (KW-0761) for Relapsed Adult T-Cell Leukemia-Lymphoma: A Multicenter Phase II Study,2012-03-10,KW-0761,True,['Kyowa Hakko Kirin'],0,Japan,20,3,1,1,0,1,1,1,1,0,0,0,0,0,0,0
Sequential Versus Single High-Dose Chemotherapy in Patients With Relapsed or Refractory Germ Cell Tumors: Long-Term Results of a Prospective Randomized Trial,2012-03-10,,False,[],0,Canada,8,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Short, Full-Dose Adjuvant Chemotherapy in High-Risk Adult Soft Tissue Sarcomas: A Randomized Clinical Trial From the Italian Sarcoma Group and the Spanish Sarcoma Group",2012-03-10,epirubicin,False,[],0,Spain,18,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Randomized Phase III Study Comparing PaclitaxelÃ¢â‚¬â€œBleomycin, Etoposide, and Cisplatin (BEP) to Standard BEP in Intermediate-Prognosis Germ-Cell Cancer: Intergroup Study EORTC 30983",2012-03-10,paclitaxel,False,[],0,,12,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Recurrence and Survival After Random Assignment to Laparoscopy Versus Laparotomy for Comprehensive Surgical Staging of Uterine Cancer: Gynecologic Oncology Group LAP2 Study,2012-03-01,,False,[],0,USA,9,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Tamoxifen and Anastrozole As a Sequencing Strategy: A Randomized Controlled Trial in Postmenopausal Patients With Endocrine-Responsive Early Breast Cancer From the Austrian Breast and Colorectal Cancer Study Group,2012-03-01,anastrozole,True,['AstraZeneca'],0,,21,8,0,4,0,6,1,1,0,0,1,0,0,0,0,0
Longer-Term Outcomes of Letrozole Versus Placebo After 5 Years of Tamoxifen in the NCIC CTG MA.17 Trial: Analyses Adjusting for Treatment Crossover,2012-03-01,letrozole,True,['Novartis'],0,USA,5,2,0,2,0,1,1,1,0,0,1,0,0,0,0,0
Disease-Related Outcomes With Long-Term Follow-Up: An Updated Analysis of the Intergroup Exemestane Study,2012-03-01,exemestane,True,['Pfizer'],0,USA,17,7,2,1,0,5,1,0,1,0,0,0,0,0,0,0
"Results From a Pivotal, Open-Label, Phase II Study of Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma After Prior Systemic Therapy",2012-02-20,romidepsin,True,['Gloucester Pharmaceuticals'],0,,18,2,0,1,0,0,0,0,0,0,0,0,0,0,0,0
Effects of Abiraterone Acetate on Androgen Signaling in Castrate-Resistant Prostate Cancer in Bone,2012-02-20,abiraterone acetate,True,"['Cougar Biotechnology', 'Cougar Biotechnology/Ortho Biotech']",0,USA,12,2,2,0,0,0,1,0,1,0,0,0,0,0,0,0
Randomized Phase III Study of Thoracic Radiation in Combination With Paclitaxel and Carboplatin With or Without Thalidomide in Patients With Stage III NonÃ¢â‚¬â€œSmall-Cell Lung Cancer: The ECOG 3598 Study,2012-02-20,thalidomide,True,['Bristol-Myers Squibb'],0,USA,7,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
Treatment of Patients With Advanced Neurofibromatosis Type 2 With Novel Molecularly Targeted Therapies: From Bench to Bedside,2012-02-10,,False,[],0,USA,7,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Double-Blind, Randomized Trial of Docetaxel Plus Vandetanib Versus Docetaxel Plus Placebo in Platinum-Pretreated Metastatic Urothelial Cancer",2012-02-10,vandetanib,True,['AstraZeneca'],0,USA,20,2,0,0,0,1,0,1,0,0,0,0,0,0,0,0
Substantial Susceptibility of Chronic Lymphocytic Leukemia to BCL2 Inhibition: Results of a Phase I Study of Navitoclax in Patients With Relapsed or Refractory Disease,2012-02-10,navitoclax,True,"['Abbott Laboratories (U)', 'Abbott Laboratories']",0,,16,12,7,1,0,0,1,1,1,0,0,0,0,0,0,0
Randomized Trial Using Gonadotropin-Releasing Hormone Agonist Triptorelin for the Preservation of Ovarian Function During (Neo)Adjuvant Chemotherapy for Breast Cancer,2012-02-10,triptorelin,False,[],0,USA,9,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Advanced Stage, Increased Lactate Dehydrogenase, and Primary Site, but Not Adolescent Age (â‰¥ 15 Years), Are Associated With an Increased Risk of Treatment Failure in Children and Adolescents With Mature B-Cell Non-Hodgkin's Lymphoma: Results of the FAB LMB 96 Study",2012-02-01,,False,[],0,USA,11,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Effect of Early Palliative Care on Chemotherapy Use and End-of-Life Care in Patients With Metastatic Nonâ€“Small-Cell Lung Cancer,2012-02-01,,False,[],0,USA,8,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Association of Obesity With DNA Mismatch Repair Status and Clinical Outcome in Patients With Stage II or III Colon Carcinoma Participating in NCCTG and NSABP Adjuvant Chemotherapy Trials,2012-02-01,,False,[],0,USA,9,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Phase II, Open-Label, Randomized, Multicenter Study Comparing the Efficacy and Safety of Olaparib, a Poly (ADP-Ribose) Polymerase Inhibitor, and Pegylated Liposomal Doxorubicin in Patients With BRCA1 or BRCA2 Mutations and Recurrent Ovarian Cancer",2012-02-01,olaparib,True,"['AstraZeneca', 'AstraZeneca (U)', 'AstraZeneca Advisory Board']",0,,16,9,3,3,0,1,1,0,1,0,0,0,0,0,0,0
"Randomized, Double-Blind, Placebo-Controlled Phase II Study of AMG 386 Combined With Weekly Paclitaxel in Patients With Recurrent Ovarian Cancer",2012-02-01,AMG 386,True,"['Amgen â€“ AMG 386 Study', 'Amgen (advisory board)', 'Amgen â€“ Denosumab Studies', 'Amgen']",0,,20,9,4,0,0,1,1,1,1,0,0,0,0,0,0,0
Activation of Peripheral-Blood Granulocytes Is Strongly Correlated With Patient Outcome After Immunotherapy With Anti-GD2 Monoclonal Antibody and Granulocyte-Macrophage Colony-Stimulating Factor,2012-02-01,GM-CSF,False,[],0,USA,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Phase III Trial Comparing Capecitabine Plus Cisplatin Versus Capecitabine Plus Cisplatin With Concurrent Capecitabine Radiotherapy in Completely Resected Gastric Cancer With D2 Lymph Node Dissection: The ARTIST Trial,2012-01-20,capecitabine,False,[],0,USA,17,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Safety and Efficacy of Combination Immunotherapy With Interferon Alfa-2b and Tremelimumab in Patients With Stage IV Melanoma,2012-01-20,tremelimumab,True,['Pfizer'],0,USA,8,1,0,1,0,0,1,0,0,0,1,0,0,0,0,0
"Phase I, Dose-Escalation Study of BKM120, an Oral Pan-Class I PI3K Inhibitor, in Patients With Advanced Solid Tumors",2012-01-20,BKM120,True,"['Novartis', 'Novartis Pharma', 'Novartis Institutes of Biomedical Research', 'Novartis Oncology']",0,USA,12,9,6,2,0,1,1,1,1,0,0,0,0,0,0,0
Treatment of Colorectal Peritoneal Carcinomatosis With Systemic Chemotherapy: A Pooled Analysis of North Central Cancer Treatment Group Phase III Trials N9741 and N9841,2012-01-20,oxaliplatin,True,['sanofi-aventis'],0,USA,10,1,0,1,0,0,1,0,0,0,1,0,0,0,0,0
Phase I/II Trial and Pharmacokinetic Study of Cixutumumab in Pediatric Patients With Refractory Solid Tumors and Ewing Sarcoma: A Report From the Children's Oncology Group,2012-01-20,cixutumumab,False,[],0,USA,14,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Prognostic Effect of Circulating Adiponectin in a Randomized 2 Ã— 2 Trial of Low-Dose Tamoxifen and Fenretinide in Premenopausal Women at Risk for Breast Cancer,2012-01-10,tamoxifen,False,[],0,Italy,16,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Randomized Phase II/III Trial Assessing Gemcitabine/Carboplatin and Methotrexate/Carboplatin/Vinblastine in Patients With Advanced Urothelial Cancer Who Are Unfit for Cisplatin-Based Chemotherapy: EORTC Study 30986,2012-01-10,,False,[],0,Poland,14,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Randomized Phase III Study of Surgery Alone or Surgery Plus Preoperative Cisplatin and Gemcitabine in Stages IB to IIIA Nonâ€“Small-Cell Lung Cancer,2012-01-10,gemcitabine,True,['Eli Lilly'],0,the Netherlands,11,5,2,3,0,1,1,1,1,0,0,0,0,0,0,0
"Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III Trial",2012-01-10,vandetanib,True,"['AstraZeneca', 'AstraZeneca (U)']",0,United Kingdom,14,11,3,6,0,1,1,1,1,0,0,0,0,0,0,0
BEAM: A Randomized Phase II Study Evaluating the Activity of Bevacizumab in Combination With Carboplatin Plus Paclitaxel in Patients With Previously Untreated Advanced Melanoma,2012-01-01,bevacizumab,True,['Genentech'],0,USA,13,8,3,3,0,3,1,0,1,0,0,0,0,0,0,0
"Adjuvant Capecitabine, Docetaxel, Cyclophosphamide, and Epirubicin for Early Breast Cancer: Final Analysis of the Randomized FinXX Trial",2012-01-01,capecitabine,True,['Roche'],0,Sweden,20,8,0,2,0,6,0,1,0,0,0,0,0,0,0,0
Phase II Study of the Mammalian Target of Rapamycin Inhibitor Ridaforolimus in Patients With Advanced Bone and Soft Tissue Sarcomas,2012-01-01,ridaforolimus,True,"['ARIAD Pharmaceuticals (U)', 'ARIAD Pharmaceuticals']",0,USA,15,13,5,5,0,1,1,1,1,0,0,0,0,0,0,0
Use of a Decision Aid to Help Caregivers Discuss Terminal Disease Status With a Family Member With Cancer: A Randomized Controlled Trial,2011-12-20,,False,[],0,Korea,18,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Evaluating Survivorship Care Plans: Results of a Randomized, Clinical Trial of Patients With Breast Cancer",2011-12-20,,False,[],0,,20,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
MET Amplification Identifies a Small and Aggressive Subgroup of Esophagogastric Adenocarcinoma With Evidence of Responsiveness to Crizotinib,2011-12-20,crizotinib,True,['Pfizer'],0,South Korea,15,8,2,4,0,1,1,1,1,0,0,0,0,0,0,0
"Gemcitabine Plus Docetaxel Versus Docetaxel in Patients With Predominantly Human Epidermal Growth Factor Receptor 2Ã¢â‚¬â€œNegative Locally Advanced or Metastatic Breast Cancer: A Randomized, Phase III Study by the Danish Breast Cancer Cooperative Group",2011-12-20,gemcitabine,False,[],0,Denmark,10,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Prognostic Impact of Morphologic and Phenotypic Features of Childhood ALK-Positive Anaplastic Large-Cell Lymphoma: Results of the ALCL99 Study,2011-12-10,,False,[],0,Austria,13,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Wait-and-See Policy for Clinical Complete Responders After Chemoradiation for Rectal Cancer,2011-12-10,,False,[],0,the Netherlands,13,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Phase II Study of Intraperitoneal Paclitaxel Plus Cisplatin and Intravenous Paclitaxel Plus Bevacizumab As Adjuvant Treatment of Optimal Stage II/III Epithelial Ovarian Cancer,2011-12-10,bevacizumab,True,['Genentech'],0,USA,12,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0
Duration of Short-Course Androgen Suppression Therapy and the Risk of Death As a Result of Prostate Cancer,2011-12-10,,False,[],0,Australia,9,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Risk-Adapted Treatment in Clinical Stage I Testicular Seminoma: The Third Spanish Germ Cell Cancer Group Study,2011-12-10,carboplatin,False,[],0,Spain,18,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
First-in-Man Clinical Trial of the Oral Pan-AKT Inhibitor MK-2206 in Patients With Advanced Solid Tumors,2011-12-10,MK-2206,True,"['Merck', 'Merck (U)']",0,,18,12,4,3,0,2,0,1,0,0,0,0,0,0,0,0
Sequential Versus Concurrent Trastuzumab in Adjuvant Chemotherapy for Breast Cancer,2011-12-01,trastuzumab,True,['Genentech'],0,USA,13,4,0,1,0,0,1,0,0,0,1,0,0,0,0,0
"Randomized Phase II Study of Erlotinib in Combination With Placebo or R1507, a Monoclonal Antibody to Insulin-Like Growth Factor-1 Receptor, for Advanced-Stage Nonâ€“Small-Cell Lung Cancer",2011-12-01,R1507,True,"['Roche (U)', 'F. Hoffmann-La Roche', 'Roche']",0,Italy,14,12,4,6,0,5,1,0,1,0,0,0,0,0,0,0
Preliminary Efficacy of the Anti-Insulinâ€“Like Growth Factor Type 1 Receptor Antibody Figitumumab in Patients With Refractory Ewing Sarcoma,2011-12-01,figitumumab,True,['Pfizer'],0,USA,14,11,5,0,0,0,1,1,1,0,0,0,0,0,0,0
"S0356: A Phase II Clinical and Prospective Molecular Trial With Oxaliplatin, Fluorouracil, and External-Beam Radiation Therapy Before Surgery for Patients With Esophageal Adenocarcinoma",2011-12-01,oxaliplatin,True,['sanofi-aventis'],0,Canada,12,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0
"Capecitabine Versus Classical Cyclophosphamide, Methotrexate, and Fluorouracil As First-Line Chemotherapy for Advanced Breast Cancer",2011-12-01,capecitabine,True,"['F. Hoffman-La Roche', 'F. Hoffman-La Roche (U)', 'Roche', 'Roche (U)']",0,New Zealand,19,11,0,3,0,7,1,1,0,0,1,0,0,0,0,0
Gemcitabine Plus nab-Paclitaxel Is an Active Regimen in Patients With Advanced Pancreatic Cancer: A Phase I/II Trial,2011-12-01,nab-paclitaxel,True,['Celgene'],0,Spain,16,8,5,0,0,0,1,0,1,0,0,0,0,0,0,0
"R1507, a Monoclonal Antibody to the Insulin-Like Growth Factor 1 Receptor, in Patients With Recurrent or Refractory Ewing Sarcoma Family of Tumors: Results of a Phase II Sarcoma Alliance for Research Through Collaboration Study",2011-12-01,R1507,False,['Roche Diagnostics'],0,USA,18,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0
"Randomized Phase II Study of Dulanermin in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Advanced Nonâ€“Small-Cell Lung Cancer",2011-11-20,dulanermin,True,['Amgen'],0,USA,16,5,4,1,0,0,1,1,1,0,0,0,0,0,0,0
Five-Year Outcomes of a Randomized Phase III Trial Comparing Adjuvant Chemotherapy With S-1 Versus Surgery Alone in Stage II or III Gastric Cancer,2011-11-20,S-1,True,['Taiho Pharmaceutical'],0,Japan,10,9,0,5,0,9,1,1,0,0,1,0,0,0,0,0
"Phase II Study of SMILE Chemotherapy for Newly Diagnosed Stage IV, Relapsed, or Refractory Extranodal Natural Killer (NK)/T-Cell Lymphoma, Nasal Type: The NK-Cell Tumor Study Group Study",2011-11-20,L-asparaginase,True,['Kyowa-Hakko Kirin'],0,USA,17,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1
"Cisplatin, Irinotecan, and Bevacizumab for Untreated Extensive-Stage Small-Cell Lung Cancer: CALGB 30306, a Phase II Study",2011-11-20,bevacizumab,True,['Genentech'],0,USA,7,2,0,2,0,0,1,1,0,0,1,1,0,0,0,0
Randomized Placebo-Controlled Phase II Trial of Perifosine Plus Capecitabine As Second- or Third-Line Therapy in Patients With Metastatic Colorectal Cancer,2011-11-20,perifosine,True,['Keryx Biopharmaceuticals'],0,USA,9,3,2,0,0,0,1,1,1,0,0,0,0,0,0,0
Pilot Induction Regimen Incorporating Pharmacokinetically Guided Topotecan for Treatment of Newly Diagnosed High-Risk Neuroblastoma: A Children's Oncology Group Study,2011-11-20,topotecan,False,[],0,USA,9,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Randomized, Placebo-Controlled Phase III Study of Docetaxel Plus Carboplatin With Celecoxib and Cyclooxygenase-2 Expression As a Biomarker for Patients With Advanced Nonâ€“Small-Cell Lung Cancer: The NVALT-4 Study",2011-11-10,celecoxib,False,[],0,the Netherlands,13,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Long-Term Follow-Up Analysis of HD9601 Trial Comparing ABVD Versus Stanford V Versus MOPP/EBV/CAD in Patients With Newly Diagnosed Advanced-Stage Hodgkin's Lymphoma: A Study From the Intergruppo Italiano Linfomi,2011-11-10,doxorubicin,False,[],0,Italy,16,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Influence of Comorbidities and Age on Risk of Death Without Recurrence: A Retrospective Analysis of the Arimidex, Tamoxifen Alone or in Combination Trial",2011-11-10,anastrozole,True,['AstraZeneca'],0,Australia,8,3,0,2,0,0,1,1,0,0,1,0,0,0,0,0
Eight Cycles of Escalated-Dose BEACOPP Compared With Four Cycles of Escalated-Dose BEACOPP Followed by Four Cycles of Baseline-Dose BEACOPP With or Without Radiotherapy in Patients With Advanced-Stage Hodgkin's Lymphoma: Final Analysis of the HD12 Trial of the German Hodgkin Study Group,2011-11-10,"Bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone (BEACOPPescalated regimen)",False,[],0,Austria,20,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"RIBBON-2: A Randomized, Double-Blind, Placebo-Controlled, Phase III Trial Evaluating the Efficacy and Safety of Bevacizumab in Combination With Chemotherapy for Second-Line Treatment of Human Epidermal Growth Factor Receptor 2â€“Negative Metastatic Breast Cancer",2011-11-10,bevacizumab,True,"['Genentech', 'Genentech (U)']",0,USA,7,7,2,2,0,1,1,1,1,0,0,0,0,0,0,0
Front-Line Therapy With Second-Generation Tyrosine Kinase Inhibitors in Patients With Early Chronic Phase Chronic Myeloid Leukemia: What Is the Optimal Response?,2011-11-10,nilotinib,True,['Bristol-Myers Squibb'],0,USA,8,3,0,1,0,1,0,1,0,0,0,0,0,0,0,0
Perifosine Plus Bortezomib and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma Previously Treated With Bortezomib: Results of a Multicenter Phase I/II Trial,2011-11-10,perifosine,False,[],0,USA,22,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Randomized, Double-Blind, Placebo-Controlled Phase II Study of Single-Agent Oral Talactoferrin in Patients With Locally Advanced or Metastatic Nonâ€“Small-Cell Lung Cancer That Progressed After Chemotherapy ",2011-11-01,talactoferrin,True,['Agennix'],0,USA,14,6,4,0,0,0,1,1,1,0,0,0,0,0,0,0
Multivariable Model for Time to First Treatment in Patients With Chronic Lymphocytic Leukemia ,2011-11-01,,False,[],0,USA,16,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Gemcitabine Alone Versus Gemcitabine Plus Radiotherapy in Patients With Locally Advanced Pancreatic Cancer: An Eastern Cooperative Oncology Group Trial,2011-11-01,gemcitabine,True,['Eli Lilly'],0,USA,11,3,0,1,0,1,1,1,0,0,1,0,0,0,0,0
"Prospective Molecular Marker Analyses of EGFR and KRAS From a Randomized, Placebo-Controlled Study of Erlotinib Maintenance Therapy in Advanced Nonâ€“Small-Cell Lung Cancer",2011-11-01,erlotinib,True,"['F. Hoffmann-La Roche', 'F. Hoffman-La Roche', 'Roche']",0,Italy,12,7,3,3,0,3,1,1,1,0,0,0,0,0,0,0
Costs of Home Versus Inpatient Treatment for Fever and Neutropenia: Analysis of a Multicenter Randomized Trial,2011-10-20,,False,[],0,USA,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Safety of Early Discharge for Low-Risk Patients With Febrile Neutropenia: A Multicenter Randomized Controlled Trial,2011-10-20,,False,[],0,USA,7,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Phase II Randomized, Double-Blind, Placebo-Controlled Study of Tasquinimod in Men With Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer",2011-10-20,tasquinimod,True,['Active Biotech'],0,USA,10,8,2,3,0,0,1,1,1,0,0,0,0,0,0,0
Phase II Trial of Sorafenib Combined With Concurrent Transarterial Chemoembolization With Drug-Eluting Beads for Hepatocellular Carcinoma,2011-10-20,sorafenib,True,['Bayer HealthCare Pharmaceuticals'],0,USA,6,2,0,2,0,0,1,1,0,0,1,0,0,0,0,0
"Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study",2011-10-20,bevacizumab,True,['Genentech'],0,Switzerland,12,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Phase II/III Study of R-CHOP-21 Versus R-CHOP-14 for Untreated Indolent B-Cell Non-Hodgkin's Lymphoma: JCOG 0203 Trial,2011-10-20,rituximab,False,[],0,Japan,17,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Phase III Study of Doxorubicin/Cyclophosphamide With Concomitant Versus Sequential Docetaxel As Adjuvant Treatment in Patients With Human Epidermal Growth Factor Receptor 2â€“Normal, Node-Positive Breast Cancer: BCIRG-005 Trial",2011-10-10,docetaxel,True,['sanofi-aventis'],0,Canada,18,11,0,6,0,7,0,1,0,0,0,0,0,0,0,0
Randomized Trial of Tamoxifen Versus Combined Tamoxifen and Octreotide LAR Therapy in the Adjuvant Treatment of Early-Stage Breast Cancer in Postmenopausal Women: NCIC CTG MA.14,2011-10-10,octreotide,True,"['Novartis', 'Novartis (U)']",0,USA,16,4,0,2,0,3,1,1,0,0,1,0,0,0,0,0
"Management of Hot Flashes in Patients Who Have Breast Cancer With Venlafaxine and Clonidine: A Randomized, Double-Blind, Placebo-Controlled Trial",2011-10-10,venlafaxine,False,[],0,the Netherlands,10,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Treatment of Polycythemia Vera With Hydroxyurea and Pipobroman: Final Results of a Randomized Trial Initiated in 1980,2011-10-10,hydroxyurea,False,[],0,France,5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Phase I Pharmacokinetic and Pharmacodynamic Dose-Escalation Study of RG7160 (GA201), the First Glycoengineered Monoclonal Antibody Against the Epidermal Growth Factor Receptor, in Patients With Advanced Solid Tumors ",2011-10-01,RG7160,True,['Roche Glycart'],0,Switzerland,15,2,2,0,0,0,0,0,0,0,0,0,0,0,0,0
Magnetic Resonance Imagingâ€“Detected Tumor Response for Locally Advanced Rectal Cancer Predicts Survival Outcomes: MERCURY Experience,2011-10-01,,False,[],0,Sweden,15,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Randomized Phase III Trial of Sequential Adjuvant Chemoradiotherapy With or Without Erythropoietin Alfa in Patients With High-Risk Cervical Cancer: Results of the NOGGO-AGO Intergroup Study ,2011-10-01,erythropoietin alfa,True,['Amgen'],0,United Kingdom,17,3,0,1,0,3,1,1,0,0,1,0,0,0,0,0
"Oxaliplatin As Adjuvant Therapy for Colon Cancer: Updated Results of NSABP C-07 Trial, Including Survival and  Subset Analyses ",2011-10-01,oxaliplatin,True,"['sanofi-aventis', 'sanofi-aventis (U)']",0,USA,7,3,0,3,0,0,1,1,0,0,1,1,0,0,0,0
Randomized Phase II Placebo-Controlled Trial of Maintenance Therapy Using the Oral Triple Angiokinase Inhibitor BIBF 1120 After Chemotherapy for Relapsed Ovarian Cancer,2011-10-01,nintedanib,True,"['Boehringer Ingelheim', 'Boeringher Ingleheim']",0,United Kingdom,15,8,2,4,0,3,1,1,1,0,0,0,0,0,0,0
Elevated Bone Turnover Predicts for Bone Metastasis in Postmenopausal Breast Cancer: Results of NCIC CTG MA.14,2011-09-20,tamoxifen,False,[],0,Canada,10,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Phase IB Study of Gene-Mediated Cytotoxic Immunotherapy Adjuvant to Up-Front Surgery and Intensive Timing Radiation for Malignant Glioma,2011-09-20,AdV-tk,True,['Advantagene'],0,USA,20,4,4,0,0,0,1,1,1,0,0,0,0,0,0,0
Carboplatin Plus Paclitaxel Versus Carboplatin Plus Pegylated Liposomal Doxorubicin As First-Line Treatment for Patients With Ovarian Cancer: The MITO-2 Randomized Phase III Trial,2011-09-20,pegylated liposomal doxorubicin,True,['Schering-Plough'],0,,30,4,0,1,0,4,1,1,0,0,1,0,0,0,0,0
"Randomized, Double-Blind, Controlled Trial of Early Endoscopic Ultrasoundâ€“Guided Celiac Plexus Neurolysis  to Prevent Pain Progression in Patients With Newly Diagnosed, Painful, Inoperable Pancreatic Cancer",2011-09-10,,False,[],0,USA,5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Bendamustine Combined With Rituximab in Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia: A Multicenter Phase II Trial of the German Chronic Lymphocytic Leukemia Study Group ,2011-09-10,bendamustine,True,['Cephalon'],0,Germany,20,2,0,2,0,2,1,0,0,0,1,0,0,0,0,0
Phase I Trial of MK-0752 in Children With Refractory CNS Malignancies: A Pediatric Brain Tumor Consortium Study,2011-09-10,MK-0752,True,['Merck'],0,USA,14,4,1,0,0,0,1,1,1,0,0,0,0,0,0,0
"A Randomized, Phase II, Biomarker-Selected Study Comparing Erlotinib to Erlotinib Intercalated With Chemotherapy in First-Line Therapy for Advanced NonÃ¢â‚¬â€œSmall-Cell Lung Cancer",2011-09-10,erlotinib,True,['Roche'],0,USA,15,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0
Specific Training Program Improves Oncologists' Palliative Care Communication Skills in a Randomized Controlled Trial,2011-09-01,,False,[],0,Germany,8,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Phase I Trial of Lenalidomide and CCI-779 in Patients With Relapsed Multiple Myeloma: Evidence for Lenalidomideâ€“CCI-779 Interaction via P-Glycoprotein ,2011-09-01,lenalidomide,True,['Celgene'],0,USA,21,1,0,0,0,1,1,1,0,0,0,0,0,0,1,0
"Bortezomib, Bendamustine, and Rituximab in Patients With Relapsed or Refractory Follicular Lymphoma: The Phase II VERTICAL Study",2011-09-01,bortezomib,True,"['Millennium', 'Millennium Pharmaceuticals']",0,USA,15,10,2,4,0,1,1,1,1,0,0,0,0,0,0,0
Phase II Study of Cetuximab As First-Line Single-Drug Therapy in Patients With Unresectable Squamous Cell Carcinoma of the Skin,2011-09-01,cetuximab,True,['Merck Serono'],0,France,20,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1
Phase III Study of Molecularly Targeted Adjuvant Therapy in Locally Advanced Urothelial Cancer of the Bladder Based on p53 Status ,2011-09-01,"methotrexate, vinblastine, doxorubicin, cisplatin (MVAC)",False,[],0,USA,13,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Pathologic Complete Response After Neoadjuvant Chemotherapy Plus Trastuzumab Predicts Favorable Survival in Human Epidermal Growth Factor Receptor 2â€“Overexpressing Breast Cancer: Results From the TECHNO Trial of the AGO and GBG Study Groups,2011-09-01,trastuzumab,True,['Genentech'],0,USA,19,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
Four-Year Follow-Up of Trastuzumab Plus Adjuvant Chemotherapy for Operable Human Epidermal Growth Factor Receptor 2â€“Positive Breast Cancer: Joint Analysis of Data From NCCTG N9831 and NSABP B-31,2011-09-01,trastuzumab,True,"['Genentech', 'Genentech/Roche (U)']",0,USA,10,5,0,4,0,2,1,1,0,0,1,0,0,0,0,0
Bortezomib Added to R-CVP Is Safe and Effective for Previously Untreated Advanced-Stage Follicular Lymphoma: A Phase II Study by the National Cancer Institute of Canada Clinical Trials Group,2011-09-01,bortezomib,False,[],0,Canada,15,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Phase II Study of Temsirolimus in Women With Recurrent or Metastatic Endometrial Cancer: A Trial of the NCIC Clinical Trials Group,2011-08-20,temsirolimus,False,[],0,USA,16,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Phase I Pharmacokinetic and Pharmacodynamic Study of the Multikinase Inhibitor Sorafenib in Combination With Clofarabine and Cytarabine in Pediatric Relapsed/Refractory Leukemia,2011-08-20,sorafenib,True,['Bayer Pharmaceuticals'],0,USA,15,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0
Randomized Phase II Study of Erlotinib Plus Tivantinib Versus Erlotinib Plus Placebo in Previously Treated Nonâ€“Small-Cell Lung Cancer,2011-08-20,tivantinib,True,"['ArQule', 'ArQule (U)']",0,USA,15,11,3,2,0,0,1,1,1,0,0,0,0,0,0,0
"Randomized, Phase III Trial of Sequential Epirubicin and Docetaxel Versus Epirubicin Alone in Postmenopausal Patients With Node-Positive Breast Cancer",2011-08-20,docetaxel,True,['sanofi-aventis'],0,Spain,17,6,0,3,0,3,1,1,0,0,1,0,0,0,0,0
Complete Surgical Resection Is Curative for Children With Hepatoblastoma With Pure Fetal Histology: A Report From the Children's Oncology Group,2011-08-20,doxorubicin,False,[],0,USA,7,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Dextromethorphan As a Phenotyping Test to Predict Endoxifen Exposure in Patients on Tamoxifen Treatment,2011-08-20,tamoxifen,False,[],0,the Netherlands,13,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Microsatellite Instability and Loss of Heterozygosity at Chromosomal Location 18q: Prospective Evaluation of Biomarkers for Stages II and III Colon Cancerâ€”A Study of CALGB 9581 and 89803,2011-08-10,,False,[],0,USA,9,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Documenting the Natural History of Patients With Resected Stage II Adenocarcinoma of the Colon After Random Assignment to Adjuvant Treatment With Edrecolomab or Observation: Results From CALGB 9581,2011-08-10,edrecolomab,True,['Centocor'],0,France,20,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0
"Randomized Phase II Study of Pemetrexed, Carboplatin, and Thoracic Radiation With or Without Cetuximab in Patients With Locally Advanced Unresectable Nonâ€“Small-Cell Lung Cancer: Cancer and Leukemia Group B Trial 30407",2011-08-10,pemetrexed,True,['Eli Lilly'],0,USA,9,2,0,1,0,1,1,1,0,0,1,0,0,0,0,1
Phase I/II Study of Trastuzumab in Combination With Everolimus (RAD001) in Patients With HER2-Overexpressing Metastatic Breast Cancer Who Progressed on Trastuzumab-Based Therapy,2011-08-10,everolimus,True,"['Novartis (U)', 'Novartis']",0,USA,17,4,0,2,0,0,1,1,0,0,1,0,0,0,0,0
Variability of Lung Tumor Measurements on Repeat Computed Tomography Scans Taken Within 15 Minutes,2011-08-10,,False,[],0,USA,10,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Randomized Phase III Placebo-Controlled Trial of Carboplatin and Paclitaxel With or Without the Vascular Disrupting Agent Vadimezan (ASA404) in Advanced Nonâ€“Small-Cell Lung Cancer,2011-08-01,vadimezan,True,['Antisoma'],0,Italy,12,2,0,2,0,1,0,1,0,0,0,0,0,0,0,0
Calcium Plus Vitamin D Supplementation and the Risk of Nonmelanoma and Melanoma Skin Cancer: Post Hoc Analyses of the Women's Health Initiative Randomized Controlled Trial,2011-08-01,vitamin D3,False,[],0,USA,10,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Temozolomide in Elderly Patients With Newly Diagnosed Glioblastoma and Poor Performance Status: An ANOCEF Phase II Trial,2011-08-01,temozolomide,True,['Schering-Plough'],0,France,17,2,0,0,0,1,1,1,0,0,0,0,0,0,1,0
"Phase II Trial of Cetuximab, Gemcitabine, and Oxaliplatin Followed by Chemoradiation With Cetuximab for Locally Advanced (T4) Pancreatic Adenocarcinoma: Correlation of Smad4(Dpc4) Immunostaining With Pattern of Disease Progression",2011-08-01,cetuximab,True,['Bristol Myers-Squibb'],0,USA,14,1,0,0,0,1,1,0,0,0,0,0,0,0,1,0
Randomized Multicenter Trial of the Effects of Melanoma-Associated Helper Peptides and Cyclophosphamide on the Immunogenicity of a Multipeptide Melanoma Vaccine,2011-07-20,cyclophosphamide,False,[],0,USA,8,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Phase I Study of Temsirolimus in Pediatric Patients With Recurrent/Refractory Solid Tumors,2011-07-20,temsirolimus,True,"['Pfizer', 'Wyeth/Pfizer']",0,USA,11,4,3,1,0,0,0,1,0,0,0,0,0,0,0,0
"Phase II, Open-Label, Single-Arm Trial of Imatinib Mesylate in Patients With Metastatic Melanoma Harboring c-Kit Mutation or Amplification",2011-07-20,imatinib,True,['Novartis'],0,USA,21,1,0,1,0,1,1,1,0,0,1,0,0,0,0,0
Impact of Patient-Reported Outcomes in Oncology: A Longitudinal Analysis of Patient-Physician Communication,2011-07-20,,False,[],0,United Kingdom,8,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Nonâ€“Small-Cell Lung Cancer in Asia (IPASS)",2011-07-20,gefitinib,False,[],0,United Kingdom,18,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Incidence and Prognostic Influence of DNMT3A Mutations in Acute Myeloid Leukemia,2011-07-20,,False,[],0,Germany,18,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Single-Injection Depot Progesterone Before Surgery and Survival in Women With Operable Breast Cancer: A Randomized Controlled Trial,2011-07-20,hydroxyprogesterone,False,[],0,India,11,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Palifermin Reduces Severe Mucositis in Definitive Chemoradiotherapy of Locally Advanced Head and Neck Cancer: A Randomized, Placebo-Controlled Study",2011-07-10,palifermin,True,['Amgen'],0,Germany,13,8,5,0,0,0,1,1,1,0,0,0,0,0,0,0
"Palifermin Decreases Severe Oral Mucositis of Patients Undergoing Postoperative Radiochemotherapy for Head and Neck Cancer: A Randomized, Placebo-Controlled Trial",2011-07-10,palifermin,True,['Amgen'],0,United Kingdom,11,4,4,0,0,0,1,1,1,0,0,0,0,0,0,0
Phase II Study of Single-Agent Arsenic Trioxide for the Front-Line Therapy of Acute Promyelocytic Leukemia,2011-07-10,arsenic trioxide,False,[],0,Iran,9,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"First-Line Treatment for Primary Testicular Diffuse Large B-Cell Lymphoma With Rituximab-CHOP, CNS Prophylaxis, and Contralateral Testis Irradiation: Final Results of an International Phase II Trial",2011-07-10,rituximab,True,"['Roche', 'Roche Italy']",0,Greece,21,2,0,2,0,0,1,1,0,0,1,1,0,0,0,0
Vaccination With Patient-Specific Tumor-Derived Antigen in First Remission Improves Disease-Free Survival in Follicular Lymphoma,2011-07-10,hybridoma-derived autologous tumor immunoglobulin idiotype (Id) vaccine conjugated to KLH,True,['Biovest International'],0,USA,19,11,3,3,0,0,1,1,1,0,0,0,0,0,0,0
Primary Tumor Response to Preoperative Chemoradiation With or Without Oxaliplatin in Locally Advanced Rectal Cancer: Pathologic Results of the STAR-01 Randomized Phase III Trial,2011-07-10,oxaliplatin,True,['sanofi-aventis'],0,Italy,20,1,0,1,0,1,1,0,0,0,1,0,0,0,0,0
Imatinib Is Effective in Children With Previously Untreated Chronic Myelogenous Leukemia in Early Chronic Phase: Results of the French National Phase IV Trial,2011-07-10,imatinib,False,[],0,France,20,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Impact of KRAS and BRAF Gene Mutation Status on Outcomes From the Phase III AGITG MAX Trial of Capecitabine Alone or in Combination With Bevacizumab and Mitomycin in Advanced Colorectal Cancer,2011-07-01,bevacizumab,True,"['Roche', 'Roche Australia', 'Roche (U)']",0,Australia,11,4,0,2,0,0,1,1,0,0,1,0,0,0,0,0
Randomized Phase III Trial of Paclitaxel/Carboplatin With or Without PF-3512676 (Toll-Like Receptor 9 Agonist) As First-Line Treatment for Advanced Nonâ€“Small-Cell Lung Cancer,2011-07-01,PF-3512676,True,['Pfizer'],0,USA,18,10,4,5,0,3,1,1,1,0,0,0,0,0,0,0
Cytarabine Dose of 36 g/m2 Compared With 12 g/m2 Within First Consolidation in Acute Myeloid Leukemia: Results of Patients Enrolled Onto the Prospective Randomized AML96 Study,2011-07-01,cytarabine,False,[],0,Germany,20,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Activity of XL184 (Cabozantinib), an Oral Tyrosine Kinase Inhibitor, in Patients With Medullary Thyroid Cancer",2011-07-01,cabozantinib,True,"['Exelixis (U)', 'Exelixis']",0,USA,18,9,2,2,0,3,1,1,1,0,0,0,0,0,0,0
Impact of Body Mass Index on the Efficacy of Endocrine Therapy in Premenopausal Patients With Breast Cancer: An Analysis of the Prospective ABCSG-12 Trial,2011-07-01,anastrozole,True,['AstraZeneca'],0,Austria,16,7,0,1,0,6,0,1,0,0,0,0,0,0,0,0
"Responses to Liposomal Doxorubicin, Bevacizumab, and Temsirolimus in Metaplastic Carcinoma of the Breast: Biologic Rationale and Implications for Stem-Cell Research in Breast Cancer",2011-07-01,,False,[],0,USA,9,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Phase II Study of Aflibercept in Recurrent Malignant Glioma: A North American Brain Tumor Consortium Study,2011-07-01,aflibercept,False,[],0,USA,17,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Persistent, Biologically Meaningful Prostate Cancer After 1 Year of Androgen Ablation and Docetaxel Treatment",2011-06-20,docetaxel,True,['sanofi-aventis'],0,Greece,10,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0
"Phase I Study of Oral Azacitidine in Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, and Acute Myeloid Leukemia",2011-06-20,azacitidine,True,['Celgene'],0,USA,12,10,5,2,0,1,1,1,1,0,0,0,0,0,0,0
Targeted Therapy With the T-Cellâ€“Engaging Antibody Blinatumomab of Chemotherapy-Refractory Minimal Residual Disease in B-Lineage Acute Lymphoblastic Leukemia Patients Results in High Response Rate and Prolonged Leukemia-Free Survival,2011-06-20,blinatumomab,True,['Micromet AG'],0,Germany,29,15,8,3,0,2,1,1,1,0,0,0,0,0,0,0
Persistence of Cytogenetic Abnormalities at Complete Remission After Induction in Patients With Acute Myeloid Leukemia: Prognostic Significance and the Potential Role of Allogeneic Stem-Cell Transplantation,2011-06-20,,False,[],0,USA,14,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Randomized, Placebo-Controlled, Double-Blind, Phase II Study of Axitinib Plus Docetaxel Versus Docetaxel Plus Placebo in Patients With Metastatic Breast Cancer ",2011-06-20,axitinib,True,"['Pfizer Oncology', 'Pfizer']",0,Spain,12,8,4,2,0,1,1,1,1,0,0,0,0,0,0,0
Randomized Phase II Study Comparing Gemcitabine Plus Dacarbazine Versus Dacarbazine Alone in Patients With Previously Treated Soft Tissue Sarcoma: A Spanish Group for Research on Sarcomas Study,2011-06-20,gemcitabine,False,[],0,Spain,19,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Randomized, Double-Blind, Placebo-Controlled, Phase II Trial of Sorafenib and Erlotinib or Erlotinib Alone in Previously Treated Advanced NonÃ¢â‚¬â€œSmall-Cell Lung Cancer",2011-06-20,sorafenib,True,['Bayer HealthCare Pharmaceuticals (U)'],0,USA,12,1,0,1,0,0,1,0,0,0,1,0,0,0,0,0
Longitudinal Perceptions of Prognosis and Goals of Therapy in Patients With Metastatic Nonâ€“Small-Cell Lung Cancer: Results of a Randomized Study of Early Palliative Care,2011-06-10,,False,[],0,USA,9,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Randomized Phase II Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women With Estrogen Receptorâ€“Rich Stage 2 to 3 Breast Cancer: Clinical and Biomarker Outcomes and Predictive Value of the Baseline PAM50-Based Intrinsic  Subtypeâ€”ACOSOG Z1031",2011-06-10,exemestane,True,['Pfizer'],0,USA,20,2,0,2,0,0,0,0,0,0,0,0,0,0,0,0
Phase II Study of Cetuximab in Combination With Chemoradiation in Patients With Stage IIIA/B Nonâ€“Small-Cell Lung Cancer: RTOG 0324,2011-06-10,cetuximab,True,['ImClone Systems'],0,USA,10,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Progression From High-Grade Prostatic Intraepithelial Neoplasia to Cancer: A Randomized Trial of Combination Vitamin-E, Soy, and Selenium",2011-06-10,,False,[],0,Canada,14,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Effect of Luteinizing Hormoneâ€“Releasing Hormone Agonist on Ovarian Function After Modern Adjuvant Breast Cancer Chemotherapy: The GBG 37 ZORO Study,2011-06-10,goserelin,True,['AstraZeneca'],0,Germany,14,3,0,0,0,2,1,0,0,0,0,0,0,0,1,0
Multi-Institutional Phase II Study of Selumetinib in Patients With Metastatic Biliary Cancers,2011-06-10,selumetinib,True,['AstraZeneca'],0,United Kingdom,18,2,1,0,0,1,1,1,1,0,0,0,0,0,0,1
Phase II Study of the Mitogen-Activated Protein Kinase 1/2 Inhibitor Selumetinib in Patients With Advanced Hepatocellular Carcinoma,2011-06-10,Selumetinib,True,['AstraZeneca'],0,United Kingdom,12,2,1,1,0,0,0,1,0,0,0,0,0,0,0,0
"Response, Survival, and Long-Term Toxicity After  Therapy With the Radiolabeled Somatostatin Analogue [90Y-DOTA]-TOC in Metastasized Neuroendocrine Cancers",2011-06-10,yttrium-90-DOTA-TOC,False,[],0,USA,10,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Phase II Trial of Bevacizumab in Recurrent or Persistent Endometrial Cancer: A Gynecologic Oncology Group Study,2011-06-01,bevacizumab,True,['Genentech'],0,USA,10,3,0,0,0,0,1,1,0,0,0,0,0,0,0,0
"International Phase III Trial Assessing Neoadjuvant Cisplatin, Methotrexate, and Vinblastine Chemotherapy for Muscle-Invasive Bladder Cancer: Long-Term Results of the BA06 30894 Trial",2011-06-01,cisplatin,False,[],0,and Club Urologico Espanol de Tratamiento Oncologico Group. The members and affiliations of the writing committee are listed in the online-only Appendix,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Randomized Phase II Study of Bevacizumab in Combination With Chemotherapy in Previously Untreated Extensive-Stage Small-Cell Lung Cancer: Results From the SALUTE Trial,2011-06-01,bevacizumab,True,"['Genentech', 'Genentech (U)']",0,USA,10,7,4,2,0,1,1,1,1,0,0,0,0,0,0,0
"Randomized, Open-Label Phase III Trial of Docetaxel Plus High-Dose Calcitriol Versus Docetaxel Plus Prednisone for Patients With Castration-Resistant Prostate Cancer",2011-06-01,docetaxel,False,[],0,USA,16,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Mutational Status of the TP53 Gene As a Predictor of Response and Survival in Patients With Chronic Lymphocytic Leukemia: Results From the LRF CLL4 Trial,2011-06-01,chlorambucil,False,[],0,United Kingdom,10,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Active Surveillance Program for Prostate Cancer: An Update of the Johns Hopkins Experience,2011-06-01,,False,[],0,USA,8,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Phase II Study of Carboplatin and Paclitaxel in Advanced Thymoma and Thymic Carcinoma,2011-05-20,carboplatin,False,[],0,USA,7,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Phase II Study of Belinostat in Patients With Recurrent or Refractory Advanced Thymic Epithelial Tumors,2011-05-20,belinostat,False,[],0,USA,12,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Adjuvant Androgen Deprivation for High-Risk Prostate Cancer After Radical Prostatectomy: SWOG S9921 Study,2011-05-20,goserelin,True,['AstraZeneca'],0,USA,13,1,0,0,0,1,1,0,0,0,0,0,0,0,1,0
"Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status",2011-05-20,cetuximab,True,"['Merck KGaA', 'Merck Serono']",0,France,15,11,3,5,0,5,1,1,1,0,0,0,0,0,0,0
Supporting Treatment Decision Making in Advanced Cancer: A Randomized Trial of a Decision Aid for Patients With Advanced Colorectal Cancer Considering Chemotherapy,2011-05-20,,False,[],0,Australia,18,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Low-Dose Decitabine Versus Best Supportive Care in Elderly Patients With Intermediate- or High-Risk Myelodysplastic Syndrome (MDS) Ineligible for Intensive Chemotherapy: Final Results of the Randomized Phase III Study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group,2011-05-20,decitabine,False,[],0,the Netherlands,20,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Population-Based Study of Treatment Guided by Tumor Marker Decline in Patients With Metastatic Nonseminomatous Germ Cell Tumor: A Report From the Swedish-Norwegian Testicular Cancer Group,2011-05-20,"Bleomycin, Etoposide, and Cisplatin (BEP)",False,[],0,Norway,16,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Phase I Dose-Escalation Study of Stereotactic Body Radiation Therapy for Low- and Intermediate-Risk Prostate Cancer,2011-05-20,stereotactic body radiation therapy,True,['Accuray'],0,USA,12,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0
"Randomized, Placebo-Controlled, Phase III Study of First-Line Oxaliplatin-Based Chemotherapy Plus PTK787/ZK 222584, an Oral Vascular Endothelial Growth Factor Receptor Inhibitor, in Patients With Metastatic Colorectal Adenocarcinoma",2011-05-20,vatalanib,True,"['Novartis', 'Novartis (U)']",0,Qatar,16,9,3,3,0,1,1,1,1,0,0,0,0,0,0,0
"Randomized, Placebo-Controlled, Phase III Study of Oxaliplatin, Fluorouracil, and Leucovorin With or Without PTK787/ZK 222584 in Patients With Previously Treated Metastatic Colorectal Adenocarcinoma",2011-05-20,PTK787/ZK 222584,True,['Bayer Schering Pharma'],0,USA,14,4,3,0,0,0,0,0,0,0,0,0,0,0,0,0
Randomized Trial of the Effect of the Low Molecular Weight Heparin Nadroparin on Survival in Patients With Cancer,2011-05-20,nadroparin,False,[],0,Italy,6,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Bilateral Negative Sentinel Nodes Accurately Predict Absence of Lymph Node Metastasis in Early Cervical Cancer: Results of the SENTICOL Study,2011-05-01,,False,[],0,France,11,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Prospective Study of Breast Cancer Incidence in Women With a BRCA1 or BRCA2 Mutation Under Surveillance With and Without Magnetic Resonance Imaging,2011-05-01,MRI,True,['General Electric Healthcare'],0,Rochester MN,14,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Phase III, Open-Label, Randomized Study Comparing Concurrent Gemcitabine Plus Cisplatin and Radiation Followed by Adjuvant Gemcitabine and Cisplatin Versus Concurrent Cisplatin and Radiation in Patients With Stage IIB to IVA Carcinoma of the Cervix",2011-05-01,gemcitabine,True,['Eli Lilly'],0,Australia,11,11,3,0,0,0,1,1,1,0,0,0,0,0,0,0
Shortening Infusion Time for High-Dose Methotrexate Alters Antileukemic Effects: A Randomized Prospective Clinical Trial,2011-05-01,methotrexate,False,[],0,Denmark,12,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Long-Term Outcome and Quality of Life of Patients With Endometrial Carcinoma Treated With or Without Pelvic Radiotherapy in the Post Operative Radiation Therapy in Endometrial Carcinoma 1 (PORTEC-1) Trial,2011-05-01,,False,[],0,the Netherlands,10,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Perioperative Chemotherapy Compared With Surgery Alone for Resectable Gastroesophageal Adenocarcinoma: An FNCLCC and FFCD Multicenter Phase III Trial,2011-05-01,fluorouracil,False,[],0,France,13,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Cetuximab for the Treatment of Advanced Bronchioloalveolar Carcinoma (BAC): An Eastern Cooperative Oncology Group Phase II Study (ECOG 1504),2011-05-01,cetuximab,True,['ImClone Systems'],0,USA,8,1,0,1,0,0,1,0,0,0,1,0,0,0,0,0
Early Prediction of Nonprogression in Advanced Nonâ€“Small-Cell Lung Cancer Treated With Erlotinib By Using [18F]Fluorodeoxyglucose and [18F]Fluorothymidine Positron Emission Tomography,2011-05-01,erlotinib,True,['Roche'],0,the Netherlands,26,7,0,4,0,5,0,0,0,0,0,0,0,0,0,0
Long-Term Benefits of 5 Years of Tamoxifen: 10-Year Follow-Up of a Large Randomized Trial in Women at Least 50 Years of Age With Early Breast Cancer,2011-05-01,tamoxifen,False,[],0,United Kingdom,7,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Vitamin D Status in Patients With Stage IV Colorectal Cancer: Findings From Intergroup Trial N9741,2011-04-20,Vitamin D (25-hydroxyvitamin D),True,['DiaSorin Corp'],0,Canada,9,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
Tolerability-Adapted Imatinib 800 mg/d Versus 400 mg/d Versus 400 mg/d Plus Interferon-Î± in Newly Diagnosed Chronic Myeloid Leukemia,2011-04-20,imatinib,True,"['Novartis Pharmaceuticals', 'Novartis']",0,Switzerland,20,6,0,2,0,5,0,1,0,0,0,0,0,0,0,0
Multifactorial Approach to Predicting Resistance to Anthracyclines,2011-04-20,epirubicin,True,['Pfizer'],0,USA,28,2,0,1,0,1,1,1,0,0,1,0,0,0,0,1
Estrogen Receptor and Progesterone Receptor As Predictive Biomarkers of Response to Endocrine Therapy: A Prospectively Powered Pathology Study in the Tamoxifen and Exemestane Adjuvant Multinational Trial,2011-04-20,exemestane,True,['Pfizer'],0,Belgium,18,5,0,3,0,5,1,1,0,0,1,0,0,0,0,0
"Phase II Trial of Cisplatin, Gemcitabine, and Bevacizumab As First-Line Therapy for Metastatic Urothelial Carcinoma: Hoosier Oncology Group GU 04-75",2011-04-20,bevacizumab,True,['Genentech'],0,USA,10,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0
"Comparison of Immunofixation, Serum Free Light Chain, and Immunophenotyping for Response Evaluation and Prognostication in Multiple Myeloma",2011-04-20,,False,[],0,Spain,20,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Elevated Serum Free Light Chains Are Associated With Event-Free and Overall Survival in Two Independent Cohorts of Patients With Diffuse Large B-Cell Lymphoma,2011-04-20,serum free light chain (FLC) assay,True,['The Binding Site'],0,USA,20,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0
Capecitabine Plus Oxaliplatin Compared With Fluorouracil and Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer,2011-04-10,oxaliplatin,False,[],0,Germany,10,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Single-Dose Fosaprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting Associated With Cisplatin Therapy: Randomized, Double-Blind Study Protocolâ€”EASE",2011-04-10,fosaprepitant,True,['Merck'],0,Denmark,12,10,6,3,0,3,1,1,1,0,0,0,0,0,0,0
Phase I Trial of a Selective c-MET Inhibitor ARQ 197 Incorporating Proof of Mechanism Pharmacodynamic Studies,2011-04-01,tivantinib,True,"['ArQule Inc', 'ArQule Inc funded standard costs of magnetic resonance imaging scans for this trial.']",0,USA,20,7,5,1,0,0,1,1,1,0,0,0,0,0,0,0
"Value of Mismatch Repair, KRAS, and BRAF Mutations in Predicting Recurrence and Benefits From Chemotherapy in Colorectal Cancer",2011-04-01,fluorouracil,False,[],0,Qatar,12,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2â€“Negative, Locally Recurrent or Metastatic Breast Cancer",2011-04-01,bevacizumab,True,"['Roche', 'Roche (U)']",0,United Kingdom,12,6,1,5,0,4,1,1,1,0,0,0,0,0,0,0
Prognostic Significance and Tumor Biology of Regional Lymph Node Disease in Patients With Rhabdomyosarcoma: A Report From the Children's Oncology Group,2011-04-01,,False,[],0,Canada,12,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Glioma-Associated Oncogene Family Zinc Finger 1 Expression and Metastasis in Patients With Head and Neck Squamous Cell Carcinoma Treated With Radiation Therapy (RTOG 9003),2011-04-01,,False,[],0,USA,12,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Results of the Intergroup Rhabdomyosarcoma Study Group D9602 Protocol, Using Vincristine and Dactinomycin With or Without Cyclophosphamide and Radiation Therapy, for Newly Diagnosed Patients With Low-Risk Embryonal Rhabdomyosarcoma: A Report From the Soft Tissue Sarcoma Committee of the Children's Oncology Group",2011-04-01,vincristine,False,[],0,USA,10,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Implementing a Geriatric Assessment in Cooperative Group Clinical Cancer Trials: CALGB 360401,2011-04-01,,False,[],0,USA,18,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Prognostic Factors After Relapse in Nonmetastatic Rhabdomyosarcoma: A Nomogram to Better Define Patients Who Can Be Salvaged With Further Therapy,2011-04-01,,False,[],0,Ireland,9,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
RUNX1 Mutations in Acute Myeloid Leukemia: Results From a Comprehensive Genetic and Clinical Analysis From the AML Study Group,2011-04-01,,False,[],0,Austria,19,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
TET2 Mutations Improve the New European LeukemiaNet Risk Classification of Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study,2011-04-01,,False,[],0,USA,23,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Chemoimmunotherapy With Fludarabine and Rituximab Produces Extended Overall Survival and Progression-Free Survival in Chronic Lymphocytic Leukemia: Long-Term Follow-Up of CALGB Study 9712,2011-04-01,rituximab,True,"['Genentech', 'Roche/Genentech']",0,USA,9,2,0,0,0,1,1,1,0,0,0,0,0,0,1,0
Prospective Multicenter Phase II Trial of Systemic ADH-1 in Combination With Melphalan via Isolated Limb Infusion in Patients With Advanced Extremity Melanoma,2011-03-20,ADH-1,True,['Adherex Technologies'],0,USA,10,2,0,0,0,2,0,1,0,0,0,0,0,0,0,0
"Randomized, Double-Blind Study of Denosumab Versus Zoledronic Acid in the Treatment of Bone Metastases in Patients With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma",2011-03-20,denosumab,True,"['Amgen', 'Amgen Advisory Boards']",0,USA,18,14,5,8,0,6,1,1,1,0,0,0,0,0,0,0
Phase II Trial of Pemetrexed and Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer,2011-03-20,bevacizumab,True,['Genentech'],0,USA,8,3,0,0,0,1,0,1,0,0,0,0,0,0,0,0
Analyses Adjusting for Selective Crossover Show Improved Overall Survival With Adjuvant Letrozole Compared With Tamoxifen in the BIG 1-98 Study,2011-03-20,letrozole,False,[],0,Poland,17,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Physical and Psychosocial Recovery in the Year After Primary Treatment of Breast Cancer,2011-03-20,,False,[],0,USA,5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Menstrual History and Quality-of-Life Outcomes in Women With Node-Positive Breast Cancer Treated With Adjuvant Therapy on the NSABP B-30 Trial,2011-03-20,docetaxel,True,"['sanofi-aventis', 'sanofi-aventis (U)']",0,USA,16,3,0,3,0,1,1,1,0,0,1,0,0,0,0,0
Phase II Study of Vorinostat for Treatment of Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma,2011-03-20,vorinostat,True,['Merck'],0,USA,14,5,0,3,0,3,1,1,0,0,1,0,0,0,0,0
Pralatrexate in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results From the Pivotal PROPEL Study,2011-03-20,pralatrexate,True,"['Allos Therapeutics', 'Allos (U)']",0,USA,20,15,1,9,0,7,1,1,1,0,0,0,0,0,0,0
Single-Agent Lenalidomide in the Treatment of Previously Untreated Chronic Lymphocytic Leukemia,2011-03-20,lenalidomide,True,['Celgene Corporation'],0,USA,17,5,0,4,0,4,1,1,0,0,1,0,0,0,0,0
Successful Multifold Dose Escalation of Anti-GD2 Monoclonal Antibody 3F8 in Patients With Neuroblastoma: A Phase I Study,2011-03-20,3F8,False,[],0,USA,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Cetuximab Plus Capecitabine and Irinotecan Compared With Cetuximab Plus Capecitabine and Oxaliplatin As  First-Line Treatment for Patients With Metastatic Colorectal Cancer: AIO KRK-0104â€”A Randomized Trial  of the German AIO CRC Study Group,2011-03-10,cetuximab,True,"['Merck', 'Merck-Serono', 'Merck Serono']",0,Germany,20,4,0,2,0,3,0,1,0,0,0,0,0,0,0,0
Phase I/II Study of Pemetrexed With or Without ABT-751 in Advanced or Metastatic Nonâ€“Small-Cell Lung Cancer,2011-03-10,ABT-751,True,['Abbott Laboratories'],0,USA,15,9,9,0,0,0,1,1,1,0,0,0,0,0,0,0
Quality of Life of Older Patients With Early-Stage Breast Cancer Receiving Adjuvant Chemotherapy: A Companion Study to Cancer and Leukemia Group B 49907,2011-03-10,capecitabine,True,['Roche'],0,USA,11,2,0,2,0,0,1,0,0,0,1,0,0,0,0,0
Enhancing Patient-Provider Communication With the Electronic Self-Report Assessment for Cancer: A Randomized Trial,2011-03-10,Electronic Self-Report Assessmentâ€“Cancer (ESRA-C),False,[],0,USA,10,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Automated Symptom Alerts Reduce Postoperative Symptom Severity After Cancer Surgery: A Randomized Controlled Clinical Trial,2011-03-10,,False,[],0,USA,12,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Phase III Trial of Vandetanib Compared With Erlotinib in Patients With Previously Treated Advanced Nonâ€“Small-Cell Lung Cancer,2011-03-10,vandetanib,True,"['AstraZeneca', 'AstraZeneca (U)']",0,Canada,15,11,3,5,0,6,1,1,1,0,0,0,0,0,0,0
First-In-Man Study of CPX-351: A Liposomal Carrier Containing Cytarabine and Daunorubicin in a Fixed 5:1 Molar Ratio for the Treatment of Relapsed and Refractory Acute Myeloid Leukemia,2011-03-10,CPX-351,True,['Celator Pharmaceuticals'],0,USA,11,4,2,1,0,0,0,1,0,0,0,0,0,0,0,0
"Aspirin, Warfarin, or Enoxaparin Thromboprophylaxis in Patients With Multiple Myeloma Treated With Thalidomide: A Phase III, Open-Label, Randomized Trial",2011-03-10,thalidomide,True,['Celgene'],0,Italy,32,10,0,3,0,8,1,1,0,0,1,0,0,0,0,0
"Vandetanib Plus Pemetrexed for the Second-Line Treatment of Advanced Nonâ€“Small-Cell Lung Cancer: A Randomized, Double-Blind Phase III Trial",2011-03-10,vandetanib,True,['AstraZeneca'],0,Belgium,14,9,3,4,0,3,1,0,1,0,0,0,0,0,0,0
Preoperative Chemoradiotherapy Using Concurrent Capecitabine and Irinotecan in Magnetic Resonance Imagingâ€“Defined Locally Advanced Rectal Cancer: Impact on Long-Term Clinical Outcomes,2011-03-10,capecitabine,True,['Roche'],0,United Kingdom,13,4,0,1,0,4,1,1,0,0,1,0,0,0,0,0
Phase III Comparison of Standard Doxorubicin and Cyclophosphamide Versus Weekly Doxorubicin and Daily Oral Cyclophosphamide Plus Granulocyte Colony-Stimulating Factor As Neoadjuvant Therapy for Inflammatory and Locally Advanced Breast Cancer: SWOG 0012,2011-03-10,doxorubicin,False,[],0,USA,9,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Randomized Trial of Carboplatin Versus Radiotherapy for Stage I Seminoma: Mature Results on Relapse and Contralateral Testis Cancer Rates in MRC TE19/EORTC 30982 Study (ISRCTN27163214),2011-03-10,Carboplatin,False,[],0,Norway,9,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Phase I Study of Navitoclax (ABT-263), a Novel Bcl-2 Family Inhibitor, in Patients With Small-Cell Lung Cancer and Other Solid Tumors",2011-03-01,navitoclax,True,['Abbott Laboratories'],0,United Kingdom,20,13,9,1,0,1,1,1,1,0,0,0,0,0,0,0
Phase III Trial of Weekly Methotrexate or Pulsed Dactinomycin for Low-Risk Gestational Trophoblastic Neoplasia: A Gynecologic Oncology Group Study,2011-03-01,dactinomycin,False,[],0,USA,10,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Pediatric Phase I Trial and Pharmacokinetic Study of Dasatinib: A Report From the Children's Oncology Group Phase I Consortium,2011-03-01,dasatinib,True,['Bristol-Myers Squibb'],0,USA,10,2,2,0,0,0,1,1,1,0,0,0,0,0,0,0
Treatment of Low-Risk Gestational  Trophoblastic Neoplasia,2011-03-01,,False,[],0,USA,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Safety and Efficacy of TG101348, a Selective JAK2 Inhibitor, in Myelofibrosis",2011-03-01,TG101348,True,['Cytopia'],0,USA,10,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Thymidylate Synthase Genotype-Directed Neoadjuvant Chemoradiation for Patients With Rectal Adenocarcinoma,2011-03-01,fluorouracil,False,[],0,France,11,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Alteration of Topoisomerase IIâ€“Alpha Gene in Human Breast Cancer: Association With Responsiveness to Anthracycline-Based Chemotherapy,2011-03-01,doxorubicin,False,[],0,France,20,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Randomized Phase II Trial of Adjuvant Hepatic Arterial Infusion and Systemic Chemotherapy With or Without Bevacizumab in Patients With Resected Hepatic Metastases From Colorectal Cancer,2011-03-01,bevacizumab,True,['Genentech'],0,USA,7,2,0,1,0,0,1,1,0,0,1,0,0,0,0,0
"Phase II Study of Modified Docetaxel, Cisplatin, and Fluorouracil With Bevacizumab in Patients With Metastatic Gastroesophageal Adenocarcinoma",2011-03-01,bevacizumab,True,['Genentech'],0,USA,7,2,0,0,0,0,1,1,0,0,0,0,0,0,0,0
Tumor Regression in Patients With Metastatic Synovial Cell Sarcoma and Melanoma Using Genetically Engineered Lymphocytes Reactive With NY-ESO-1,2011-03-01,TCR-based gene therapy against NY-ESO-1,False,[],0,USA,21,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Phase II Study of Conformal Hypofractionated Radiotherapy With Concurrent Gemcitabine in  Muscle-Invasive Bladder Cancer,2011-02-20,gemcitabine,True,['Eli Lilly'],0,United Kingdom,16,2,0,0,0,2,1,0,0,0,0,0,0,0,1,0
Bortezomib Plus CHOP-Rituximab for Previously Untreated Diffuse Large B-Cell Lymphoma and Mantle Cell Lymphoma,2011-02-20,bortezomib,True,"['Millennium', 'Millenium']",0,USA,14,4,0,2,0,0,0,0,0,0,0,0,0,0,0,0
"Cetuximab in Combination With Chemoradiotherapy Before Surgery in Patients With Resectable, Locally Advanced Esophageal Carcinoma: A Prospective, Multicenter Phase IB/II Trial (SAKK 75/06)",2011-02-20,cetuximab,True,['Merck Serono'],0,Switzerland,15,1,0,1,0,0,1,0,0,0,1,0,0,0,0,0
Intravenous Calcium and Magnesium for Oxaliplatin-Induced Sensory Neurotoxicity in Adjuvant Colon Cancer: NCCTG N04C7,2011-02-01,oxaliplatin,True,['sanofi-aventis'],0,USA,11,2,0,0,0,0,1,1,0,0,0,0,0,0,0,0
Phase II Study of the Antibody Drug Conjugate Trastuzumab-DM1 for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2) â€“Positive Breast Cancer After Prior HER2-Directed Therapy,2011-02-01,trastuzumab-DM1,True,"['Genentech', 'Genentech (U)']",0,USA,15,11,5,3,0,3,1,1,1,0,0,0,0,0,0,0
Identification of Patients With Acute Myeloblastic Leukemia Who Benefit From the Addition of Gemtuzumab Ozogamicin: Results of the MRC AML15 Trial,2011-02-01,gemtuzumab ozogamicin,True,['Wyeth (Pfizer)'],0,Denmark,10,1,0,1,0,1,1,1,0,0,1,0,0,0,0,1
Excellent Outcome With Reduced Treatment in Infants With Nonmetastatic and Unresectable Neuroblastoma Without MYCN Amplification: Results of the Prospective INES 99.1,2011-02-01,cyclophosphamide,False,[],0,Belgium,21,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Comparison of Health-Related Quality of Life 5 Years After SPIRIT: Surgical Prostatectomy Versus Interstitial Radiation Intervention Trial,2011-02-01,,False,[],0,Canada,8,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Decrease in Depression Symptoms Is Associated With Longer Survival in Patients With Metastatic Breast Cancer: A Secondary Analysis,2011-02-01,,False,[],0,Canada,6,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Improved Prognosis for Older Adolescents With Acute Lymphoblastic Leukemia,2011-02-01,asparaginase,False,[],0,USA,21,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Dose Finding Study for the Use of Subcutaneous Recombinant Interleukin-2 to Augment Natural Killer Cell Numbers in an Outpatient Setting for Stage 4 Neuroblastoma After Megatherapy and Autologous Stem-Cell Reinfusion,2011-02-01,interleukin 2,False,[],0,Germany,12,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Comorbidity and Mortality Results From a Randomized Prostate Cancer Screening Trial,2011-02-01,Prostate-specific antigen (PSA) test,False,[],0,USA,8,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Safety, Pharmacokinetics, and Immunomodulatory Effects of Lenalidomide in Children and Adolescents With Relapsed/Refractory Solid Tumors or Myelodysplastic Syndrome: A Children's Oncology Group Phase I Consortium Report",2011-01-20,lenalidomide,True,['Celgene'],0,USA,9,2,2,0,0,0,1,1,1,0,0,0,0,0,0,0
Phase I Trial of a Personalized Peptide Vaccine for Patients Positive for Human Leukocyte Antigenâ€“A24 With Recurrent or Progressive Glioblastoma Multiforme,2011-01-20,ITK-1,True,"['Green Peptide', 'Green Peptide (U)']",0,Japan,11,2,1,1,0,0,1,1,1,0,0,0,0,0,0,0
Phase III Randomized Study Comparing Docetaxel Plus Trastuzumab With Vinorelbine Plus Trastuzumab As First-Line Therapy of Metastatic or Locally Advanced Human Epidermal Growth Factor Receptor 2â€“Positive Breast Cancer: The HERNATA Study,2011-01-20,trastuzumab,True,['Roche'],0,United Kingdom,12,4,0,0,0,4,0,0,0,0,0,0,0,0,0,0
Induction of CD8+ T-Cell Responses Against Novel Gliomaâ€“Associated Antigen Peptides and Clinical Activity by Vaccinations With Î±-Type 1 Polarized Dendritic Cells and Polyinosinic-Polycytidylic Acid Stabilized by Lysine and Carboxymethylcellulose in Patients With Recurrent Malignant Glioma,2011-01-20,poly-ICLC,True,['Oncovir'],0,USA,20,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0
"Prophylaxis of Graft-Versus-Host Disease in Unrelated Donor Transplantation With Pentostatin, Tacrolimus, and Mini-Methotrexate: A Phase I/II Controlled, Adaptively Randomized Study",2011-01-20,pentostatin,True,['SuperGen'],0,USA,20,2,0,0,0,1,1,1,0,0,0,0,0,0,1,0
"Phase I Trial of Lenalidomide in Pediatric Patients With Recurrent, Refractory, or Progressive Primary CNS Tumors: Pediatric Brain Tumor Consortium Study PBTC-018",2011-01-20,lenalidomide,False,[],0,USA,13,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Phase III Comparison of Prophylactic Cranial Irradiation Versus Observation in Patients With Locally Advanced Nonâ€“Small-Cell Lung Cancer: Primary Analysis of Radiation Therapy Oncology Group Study RTOG 0214,2011-01-20,,False,[],0,USA,10,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Phase III Trial of Prophylactic Cranial Irradiation Compared With Observation in Patients With Locally Advanced Nonâ€“Small-Cell Lung Cancer: Neurocognitive and Quality-of-Life Analysis,2011-01-20,,False,[],0,USA,12,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Reduced Melanoma After Regular Sunscreen Use: Randomized Trial Follow-Up,2011-01-20,sunscreen,False,[],0,Australia,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Immunosuppressive Therapy for Patients With Myelodysplastic Syndrome: A Prospective Randomized Multicenter Phase III Trial Comparing Antithymocyte Globulin Plus Cyclosporine With Best Supportive CareÃ¢â‚¬â€SAKK 33/99,2011-01-20,antithymocyte globulin (ATG),True,[],0,the Netherlands,11,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Randomized Phase II Trial of Single-Agent Amrubicin or Topotecan as Second-Line Treatment in Patients With Small-Cell Lung Cancer Sensitive to First-Line Platinum-Based Chemotherapy,2011-01-20,amrubicin,False,['Celgene'],0,USA,9,4,3,0,0,0,1,0,1,0,0,0,0,0,0,0
"Multicenter Phase III Randomized Trial Comparing Docetaxel and Trastuzumab With Docetaxel, Carboplatin, and Trastuzumab As First-Line Chemotherapy for Patients With HER2-Gene-Amplified Metastatic Breast Cancer (BCIRG 007 Study): Two Highly Active Therapeutic Regimens",2011-01-10,trastuzumab,True,['Genentech'],0,Switzerland,20,2,0,2,0,2,0,1,0,0,0,0,0,0,0,0
Adjuvant Whole-Brain Radiotherapy Versus Observation After Radiosurgery or Surgical Resection of One to Three Cerebral Metastases: Results of the EORTC 22952-26001 Study,2011-01-10,,False,[],0,Belgium,17,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Phase II Study of Bevacizumab Plus Temozolomide During and After Radiation Therapy for Patients With Newly Diagnosed Glioblastoma Multiforme,2011-01-10,bevacizumab,True,"['Roche', 'Genentech']",0,USA,20,4,0,4,0,2,1,1,0,0,1,0,0,0,0,0
Topotecan Weekly Versus Conventional 5-Day Schedule in Patients With Platinum-Resistant Ovarian Cancer: A Randomized Multicenter Phase II Trial of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group,2011-01-10,topotecan,False,[],0,United Kingdom,20,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Phase II Study of Irinotecan and Temozolomide in Children With Relapsed or Refractory Neuroblastoma: A Children's Oncology Group Study,2011-01-10,irinotecan,True,['Pfizer'],0,USA,8,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0
Subcutaneous Compared With Intravenous Administration of Amifostine in Patients With Head and Neck Cancer Receiving Radiotherapy: Final Results of the GORTEC2000-02 Phase III Randomized Trial,2011-01-10,amifostine,False,[],0,France,12,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Activity of Sorafenib in Recurrent Ovarian Cancer and Primary Peritoneal Carcinomatosis: A Gynecologic Oncology Group Trial,2011-01-01,sorafenib,True,['Bayer'],0,USA,12,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
"Phase III, Randomized Study of the Effects of Parenteral Iron, Oral Iron, or No Iron Supplementation on the Erythropoietic Response to Darbepoetin Alfa for Patients With Chemotherapy-Associated Anemia",2011-01-01,darbepoetin alfa,True,['Amgen'],0,USA,10,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0
Phase III Trial Assessing Bevacizumab in Stages II and III Carcinoma of the Colon: Results of NSABP Protocol C-08,2011-01-01,bevacizumab,True,"['Genentech', 'Genentech Studies', 'Genentech (U)']",0,USA,15,7,0,5,0,1,1,1,0,0,1,0,0,0,0,0
Fluorouracil Induces Myocardial Ischemia With Increases of Plasma Brain Natriuretic Peptide and Lactic Acid but Without Dysfunction of Left Ventricle,2010-12-20,fluorouracil,False,[],0,Denmark,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Phase III Trial Comparing Oral S-1 Plus Carboplatin With Paclitaxel Plus Carboplatin in Chemotherapy-NaÃ¯ve Patients With Advanced Nonâ€“Small-Cell Lung Cancer: Results of a West Japan Oncology Group Study,2010-12-20,S-1,True,['Taiho Pharmaciutical'],0,Japan,20,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1
BRCA1-Associated Breast Cancers Present Differently From BRCA2-Associated and Familial Cases: Long-Term Follow-Up of the Dutch MRISC Screening Study,2010-12-20,,False,[],0,the Netherlands,23,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Placebo-Controlled Trial to Determine the Effectiveness of a Urea/Lactic Acidâ€“Based Topical Keratolytic Agent for Prevention of Capecitabine-Induced Hand-Foot Syndrome: North Central Cancer Treatment Group Study N05C5,2010-12-10,capecitabine,False,[],0,USA,11,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Denosumab Compared With Zoledronic Acid for the Treatment of Bone Metastases in Patients With Advanced Breast Cancer: A Randomized, Double-Blind Study",2010-12-10,denosumab,True,['Amgen'],0,USA,15,12,5,5,0,5,1,0,1,0,0,0,0,0,0,0
"Multicenter, Randomized, Cross-Over Clinical Trial of Venlafaxine Versus Gabapentin for the Management of Hot Flashes in Breast Cancer Survivors",2010-12-10,venlafaxine,False,[],0,USA,8,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"A Phase 1 Trial and Pharmacokinetic Study of Cediranib, an Orally Bioavailable Panâ€“Vascular Endothelial Growth Factor Receptor Inhibitor, in Children and Adolescents With Refractory Solid Tumors",2010-12-10,cediranib,True,['AstraZeneca'],0,USA,15,3,3,1,0,0,1,1,1,0,0,0,0,0,0,0
Neoadjuvant Chemotherapy Compared With Surgery Alone for Locally Advanced Cancer of the Stomach and Cardia: European Organisation for Research and Treatment of Cancer Randomized Trial 40954,2010-12-10,,False,[],0,France,20,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Alemtuzumab Treatment of Intermediate-1 Myelodysplasia Patients Is Associated With Sustained Improvement in Blood Counts and Cytogenetic Remissions,2010-12-10,Alemtuzumab,False,[],0,USA,11,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Impact of Androgen-Deprivation Therapy on Physical Function and Quality of Life in Men With Nonmetastatic Prostate Cancer,2010-12-01,androgen deprivation therapy (ADT),False,[],0,Canada,12,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Impact of Androgen-Deprivation Therapy on Cognitive Function in Men With Nonmetastatic Prostate Cancer,2010-12-01,,False,[],0,Canada,12,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Phase I Study of Everolimus Plus Weekly Paclitaxel and Trastuzumab in Patients With Metastatic Breast Cancer Pretreated With Trastuzumab,2010-12-01,everolimus,True,['Novartis'],0,USA,10,9,4,2,0,3,1,1,1,0,0,0,0,0,0,0
Dose Intensity of Chemotherapy in Patients With Relapsed Hodgkin's Lymphoma,2010-12-01,dexamethasone,False,[],0,Spain,19,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Bortezomib-Melphalan-Prednisone-Thalidomide Followed by Maintenance With Bortezomib-Thalidomide Compared With Bortezomib-Melphalan-Prednisone for Initial Treatment of Multiple Myeloma: A Randomized Controlled Trial,2010-12-01,bortezomib,True,['Janssen-Cilag'],0,Italy,24,9,0,2,0,7,1,1,0,0,1,0,0,0,0,0
Multicenter Phase II Trial of S-1 in Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma,2010-12-01,tegafur/gimeracil/oteracil,False,[],0,Japan,10,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Dose Escalation of Lenalidomide in Relapsed or Refractory Acute Leukemias,2010-11-20,lenalidomide,True,['Celgene'],0,USA,19,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0
Radiotherapy With Concurrent Carbogen and Nicotinamide in Bladder Carcinoma,2010-11-20,nicotinamide,False,[],0,USA,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Screening for Distress in Lung and Breast Cancer Outpatients: A Randomized Controlled Trial,2010-11-20,,False,[],0,Canada,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Activity of IPI-504, a Novel Heat-Shock Protein 90 Inhibitor, in Patients With Molecularly Defined Nonâ€“Small-Cell Lung Cancer",2010-11-20,IPI-504,True,"['Infinity Pharmaceuticals', 'Infinity Pharmacueticals']",0,USA,19,10,6,0,0,0,1,0,1,0,0,0,0,0,0,0
Antitumor Activity of Hu14.18-IL2 in Patients With Relapsed/Refractory Neuroblastoma: A Children's Oncology Group (COG) Phase II Study,2010-11-20,hu14.18-IL2,False,[],0,USA,19,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Phase II Selection Design Trial of Concurrent Chemotherapy and Cetuximab Versus Chemotherapy Followed by Cetuximab in Advanced-Stage Nonâ€“Small-Cell Lung Cancer: Southwest Oncology Group Study S0342,2010-11-01,cetuximab,True,['ImClone Systems'],0,USA,13,3,0,2,0,1,1,0,0,0,1,0,0,0,0,0
"Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study",2010-11-01,panitumumab,True,"['Amgen  Roche', 'Amgen']",0,USA,20,16,3,13,0,9,1,1,1,0,0,0,0,0,0,0
"Randomized Phase III Study of Panitumumab With Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) Compared With FOLFIRI Alone As Second-Line Treatment in Patients With Metastatic Colorectal Cancer",2010-11-01,panitumumab,True,"['Amgen (U)', 'Amgen', 'Amgen Roche']",0,USA,20,18,5,7,0,9,1,1,1,0,0,0,0,0,0,0
Immunologic Escape After Prolonged Progression-Free Survival With Epidermal Growth Factor Receptor Variant III Peptide Vaccination in Patients With Newly Diagnosed Glioblastoma,2010-11-01,EGFRvIII-targeted peptide vaccine,True,['Celldex Therapeutics'],0,USA,16,3,0,3,0,1,1,0,0,0,1,0,0,0,0,0
Phase I Study of Vandetanib During and After Radiotherapy in Children With Diffuse Intrinsic Pontine Glioma,2010-11-01,vandetanib,True,['AstraZeneca'],0,USA,15,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0
Temsirolimus Has Activity in Nonâ€“Mantle Cell Non-Hodgkin's Lymphoma Subtypes: The University of Chicago Phase II Consortium,2010-11-01,temsirolimus,True,['Wyeth'],0,USA,13,2,0,0,0,1,1,1,0,0,0,0,0,0,1,0
"Temozolomide Versus Procarbazine, Lomustine, and Vincristine in Recurrent High-Grade Glioma",2010-10-20,temozolomide,True,['Schering-Plough'],0,United Kingdom,13,3,0,2,0,3,0,1,0,0,0,0,0,0,0,0
Phase IB Study of the mTOR Inhibitor Ridaforolimus With Capecitabine,2010-10-20,ridaforolimus,True,['ARIAD Pharmaceuticals'],0,USA,17,3,3,0,0,0,1,1,1,0,0,0,0,0,0,0
Castration-Dependent Pharmacokinetics of Docetaxel in Patients With Prostate Cancer,2010-10-20,docetaxel,True,['sanofi-aventis'],0,USA,5,1,0,1,0,1,1,1,0,0,1,0,0,0,0,1
Results of the CONFIRM Phase III Trial Comparing Fulvestrant 250 mg With Fulvestrant 500 mg in Postmenopausal Women With Estrogen Receptorâ€“Positive Advanced Breast Cancer,2010-10-20,fulvestrant,True,['AstraZeneca'],0,Spain,15,7,3,2,0,2,1,1,1,0,0,0,0,0,0,0
Phase II Study of Dasatinib in Patients With Advanced Nonâ€“Small-Cell Lung Cancer,2010-10-20,dasatinib,True,['Bristol-Myers Squibb'],0,USA,12,1,0,1,0,0,1,1,0,0,1,1,0,0,0,0
Phase III Randomized Trial Assessing Rofecoxib in the Adjuvant Setting of Colorectal Cancer: Final Results of the VICTOR Trial,2010-10-20,rofecoxib,True,"['Merck', 'Merck - educational grant to support VICTOR trials']",0,United Kingdom,12,2,0,1,0,0,1,1,0,0,1,0,0,0,0,0
Bortezomib Plus Dexamethasone Is Superior to Vincristine Plus Doxorubicin Plus Dexamethasone As Induction Treatment Prior to Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: Results of the IFM 2005-01 Phase III Trial,2010-10-20,bortezomib,True,['Millennium Pharmaceuticals'],0,USA,18,2,1,0,0,1,1,0,1,0,0,0,0,0,0,0
Prospective Evaluation of Allogeneic Hematopoietic Stem-Cell Transplantation From Matched Related and Matched Unrelated Donors in Younger Adults With High-Risk Acute Myeloid Leukemia: German-Austrian Trial AMLHD98A,2010-10-20,,False,[],0,Austria,20,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Best Supportive Care Compared With Chemotherapy for Unresectable Gall Bladder Cancer: A Randomized Controlled Study,2010-10-20,gemcitabine,False,[],0,India,11,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Randomized Phase II Window Trial of Two Schedules of Irinotecan With Vincristine in Patients With First Relapse or Progression of Rhabdomyosarcoma: A Report From the Children's Oncology Group,2010-10-20,irinotecan,False,[],0,USA,10,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Light ChainÃ¢â‚¬â€œInduced Acute Renal Failure Can Be Reversed by Bortezomib-Doxorubicin-Dexamethasone in Multiple Myeloma: Results of a Phase II Study,2010-10-20,bortezomib,True,['Janssen-Cilag'],0,Hungary,13,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
Adjuvant Gemcitabine Alone Versus Gemcitabine-Based Chemoradiotherapy After Curative Resection for Pancreatic Cancer: A Randomized EORTC-40013-22012/FFCD-9203/GERCOR Phase II Study,2010-10-10,gemcitabine,False,[],0,Germany,15,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
A Phase I Study of Sunitinib Plus Capecitabine in Patients With Advanced Solid Tumors,2010-10-10,sunitinib,True,['Pfizer'],0,USA,11,6,4,0,0,0,1,1,1,0,0,0,0,0,0,0
"Final Results From a Multicenter, International, Pivotal Study of Romidepsin in Refractory Cutaneous T-Cell Lymphoma",2010-10-10,romidepsin,True,['Gloucester Pharmaceuticals'],0,Russia,13,4,1,3,0,2,1,1,1,0,0,0,0,0,0,0
Long-Term Follow-Up of Patients With Follicular Lymphoma Receiving Single-Agent Rituximab at Two Different Schedules in Trial SAKK 35/98,2010-10-10,rituximab,True,['Roche'],0,South Africa,15,4,0,3,0,4,1,1,0,0,1,0,0,0,0,0
Longitudinal Assessment of Cognitive Changes Associated With Adjuvant Treatment for Breast Cancer: Impact of Age and Cognitive Reserve,2010-10-10,tamoxifen,False,[],0,USA,9,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Long-Term Efficacy of Methylphenidate in Enhancing Attention Regulation, Social Skills, and Academic Abilities of Childhood Cancer Survivors",2010-10-10,methylphenidate,False,[],0,Durham NC,12,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Phase I Study of Vorinostat in Patients With Advanced Solid Tumors and Hepatic Dysfunction: A National Cancer Institute Organ Dysfunction Working Group Study,2010-10-10,vorinostat,True,['Merck'],0,USA,13,5,0,2,0,0,1,1,0,0,1,0,0,0,0,0
TP53 Mutation and Survival in Chronic Lymphocytic Leukemia,2010-10-10,fludarabine,False,[],0,Austria,14,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Consolidation Therapy With Subcutaneous Alemtuzumab After Fludarabine and Rituximab Induction Therapy for Previously Untreated Chronic Lymphocytic Leukemia: Final Analysis of CALGB 10101,2010-10-10,alemtuzumab,True,['GlaxoSmithKline'],0,USA,10,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0
"Phase IIB Trial of Oral Midostaurin (PKC412), the FMS-Like Tyrosine Kinase 3 Receptor (FLT3) and Multi-Targeted Kinase Inhibitor, in Patients With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome With Either Wild-Type or Mutated FLT3",2010-10-01,midostaurin,True,['Novartis'],0,USA,17,10,2,4,0,4,0,1,0,0,0,0,0,0,0,0
"Phase I/II Clinical Study of Tosedostat, an Inhibitor of Aminopeptidases, in Patients With Acute Myeloid Leukemia and Myelodysplasia",2010-10-01,tosedostat,True,['Chroma Therapeutics'],0,Germany,17,4,4,0,0,0,1,1,1,0,0,0,0,0,0,0
In Situ Vaccination With a TLR9 Agonist Induces Systemic Lymphoma Regression: A Phase I/II Study,2010-10-01,PF-3512676,False,[],0,USA,13,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Randomized Phase II Study of Docetaxel and Prednisone With or Without OGX-011 in Patients With Metastatic Castration-Resistant Prostate Cancer,2010-09-20,OGX-011,True,['OncoGenex Technologies'],0,USA,11,5,1,0,0,0,1,1,1,0,0,0,0,0,0,0
Phase III Trial of Carboplatin Plus Paclitaxel With or Without Gemcitabine in First-Line Treatment of Epithelial Ovarian Cancer,2010-09-20,gemcitabine,True,"['Eli Lilly', 'Study Groups were funded by Eli Lilly']",0,Serbia,20,3,0,0,0,2,0,0,0,0,0,0,0,0,0,0
"Randomized, Phase II Study of the Insulin-Like Growth Factor-1 Receptor Inhibitor IMC-A12, With or Without Cetuximab, in Patients With Cetuximab- or Panitumumab-Refractory Metastatic Colorectal Cancer",2010-09-20,IMC-A12,True,['ImClone Systems'],0,USA,14,8,4,2,0,0,1,1,1,0,0,0,0,0,0,0
Phase I Trial of Lapatinib in Children With Refractory CNS Malignancies: A Pediatric Brain Tumor Consortium Study,2010-09-20,lapatinib,False,[],0,USA,10,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Intensified Chemotherapy and Dose-Reduced Involved-Field Radiotherapy in Patients With Early Unfavorable Hodgkin's Lymphoma: Final Analysis of the German Hodgkin Study Group HD11 Trial,2010-09-20,ABVD,False,[],0,Austria,20,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Prognostic Significance of p16INK4A and Human Papillomavirus in Patients With Oropharyngeal Cancer Treated on TROG 02.02 Phase III Trial,2010-09-20,cisplatin,False,[],0,Canada,11,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Salvage Regimens With Autologous Transplantation for Relapsed Large B-Cell Lymphoma in the Rituximab Era,2010-09-20,rituximab,True,['Genentech'],0,USA,14,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Pitfalls of Interim Positron Emission Tomography Scanning in Diffuse Large B-Cell Lymphoma,2010-09-20,,False,[],0,Germany,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Impact of Short-Course Preoperative Radiotherapy for Rectal Cancer on Patients' Quality of Life: Data From the Medical Research Council CR07/National Cancer Institute of Canada Clinical Trials Group C016 Randomized Clinical Trial,2010-09-20,,False,[],0,Canada,8,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Control of Plasma Uric Acid in Adults at Risk for Tumor Lysis Syndrome: Efficacy and Safety of Rasburicase Alone and Rasburicase Followed by Allopurinol Compared With Allopurinol AloneÃ¢â‚¬â€Results of a Multicenter Phase III Study,2010-09-20,rasburicase,True,['sanofi-aventis'],0,USA,15,7,1,0,0,0,1,1,1,0,0,0,0,0,0,0
Vinblastine in Children and Adolescents With High-Risk Anaplastic Large-Cell Lymphoma: Results of the Randomized ALCL99-Vinblastine Trial,2010-09-01,vinblastine,False,[],0,Germany,16,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Epirubicin, Oxaliplatin, and Capecitabine With or Without Panitumumab for Advanced Esophagogastric Cancer: Dose-Finding Study for the Prospective Multicenter, Randomized, Phase II/III REAL-3 Trial",2010-09-01,panitumumab,True,['Amgen'],0,USA,9,1,0,1,0,0,1,0,0,0,1,0,0,0,0,0
Phase I Trial of the Irreversible EGFR and HER2 Kinase Inhibitor BIBW 2992 in Patients With Advanced Solid Tumors,2010-09-01,afatinib,True,"['Boehringer Ingleheim', 'Boehringer Ingelheim']",0,Germany,16,7,5,2,0,2,1,1,1,0,0,0,0,0,0,1
"Phase II Trial of Anastrozole Plus Goserelin in the Treatment of Hormone Receptorâ€“Positive, Metastatic Carcinoma of the Breast in Premenopausal Women",2010-09-01,anastrozole,True,['AstraZeneca'],0,USA,11,4,0,1,0,1,1,1,0,0,1,0,0,0,0,0
"Phase II Study of the Halichondrin B Analog Eribulin Mesylate in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane, and Capecitabine",2010-09-01,eribulin mesylate,True,['Eisai'],0,Belgium,18,11,5,4,0,1,0,1,0,0,0,0,0,0,0,0
Patient-Reported Outcomes in Sentinel Nodeâ€“Negative Adjuvant Breast Cancer Patients Receiving Sentinel-Node Biopsy or Axillary Dissection: National Surgical Adjuvant Breast and Bowel Project Phase III Protocol B-32,2010-09-01,,False,[],0,USA,10,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Chemoimmunotherapy With a Modified Hyper-CVAD and Rituximab Regimen Improves Outcome in De Novo Philadelphia Chromosomeâ€“Negative Precursor B-Lineage Acute Lymphoblastic Leukemia,2010-08-20,rituximab,True,['Genentech'],0,USA,16,5,0,2,0,1,1,1,0,0,1,0,0,0,0,0
"Pyridoxine Is Not Effective to Prevent Hand-Foot Syndrome Associated With Capecitabine Therapy: Results of a Randomized, Double-Blind, Placebo-Controlled Study",2010-08-20,capecitabine,True,['Roche'],0,Korea,10,1,0,1,0,1,1,1,0,0,1,0,0,0,0,1
Phase II Randomized Comparison of Topotecan Plus Cyclophosphamide Versus Topotecan Alone in Children With Recurrent or Refractory Neuroblastoma: A Children's Oncology Group Study,2010-08-20,topotecan,False,[],0,USA,9,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Single-Agent Arsenic Trioxide in the Treatment of Newly Diagnosed Acute Promyelocytic Leukemia: Long-Term Follow-Up Data,2010-08-20,arsenic trioxide,False,[],0,India,12,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Neoadjuvant Paclitaxel, Ifosfamide, and Cisplatin Chemotherapy for Metastatic Penile Cancer: A Phase II Study",2010-08-20,paclitaxel,False,[],0,USA,9,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"High Rates of Durable Responses With Anti-CD22 Fractionated Radioimmunotherapy: Results of a Multicenter, Phase I/II Study in Non-Hodgkin's Lymphoma",2010-08-10,90Y epratuzumab tetraxetan,True,['Immunomedics'],0,Germany,18,8,4,0,0,0,1,1,1,0,0,0,0,0,0,0
Hematopoietic Stem-Cell Transplantation for Acute Leukemia in Relapse or Primary Induction Failure,2010-08-10,,False,[],0,USA,20,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Randomized Clinical Trial of Telephone-Administered Cognitive-Behavioral Therapy to Reduce Post-Traumatic Stress Disorder and Distress Symptoms After Hematopoietic Stem-Cell Transplantation,2010-08-10,,False,[],0,USA,20,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Prognostic Impact of Minimal Residual Disease inCBFB-MYH11â€“Positive Acute Myeloid Leukemia,2010-08-10,,False,[],0,Austria,15,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Long-Acting Methylphenidate for Cancer-Related Fatigue: North Central Cancer Treatment Group NCCTG-N05C7 Trial",2010-08-10,methylphenidate,False,[],0,USA,13,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Siltuximab, a Novel Antiâ€“Interleukin-6 Monoclonal Antibody, for Castleman's Disease",2010-08-10,siltuximab,True,"['Centocor', 'Centocor Ortho Biotech R&D']",0,USA,14,3,0,1,0,0,0,1,0,0,0,0,0,0,0,0
Phase III Study Comparing Second- and Third-Generation Regimens With Concurrent Thoracic Radiotherapy in Patients With Unresectable Stage III Nonâ€“Small-Cell Lung Cancer: West Japan Thoracic Oncology Group WJTOG0105,2010-08-10,paclitaxel,False,[],0,Japan,20,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
T-Cellâ€“Depleted Reduced-Intensity Transplantation Followed by Donor Leukocyte Infusions to Promote Graft-Versus-Lymphoma Activity Results in Excellent Long-Term Survival in Patients With Multiply Relapsed Follicular Lymphoma,2010-08-10,alemtuzumab,False,[],0,United Kingdom,13,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Phase III Trial Comparing Protracted Intravenous Fluorouracil Infusion Alone or With Yttrium-90 Resin Microspheres Radioembolization for Liver-Limited Metastatic Colorectal Cancer Refractory to Standard Chemotherapy,2010-08-10,yttrium-90 resin microspheres,True,['Sirtex Medical'],0,Belgium,16,1,0,0,0,1,1,1,0,0,0,0,0,0,1,1
Pain and Emotional Well-Being Outcomes in Southwest Oncology Groupâ€“Directed Intergroup Trial S0205: A Phase III Study Comparing Gemcitabine Plus Cetuximab Versus Gemcitabine As First-Line Therapy in Patients With Advanced Pancreas Cancer,2010-08-01,gemcitabine,True,['Eli Lilly'],0,Canada,14,1,0,1,0,0,1,1,0,0,1,0,0,0,0,0
Phase III Study Comparing Gemcitabine Plus Cetuximab Versus Gemcitabine in Patients With Advanced Pancreatic Adenocarcinoma: Southwest Oncology Groupâ€“Directed Intergroup Trial S0205,2010-08-01,cetuximab,True,['ImClone Systems'],0,Canada,15,2,0,1,0,1,0,0,0,0,0,0,0,0,0,0
Gemcitabine Plus Bevacizumab Compared With Gemcitabine Plus Placebo in Patients With Advanced Pancreatic Cancer: Phase III Trial of the Cancer and Leukemia Group B (CALGB 80303),2010-08-01,bevacizumab,True,['Genentech'],0,USA,15,4,0,3,0,0,0,0,0,0,0,0,0,0,0,0
"Phase II, Open-Label Study of Pazopanib or Lapatinib Monotherapy Compared With Pazopanib Plus Lapatinib Combination Therapy in Patients With Advanced and Recurrent Cervical Cancer",2010-08-01,pazopanib,True,['GlaxoSmithKline'],0,USA,10,10,4,0,0,0,1,1,1,0,0,0,0,0,0,0
Pediatric Phase I Trial and Pharmacokinetic Study of Vorinostat: A Children's Oncology Group Phase I Consortium Report,2010-08-01,vorinostat,False,[],0,USA,13,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Chemotherapy-Phased Imatinib Pulses Improve Long-Term Outcome of Adult Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Northern Italy Leukemia Group Protocol 09/00,2010-08-01,imatinib,False,[],0,Italy,20,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Randomized Trial of Prophylactic Granulocyte Colony-Stimulating Factor During Rapid COJEC Induction in Pediatric Patients With High-Risk Neuroblastoma: The European HR-NBL1/SIOPEN Study,2010-07-20,filgrastim,False,[],0,Switzerland,19,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Effect of Body Mass Index on Recurrences in Tamoxifen and Anastrozole Treated Women: An Exploratory Analysis From the ATAC Trial,2010-07-20,anastrozole,True,['AstraZeneca'],0,Australia,6,5,0,3,0,4,1,1,0,0,1,0,0,0,0,0
Randomized Phase II Trial of All-Trans-Retinoic Acid With Chemotherapy Based on Paclitaxel and Cisplatin As First-Line Treatment in Patients With Advanced Nonâ€“Small-Cell Lung Cancer,2010-07-20,all-trans retinoic acid,False,[],0,Mexico,12,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Longer-Term Assessment of Trastuzumab-Related Cardiac Adverse Events in the Herceptin Adjuvant (HERA) Trial,2010-07-20,trastuzumab,True,"['F. Hoffmann-La Roche', 'F. Hoffmann-La Roche (U)', 'F. Hoffmann La-Roche']",0,the Netherlands,20,10,1,7,0,4,1,1,1,0,0,0,0,0,0,0
Independent Adjudication of Symptomatic Heart Failure With the Use of Doxorubicin and Cyclophosphamide Followed by Trastuzumab Adjuvant Therapy: A Combined Review of Cardiac Data From the National Surgical Adjuvant Breast and Bowel Project B-31 and the North Central Cancer Treatment Group N9831 Clinical Trials,2010-07-20,trastuzumab,True,['Genentech'],0,USA,9,8,2,1,0,3,1,1,1,0,0,0,0,0,0,0
Report of a Multicenter Phase II Trial Testing a Combination of Biweekly Bevacizumab and Daily Erlotinib in Patients With Unresectable Biliary Cancer: A Phase II Consortium Study,2010-07-20,erlotinib,True,['OSI Pharmaceuticals'],0,Australia,13,1,0,1,0,1,1,0,0,0,1,0,0,0,0,0
Attitudes Toward Information About Genetic Risk for Cognitive Impairment After Cancer Chemotherapy: Breast Cancer Survivors Compared With Healthy Controls,2010-07-20,,False,[],0,USA,5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Phase II Study of the Anti-Cytotoxic T-Lymphocyteâ€“Associated Antigen 4 Monoclonal Antibody, Tremelimumab, in Patients With Refractory Metastatic Colorectal Cancer",2010-07-20,tremelimumab,True,['Pfizer'],0,USA,11,12,5,1,0,1,1,1,1,0,0,0,0,0,0,0
Primary Disseminated Multifocal Ewing Sarcoma: Results of the Euro-EWING 99 Trial,2010-07-10,vincristine,False,[],0,Sweden,13,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Pharmacogenetic Predictors of Adverse Events and Response to Chemotherapy in Metastatic Colorectal Cancer: Results From North American Gastrointestinal Intergroup Trial N9741,2010-07-10,irinotecan,True,['Roche'],0,USA,13,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0
"Phase III Trial Comparing Docetaxel and Cisplatin Combination Chemotherapy With Mitomycin, Vindesine, and Cisplatin Combination Chemotherapy With Concurrent Thoracic Radiotherapy in Locally Advanced Nonâ€“Small-Cell Lung Cancer: OLCSG 0007",2010-07-10,docetaxel,True,['sanofi-aventis'],0,Japan,20,2,0,0,0,2,1,1,0,0,0,0,0,0,1,1
Randomized Phase III Trial of Ixabepilone Plus Capecitabine Versus Capecitabine in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane,2010-07-10,ixabepilone,True,"['Bristol-Myers Squibb', 'Bristol-Myers Squib']",0,Italy,14,6,2,3,0,2,1,1,1,0,0,0,0,0,0,0
Phase II Study to Evaluate the Efficacy and Safety of Neoadjuvant Lapatinib Plus Paclitaxel in Patients With Inflammatory Breast Cancer,2010-07-10,lapatinib,True,['GlaxoSmithKline'],0,USA,6,4,2,1,0,2,1,1,1,0,0,0,0,0,0,0
Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2â€“Negative Metastatic Breast Cancer,2010-07-10,bevacizumab,True,['Roche'],0,Switzerland,16,12,1,9,0,8,1,1,1,0,0,0,0,0,0,0
Consolidation Radiotherapy in Patients With Advanced Hodgkin's Lymphoma: Survival Data From the UKLG LY09 Randomized Controlled Trial (ISRCTN97144519),2010-07-10,doxorubicin,False,[],0,United Kingdom,6,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Pegylated Liposomal Doxorubicin and Carboplatin Compared With Paclitaxel and Carboplatin for Patients With Platinum-Sensitive Ovarian Cancer in Late Relapse,2010-07-10,pegylated liposomal doxorubicin,True,"['Schering-Plough Canada', 'Schering-Plough']",0,Norway,18,6,0,1,0,5,0,0,0,0,0,0,0,0,0,0
Epidermal Growth Factor Receptor Inhibitor Gefitinib Added to Chemoradiotherapy in Locally Advanced Head and Neck Cancer,2010-07-10,gefitinib,True,['AstraZeneca'],0,USA,16,2,0,2,0,1,1,1,0,0,1,0,0,0,0,1
"Phase III, Placebo-Controlled Trial of Three Doses of Citalopram for the Treatment of Hot Flashes: NCCTG Trial N05C9",2010-07-10,citalopram,False,[],0,USA,10,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Phase II Evaluation of Sorafenib in Advanced and Metastatic Squamous Cell Carcinoma of the Head and Neck: Southwest Oncology Group Study S0420,2010-07-10,sorafenib,True,['Bayer Pharmaceuticals'],0,USA,7,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0
Phase II Window Study on Rituximab in Newly Diagnosed Pediatric Mature B-Cell Non-Hodgkin's Lymphoma and Burkitt Leukemia,2010-07-01,rituximab,True,['Roche'],0,Austria,14,1,0,0,0,1,1,1,0,0,0,0,0,0,1,1
Phase II Proof-of-Concept Study of Pazopanib Monotherapy in Treatment-Naive Patients With Stage I/II Resectable Nonâ€“Small-Cell Lung Cancer,2010-07-01,pazopanib,True,['GlaxoSmithKline'],0,United Kingdom,18,11,3,0,0,0,1,1,1,0,0,0,0,0,0,0
"Phase I Study of Single-Agent Antiâ€“Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates",2010-07-01,nivolumab,True,"['Medarex (U)', 'Medarex']",0,USA,20,11,5,2,0,2,1,1,1,0,0,0,0,0,0,0
"Capecitabine, Bevacizumab, and Mitomycin in First-Line Treatment of Metastatic Colorectal Cancer: Results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study",2010-07-01,bevacizumab,True,"['Roche', 'Roche International', 'Roche (U)']",0,New Zealand,18,12,0,8,0,6,1,1,0,0,1,0,0,0,0,0
Phase III Study of the Value of Thalidomide Added to Melphalan Plus Prednisone in Elderly Patients With Newly Diagnosed Multiple Myeloma: The HOVON 49 Study,2010-07-01,thalidomide,False,[],0,the Netherlands,11,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Preoperative Chemotherapy Plus Surgery Versus Surgery Plus Adjuvant Chemotherapy Versus Surgery Alone in Early-Stage Nonâ€“Small-Cell Lung Cancer,2010-07-01,paclitaxel,False,[],0,Spain,20,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Trabectedin Plus Pegylated Liposomal Doxorubicin in Recurrent Ovarian Cancer,2010-07-01,trabectedin,True,"['Pharmamar', 'PharmaMar Board of Directors', 'PharmaMar']",0,Spain,20,5,2,2,0,2,1,0,1,0,0,0,0,0,0,0
Reiterative Survival Analyses of Total Therapy 2 for Multiple Myeloma Elucidate Follow-Up Time Dependency of Prognostic Variables and Treatment Arms,2010-06-20,thalidomide,True,['Celgene'],0,USA,8,3,0,3,0,3,1,0,0,0,1,0,0,0,0,0
Phase III Multicenter Trial of Doxorubicin Plus Cyclophosphamide Followed by Paclitaxel Compared With Doxorubicin Plus Paclitaxel Followed by Weekly Paclitaxel As Adjuvant Therapy for Women With High-Risk Breast Cancer,2010-06-20,paclitaxel,True,['Abraxis'],0,USA,19,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0
"Phase I and Pharmacologic Study of SNS-032, a Potent and Selective Cdk2, 7, and 9 Inhibitor, in Patients With Advanced Chronic Lymphocytic Leukemia and Multiple Myeloma",2010-06-20,sns-032,True,['Sunesis Pharmaceuticals'],0,USA,15,8,4,0,0,0,1,0,1,0,0,0,0,0,0,0
Dose-Dense Doxorubicin and Cyclophosphamide Followed by Weekly Paclitaxel With Trastuzumab and Lapatinib in HER2/neuâ€“Overexpressed/Amplified Breast Cancer Is Not Feasible Because of Excessive Diarrhea,2010-06-20,lapatinib,True,"['GlaxoSmithKline (U)', 'GlaxoSmithKline']",0,USA,13,3,0,2,0,1,1,0,0,0,1,0,0,0,0,0
Akt Phosphorylation at Ser473 Predicts Benefit of Paclitaxel Chemotherapy in Node-Positive Breast Cancer,2010-06-20,paclitaxel,True,['Abraxis BioScience'],0,USA,10,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
Hypofractionated Stereotactic Radiation Therapy: An Effective Therapy for Recurrent High-Grade Gliomas,2010-06-20,,False,[],0,USA,14,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Phase II Study of Sorafenib in Combination With Docetaxel and Cisplatin in the Treatment of Metastatic or Advanced Gastric and Gastroesophageal Junction Adenocarcinoma: ECOG 5203,2010-06-20,sorafenib,True,['Bayer/Onyx'],0,USA,6,3,0,0,0,2,1,1,0,0,0,0,0,0,1,0
"Cyclophosphamide, Vincristine, and Prednisone Followed by Tositumomab and Iodine-131â€“Tositumomab in Patients With Untreated Low-Grade Follicular Lymphoma: Eight-Year Follow-Up of a Multicenter Phase II Study",2010-06-20,tositumomab,True,"['GlaxoSmith Kline', 'GlaxoSmithKline']",0,USA,6,3,0,2,0,2,1,1,0,0,1,0,0,0,0,0
"Tirapazamine, Cisplatin, and Radiation Versus Cisplatin and Radiation for Advanced Squamous Cell Carcinoma of the Head and Neck (TROG 02.02, HeadSTART): A Phase III Trial of the Trans-Tasman Radiation Oncology Group",2010-06-20,tirapazamine,False,[],0,USA,12,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Lack of Efficacy of Bevacizumab Plus Irinotecan in Children With Recurrent Malignant Glioma and Diffuse Brainstem Glioma: A Pediatric Brain Tumor Consortium Study,2010-06-20,bevacizumab,True,['Genentech'],0,USA,11,1,0,1,0,1,1,0,0,0,1,0,0,0,0,0
"Neratinib, an Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor: Results of a Phase II Trial in Patients With Advanced NonÃ¢â‚¬â€œSmall-Cell Lung Cancer",2010-06-20,neratinib,True,['Pfizer'],0,USA,13,6,4,0,0,1,0,0,0,0,0,0,0,0,0,0
"Classical Cyclophosphamide, Methotrexate, and Fluorouracil Chemotherapy Is More Effective in Triple-Negative, Node-Negative Breast Cancer: Results From Two Randomized Trials of Adjuvant Chemoendocrine Therapy for Node-Negative Breast Cancer",2010-06-20,"cyclophosphamide, methotrexate, and fluorouracil (CMF) regimen",False,[],0,United Kingdom,12,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Phase II Study of Cediranib, an Oral Panâ€“Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Recurrent Glioblastoma",2010-06-10,cediranib,True,"['AstraZeneca', 'AstraZenca']",0,USA,20,4,0,2,0,0,0,1,0,0,0,0,0,0,0,0
"Intense Dose-Dense Sequential Chemotherapy With Epirubicin, Paclitaxel, and Cyclophosphamide Compared With Conventionally Scheduled Chemotherapy in High-Risk Primary Breast Cancer: Mature Results of an AGO Phase III Study",2010-06-10,epirubicin,True,['Pfizer'],0,USA,17,3,0,1,0,3,0,0,0,0,0,0,0,0,0,0
Rituximab Maintenance Treatment of Relapsed/Resistant Follicular Non-Hodgkin's Lymphoma: Long-Term Outcome of the EORTC 20981 Phase III Randomized Intergroup Study,2010-06-10,rituximab,True,['Roche'],0,Norway,11,7,0,3,0,5,1,1,0,0,1,0,0,0,0,0
"Phase I Dose-Escalation Study of Recombinant Human Apo2L/TRAIL, a Dual Proapoptotic Receptor Agonist, in Patients With Advanced Cancer",2010-06-10,rhApo2L/TRAIL,True,['Genentech'],0,United Kingdom,13,12,5,3,0,2,1,1,1,0,0,0,0,0,0,0
Phase I/IIa Study of Cilengitide and Temozolomide With Concomitant Radiotherapy Followed by Cilengitide and Temozolomide Maintenance Therapy in Patients With Newly Diagnosed Glioblastoma,2010-06-01,cilengitide,True,"['Merck KGaA', 'Merck', 'Merck Serono']",0,Germany,19,11,3,6,0,3,1,1,1,0,0,0,0,0,0,0
Deletions of the Derivative Chromosome 9 Do Not Influence the Response and the Outcome of Chronic Myeloid Leukemia in Early Chronic Phase Treated With Imatinib Mesylate: GIMEMA CML Working Party Analysis,2010-06-01,imatinib,True,"['Novartis', 'novartis']",0,Italy,20,7,0,5,0,7,1,1,0,0,1,0,0,0,0,0
Prognostic Impact of Specific Chromosomal Aberrations in a Large Group of Pediatric Patients With Acute Myeloid Leukemia Treated Uniformly According to Trial AML-BFM 98,2010-06-01,,False,[],0,Austria,12,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Estrogen Alone in Postmenopausal Women and Breast Cancer Detection by Means of Mammography and Breast Biopsy,2010-06-01,conjugated equine estrogen,True,['Wyeth'],0,USA,12,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0
Duration of First Off-Treatment Interval Is Prognostic for Time to Castration Resistance and Death in Men With Biochemical Relapse of Prostate Cancer Treated on a Prospective Trial of Intermittent Androgen Deprivation,2010-06-01,leuprolide,True,['TAP Pharmaceuticals'],0,USA,9,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0
"Phase I Study of Trastuzumab-DM1, an HER2 Antibody-Drug Conjugate, Given Every 3 Weeks to Patients With HER2-Positive Metastatic Breast Cancer",2010-06-01,trastuzumab emtansine,True,"['Genentech', 'Genentech (U)']",0,USA,13,12,8,1,0,2,1,1,1,0,0,0,0,0,0,0
Oral Clofarabine in the Treatment of Patients With Higher-Risk Myelodysplastic Syndrome,2010-06-01,clofarabine,True,"['Genzyme (U)', 'Genzyme', 'Genzyme Oncology']",0,USA,12,5,0,4,0,0,1,1,0,0,1,0,0,0,0,0
Functional Activity of the OCT-1 Protein Is Predictive of Long-Term Outcome in Patients With Chronic-Phase Chronic Myeloid Leukemia Treated With Imatinib,2010-06-01,imatinib,True,['Novartis Pharmaceuticals'],0,Switzerland,9,4,1,2,0,2,1,1,1,0,0,0,0,0,0,0
Phase II Parallel Group Study Showing Comparable Efficacy Between Premenopausal Metastatic Breast Cancer Patients Treated With Letrozole Plus Goserelin and Postmenopausal Patients Treated With Letrozole Alone As First-Line Hormone Therapy,2010-06-01,goserelin,False,[],0,Korea,10,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Phase II Evaluation of Paclitaxel and Carboplatin in the Treatment of Carcinosarcoma of the Uterus: A Gynecologic Oncology Group Study,2010-06-01,paclitaxel,True,['Bristol-Myers Squibb'],0,USA,9,1,0,0,0,1,1,1,0,0,0,0,0,0,1,1
Reducing Unnecessary Biopsy During Prostate Cancer Screening Using a Four-Kallikrein Panel: An Independent Replication,2010-05-20,,False,[],0,the Netherlands,9,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Successful Treatment of Childhood High-Risk Hepatoblastoma With Dose-Intensive Multiagent Chemotherapy and Surgery: Final Results of the SIOPEL-3HR Study,2010-05-20,cisplatin,False,[],0,Italy,17,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Acupuncture for Pain and Dysfunction After Neck Dissection: Results of a Randomized Controlled Trial,2010-05-20,,False,[],0,USA,12,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Poly(ADP)-Ribose Polymerase Inhibition: Frequent Durable Responses in BRCA Carrier Ovarian Cancer Correlating With Platinum-Free Interval,2010-05-20,olaparib,True,['KuDOS Pharmaceuticals (a wholly owned subsidiary of AstraZeneca)'],0,Poland,18,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0
"Phase II Study of Asparagine-Glycine-Arginineâ€“Human Tumor Necrosis Factor Î±, a Selective Vascular Targeting Agent, in Previously Treated Patients With Malignant Pleural Mesothelioma",2010-05-20,NGR-hTNF,True,['MolMed'],0,Italy,19,3,3,0,0,0,1,1,1,1,0,0,0,0,0,0
Phase II Study of Amrubicin As Second-Line Therapy in Patients With Platinum-Refractory Small-Cell Lung Cancer,2010-05-20,amrubicin,True,['Eisai'],0,USA,14,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
Granulocyte Colony-Stimulating Factor (G-CSF) Treatment of Childhood Acute Myeloid Leukemias That Overexpress the Differentiation-Defective G-CSF Receptor Isoform IV Is Associated With a Higher Incidence of Relapse,2010-05-20,filgrastim,False,[],0,Austria,17,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Pharmacogenetic Assessment of Toxicity and Outcome in Patients With Metastatic Colorectal Cancer Treated With LV5FU2, FOLFOX, and FOLFIRI: FFCD 2000-05",2010-05-20,fluorouracil,False,[],0,France,15,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Phase III Trial Comparing Adjuvant Treatment With Pegylated Interferon Alfa-2b Versus Observation: Prognostic Significance of Autoantibodiesâ€”EORTC 18991,2010-05-10,pegylated interferon alfa-2b (PEG-IFN),True,['Schering-Plough'],0,France,11,4,0,2,0,3,1,1,0,0,1,0,0,0,0,0
Long-Term Outcome in Children With Relapsed Acute Lymphoblastic Leukemia After Time-Point and Site-of-Relapse Stratification and Intensified Short-Course Multidrug Chemotherapy: Results of Trial ALL-REZ BFM 90,2010-05-10,,False,[],0,Russia,13,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Standard International Prognostic Index Remains a Valid Predictor of Outcome for Patients With Aggressive CD20+ B-Cell Lymphoma in the Rituximab Era,2010-05-10,rituximab,True,"['Roche', 'Roche Pharma AG']",0,Germany,7,3,0,2,0,2,1,1,0,0,1,0,0,0,0,0
European Development of Clofarabine as Treatment for Older Patients With Acute Myeloid Leukemia Considered Unsuitable for Intensive Chemotherapy,2010-05-10,clofarabine,True,['Genzyme'],0,Bologna Italy,16,2,0,1,0,2,1,0,0,0,1,0,0,0,0,0
Phase II Clinical Trial of Sorafenib in Metastatic Medullary Thyroid Cancer,2010-05-10,sorafenib,True,"['Bayer HealthCare Pharmaceuticals (U)', 'Bayer HealthCare']",0,USA,19,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
Adherence and Persistence With Oral Adjuvant Chemotherapy in Older Women With Early-Stage Breast Cancer in CALGB 49907: Adherence Companion Study 60104,2010-05-10,capecitabine,True,"['Hoffman-LaRoche', 'Roche']",0,USA,13,5,0,2,0,1,1,1,0,0,1,0,0,0,0,0
Primary Analysis of the Phase II Component of a Phase I/II Dose Intensification Study Using Three-Dimensional Conformal Radiation Therapy and Concurrent Chemotherapy for Patients With Inoperable Nonâ€“Small-Cell Lung Cancer: RTOG 0117,2010-05-10,carboplatin,False,[],0,USA,10,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Total Skin Electron Beam and Non-Myeloablative Allogeneic Hematopoietic Stem-Cell Transplantation in Advanced Mycosis Fungoides and SÃƒÂ©zary Syndrome,2010-05-10,allogeneic hematopoietic stem-cell transplantation,False,[],0,USA,10,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Rituximab and Subcutaneous 2-Chloro-2â€²-Deoxyadenosine Combination Treatment for Patients With WaldenstrÃ¶m Macroglobulinemia: Clinical and Biologic Results of a Phase II Multicenter Study,2010-05-01,2-chlorodeoxyadenosine,False,[],0,Italy,14,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Epoetin Alfa in Patients With Advanced-Stage Hodgkin's Lymphoma: Results of the Randomized Placebo-Controlled GHSG HD15EPO Trial,2010-05-01,epoetin alfa,False,[],0,the Netherlands,17,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Bortezomib Plus Melphalan and Prednisone Compared With Melphalan and Prednisone in Previously Untreated Multiple Myeloma: Updated Follow-Up and Impact of Subsequent Therapy in the Phase III VISTA Trial,2010-05-01,bortezomib,True,['Millennium Pharmaceuticals'],0,United Kingdom,20,4,1,2,0,1,1,0,1,0,0,0,0,0,0,0
Phase II Trial of Bevacizumab and Everolimus in Patients With Advanced Renal Cell Carcinoma,2010-05-01,bevacizumab,True,"['Genentech (U)', 'Genentech']",0,USA,6,3,0,2,0,0,1,1,0,0,1,0,0,0,0,0
Phase III Trial of Bevacizumab Plus Interferon Alfa Versus Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: Final Results of CALGB 90206,2010-05-01,bevacizumab,True,['Genentech'],0,Canada,11,5,0,4,0,1,1,1,0,0,1,0,0,0,0,0
Phase III Trial of Bevacizumab Plus Interferon Alfa-2a in Patients With Metastatic Renal Cell Carcinoma (AVOREN): Final Analysis of Overall Survival,2010-05-01,bevacizumab,True,"['F. Hoffmann-La Roche', 'F. Hoffmann-La Roche (U)']",0,Switzerland,10,9,3,5,0,5,1,1,1,0,0,0,0,0,0,0
Phase I Combination Trial of Lenalidomide and Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes,2010-05-01,Lenalidomide,True,['Celgene'],0,USA,11,3,0,2,0,1,1,1,0,0,1,0,0,0,0,0
"Phase I/II Trial of Preoperative Oxaliplatin, Docetaxel, and Capecitabine With Concurrent Radiation Therapy in Localized Carcinoma of the Esophagus or Gastroesophageal Junction",2010-05-01,oxaliplatin,True,['sanofi-aventis'],0,USA,9,4,0,2,0,2,1,1,0,0,1,0,0,0,0,0
BCL-2/IgH Polymerase Chain Reaction Status at the End of Induction Treatment Is Not Predictive for Progression-Free Survival in Relapsed/Resistant Follicular Lymphoma: Results of a Prospective Randomized EORTC 20981 Phase III Intergroup Study,2010-05-01,rituximab,True,['Genentech'],0,Norway,13,1,0,1,0,1,1,1,0,0,1,0,0,0,0,0
Phase III Trial Comparing Vinflunine With Docetaxel in Second-Line Advanced NonÃ¢â‚¬â€œSmall-Cell Lung Cancer Previously Treated With Platinum-Containing Chemotherapy,2010-05-01,vinflunine,False,[],0,Spain,18,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Phase II Study of Pegylated Arginine Deiminase for Nonresectable and Metastatic Hepatocellular Carcinoma,2010-05-01,pegylated arginine deiminase,False,[],0,Italy,13,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Capecitabine in Addition to Anthracycline- and Taxane-Based Neoadjuvant Treatment in Patients With Primary Breast Cancer: Phase III GeparQuattro Study,2010-04-20,capecitabine,True,"['Hoffmann-La Roche', 'Roche']",0,Germany,20,12,0,4,0,12,1,1,0,0,1,0,0,0,0,0
Neoadjuvant Treatment With Trastuzumab in HER2-Positive Breast Cancer: Results From the GeparQuattro Study,2010-04-20,trastuzumab,True,"['Hoffmann-La Roche', 'Roche']",0,Germany,20,13,0,5,0,12,1,1,0,0,1,0,0,0,0,0
"Phase II Trial of Bevacizumab, Thalidomide, Docetaxel, and Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer",2010-04-20,docetaxel,False,[],0,USA,17,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Phase II Trial of Continuous Dose-Intense Temozolomide in Recurrent Malignant Glioma: RESCUE Study,2010-04-20,temozolomide,True,"['Schering-Plough', 'Schering-Plough Canada']",0,Canada,13,9,1,6,0,8,1,1,1,0,0,0,0,0,0,0
Pancreatic Proteolytic Enzyme Therapy Compared With Gemcitabine-Based Chemotherapy for the Treatment of Pancreatic Cancer,2010-04-20,gemcitabine,False,[],0,Taiwan,7,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Major Tumor Shrinking and Persistent Molecular Remissions After Consolidation With Bortezomib, Thalidomide, and Dexamethasone in Patients With Autografted Myeloma",2010-04-20,bortezomib,True,"['Janssen-Cilag (U)', 'Janssen-Cilag']",0,Italy,20,5,0,1,0,3,1,0,0,0,1,0,0,0,0,0
"Safety, Pharmacokinetics, and Preliminary Clinical Activity of Inotuzumab Ozogamicin, a Novel Immunoconjugate for the Treatment of B-Cell Non-Hodgkin's Lymphoma: Results of a Phase I Study",2010-04-20,Inotuzumab ozogamicin,True,"['Wyeth', 'Wyeth (U)']",0,Belgium,20,12,2,6,0,2,1,1,1,0,0,0,0,0,0,0
Functional Promoter âˆ’1271G>C Variant of HSPB1 Predicts Lung Cancer Risk and Survival,2010-04-10,,False,[],0,China,14,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Prognostic Factors in Patients With Advanced Transitional Cell Carcinoma of the Urothelial Tract Experiencing Treatment Failure With Platinum-Containing Regimens,2010-04-10,vinflunine,True,"['Pierre Fabre', 'Pierre Fabre (U)']",0,Denmark,10,5,2,3,0,1,1,1,1,0,0,0,0,0,0,1
Multicenter Phase II Study of Everolimus in Patients With Previously Treated Metastatic Gastric Cancer,2010-04-10,everolimus,True,"['Novartis Pharma', 'Novartis']",0,USA,12,3,3,0,0,0,1,1,1,0,0,0,0,0,0,0
Prediction of Risk of Distant Recurrence Using the 21-Gene Recurrence Score in Node-Negative and Node-Positive Postmenopausal Patients With Breast Cancer Treated With Anastrozole or Tamoxifen: A TransATAC Study,2010-04-10,Recurrence Score (RS),True,['Genomic Health'],0,USA,14,3,3,0,0,0,1,0,1,0,0,0,0,0,0,0
"Phase I/II Study of Combination Therapy With Sorafenib, Idarubicin, and Cytarabine in Younger Patients With Acute Myeloid Leukemia",2010-04-10,sorafenib,True,['Bayer Pharmaceuticals/Onyx Pharmaceuticals'],0,USA,19,2,0,2,0,1,1,0,0,0,1,0,0,0,0,0
Benefits of the Intermittent Use of 6-Mercaptopurine and Methotrexate in Maintenance Treatment for Low-Risk Acute Lymphoblastic Leukemia in Children: Randomized Trial From the Brazilian Childhood Cooperative Groupâ€”Protocol ALL-99,2010-04-10,6-mercaptopurine,False,[],0,Brazil,20,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Phase III Study of Carboplatin and Paclitaxel Alone or With Sorafenib in Advanced Nonâ€“Small-Cell Lung Cancer,2010-04-10,sorafenib,True,['Bayer Pharmaceuticals'],0,USA,20,4,3,0,0,0,1,0,1,0,0,0,0,0,0,0
"Surgery With or Without Preoperative Paclitaxel and Carboplatin in Early-Stage NonÃ¢â‚¬â€œSmall-Cell Lung Cancer: Southwest Oncology Group Trial S9900, an Intergroup, Randomized, Phase III Trial",2010-04-10,paclitaxel,False,[],0,USA,9,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Comparison of Cladribine Plus Cyclophosphamide With Fludarabine Plus Cyclophosphamide As First-Line Therapy for Chronic Lymphocytic Leukemia: A Phase III Randomized Study by the Polish Adult Leukemia Group (PALG-CLL3 Study),2010-04-10,cladribine,False,[],0,Poland,20,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Phase III Placebo-Controlled Trial of Denileukin Diftitox for Patients With Cutaneous T-Cell Lymphoma,2010-04-10,denileukin diftitox,True,['Eisai'],0,USA,9,7,2,5,0,5,1,1,1,0,0,0,0,0,0,0
TI-CE High-Dose Chemotherapy for Patients With Previously Treated Germ Cell Tumors: Results and Prognostic Factor Analysis,2010-04-01,paclitaxel,True,['Bristol-Myers Squibb'],0,USA,11,1,0,1,0,0,1,1,0,0,1,0,0,0,0,0
Ofatumumab As Single-Agent CD20 Immunotherapy in Fludarabine-Refractory Chronic Lymphocytic Leukemia,2010-04-01,ofatumumab,True,['Genmab'],0,Sweden,20,6,3,2,0,1,0,0,0,0,0,0,0,0,0,0
90Y-Edotreotide for Metastatic Carcinoid Refractory to Octreotide,2010-04-01,Yttrium-90 (90Y)-edotreotide,True,"['Molecular Insight Pharmaceuticals (U)', 'Molecular Insight Pharmaceuticals']",0,Belgium,18,8,4,4,0,2,1,0,1,0,0,0,0,0,0,0
"Large Randomized Study of Thymosin Î± 1, Interferon Alfa, or Both in Combination With Dacarbazine in Patients With Metastatic Melanoma",2010-04-01,thymosin alpha 1,True,"['SciClone Pharmaceuticals inc (U)', 'SciClone Pharmaceuticals inc']",0,Hungary,13,2,0,1,0,0,0,0,0,0,0,0,0,0,0,0
Rituximab Plus Fludarabine and Cyclophosphamide Prolongs Progression-Free Survival Compared With Fludarabine and Cyclophosphamide Alone in Previously Treated Chronic Lymphocytic Leukemia,2010-04-01,rituximab,True,"['F. Hoffman-La Roche', 'F. Hoffmann-La Roche (U)', 'F. Hoffmann-La Roche']",0,USA,20,13,3,6,0,8,1,1,1,0,0,0,0,0,0,0
Randomized Phase III Trial of Gemcitabine Plus Cisplatin Compared With Single-Agent Gemcitabine As First-Line Treatment of Patients With Advanced Pancreatic Cancer: The GIP-1 Study,2010-04-01,gemcitabine,False,[],0,Italy,20,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Comparison of Two Neoadjuvant Chemoradiotherapy Regimens for Locally Advanced Rectal Cancer: Results of the Phase III Trial ACCORD 12/0405-Prodige 2,2010-04-01,capecitabine,False,[],0,France,20,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"First-Line Trastuzumab Plus Epirubicin and Cyclophosphamide Therapy in Patients With Human Epidermal Growth Factor Receptor 2â€“Positive Metastatic Breast Cancer: Cardiac Safety and Efficacy Data From the Herceptin, Cyclophosphamide, and Epirubicin (HERCULES) Trial",2010-03-20,trastuzumab,True,"['F. Hoffmann-La Roche', 'Roche']",0,Switzerland,18,10,2,6,0,8,1,1,1,0,0,0,0,0,0,0
Prospective Multicenter Cohort Study to Refine Management Recommendations for Women at Elevated Familial Risk of Breast Cancer: The EVA Trial,2010-03-20,MRI (Magnetic Resonance Imaging),False,[],0,Germany,13,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Phase I Study of KW-0761, a Defucosylated Humanized Anti-CCR4 Antibody, in Relapsed Patients With Adult T-Cell Leukemia-Lymphoma and Peripheral T-Cell Lymphoma",2010-03-20,mogamulizumab,True,['Kyowa Hakko Kirin Co Ltd'],0,Japan,20,2,1,1,0,0,1,1,1,0,0,1,0,0,0,0
Early Detection of Superficial Squamous Cell Carcinoma in the Head and Neck Region and Esophagus by Narrow Band Imaging: A Multicenter Randomized Controlled Trial,2010-03-20,narrow band imaging,False,[],0,Japan,17,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Phase I Clinical Trial of the CYP17 Inhibitor Abiraterone Acetate Demonstrating Clinical Activity in Patients With Castration-Resistant Prostate Cancer Who Received Prior Ketoconazole Therapy,2010-03-20,abiraterone acetate,True,"['Cougar Biotechnology (U)', 'Cougar Biotechnology']",0,United Kingdom,12,8,2,4,0,0,1,1,1,0,0,0,0,0,0,0
"Significant and Sustained Antitumor Activity in Post-Docetaxel, Castration-Resistant Prostate Cancer With the CYP17 Inhibitor Abiraterone Acetate",2010-03-20,abiraterone acetate,True,"['Cougar Biotechnology (U)', 'Cougar Biotechnology', 'Cougar Biotecnology (U)']",0,USA,20,8,2,6,0,0,1,1,1,0,0,0,0,0,0,0
Neoadjuvant Clinical Trial With Sorafenib for Patients With Stage II or Higher Renal Cell Carcinoma,2010-03-20,sorafenib,True,['Bayer/Onyx'],0,USA,16,1,0,1,0,1,1,1,0,0,1,0,0,0,0,0
Alberta Physical Activity and Breast Cancer Prevention Trial: Sex Hormone Changes in a Year-Long Exercise Intervention Among Postmenopausal Women,2010-03-20,,False,[],0,USA,17,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Multicenter Phase III Comparison of Cisplatin/S-1 With Cisplatin/Infusional Fluorouracil in Advanced Gastric or Gastroesophageal Adenocarcinoma Study: The FLAGS Trial,2010-03-20,S-1,True,"['Taiho (U)', 'Taiho']",0,Ukraine,10,8,0,1,0,0,1,1,0,0,1,0,0,0,0,0
"Phase 1b Study of Dulanermin (recombinant human Apo2L/TRAIL) in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Patients With Advanced Non-Squamous Nonâ€“Small-Cell Lung Cancer",2010-03-20,dulanermin,True,['Amgen'],0,United Kingdom,9,6,4,1,0,0,1,1,1,0,0,0,0,0,0,0
Phase II Multicenter Study of Abiraterone Acetate Plus Prednisone Therapy in Patients With Docetaxel-Treated Castration-Resistant Prostate Cancer,2010-03-20,abiraterone acetate,True,"['Cougar Biotechnology (U)', 'Cougar Biotechnology', 'Ortho Biotech/Cougar Biotechnology']",0,USA,17,9,3,5,0,0,1,1,1,0,0,0,0,0,0,0
"Phase I Pharmacokinetic and Pharmacodynamic Study of 17-dimethylaminoethylamino-17-demethoxygeldanamycin, an Inhibitor of Heat-Shock Protein 90, in Patients With Advanced Solid Tumors",2010-03-20,17DMAG,False,[],0,USA,10,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Skin Toxicity Evaluation Protocol With Panitumumab (STEPP), a Phase II, Open-Label, Randomized Trial Evaluating the Impact of a Pre-Emptive Skin Treatment Regimen on Skin Toxicities and Quality of Life in Patients With Metastatic Colorectal Cancer",2010-03-10,panitumumab,True,['Amgen'],0,USA,8,5,2,2,0,3,1,1,1,0,0,0,0,0,0,0
Phase II Trial of the Oral Mammalian Target of Rapamycin Inhibitor Everolimus in Relapsed or Refractory WaldenstrÃ¶m Macroglobulinemia,2010-03-10,everolimus,True,['Novartis'],0,USA,19,4,0,1,0,2,0,1,0,0,0,0,0,0,0,0
"Phase II, Randomized, Open-Label Study of Pegfilgrastim-Supported VDC/IE Chemotherapy in Pediatric Sarcoma Patients",2010-03-10,pegfilgrastim,True,['Amgen'],0,USA,8,5,3,0,0,0,1,1,1,0,0,0,0,0,0,0
Facilitating Informed Decisions Regarding Microsatellite Instability Testing Among High-Risk Individuals Diagnosed With Colorectal Cancer,2010-03-10,,False,[],0,USA,9,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Phase II Study of Sunitinib in Patients With Metastatic Urothelial Cancer,2010-03-10,sunitinib,True,['Pfizer'],0,USA,10,1,0,1,0,0,1,1,0,0,1,0,0,0,0,0
Sustained Molecular Response With Interferon Alfa Maintenance After Induction Therapy With Imatinib Plus Interferon Alfa in Patients With Chronic Myeloid Leukemia,2010-03-10,imatinib,True,['Novartis'],0,Germany,9,1,0,0,0,1,1,0,0,0,0,0,0,0,1,0
Phase II Trial of Weekly Bortezomib in Combination With Rituximab in Relapsed or Relapsed and Refractory WaldenstrÃ¶m Macroglobulinemia,2010-03-10,bortezomib,True,"['Millennium', 'Millennium (U)']",0,USA,16,6,0,3,0,4,1,1,0,0,1,0,0,0,0,0
Phase I/II Study of the Src Inhibitor Dasatinib in Combination With Erlotinib in Advanced NonÃ¢â‚¬â€œSmall-Cell Lung Cancer,2010-03-10,erlotinib,True,['OSI Pharmaceuticals'],0,USA,14,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
"Neratinib, an Irreversible ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced ErbB2-Positive Breast Cancer",2010-03-10,neratinib,True,['Wyeth'],0,USA,16,10,5,2,0,0,1,1,1,0,0,0,0,0,0,0
Phase III Study of Enzastaurin Compared With Lomustine in the Treatment of Recurrent Intracranial Glioblastoma,2010-03-01,enzastaurin,True,['Eli Lilly'],0,USA,13,10,4,4,0,0,1,0,1,0,0,0,0,0,0,0
"Open-Label, Phase II, Multicenter, Randomized Study of the Efficacy and Safety of Two Dose Levels of Pertuzumab, a Human Epidermal Growth Factor Receptor 2 Dimerization Inhibitor, in Patients With Human Epidermal Growth Factor Receptor 2â€“Negative Metastatic Breast Cancer",2010-03-01,pertuzumab,True,['Genentech'],0,Switzerland,12,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
Phase II Trial of Pertuzumab and Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2â€“Positive Metastatic Breast Cancer That Progressed During Prior Trastuzumab Therapy,2010-03-01,pertuzumab,True,['Genentech'],0,France,12,2,0,1,0,1,0,0,0,0,0,0,0,0,0,0
Randomized Trial Comparing Conventional-Dose With High-Dose Conformal Radiation Therapy in Early-Stage Adenocarcinoma of the Prostate: Long-Term Results From Proton Radiation Oncology Group/American College of Radiology 95-09,2010-03-01,,False,[],0,USA,12,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Pharmacogenomic and Pharmacoproteomic Studies of Cetuximab in Metastatic Colorectal Cancer: Biomarker Analysis of a Phase I Dose-Escalation Study,2010-03-01,cetuximab,True,['Imclone Systems'],0,Germany,16,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
"Randomized, Blinded, Sham-Controlled Trial of Acupuncture for the Management of Aromatase Inhibitorâ€“Associated Joint Symptoms in Women With Early-Stage Breast Cancer",2010-03-01,aromatase inhibitors,False,[],0,Taiwan,8,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Overall Survival Analysis of a Phase II Randomized Controlled Trial of a Poxviral-Based PSA-Targeted Immunotherapy in Metastatic Castration-Resistant Prostate Cancer,2010-03-01,PROSTVAC-VF,True,['BN ImmunoTherapeutics'],0,USA,14,4,2,2,0,0,1,0,1,0,0,0,0,0,0,0
"Clinical Activity of Gemcitabine Plus Pertuzumab in Platinum-Resistant Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer",2010-03-01,pertuzumab,True,['Genentech'],0,Germany,14,11,6,3,0,1,1,1,1,0,0,0,0,0,0,0
"Randomized Study of Lapatinib Alone or in Combination With Trastuzumab in Women With ErbB2-Positive, Trastuzumab-Refractory Metastatic Breast Cancer",2010-03-01,lapatinib,True,['GlaxoSmithKline'],0,Spain,12,9,2,3,0,4,1,1,1,0,0,0,0,0,0,0
"Cytokine Working Group Study of Lymphodepleting Chemotherapy, Interleukin-2, and Granulocyte-Macrophage Colony-Stimulating Factor in Patients With Metastatic Melanoma: Clinical Outcomes and Peripheral-Blood Cell Recovery",2010-03-01,aldesleukin,True,"['Novartis/Chiron', 'Novartis']",0,USA,16,5,0,2,0,2,1,1,0,0,1,0,0,0,0,0
Phase II Trial of a Trimodality Regimen for Stage III Nonâ€“Small-Cell Lung Cancer Using Chemotherapy As Induction Treatment With Concurrent Hyperfractionated Chemoradiation With Carboplatin and Paclitaxel Followed by Subsequent Resection: A Single-Center Study,2010-02-20,carboplatin/paclitaxel,False,[],0,Jordan,16,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Cetuximab and First-Line Taxane/Carboplatin Chemotherapy in Advanced Nonâ€“Small-Cell Lung Cancer: Results of the Randomized Multicenter Phase III Trial BMS099,2010-02-20,cetuximab,True,"['ImClone Systems', 'Imclone Systems']",0,Belgium,13,2,0,1,0,1,0,0,0,0,0,0,0,0,0,0
Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial,2010-02-20,pazopanib,True,['GlaxoSmithKline'],0,USA,16,9,3,3,0,3,1,1,1,0,0,0,0,0,0,0
"Analysis of Potential Predictive Markers of Cetuximab Benefit in BMS099, a Phase III Study of Cetuximab and First-Line Taxane/Carboplatin in Advanced Nonâ€“Small-Cell Lung Cancer",2010-02-20,cetuximab,True,['ImClone Systems Incorporated'],0,USA,10,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
Association of Skeletal Muscle Wasting With Treatment With Sorafenib in Patients With Advanced Renal Cell Carcinoma: Results From a Placebo-Controlled Study,2010-02-20,sorafenib,True,"['Bayer', 'Bayer Pharma']",0,Canada,6,1,0,1,0,1,1,1,0,0,1,0,0,0,0,1
Clinical Course of Advanced Nonâ€“Small-Cell Lung Cancer Patients Experiencing Hypertension During Treatment With Bevacizumab in Combination With Carboplatin and Paclitaxel on ECOG 4599,2010-02-20,bevacizumab,True,['Genentech'],0,USA,5,2,0,2,0,1,1,0,0,0,1,0,0,0,0,0
Single Cycle of Arsenic Trioxideâ€“Based Consolidation Chemotherapy Spares Anthracycline Exposure in the Primary Management of Acute Promyelocytic Leukemia,2010-02-20,arsenic trioxide,True,['Cephalon'],0,USA,12,2,0,1,0,1,1,1,0,0,1,0,0,0,0,0
Prevention of Aromatase Inhibitorâ€“Induced Bone Loss Using Risedronate: The SABRE Trial,2010-02-20,anastrozole,True,['AstraZeneca'],0,South Africa,9,7,1,4,0,3,1,1,1,0,0,0,0,0,0,0
Outcomes After Stereotactic Lung Radiotherapy or Wedge Resection for Stage I Nonâ€“Small-Cell Lung Cancer,2010-02-20,,False,[],0,USA,9,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Randomized Phase II Trial of First-Line Trastuzumab Plus Docetaxel and Capecitabine Compared With Trastuzumab Plus Docetaxel in HER2-Positive Metastatic Breast Cancer,2010-02-20,trastuzumab,True,"['Roche', 'F. Hoffmann La Roche']",0,Spain,11,7,3,4,0,3,1,1,1,0,0,0,0,0,0,0
Intensive Loading Dose of Trastuzumab Achieves Higher-Than-Steadyâ€“State Serum Concentrations and Is Well Tolerated,2010-02-20,trastuzumab,True,"['Roche', 'Roche Canada']",0,Switzerland,13,11,5,5,0,6,1,1,1,0,0,0,0,0,0,0
"HER2, TOP2A, and TIMP-1 and Responsiveness to Adjuvant Anthracycline-Containing Chemotherapy in High-Risk Breast Cancer Patients",2010-02-20,epirubicin,False,[],0,Denmark,10,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Vandetanib for the Treatment of Patients With Locally Advanced or Metastatic Hereditary Medullary Thyroid Cancer,2010-02-10,vandetanib,True,"['Astra Zeneca', 'AstraZeneca']",0,France,10,6,2,3,0,3,1,1,1,0,0,0,0,0,0,0
"Phase II, Randomized Study of Concomitant Chemoradiotherapy Followed by Surgery and Adjuvant Capecitabine Plus Oxaliplatin (CAPOX) Compared With Induction CAPOX Followed by Concomitant Chemoradiotherapy and Surgery in Magnetic Resonance Imagingâ€“Defined, Locally Advanced Rectal Cancer: Grupo CÃ¡ncer de Recto 3 Study",2010-02-10,capecitabine,True,['Roche'],0,Spain,20,1,0,1,0,0,1,0,0,0,1,0,0,0,0,0
TP53 Mutations and Pathologic Complete Response to Neoadjuvant Cisplatin and Fluorouracil Chemotherapy in Resected Oral Cavity Squamous Cell Carcinoma,2010-02-10,cisplatin,False,[],0,Italy,8,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Bortezomib As Induction Before Autologous Transplantation, Followed by Lenalidomide As Consolidation-Maintenance in Untreated Multiple Myeloma Patients",2010-02-10,bortezomib,True,['Janssen-Cilag'],0,Italy,20,7,0,1,0,4,0,1,0,0,0,0,0,0,0,0
Efficacy of Low-Dose Interferon Î±2a 18 Versus 60 Months of Treatment in Patients With Primary Melanoma of â‰¥ 1.5 mm Tumor Thickness: Results of a Randomized Phase III DeCOG Trial,2010-02-10,interferon alfa-2a,True,['Roche Pharma AG'],0,Germany,20,6,0,3,0,5,1,0,0,0,1,0,0,0,0,0
Randomized Study of Intensified Anthracycline Doses for Induction and Recombinant Interleukin-2 for Maintenance in Patients With Acute Myeloid Leukemia Age 50 to 70 Years: Results of the ALFA-9801 Study,2010-02-10,idarubicin,False,[],0,France,20,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Phase I Pharmacologic and Biologic Study of Ramucirumab (IMC-1121B), a Fully Human Immunoglobulin G1 Monoclonal Antibody Targeting the Vascular Endothelial Growth Factor Receptor-2",2010-02-10,ramucirumab,True,['ImClone Systems'],0,USA,17,7,3,1,0,2,1,1,1,0,0,0,0,0,0,0
"Alternating Systemic and Hepatic Artery Infusion Therapy for Resected Liver Metastases From Colorectal Cancer: A North Central Cancer Treatment Group (NCCTG)/ National Surgical Adjuvant Breast and Bowel Project (NSABP) Phase II Intergroup Trial, N9945/CI-66",2010-02-10,oxaliplatin,True,['sanofi-aventis'],0,USA,13,2,0,0,0,1,0,1,0,0,0,0,0,0,0,0
Role of Axillary Clearance After a Tumor-Positive Sentinel Node in the Administration of Adjuvant Therapy in Early Breast Cancer,2010-02-10,,False,[],0,Italy,14,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Randomized Phase III Trial of Platinum-Doublet Chemotherapy Followed by Gefitinib Compared With Continued Platinum-Doublet Chemotherapy in Japanese Patients With Advanced Nonâ€“Small-Cell Lung Cancer: Results of a West Japan Thoracic Oncology Group Trial (WJTOG0203),2010-02-10,gefitinib,True,['AstraZeneca'],0,Japan,20,6,0,0,0,6,0,1,0,0,0,0,0,0,0,1
Molecular Predictors of Outcome With Gefitinib and Docetaxel in Previously Treated Nonâ€“Small-Cell Lung Cancer: Data From the Randomized Phase III INTEREST Trial,2010-02-10,gefitinib,False,[],0,USA,14,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Phase I/II Trial of Metronomic Chemotherapy With Daily Dalteparin and Cyclophosphamide, Twice-Weekly Methotrexate, and Daily Prednisone As Therapy for Metastatic Breast Cancer Using Vascular Endothelial Growth Factor and Soluble Vascular Endothelial Growth Factor Receptor Levels As Markers of Response",2010-02-10,dalteparin,True,['Aventis'],0,Canada,15,1,0,1,0,1,1,1,0,0,1,0,0,0,0,0
"Single-Agent Laromustine, A Novel Alkylating Agent, Has Significant Activity in Older Patients With Previously Untreated Poor-Risk Acute Myeloid Leukemia",2010-02-10,laromustine,True,['Vion Pharmaceuticals'],0,USA,12,11,2,4,0,3,1,1,1,0,0,0,0,0,0,0
Genotype-Driven Phase I Study of Irinotecan Administered in Combination With Fluorouracil/Leucovorin in Patients With Metastatic Colorectal Cancer,2010-02-10,irinotecan,False,[],0,USA,14,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Attempts to Optimize Induction and Consolidation Treatment in Acute Myeloid Leukemia: Results of the MRC AML12 Trial,2010-02-01,mitoxantrone,False,[],0,United Kingdom,9,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Azacitidine Prolongs Overall Survival Compared With Conventional Care Regimens in Elderly Patients With Low Bone Marrow Blast Count Acute Myeloid Leukemia,2010-02-01,azacitidine,True,['Celgene'],0,USA,16,16,3,6,0,10,1,0,1,0,0,0,0,0,0,0
"Multicenter, Phase II Study of Decitabine for the First-Line Treatment of Older Patients With Acute Myeloid Leukemia",2010-02-01,decitabine,True,['Eisai'],0,USA,4,3,0,2,0,0,1,1,0,0,1,0,0,0,0,0
"Phase III, Randomized, Double-Blind, Placebo-Controlled Evaluation of Pregabalin for Alleviating Hot Flashes, N07C1",2010-02-01,pregabalin,False,[],0,USA,10,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Randomized Phase III Trial on Gemcitabine Versus Mytomicin in Recurrent Superficial Bladder Cancer: Evaluation of Efficacy and Tolerance,2010-02-01,gemcitabine,False,[],0,Italy,12,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Phase II Trial of Pemetrexed Plus Bevacizumab for Second-Line Therapy of Patients With Advanced Nonâ€“Small-Cell Lung Cancer: NCCTG and SWOG Study N0426,2010-02-01,pemetrexed,False,[],0,USA,11,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Acupuncture Versus Venlafaxine for the Management of Vasomotor Symptoms in Patients With Hormone ReceptorÃ¢â‚¬â€œPositive Breast Cancer: A Randomized Controlled Trial,2010-02-01,Venlafaxine,False,[],0,USA,10,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Phase II Study of Clofarabine Monotherapy in Previously Untreated Older Adults With Acute Myeloid Leukemia and Unfavorable Prognostic Factors,2010-02-01,clofarabine,True,"['Genyzme', 'Genyzme Oncology', 'Genzyme', 'Genzyme Oncology']",0,USA,16,14,2,9,0,4,1,1,1,0,0,0,0,0,0,0
Efficacy and Safety of Pazopanib in Patients With Metastatic Renal Cell Carcinoma,2010-01-20,pazopanib,True,['GlaxoSmithKline'],0,USA,12,9,4,2,0,0,1,1,1,0,0,0,0,0,0,0
"Prognostic Role of KRAS and BRAF in Stage II and III Resected Colon Cancer: Results of the Translational Study on the PETACC-3, EORTC 40993, SAKK 60-00 Trial",2010-01-20,,False,"['Pfizer Inc', 'Pfizer Oncology']",0,United Kingdom,17,9,1,6,0,4,1,1,1,0,0,0,0,0,0,0
Safety and Efficacy of Romiplostim in Patients With Lower-Risk Myelodysplastic Syndrome and Thrombocytopenia,2010-01-20,romiplostim,True,['Amgen'],0,USA,15,12,3,3,0,3,1,1,1,0,0,0,0,0,0,0
Provision of Spiritual Care to Patients With Advanced Cancer: Associations With Medical Care and Quality of Life Near Death,2010-01-20,,False,[],0,USA,10,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
"Phase II Trial of Infusional Fluorouracil, Irinotecan, and Bevacizumab for Metastatic Colorectal Cancer: Efficacy and Circulating Angiogenic Biomarkers Associated With Therapeutic Resistance",2010-01-20,bevacizumab,True,['Genentech'],0,Brazil,16,3,0,2,0,1,0,0,0,0,0,0,0,0,0,0
"Phase III, Randomized, Open-Label Study of Daily Imatinib Mesylate 400 mg Versus 800 mg in Patients With Newly Diagnosed, Previously Untreated Chronic Myeloid Leukemia in Chronic Phase Using Molecular End Points: Tyrosine Kinase Inhibitor Optimization and Selectivity Study",2010-01-20,imatinib,True,"['Novartis', 'Novarits', 'Novartis (U)']",0,USA,20,16,3,8,0,9,1,0,1,0,0,0,0,0,0,0
Results of Dasatinib Therapy in Patients With Early Chronic-Phase Chronic Myeloid Leukemia,2010-01-20,Dasatinib,True,['Bristol-Myers Squibb'],0,USA,11,6,0,1,0,3,0,1,0,0,0,0,0,0,0,0
"Flavopiridol, Fludarabine, and Rituximab in Mantle Cell Lymphoma and Indolent B-Cell Lymphoproliferative Disorders",2010-01-20,flavopiridol,True,['sanofi-aventis'],0,USA,13,3,0,2,0,1,1,1,0,0,1,0,0,0,0,0
Distinct Patterns of Cytokine and Angiogenic Factor Modulation and Markers of Benefit for Vandetanib and/or Chemotherapy in Patients With Nonâ€“Small-Cell Lung Cancer,2010-01-10,vandetanib,True,['AstraZeneca'],0,United Kingdom,12,4,2,2,0,0,1,0,1,0,0,0,0,0,0,0
"Phase I Study of Intravenous Vascular Endothelial Growth Factor Trap, Aflibercept, in Patients With Advanced Solid Tumors",2010-01-10,aflibercept,True,['Regeneron'],0,USA,17,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Combined Resistance and Aerobic Exercise Program Reverses Muscle Loss in Men Undergoing Androgen Suppression Therapy for Prostate Cancer Without Bone Metastases: A Randomized Controlled Trial,2010-01-10,,False,[],0,Australia,5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Use of Video to Facilitate End-of-Life Discussions With Patients With Cancer: A Randomized Controlled Trial,2010-01-10,,False,[],0,USA,9,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Phase I Clinical and Pharmacokinetic Study of Oral Sapacitabine in Patients With Acute Leukemia and Myelodysplastic Syndrome,2010-01-10,sapacitabine,True,"['Cyclacel Pharmaceuticals (U)', 'Cyclacel Pharmaceuticals']",0,United Kingdom,11,3,2,0,0,0,1,1,1,0,0,0,0,0,0,0
Phase I Study of Accelerated Conformal Radiotherapy for Stage I Nonâ€“Small-Cell Lung Cancer in Patients With Pulmonary Dysfunction: CALGB 39904,2010-01-10,,False,"['sanofi-aventis', 'sanofi-aventis (U)']",0,USA,11,1,0,1,0,0,1,1,0,0,1,0,0,0,0,0
Long-Term Results of the International Adjuvant Lung Cancer Trial Evaluating Adjuvant Cisplatin-Based Chemotherapy in Resected Lung Cancer,2010-01-01,cisplatin,False,[],0,Brazil,12,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Randomized Phase III Trial of Vinorelbine Plus Cisplatin Compared With Observation in Completely Resected Stage IB and II Nonâ€“Small-Cell Lung Cancer: Updated Survival Analysis of JBR-10,2010-01-01,cisplatin,False,[],0,USA,16,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Daily Oral Everolimus Activity in Patients With Metastatic Pancreatic Neuroendocrine Tumors After Failure of Cytotoxic Chemotherapy: A Phase II Trial,2010-01-01,everolimus,True,"['Novartis', 'member of the Novartis board', 'Novartis Oncology']",0,Germany,19,16,4,7,0,9,1,1,1,0,0,0,0,0,0,0
Carboplatin and Paclitaxel in Combination With Either Vorinostat or Placebo for First-Line Therapy of Advanced Nonâ€“Small-Cell Lung Cancer,2010-01-01,vorinostat,True,['Merck'],0,USA,11,4,0,4,0,0,1,1,0,0,1,0,0,0,0,0
Tumor-Associated Lymphocytes As an Independent Predictor of Response to Neoadjuvant Chemotherapy in Breast Cancer,2010-01-01,Anthracyclines and Taxanes,False,[],0,Germany,17,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Phase II Study of Sunitinib in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: GORTEC 2006-01,2010-01-01,sunitinib,True,['Pfizer'],0,France,13,2,0,0,0,1,0,0,0,0,0,0,0,0,0,0
"Phase II Study of Carboplatin, Paclitaxel, and Bevacizumab With Maintenance Bevacizumab As First-Line Chemotherapy for Advanced MÃ¼llerian Tumors",2010-01-01,bevacizumab,True,['Genentech'],0,USA,12,5,1,2,0,1,1,0,1,0,0,0,0,0,0,0
"Randomized, Double-Blind Trial of Carboplatin and Paclitaxel With Either Daily Oral Cediranib or Placebo in Advanced Nonâ€“Small-Cell Lung Cancer: NCIC Clinical Trials Group BR24 Study",2010-01-01,cediranib,True,['AstraZeneca'],0,Canada,20,9,0,4,0,6,1,0,0,0,1,0,0,0,0,0
Induction Chemotherapy and Cetuximab for Locally Advanced Squamous Cell Carcinoma of the Head and Neck: Results From a Phase II Prospective Trial,2010-01-01,cetuximab,True,['ImClone Systems'],0,USA,16,2,0,1,0,0,1,1,0,0,1,0,0,0,0,0
"Cyclophosphamide, Epirubicin, and Fluorouracil Versus Dose-Dense Epirubicin and Cyclophosphamide Followed by Paclitaxel Versus Doxorubicin and Cyclophosphamide Followed by Paclitaxel in Node-Positive or High-Risk Node-Negative Breast Cancer",2010-01-01,cyclophosphamide,False,[],0,USA,14,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Neoadjuvant Chemotherapy Shows Similar Response in Patients With Inflammatory or Locally Advanced Breast Cancer When Compared With Operable Breast Cancer: A Secondary Analysis of the GeparTrio Trial Data,2010-01-01,docetaxel,True,"['sanofi-aventis', 'sanofi-aventis (U)']",0,Switzerland,20,11,0,2,0,11,1,1,0,0,1,0,0,0,0,0
Tracheoesophageal Fistula Formation in Patients With Lung Cancer Treated With Chemoradiation and Bevacizumab,2010-01-01,bevacizumab,True,"['Genentech', 'Genentech (U)']",0,USA,9,4,0,2,0,1,1,1,0,0,1,0,0,0,0,0
Phase II Clinical Trial of Ixabepilone in Patients With Recurrent or Persistent Platinum- and Taxane-Resistant Ovarian or Primary Peritoneal Cancer: A Gynecologic Oncology Group Study,2010-01-01,Ixabepilone,False,[],0,USA,9,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
